INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7501, 516, 'Metoclopramide', 'Gastrointestinal Diseases', 'The use of metoclopramide is contraindicated in patients with conditions where stimulation of gastrointestinal motility might be harmful, such as mechanical bowel obstruction, bowel perforation, or gastrointestinal hemorrhage.', '3', '"Product Information. Reglan (metoclopramide)." Wyeth-Ayerst Laboratories  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7502, 2797, 'Metoclopramide', 'Gastrointestinal Diseases', 'The use of metoclopramide is contraindicated in patients with conditions where stimulation of gastrointestinal motility might be harmful, such as mechanical bowel obstruction, bowel perforation, or gastrointestinal hemorrhage.', '3', '"Product Information. Reglan (metoclopramide)." Wyeth-Ayerst Laboratories  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7503, 7824, 'Metoclopramide', 'Gastrointestinal Diseases', 'The use of metoclopramide is contraindicated in patients with conditions where stimulation of gastrointestinal motility might be harmful, such as mechanical bowel obstruction, bowel perforation, or gastrointestinal hemorrhage.', '3', '"Product Information. Reglan (metoclopramide)." Wyeth-Ayerst Laboratories  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7504, 7825, 'Metoclopramide', 'Gastrointestinal Diseases', 'The use of metoclopramide is contraindicated in patients with conditions where stimulation of gastrointestinal motility might be harmful, such as mechanical bowel obstruction, bowel perforation, or gastrointestinal hemorrhage.', '3', '"Product Information. Reglan (metoclopramide)." Wyeth-Ayerst Laboratories  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7505, 7826, 'Metoclopramide', 'Gastrointestinal Diseases', 'The use of metoclopramide is contraindicated in patients with conditions where stimulation of gastrointestinal motility might be harmful, such as mechanical bowel obstruction, bowel perforation, or gastrointestinal hemorrhage.', '3', '"Product Information. Reglan (metoclopramide)." Wyeth-Ayerst Laboratories  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7506, 7827, 'Metoclopramide', 'Gastrointestinal Diseases', 'The use of metoclopramide is contraindicated in patients with conditions where stimulation of gastrointestinal motility might be harmful, such as mechanical bowel obstruction, bowel perforation, or gastrointestinal hemorrhage.', '3', '"Product Information. Reglan (metoclopramide)." Wyeth-Ayerst Laboratories  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7507, 7828, 'Metoclopramide', 'Gastrointestinal Diseases', 'The use of metoclopramide is contraindicated in patients with conditions where stimulation of gastrointestinal motility might be harmful, such as mechanical bowel obstruction, bowel perforation, or gastrointestinal hemorrhage.', '3', '"Product Information. Reglan (metoclopramide)." Wyeth-Ayerst Laboratories  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7508, 8097, 'Metoclopramide', 'Gastrointestinal Diseases', 'The use of metoclopramide is contraindicated in patients with conditions where stimulation of gastrointestinal motility might be harmful, such as mechanical bowel obstruction, bowel perforation, or gastrointestinal hemorrhage.', '3', '"Product Information. Reglan (metoclopramide)." Wyeth-Ayerst Laboratories  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7509, 25000, 'Metoclopramide', 'Gastrointestinal Diseases', 'The use of metoclopramide is contraindicated in patients with conditions where stimulation of gastrointestinal motility might be harmful, such as mechanical bowel obstruction, bowel perforation, or gastrointestinal hemorrhage.', '3', '"Product Information. Reglan (metoclopramide)." Wyeth-Ayerst Laboratories  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7510, 25001, 'Metoclopramide', 'Gastrointestinal Diseases', 'The use of metoclopramide is contraindicated in patients with conditions where stimulation of gastrointestinal motility might be harmful, such as mechanical bowel obstruction, bowel perforation, or gastrointestinal hemorrhage.', '3', '"Product Information. Reglan (metoclopramide)." Wyeth-Ayerst Laboratories  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7511, 25002, 'Metoclopramide', 'Gastrointestinal Diseases', 'The use of metoclopramide is contraindicated in patients with conditions where stimulation of gastrointestinal motility might be harmful, such as mechanical bowel obstruction, bowel perforation, or gastrointestinal hemorrhage.', '3', '"Product Information. Reglan (metoclopramide)." Wyeth-Ayerst Laboratories  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7512, 25257, 'Metoclopramide', 'Gastrointestinal Diseases', 'The use of metoclopramide is contraindicated in patients with conditions where stimulation of gastrointestinal motility might be harmful, such as mechanical bowel obstruction, bowel perforation, or gastrointestinal hemorrhage.', '3', '"Product Information. Reglan (metoclopramide)." Wyeth-Ayerst Laboratories  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7513, 25259, 'Metoclopramide', 'Gastrointestinal Diseases', 'The use of metoclopramide is contraindicated in patients with conditions where stimulation of gastrointestinal motility might be harmful, such as mechanical bowel obstruction, bowel perforation, or gastrointestinal hemorrhage.', '3', '"Product Information. Reglan (metoclopramide)." Wyeth-Ayerst Laboratories  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7514, 25261, 'Metoclopramide', 'Gastrointestinal Diseases', 'The use of metoclopramide is contraindicated in patients with conditions where stimulation of gastrointestinal motility might be harmful, such as mechanical bowel obstruction, bowel perforation, or gastrointestinal hemorrhage.', '3', '"Product Information. Reglan (metoclopramide)." Wyeth-Ayerst Laboratories  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7515, 27683, 'Metoclopramide', 'Gastrointestinal Diseases', 'The use of metoclopramide is contraindicated in patients with conditions where stimulation of gastrointestinal motility might be harmful, such as mechanical bowel obstruction, bowel perforation, or gastrointestinal hemorrhage.', '3', '"Product Information. Reglan (metoclopramide)." Wyeth-Ayerst Laboratories  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7516, 29582, 'Metoclopramide', 'Gastrointestinal Diseases', 'The use of metoclopramide is contraindicated in patients with conditions where stimulation of gastrointestinal motility might be harmful, such as mechanical bowel obstruction, bowel perforation, or gastrointestinal hemorrhage.', '3', '"Product Information. Reglan (metoclopramide)." Wyeth-Ayerst Laboratories  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7517, 29583, 'Metoclopramide', 'Gastrointestinal Diseases', 'The use of metoclopramide is contraindicated in patients with conditions where stimulation of gastrointestinal motility might be harmful, such as mechanical bowel obstruction, bowel perforation, or gastrointestinal hemorrhage.', '3', '"Product Information. Reglan (metoclopramide)." Wyeth-Ayerst Laboratories  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7518, 516, 'Metoclopramide', 'Neuroleptic Malignant Syndrome', 'Although not a neuroleptic agent, metoclopramide has antidopaminergic effects and may rarely precipitate or aggravate a potentially fatal symptom complex known as Neuroleptic Malignant Syndrome (NMS).  Clinical manifestations of NMS include hyperpyrexia, muscle rigidity, involuntary movements, altered mental status and autonomic instability (irregular pulse or blood pressure, tachycardia, diaphoresis and cardiac arrhythmias).  Metoclopramide therapy should not be initiated in patients with active NMS and should be immediately discontinued if currently being administered in such patients.  In patients with a history of NMS, introduction or reintroduction of metoclopramide or other antidopaminergic therapy should be carefully considered, since NMS may recur.', '3', 'Henderson A, Longdon P "Fulminant metoclopramide induced neuroleptic malignant syndrome rapidly responsive to intravenous dantrolene." Aust N Z J Med 21 (1991):  742-3|Friedman LS, Weinrauch LA, D''Elia JA "Metoclopramide-induced neuroleptic malignant syndrome." Arch Intern Med 147 (1987):  1495-7|Cassidy T, Bansal SK "Neuroleptic malignant syndrome associated with metoclopramide." Br Med J (Clin Res Ed) 296 (1988):  214|Patterson JF "Neuroleptic malignant syndrome associated with metoclopramide." South Med J 81 (1988):  674-5|Donnet A, Harle JR, Dumont JC, Alif Cherif A "Neuroleptic malignant syndrome induced by metoclopramide." Biomed Pharmacother 45 (1991):  461-2|Bakri YN, Khan R, Subhi J, Kawi Z "Neuroleptic malignant syndrome associated with metoclopramide antiemetic therapy." Gynecol Oncol 44 (1992):  189-90|"Product Information. Reglan (metoclopramide)." Wyeth-Ayerst Laboratories  (2001):|Shintani S, Shiigai T, Tsuchiya K, Kikuchi M "Hyperventilation alternating with apnea in neuroleptic malignant syndrome associated with metoclopramide and cisapride." J Neurol Sci 128 (1995):  232-3|Brower RD, Dreyer CF, Kent TA "Neuroleptic malignant syndrome in a child treated with metoclopramide for chemotherapy-related nausea." J Child Neurol 4 (1989):  230-2|Patel P, Bristow G "Postoperative neuroleptic malignant syndrome. A case report." Can J Anaesth 34 (1987):  515-8|Nonino F "Neuroleptic malignant syndrome associated with metoclopramide." Ann Pharmacother 33 (1999):  644-5', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7519, 2797, 'Metoclopramide', 'Neuroleptic Malignant Syndrome', 'Although not a neuroleptic agent, metoclopramide has antidopaminergic effects and may rarely precipitate or aggravate a potentially fatal symptom complex known as Neuroleptic Malignant Syndrome (NMS).  Clinical manifestations of NMS include hyperpyrexia, muscle rigidity, involuntary movements, altered mental status and autonomic instability (irregular pulse or blood pressure, tachycardia, diaphoresis and cardiac arrhythmias).  Metoclopramide therapy should not be initiated in patients with active NMS and should be immediately discontinued if currently being administered in such patients.  In patients with a history of NMS, introduction or reintroduction of metoclopramide or other antidopaminergic therapy should be carefully considered, since NMS may recur.', '3', 'Henderson A, Longdon P "Fulminant metoclopramide induced neuroleptic malignant syndrome rapidly responsive to intravenous dantrolene." Aust N Z J Med 21 (1991):  742-3|Friedman LS, Weinrauch LA, D''Elia JA "Metoclopramide-induced neuroleptic malignant syndrome." Arch Intern Med 147 (1987):  1495-7|Cassidy T, Bansal SK "Neuroleptic malignant syndrome associated with metoclopramide." Br Med J (Clin Res Ed) 296 (1988):  214|Patterson JF "Neuroleptic malignant syndrome associated with metoclopramide." South Med J 81 (1988):  674-5|Donnet A, Harle JR, Dumont JC, Alif Cherif A "Neuroleptic malignant syndrome induced by metoclopramide." Biomed Pharmacother 45 (1991):  461-2|Bakri YN, Khan R, Subhi J, Kawi Z "Neuroleptic malignant syndrome associated with metoclopramide antiemetic therapy." Gynecol Oncol 44 (1992):  189-90|"Product Information. Reglan (metoclopramide)." Wyeth-Ayerst Laboratories  (2001):|Shintani S, Shiigai T, Tsuchiya K, Kikuchi M "Hyperventilation alternating with apnea in neuroleptic malignant syndrome associated with metoclopramide and cisapride." J Neurol Sci 128 (1995):  232-3|Brower RD, Dreyer CF, Kent TA "Neuroleptic malignant syndrome in a child treated with metoclopramide for chemotherapy-related nausea." J Child Neurol 4 (1989):  230-2|Patel P, Bristow G "Postoperative neuroleptic malignant syndrome. A case report." Can J Anaesth 34 (1987):  515-8|Nonino F "Neuroleptic malignant syndrome associated with metoclopramide." Ann Pharmacother 33 (1999):  644-5', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7520, 7824, 'Metoclopramide', 'Neuroleptic Malignant Syndrome', 'Although not a neuroleptic agent, metoclopramide has antidopaminergic effects and may rarely precipitate or aggravate a potentially fatal symptom complex known as Neuroleptic Malignant Syndrome (NMS).  Clinical manifestations of NMS include hyperpyrexia, muscle rigidity, involuntary movements, altered mental status and autonomic instability (irregular pulse or blood pressure, tachycardia, diaphoresis and cardiac arrhythmias).  Metoclopramide therapy should not be initiated in patients with active NMS and should be immediately discontinued if currently being administered in such patients.  In patients with a history of NMS, introduction or reintroduction of metoclopramide or other antidopaminergic therapy should be carefully considered, since NMS may recur.', '3', 'Henderson A, Longdon P "Fulminant metoclopramide induced neuroleptic malignant syndrome rapidly responsive to intravenous dantrolene." Aust N Z J Med 21 (1991):  742-3|Friedman LS, Weinrauch LA, D''Elia JA "Metoclopramide-induced neuroleptic malignant syndrome." Arch Intern Med 147 (1987):  1495-7|Cassidy T, Bansal SK "Neuroleptic malignant syndrome associated with metoclopramide." Br Med J (Clin Res Ed) 296 (1988):  214|Patterson JF "Neuroleptic malignant syndrome associated with metoclopramide." South Med J 81 (1988):  674-5|Donnet A, Harle JR, Dumont JC, Alif Cherif A "Neuroleptic malignant syndrome induced by metoclopramide." Biomed Pharmacother 45 (1991):  461-2|Bakri YN, Khan R, Subhi J, Kawi Z "Neuroleptic malignant syndrome associated with metoclopramide antiemetic therapy." Gynecol Oncol 44 (1992):  189-90|"Product Information. Reglan (metoclopramide)." Wyeth-Ayerst Laboratories  (2001):|Shintani S, Shiigai T, Tsuchiya K, Kikuchi M "Hyperventilation alternating with apnea in neuroleptic malignant syndrome associated with metoclopramide and cisapride." J Neurol Sci 128 (1995):  232-3|Brower RD, Dreyer CF, Kent TA "Neuroleptic malignant syndrome in a child treated with metoclopramide for chemotherapy-related nausea." J Child Neurol 4 (1989):  230-2|Patel P, Bristow G "Postoperative neuroleptic malignant syndrome. A case report." Can J Anaesth 34 (1987):  515-8|Nonino F "Neuroleptic malignant syndrome associated with metoclopramide." Ann Pharmacother 33 (1999):  644-5', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7521, 7825, 'Metoclopramide', 'Neuroleptic Malignant Syndrome', 'Although not a neuroleptic agent, metoclopramide has antidopaminergic effects and may rarely precipitate or aggravate a potentially fatal symptom complex known as Neuroleptic Malignant Syndrome (NMS).  Clinical manifestations of NMS include hyperpyrexia, muscle rigidity, involuntary movements, altered mental status and autonomic instability (irregular pulse or blood pressure, tachycardia, diaphoresis and cardiac arrhythmias).  Metoclopramide therapy should not be initiated in patients with active NMS and should be immediately discontinued if currently being administered in such patients.  In patients with a history of NMS, introduction or reintroduction of metoclopramide or other antidopaminergic therapy should be carefully considered, since NMS may recur.', '3', 'Henderson A, Longdon P "Fulminant metoclopramide induced neuroleptic malignant syndrome rapidly responsive to intravenous dantrolene." Aust N Z J Med 21 (1991):  742-3|Friedman LS, Weinrauch LA, D''Elia JA "Metoclopramide-induced neuroleptic malignant syndrome." Arch Intern Med 147 (1987):  1495-7|Cassidy T, Bansal SK "Neuroleptic malignant syndrome associated with metoclopramide." Br Med J (Clin Res Ed) 296 (1988):  214|Patterson JF "Neuroleptic malignant syndrome associated with metoclopramide." South Med J 81 (1988):  674-5|Donnet A, Harle JR, Dumont JC, Alif Cherif A "Neuroleptic malignant syndrome induced by metoclopramide." Biomed Pharmacother 45 (1991):  461-2|Bakri YN, Khan R, Subhi J, Kawi Z "Neuroleptic malignant syndrome associated with metoclopramide antiemetic therapy." Gynecol Oncol 44 (1992):  189-90|"Product Information. Reglan (metoclopramide)." Wyeth-Ayerst Laboratories  (2001):|Shintani S, Shiigai T, Tsuchiya K, Kikuchi M "Hyperventilation alternating with apnea in neuroleptic malignant syndrome associated with metoclopramide and cisapride." J Neurol Sci 128 (1995):  232-3|Brower RD, Dreyer CF, Kent TA "Neuroleptic malignant syndrome in a child treated with metoclopramide for chemotherapy-related nausea." J Child Neurol 4 (1989):  230-2|Patel P, Bristow G "Postoperative neuroleptic malignant syndrome. A case report." Can J Anaesth 34 (1987):  515-8|Nonino F "Neuroleptic malignant syndrome associated with metoclopramide." Ann Pharmacother 33 (1999):  644-5', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7522, 7826, 'Metoclopramide', 'Neuroleptic Malignant Syndrome', 'Although not a neuroleptic agent, metoclopramide has antidopaminergic effects and may rarely precipitate or aggravate a potentially fatal symptom complex known as Neuroleptic Malignant Syndrome (NMS).  Clinical manifestations of NMS include hyperpyrexia, muscle rigidity, involuntary movements, altered mental status and autonomic instability (irregular pulse or blood pressure, tachycardia, diaphoresis and cardiac arrhythmias).  Metoclopramide therapy should not be initiated in patients with active NMS and should be immediately discontinued if currently being administered in such patients.  In patients with a history of NMS, introduction or reintroduction of metoclopramide or other antidopaminergic therapy should be carefully considered, since NMS may recur.', '3', 'Henderson A, Longdon P "Fulminant metoclopramide induced neuroleptic malignant syndrome rapidly responsive to intravenous dantrolene." Aust N Z J Med 21 (1991):  742-3|Friedman LS, Weinrauch LA, D''Elia JA "Metoclopramide-induced neuroleptic malignant syndrome." Arch Intern Med 147 (1987):  1495-7|Cassidy T, Bansal SK "Neuroleptic malignant syndrome associated with metoclopramide." Br Med J (Clin Res Ed) 296 (1988):  214|Patterson JF "Neuroleptic malignant syndrome associated with metoclopramide." South Med J 81 (1988):  674-5|Donnet A, Harle JR, Dumont JC, Alif Cherif A "Neuroleptic malignant syndrome induced by metoclopramide." Biomed Pharmacother 45 (1991):  461-2|Bakri YN, Khan R, Subhi J, Kawi Z "Neuroleptic malignant syndrome associated with metoclopramide antiemetic therapy." Gynecol Oncol 44 (1992):  189-90|"Product Information. Reglan (metoclopramide)." Wyeth-Ayerst Laboratories  (2001):|Shintani S, Shiigai T, Tsuchiya K, Kikuchi M "Hyperventilation alternating with apnea in neuroleptic malignant syndrome associated with metoclopramide and cisapride." J Neurol Sci 128 (1995):  232-3|Brower RD, Dreyer CF, Kent TA "Neuroleptic malignant syndrome in a child treated with metoclopramide for chemotherapy-related nausea." J Child Neurol 4 (1989):  230-2|Patel P, Bristow G "Postoperative neuroleptic malignant syndrome. A case report." Can J Anaesth 34 (1987):  515-8|Nonino F "Neuroleptic malignant syndrome associated with metoclopramide." Ann Pharmacother 33 (1999):  644-5', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7523, 7827, 'Metoclopramide', 'Neuroleptic Malignant Syndrome', 'Although not a neuroleptic agent, metoclopramide has antidopaminergic effects and may rarely precipitate or aggravate a potentially fatal symptom complex known as Neuroleptic Malignant Syndrome (NMS).  Clinical manifestations of NMS include hyperpyrexia, muscle rigidity, involuntary movements, altered mental status and autonomic instability (irregular pulse or blood pressure, tachycardia, diaphoresis and cardiac arrhythmias).  Metoclopramide therapy should not be initiated in patients with active NMS and should be immediately discontinued if currently being administered in such patients.  In patients with a history of NMS, introduction or reintroduction of metoclopramide or other antidopaminergic therapy should be carefully considered, since NMS may recur.', '3', 'Henderson A, Longdon P "Fulminant metoclopramide induced neuroleptic malignant syndrome rapidly responsive to intravenous dantrolene." Aust N Z J Med 21 (1991):  742-3|Friedman LS, Weinrauch LA, D''Elia JA "Metoclopramide-induced neuroleptic malignant syndrome." Arch Intern Med 147 (1987):  1495-7|Cassidy T, Bansal SK "Neuroleptic malignant syndrome associated with metoclopramide." Br Med J (Clin Res Ed) 296 (1988):  214|Patterson JF "Neuroleptic malignant syndrome associated with metoclopramide." South Med J 81 (1988):  674-5|Donnet A, Harle JR, Dumont JC, Alif Cherif A "Neuroleptic malignant syndrome induced by metoclopramide." Biomed Pharmacother 45 (1991):  461-2|Bakri YN, Khan R, Subhi J, Kawi Z "Neuroleptic malignant syndrome associated with metoclopramide antiemetic therapy." Gynecol Oncol 44 (1992):  189-90|"Product Information. Reglan (metoclopramide)." Wyeth-Ayerst Laboratories  (2001):|Shintani S, Shiigai T, Tsuchiya K, Kikuchi M "Hyperventilation alternating with apnea in neuroleptic malignant syndrome associated with metoclopramide and cisapride." J Neurol Sci 128 (1995):  232-3|Brower RD, Dreyer CF, Kent TA "Neuroleptic malignant syndrome in a child treated with metoclopramide for chemotherapy-related nausea." J Child Neurol 4 (1989):  230-2|Patel P, Bristow G "Postoperative neuroleptic malignant syndrome. A case report." Can J Anaesth 34 (1987):  515-8|Nonino F "Neuroleptic malignant syndrome associated with metoclopramide." Ann Pharmacother 33 (1999):  644-5', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7524, 7828, 'Metoclopramide', 'Neuroleptic Malignant Syndrome', 'Although not a neuroleptic agent, metoclopramide has antidopaminergic effects and may rarely precipitate or aggravate a potentially fatal symptom complex known as Neuroleptic Malignant Syndrome (NMS).  Clinical manifestations of NMS include hyperpyrexia, muscle rigidity, involuntary movements, altered mental status and autonomic instability (irregular pulse or blood pressure, tachycardia, diaphoresis and cardiac arrhythmias).  Metoclopramide therapy should not be initiated in patients with active NMS and should be immediately discontinued if currently being administered in such patients.  In patients with a history of NMS, introduction or reintroduction of metoclopramide or other antidopaminergic therapy should be carefully considered, since NMS may recur.', '3', 'Henderson A, Longdon P "Fulminant metoclopramide induced neuroleptic malignant syndrome rapidly responsive to intravenous dantrolene." Aust N Z J Med 21 (1991):  742-3|Friedman LS, Weinrauch LA, D''Elia JA "Metoclopramide-induced neuroleptic malignant syndrome." Arch Intern Med 147 (1987):  1495-7|Cassidy T, Bansal SK "Neuroleptic malignant syndrome associated with metoclopramide." Br Med J (Clin Res Ed) 296 (1988):  214|Patterson JF "Neuroleptic malignant syndrome associated with metoclopramide." South Med J 81 (1988):  674-5|Donnet A, Harle JR, Dumont JC, Alif Cherif A "Neuroleptic malignant syndrome induced by metoclopramide." Biomed Pharmacother 45 (1991):  461-2|Bakri YN, Khan R, Subhi J, Kawi Z "Neuroleptic malignant syndrome associated with metoclopramide antiemetic therapy." Gynecol Oncol 44 (1992):  189-90|"Product Information. Reglan (metoclopramide)." Wyeth-Ayerst Laboratories  (2001):|Shintani S, Shiigai T, Tsuchiya K, Kikuchi M "Hyperventilation alternating with apnea in neuroleptic malignant syndrome associated with metoclopramide and cisapride." J Neurol Sci 128 (1995):  232-3|Brower RD, Dreyer CF, Kent TA "Neuroleptic malignant syndrome in a child treated with metoclopramide for chemotherapy-related nausea." J Child Neurol 4 (1989):  230-2|Patel P, Bristow G "Postoperative neuroleptic malignant syndrome. A case report." Can J Anaesth 34 (1987):  515-8|Nonino F "Neuroleptic malignant syndrome associated with metoclopramide." Ann Pharmacother 33 (1999):  644-5', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7525, 8097, 'Metoclopramide', 'Neuroleptic Malignant Syndrome', 'Although not a neuroleptic agent, metoclopramide has antidopaminergic effects and may rarely precipitate or aggravate a potentially fatal symptom complex known as Neuroleptic Malignant Syndrome (NMS).  Clinical manifestations of NMS include hyperpyrexia, muscle rigidity, involuntary movements, altered mental status and autonomic instability (irregular pulse or blood pressure, tachycardia, diaphoresis and cardiac arrhythmias).  Metoclopramide therapy should not be initiated in patients with active NMS and should be immediately discontinued if currently being administered in such patients.  In patients with a history of NMS, introduction or reintroduction of metoclopramide or other antidopaminergic therapy should be carefully considered, since NMS may recur.', '3', 'Henderson A, Longdon P "Fulminant metoclopramide induced neuroleptic malignant syndrome rapidly responsive to intravenous dantrolene." Aust N Z J Med 21 (1991):  742-3|Friedman LS, Weinrauch LA, D''Elia JA "Metoclopramide-induced neuroleptic malignant syndrome." Arch Intern Med 147 (1987):  1495-7|Cassidy T, Bansal SK "Neuroleptic malignant syndrome associated with metoclopramide." Br Med J (Clin Res Ed) 296 (1988):  214|Patterson JF "Neuroleptic malignant syndrome associated with metoclopramide." South Med J 81 (1988):  674-5|Donnet A, Harle JR, Dumont JC, Alif Cherif A "Neuroleptic malignant syndrome induced by metoclopramide." Biomed Pharmacother 45 (1991):  461-2|Bakri YN, Khan R, Subhi J, Kawi Z "Neuroleptic malignant syndrome associated with metoclopramide antiemetic therapy." Gynecol Oncol 44 (1992):  189-90|"Product Information. Reglan (metoclopramide)." Wyeth-Ayerst Laboratories  (2001):|Shintani S, Shiigai T, Tsuchiya K, Kikuchi M "Hyperventilation alternating with apnea in neuroleptic malignant syndrome associated with metoclopramide and cisapride." J Neurol Sci 128 (1995):  232-3|Brower RD, Dreyer CF, Kent TA "Neuroleptic malignant syndrome in a child treated with metoclopramide for chemotherapy-related nausea." J Child Neurol 4 (1989):  230-2|Patel P, Bristow G "Postoperative neuroleptic malignant syndrome. A case report." Can J Anaesth 34 (1987):  515-8|Nonino F "Neuroleptic malignant syndrome associated with metoclopramide." Ann Pharmacother 33 (1999):  644-5', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7526, 25000, 'Metoclopramide', 'Neuroleptic Malignant Syndrome', 'Although not a neuroleptic agent, metoclopramide has antidopaminergic effects and may rarely precipitate or aggravate a potentially fatal symptom complex known as Neuroleptic Malignant Syndrome (NMS).  Clinical manifestations of NMS include hyperpyrexia, muscle rigidity, involuntary movements, altered mental status and autonomic instability (irregular pulse or blood pressure, tachycardia, diaphoresis and cardiac arrhythmias).  Metoclopramide therapy should not be initiated in patients with active NMS and should be immediately discontinued if currently being administered in such patients.  In patients with a history of NMS, introduction or reintroduction of metoclopramide or other antidopaminergic therapy should be carefully considered, since NMS may recur.', '3', 'Henderson A, Longdon P "Fulminant metoclopramide induced neuroleptic malignant syndrome rapidly responsive to intravenous dantrolene." Aust N Z J Med 21 (1991):  742-3|Friedman LS, Weinrauch LA, D''Elia JA "Metoclopramide-induced neuroleptic malignant syndrome." Arch Intern Med 147 (1987):  1495-7|Cassidy T, Bansal SK "Neuroleptic malignant syndrome associated with metoclopramide." Br Med J (Clin Res Ed) 296 (1988):  214|Patterson JF "Neuroleptic malignant syndrome associated with metoclopramide." South Med J 81 (1988):  674-5|Donnet A, Harle JR, Dumont JC, Alif Cherif A "Neuroleptic malignant syndrome induced by metoclopramide." Biomed Pharmacother 45 (1991):  461-2|Bakri YN, Khan R, Subhi J, Kawi Z "Neuroleptic malignant syndrome associated with metoclopramide antiemetic therapy." Gynecol Oncol 44 (1992):  189-90|"Product Information. Reglan (metoclopramide)." Wyeth-Ayerst Laboratories  (2001):|Shintani S, Shiigai T, Tsuchiya K, Kikuchi M "Hyperventilation alternating with apnea in neuroleptic malignant syndrome associated with metoclopramide and cisapride." J Neurol Sci 128 (1995):  232-3|Brower RD, Dreyer CF, Kent TA "Neuroleptic malignant syndrome in a child treated with metoclopramide for chemotherapy-related nausea." J Child Neurol 4 (1989):  230-2|Patel P, Bristow G "Postoperative neuroleptic malignant syndrome. A case report." Can J Anaesth 34 (1987):  515-8|Nonino F "Neuroleptic malignant syndrome associated with metoclopramide." Ann Pharmacother 33 (1999):  644-5', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7527, 25001, 'Metoclopramide', 'Neuroleptic Malignant Syndrome', 'Although not a neuroleptic agent, metoclopramide has antidopaminergic effects and may rarely precipitate or aggravate a potentially fatal symptom complex known as Neuroleptic Malignant Syndrome (NMS).  Clinical manifestations of NMS include hyperpyrexia, muscle rigidity, involuntary movements, altered mental status and autonomic instability (irregular pulse or blood pressure, tachycardia, diaphoresis and cardiac arrhythmias).  Metoclopramide therapy should not be initiated in patients with active NMS and should be immediately discontinued if currently being administered in such patients.  In patients with a history of NMS, introduction or reintroduction of metoclopramide or other antidopaminergic therapy should be carefully considered, since NMS may recur.', '3', 'Henderson A, Longdon P "Fulminant metoclopramide induced neuroleptic malignant syndrome rapidly responsive to intravenous dantrolene." Aust N Z J Med 21 (1991):  742-3|Friedman LS, Weinrauch LA, D''Elia JA "Metoclopramide-induced neuroleptic malignant syndrome." Arch Intern Med 147 (1987):  1495-7|Cassidy T, Bansal SK "Neuroleptic malignant syndrome associated with metoclopramide." Br Med J (Clin Res Ed) 296 (1988):  214|Patterson JF "Neuroleptic malignant syndrome associated with metoclopramide." South Med J 81 (1988):  674-5|Donnet A, Harle JR, Dumont JC, Alif Cherif A "Neuroleptic malignant syndrome induced by metoclopramide." Biomed Pharmacother 45 (1991):  461-2|Bakri YN, Khan R, Subhi J, Kawi Z "Neuroleptic malignant syndrome associated with metoclopramide antiemetic therapy." Gynecol Oncol 44 (1992):  189-90|"Product Information. Reglan (metoclopramide)." Wyeth-Ayerst Laboratories  (2001):|Shintani S, Shiigai T, Tsuchiya K, Kikuchi M "Hyperventilation alternating with apnea in neuroleptic malignant syndrome associated with metoclopramide and cisapride." J Neurol Sci 128 (1995):  232-3|Brower RD, Dreyer CF, Kent TA "Neuroleptic malignant syndrome in a child treated with metoclopramide for chemotherapy-related nausea." J Child Neurol 4 (1989):  230-2|Patel P, Bristow G "Postoperative neuroleptic malignant syndrome. A case report." Can J Anaesth 34 (1987):  515-8|Nonino F "Neuroleptic malignant syndrome associated with metoclopramide." Ann Pharmacother 33 (1999):  644-5', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7528, 25002, 'Metoclopramide', 'Neuroleptic Malignant Syndrome', 'Although not a neuroleptic agent, metoclopramide has antidopaminergic effects and may rarely precipitate or aggravate a potentially fatal symptom complex known as Neuroleptic Malignant Syndrome (NMS).  Clinical manifestations of NMS include hyperpyrexia, muscle rigidity, involuntary movements, altered mental status and autonomic instability (irregular pulse or blood pressure, tachycardia, diaphoresis and cardiac arrhythmias).  Metoclopramide therapy should not be initiated in patients with active NMS and should be immediately discontinued if currently being administered in such patients.  In patients with a history of NMS, introduction or reintroduction of metoclopramide or other antidopaminergic therapy should be carefully considered, since NMS may recur.', '3', 'Henderson A, Longdon P "Fulminant metoclopramide induced neuroleptic malignant syndrome rapidly responsive to intravenous dantrolene." Aust N Z J Med 21 (1991):  742-3|Friedman LS, Weinrauch LA, D''Elia JA "Metoclopramide-induced neuroleptic malignant syndrome." Arch Intern Med 147 (1987):  1495-7|Cassidy T, Bansal SK "Neuroleptic malignant syndrome associated with metoclopramide." Br Med J (Clin Res Ed) 296 (1988):  214|Patterson JF "Neuroleptic malignant syndrome associated with metoclopramide." South Med J 81 (1988):  674-5|Donnet A, Harle JR, Dumont JC, Alif Cherif A "Neuroleptic malignant syndrome induced by metoclopramide." Biomed Pharmacother 45 (1991):  461-2|Bakri YN, Khan R, Subhi J, Kawi Z "Neuroleptic malignant syndrome associated with metoclopramide antiemetic therapy." Gynecol Oncol 44 (1992):  189-90|"Product Information. Reglan (metoclopramide)." Wyeth-Ayerst Laboratories  (2001):|Shintani S, Shiigai T, Tsuchiya K, Kikuchi M "Hyperventilation alternating with apnea in neuroleptic malignant syndrome associated with metoclopramide and cisapride." J Neurol Sci 128 (1995):  232-3|Brower RD, Dreyer CF, Kent TA "Neuroleptic malignant syndrome in a child treated with metoclopramide for chemotherapy-related nausea." J Child Neurol 4 (1989):  230-2|Patel P, Bristow G "Postoperative neuroleptic malignant syndrome. A case report." Can J Anaesth 34 (1987):  515-8|Nonino F "Neuroleptic malignant syndrome associated with metoclopramide." Ann Pharmacother 33 (1999):  644-5', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7529, 25257, 'Metoclopramide', 'Neuroleptic Malignant Syndrome', 'Although not a neuroleptic agent, metoclopramide has antidopaminergic effects and may rarely precipitate or aggravate a potentially fatal symptom complex known as Neuroleptic Malignant Syndrome (NMS).  Clinical manifestations of NMS include hyperpyrexia, muscle rigidity, involuntary movements, altered mental status and autonomic instability (irregular pulse or blood pressure, tachycardia, diaphoresis and cardiac arrhythmias).  Metoclopramide therapy should not be initiated in patients with active NMS and should be immediately discontinued if currently being administered in such patients.  In patients with a history of NMS, introduction or reintroduction of metoclopramide or other antidopaminergic therapy should be carefully considered, since NMS may recur.', '3', 'Henderson A, Longdon P "Fulminant metoclopramide induced neuroleptic malignant syndrome rapidly responsive to intravenous dantrolene." Aust N Z J Med 21 (1991):  742-3|Friedman LS, Weinrauch LA, D''Elia JA "Metoclopramide-induced neuroleptic malignant syndrome." Arch Intern Med 147 (1987):  1495-7|Cassidy T, Bansal SK "Neuroleptic malignant syndrome associated with metoclopramide." Br Med J (Clin Res Ed) 296 (1988):  214|Patterson JF "Neuroleptic malignant syndrome associated with metoclopramide." South Med J 81 (1988):  674-5|Donnet A, Harle JR, Dumont JC, Alif Cherif A "Neuroleptic malignant syndrome induced by metoclopramide." Biomed Pharmacother 45 (1991):  461-2|Bakri YN, Khan R, Subhi J, Kawi Z "Neuroleptic malignant syndrome associated with metoclopramide antiemetic therapy." Gynecol Oncol 44 (1992):  189-90|"Product Information. Reglan (metoclopramide)." Wyeth-Ayerst Laboratories  (2001):|Shintani S, Shiigai T, Tsuchiya K, Kikuchi M "Hyperventilation alternating with apnea in neuroleptic malignant syndrome associated with metoclopramide and cisapride." J Neurol Sci 128 (1995):  232-3|Brower RD, Dreyer CF, Kent TA "Neuroleptic malignant syndrome in a child treated with metoclopramide for chemotherapy-related nausea." J Child Neurol 4 (1989):  230-2|Patel P, Bristow G "Postoperative neuroleptic malignant syndrome. A case report." Can J Anaesth 34 (1987):  515-8|Nonino F "Neuroleptic malignant syndrome associated with metoclopramide." Ann Pharmacother 33 (1999):  644-5', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7530, 25259, 'Metoclopramide', 'Neuroleptic Malignant Syndrome', 'Although not a neuroleptic agent, metoclopramide has antidopaminergic effects and may rarely precipitate or aggravate a potentially fatal symptom complex known as Neuroleptic Malignant Syndrome (NMS).  Clinical manifestations of NMS include hyperpyrexia, muscle rigidity, involuntary movements, altered mental status and autonomic instability (irregular pulse or blood pressure, tachycardia, diaphoresis and cardiac arrhythmias).  Metoclopramide therapy should not be initiated in patients with active NMS and should be immediately discontinued if currently being administered in such patients.  In patients with a history of NMS, introduction or reintroduction of metoclopramide or other antidopaminergic therapy should be carefully considered, since NMS may recur.', '3', 'Henderson A, Longdon P "Fulminant metoclopramide induced neuroleptic malignant syndrome rapidly responsive to intravenous dantrolene." Aust N Z J Med 21 (1991):  742-3|Friedman LS, Weinrauch LA, D''Elia JA "Metoclopramide-induced neuroleptic malignant syndrome." Arch Intern Med 147 (1987):  1495-7|Cassidy T, Bansal SK "Neuroleptic malignant syndrome associated with metoclopramide." Br Med J (Clin Res Ed) 296 (1988):  214|Patterson JF "Neuroleptic malignant syndrome associated with metoclopramide." South Med J 81 (1988):  674-5|Donnet A, Harle JR, Dumont JC, Alif Cherif A "Neuroleptic malignant syndrome induced by metoclopramide." Biomed Pharmacother 45 (1991):  461-2|Bakri YN, Khan R, Subhi J, Kawi Z "Neuroleptic malignant syndrome associated with metoclopramide antiemetic therapy." Gynecol Oncol 44 (1992):  189-90|"Product Information. Reglan (metoclopramide)." Wyeth-Ayerst Laboratories  (2001):|Shintani S, Shiigai T, Tsuchiya K, Kikuchi M "Hyperventilation alternating with apnea in neuroleptic malignant syndrome associated with metoclopramide and cisapride." J Neurol Sci 128 (1995):  232-3|Brower RD, Dreyer CF, Kent TA "Neuroleptic malignant syndrome in a child treated with metoclopramide for chemotherapy-related nausea." J Child Neurol 4 (1989):  230-2|Patel P, Bristow G "Postoperative neuroleptic malignant syndrome. A case report." Can J Anaesth 34 (1987):  515-8|Nonino F "Neuroleptic malignant syndrome associated with metoclopramide." Ann Pharmacother 33 (1999):  644-5', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7531, 25261, 'Metoclopramide', 'Neuroleptic Malignant Syndrome', 'Although not a neuroleptic agent, metoclopramide has antidopaminergic effects and may rarely precipitate or aggravate a potentially fatal symptom complex known as Neuroleptic Malignant Syndrome (NMS).  Clinical manifestations of NMS include hyperpyrexia, muscle rigidity, involuntary movements, altered mental status and autonomic instability (irregular pulse or blood pressure, tachycardia, diaphoresis and cardiac arrhythmias).  Metoclopramide therapy should not be initiated in patients with active NMS and should be immediately discontinued if currently being administered in such patients.  In patients with a history of NMS, introduction or reintroduction of metoclopramide or other antidopaminergic therapy should be carefully considered, since NMS may recur.', '3', 'Henderson A, Longdon P "Fulminant metoclopramide induced neuroleptic malignant syndrome rapidly responsive to intravenous dantrolene." Aust N Z J Med 21 (1991):  742-3|Friedman LS, Weinrauch LA, D''Elia JA "Metoclopramide-induced neuroleptic malignant syndrome." Arch Intern Med 147 (1987):  1495-7|Cassidy T, Bansal SK "Neuroleptic malignant syndrome associated with metoclopramide." Br Med J (Clin Res Ed) 296 (1988):  214|Patterson JF "Neuroleptic malignant syndrome associated with metoclopramide." South Med J 81 (1988):  674-5|Donnet A, Harle JR, Dumont JC, Alif Cherif A "Neuroleptic malignant syndrome induced by metoclopramide." Biomed Pharmacother 45 (1991):  461-2|Bakri YN, Khan R, Subhi J, Kawi Z "Neuroleptic malignant syndrome associated with metoclopramide antiemetic therapy." Gynecol Oncol 44 (1992):  189-90|"Product Information. Reglan (metoclopramide)." Wyeth-Ayerst Laboratories  (2001):|Shintani S, Shiigai T, Tsuchiya K, Kikuchi M "Hyperventilation alternating with apnea in neuroleptic malignant syndrome associated with metoclopramide and cisapride." J Neurol Sci 128 (1995):  232-3|Brower RD, Dreyer CF, Kent TA "Neuroleptic malignant syndrome in a child treated with metoclopramide for chemotherapy-related nausea." J Child Neurol 4 (1989):  230-2|Patel P, Bristow G "Postoperative neuroleptic malignant syndrome. A case report." Can J Anaesth 34 (1987):  515-8|Nonino F "Neuroleptic malignant syndrome associated with metoclopramide." Ann Pharmacother 33 (1999):  644-5', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7532, 27683, 'Metoclopramide', 'Neuroleptic Malignant Syndrome', 'Although not a neuroleptic agent, metoclopramide has antidopaminergic effects and may rarely precipitate or aggravate a potentially fatal symptom complex known as Neuroleptic Malignant Syndrome (NMS).  Clinical manifestations of NMS include hyperpyrexia, muscle rigidity, involuntary movements, altered mental status and autonomic instability (irregular pulse or blood pressure, tachycardia, diaphoresis and cardiac arrhythmias).  Metoclopramide therapy should not be initiated in patients with active NMS and should be immediately discontinued if currently being administered in such patients.  In patients with a history of NMS, introduction or reintroduction of metoclopramide or other antidopaminergic therapy should be carefully considered, since NMS may recur.', '3', 'Henderson A, Longdon P "Fulminant metoclopramide induced neuroleptic malignant syndrome rapidly responsive to intravenous dantrolene." Aust N Z J Med 21 (1991):  742-3|Friedman LS, Weinrauch LA, D''Elia JA "Metoclopramide-induced neuroleptic malignant syndrome." Arch Intern Med 147 (1987):  1495-7|Cassidy T, Bansal SK "Neuroleptic malignant syndrome associated with metoclopramide." Br Med J (Clin Res Ed) 296 (1988):  214|Patterson JF "Neuroleptic malignant syndrome associated with metoclopramide." South Med J 81 (1988):  674-5|Donnet A, Harle JR, Dumont JC, Alif Cherif A "Neuroleptic malignant syndrome induced by metoclopramide." Biomed Pharmacother 45 (1991):  461-2|Bakri YN, Khan R, Subhi J, Kawi Z "Neuroleptic malignant syndrome associated with metoclopramide antiemetic therapy." Gynecol Oncol 44 (1992):  189-90|"Product Information. Reglan (metoclopramide)." Wyeth-Ayerst Laboratories  (2001):|Shintani S, Shiigai T, Tsuchiya K, Kikuchi M "Hyperventilation alternating with apnea in neuroleptic malignant syndrome associated with metoclopramide and cisapride." J Neurol Sci 128 (1995):  232-3|Brower RD, Dreyer CF, Kent TA "Neuroleptic malignant syndrome in a child treated with metoclopramide for chemotherapy-related nausea." J Child Neurol 4 (1989):  230-2|Patel P, Bristow G "Postoperative neuroleptic malignant syndrome. A case report." Can J Anaesth 34 (1987):  515-8|Nonino F "Neuroleptic malignant syndrome associated with metoclopramide." Ann Pharmacother 33 (1999):  644-5', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7533, 29582, 'Metoclopramide', 'Neuroleptic Malignant Syndrome', 'Although not a neuroleptic agent, metoclopramide has antidopaminergic effects and may rarely precipitate or aggravate a potentially fatal symptom complex known as Neuroleptic Malignant Syndrome (NMS).  Clinical manifestations of NMS include hyperpyrexia, muscle rigidity, involuntary movements, altered mental status and autonomic instability (irregular pulse or blood pressure, tachycardia, diaphoresis and cardiac arrhythmias).  Metoclopramide therapy should not be initiated in patients with active NMS and should be immediately discontinued if currently being administered in such patients.  In patients with a history of NMS, introduction or reintroduction of metoclopramide or other antidopaminergic therapy should be carefully considered, since NMS may recur.', '3', 'Henderson A, Longdon P "Fulminant metoclopramide induced neuroleptic malignant syndrome rapidly responsive to intravenous dantrolene." Aust N Z J Med 21 (1991):  742-3|Friedman LS, Weinrauch LA, D''Elia JA "Metoclopramide-induced neuroleptic malignant syndrome." Arch Intern Med 147 (1987):  1495-7|Cassidy T, Bansal SK "Neuroleptic malignant syndrome associated with metoclopramide." Br Med J (Clin Res Ed) 296 (1988):  214|Patterson JF "Neuroleptic malignant syndrome associated with metoclopramide." South Med J 81 (1988):  674-5|Donnet A, Harle JR, Dumont JC, Alif Cherif A "Neuroleptic malignant syndrome induced by metoclopramide." Biomed Pharmacother 45 (1991):  461-2|Bakri YN, Khan R, Subhi J, Kawi Z "Neuroleptic malignant syndrome associated with metoclopramide antiemetic therapy." Gynecol Oncol 44 (1992):  189-90|"Product Information. Reglan (metoclopramide)." Wyeth-Ayerst Laboratories  (2001):|Shintani S, Shiigai T, Tsuchiya K, Kikuchi M "Hyperventilation alternating with apnea in neuroleptic malignant syndrome associated with metoclopramide and cisapride." J Neurol Sci 128 (1995):  232-3|Brower RD, Dreyer CF, Kent TA "Neuroleptic malignant syndrome in a child treated with metoclopramide for chemotherapy-related nausea." J Child Neurol 4 (1989):  230-2|Patel P, Bristow G "Postoperative neuroleptic malignant syndrome. A case report." Can J Anaesth 34 (1987):  515-8|Nonino F "Neuroleptic malignant syndrome associated with metoclopramide." Ann Pharmacother 33 (1999):  644-5', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7534, 29583, 'Metoclopramide', 'Neuroleptic Malignant Syndrome', 'Although not a neuroleptic agent, metoclopramide has antidopaminergic effects and may rarely precipitate or aggravate a potentially fatal symptom complex known as Neuroleptic Malignant Syndrome (NMS).  Clinical manifestations of NMS include hyperpyrexia, muscle rigidity, involuntary movements, altered mental status and autonomic instability (irregular pulse or blood pressure, tachycardia, diaphoresis and cardiac arrhythmias).  Metoclopramide therapy should not be initiated in patients with active NMS and should be immediately discontinued if currently being administered in such patients.  In patients with a history of NMS, introduction or reintroduction of metoclopramide or other antidopaminergic therapy should be carefully considered, since NMS may recur.', '3', 'Henderson A, Longdon P "Fulminant metoclopramide induced neuroleptic malignant syndrome rapidly responsive to intravenous dantrolene." Aust N Z J Med 21 (1991):  742-3|Friedman LS, Weinrauch LA, D''Elia JA "Metoclopramide-induced neuroleptic malignant syndrome." Arch Intern Med 147 (1987):  1495-7|Cassidy T, Bansal SK "Neuroleptic malignant syndrome associated with metoclopramide." Br Med J (Clin Res Ed) 296 (1988):  214|Patterson JF "Neuroleptic malignant syndrome associated with metoclopramide." South Med J 81 (1988):  674-5|Donnet A, Harle JR, Dumont JC, Alif Cherif A "Neuroleptic malignant syndrome induced by metoclopramide." Biomed Pharmacother 45 (1991):  461-2|Bakri YN, Khan R, Subhi J, Kawi Z "Neuroleptic malignant syndrome associated with metoclopramide antiemetic therapy." Gynecol Oncol 44 (1992):  189-90|"Product Information. Reglan (metoclopramide)." Wyeth-Ayerst Laboratories  (2001):|Shintani S, Shiigai T, Tsuchiya K, Kikuchi M "Hyperventilation alternating with apnea in neuroleptic malignant syndrome associated with metoclopramide and cisapride." J Neurol Sci 128 (1995):  232-3|Brower RD, Dreyer CF, Kent TA "Neuroleptic malignant syndrome in a child treated with metoclopramide for chemotherapy-related nausea." J Child Neurol 4 (1989):  230-2|Patel P, Bristow G "Postoperative neuroleptic malignant syndrome. A case report." Can J Anaesth 34 (1987):  515-8|Nonino F "Neuroleptic malignant syndrome associated with metoclopramide." Ann Pharmacother 33 (1999):  644-5', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7535, 516, 'Metoclopramide', 'Pheochromocytoma', 'The use of metoclopramide is contraindicated in patients with pheochromocytoma.  In a study involving patients with essential hypertension, intravenously administered metoclopramide was shown to induce the release of catecholamines.  Hypertensive crises may occur in patients with pheochromocytoma due to induction of catecholamine release from the tumor.', '3', 'Abe M, Orita Y, Nakashima Y, Nakamura M "Hypertensive crisis induced by metoclopramide in patient with pheochromocytoma." Angiology 35 (1984):  122-8|Filibeck DJ, Grimm D, Forman WB, Leidner BA "Metoclopramide-induced hypertensive crisis." Clin Pharm 3 (1984):  548-9|Agabiti-Rosei E, Aliccandri CL, Corea L "Hyperstensive crisis in patients with phaeochromocytoma given metoclopramide." Lancet 1 (1977):  600|Plouin PF, Menard J, Corval P "Hypertensive crisis in patient with phaeochromocytoma given metoclopramide." Lancet 2 (1976):  1357-8|"Product Information. Reglan (metoclopramide)." Wyeth-Ayerst Laboratories  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7536, 2797, 'Metoclopramide', 'Pheochromocytoma', 'The use of metoclopramide is contraindicated in patients with pheochromocytoma.  In a study involving patients with essential hypertension, intravenously administered metoclopramide was shown to induce the release of catecholamines.  Hypertensive crises may occur in patients with pheochromocytoma due to induction of catecholamine release from the tumor.', '3', 'Abe M, Orita Y, Nakashima Y, Nakamura M "Hypertensive crisis induced by metoclopramide in patient with pheochromocytoma." Angiology 35 (1984):  122-8|Filibeck DJ, Grimm D, Forman WB, Leidner BA "Metoclopramide-induced hypertensive crisis." Clin Pharm 3 (1984):  548-9|Agabiti-Rosei E, Aliccandri CL, Corea L "Hyperstensive crisis in patients with phaeochromocytoma given metoclopramide." Lancet 1 (1977):  600|Plouin PF, Menard J, Corval P "Hypertensive crisis in patient with phaeochromocytoma given metoclopramide." Lancet 2 (1976):  1357-8|"Product Information. Reglan (metoclopramide)." Wyeth-Ayerst Laboratories  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7537, 7824, 'Metoclopramide', 'Pheochromocytoma', 'The use of metoclopramide is contraindicated in patients with pheochromocytoma.  In a study involving patients with essential hypertension, intravenously administered metoclopramide was shown to induce the release of catecholamines.  Hypertensive crises may occur in patients with pheochromocytoma due to induction of catecholamine release from the tumor.', '3', 'Abe M, Orita Y, Nakashima Y, Nakamura M "Hypertensive crisis induced by metoclopramide in patient with pheochromocytoma." Angiology 35 (1984):  122-8|Filibeck DJ, Grimm D, Forman WB, Leidner BA "Metoclopramide-induced hypertensive crisis." Clin Pharm 3 (1984):  548-9|Agabiti-Rosei E, Aliccandri CL, Corea L "Hyperstensive crisis in patients with phaeochromocytoma given metoclopramide." Lancet 1 (1977):  600|Plouin PF, Menard J, Corval P "Hypertensive crisis in patient with phaeochromocytoma given metoclopramide." Lancet 2 (1976):  1357-8|"Product Information. Reglan (metoclopramide)." Wyeth-Ayerst Laboratories  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7538, 7825, 'Metoclopramide', 'Pheochromocytoma', 'The use of metoclopramide is contraindicated in patients with pheochromocytoma.  In a study involving patients with essential hypertension, intravenously administered metoclopramide was shown to induce the release of catecholamines.  Hypertensive crises may occur in patients with pheochromocytoma due to induction of catecholamine release from the tumor.', '3', 'Abe M, Orita Y, Nakashima Y, Nakamura M "Hypertensive crisis induced by metoclopramide in patient with pheochromocytoma." Angiology 35 (1984):  122-8|Filibeck DJ, Grimm D, Forman WB, Leidner BA "Metoclopramide-induced hypertensive crisis." Clin Pharm 3 (1984):  548-9|Agabiti-Rosei E, Aliccandri CL, Corea L "Hyperstensive crisis in patients with phaeochromocytoma given metoclopramide." Lancet 1 (1977):  600|Plouin PF, Menard J, Corval P "Hypertensive crisis in patient with phaeochromocytoma given metoclopramide." Lancet 2 (1976):  1357-8|"Product Information. Reglan (metoclopramide)." Wyeth-Ayerst Laboratories  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7539, 7826, 'Metoclopramide', 'Pheochromocytoma', 'The use of metoclopramide is contraindicated in patients with pheochromocytoma.  In a study involving patients with essential hypertension, intravenously administered metoclopramide was shown to induce the release of catecholamines.  Hypertensive crises may occur in patients with pheochromocytoma due to induction of catecholamine release from the tumor.', '3', 'Abe M, Orita Y, Nakashima Y, Nakamura M "Hypertensive crisis induced by metoclopramide in patient with pheochromocytoma." Angiology 35 (1984):  122-8|Filibeck DJ, Grimm D, Forman WB, Leidner BA "Metoclopramide-induced hypertensive crisis." Clin Pharm 3 (1984):  548-9|Agabiti-Rosei E, Aliccandri CL, Corea L "Hyperstensive crisis in patients with phaeochromocytoma given metoclopramide." Lancet 1 (1977):  600|Plouin PF, Menard J, Corval P "Hypertensive crisis in patient with phaeochromocytoma given metoclopramide." Lancet 2 (1976):  1357-8|"Product Information. Reglan (metoclopramide)." Wyeth-Ayerst Laboratories  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7540, 7827, 'Metoclopramide', 'Pheochromocytoma', 'The use of metoclopramide is contraindicated in patients with pheochromocytoma.  In a study involving patients with essential hypertension, intravenously administered metoclopramide was shown to induce the release of catecholamines.  Hypertensive crises may occur in patients with pheochromocytoma due to induction of catecholamine release from the tumor.', '3', 'Abe M, Orita Y, Nakashima Y, Nakamura M "Hypertensive crisis induced by metoclopramide in patient with pheochromocytoma." Angiology 35 (1984):  122-8|Filibeck DJ, Grimm D, Forman WB, Leidner BA "Metoclopramide-induced hypertensive crisis." Clin Pharm 3 (1984):  548-9|Agabiti-Rosei E, Aliccandri CL, Corea L "Hyperstensive crisis in patients with phaeochromocytoma given metoclopramide." Lancet 1 (1977):  600|Plouin PF, Menard J, Corval P "Hypertensive crisis in patient with phaeochromocytoma given metoclopramide." Lancet 2 (1976):  1357-8|"Product Information. Reglan (metoclopramide)." Wyeth-Ayerst Laboratories  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7541, 7828, 'Metoclopramide', 'Pheochromocytoma', 'The use of metoclopramide is contraindicated in patients with pheochromocytoma.  In a study involving patients with essential hypertension, intravenously administered metoclopramide was shown to induce the release of catecholamines.  Hypertensive crises may occur in patients with pheochromocytoma due to induction of catecholamine release from the tumor.', '3', 'Abe M, Orita Y, Nakashima Y, Nakamura M "Hypertensive crisis induced by metoclopramide in patient with pheochromocytoma." Angiology 35 (1984):  122-8|Filibeck DJ, Grimm D, Forman WB, Leidner BA "Metoclopramide-induced hypertensive crisis." Clin Pharm 3 (1984):  548-9|Agabiti-Rosei E, Aliccandri CL, Corea L "Hyperstensive crisis in patients with phaeochromocytoma given metoclopramide." Lancet 1 (1977):  600|Plouin PF, Menard J, Corval P "Hypertensive crisis in patient with phaeochromocytoma given metoclopramide." Lancet 2 (1976):  1357-8|"Product Information. Reglan (metoclopramide)." Wyeth-Ayerst Laboratories  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7542, 8097, 'Metoclopramide', 'Pheochromocytoma', 'The use of metoclopramide is contraindicated in patients with pheochromocytoma.  In a study involving patients with essential hypertension, intravenously administered metoclopramide was shown to induce the release of catecholamines.  Hypertensive crises may occur in patients with pheochromocytoma due to induction of catecholamine release from the tumor.', '3', 'Abe M, Orita Y, Nakashima Y, Nakamura M "Hypertensive crisis induced by metoclopramide in patient with pheochromocytoma." Angiology 35 (1984):  122-8|Filibeck DJ, Grimm D, Forman WB, Leidner BA "Metoclopramide-induced hypertensive crisis." Clin Pharm 3 (1984):  548-9|Agabiti-Rosei E, Aliccandri CL, Corea L "Hyperstensive crisis in patients with phaeochromocytoma given metoclopramide." Lancet 1 (1977):  600|Plouin PF, Menard J, Corval P "Hypertensive crisis in patient with phaeochromocytoma given metoclopramide." Lancet 2 (1976):  1357-8|"Product Information. Reglan (metoclopramide)." Wyeth-Ayerst Laboratories  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7543, 25000, 'Metoclopramide', 'Pheochromocytoma', 'The use of metoclopramide is contraindicated in patients with pheochromocytoma.  In a study involving patients with essential hypertension, intravenously administered metoclopramide was shown to induce the release of catecholamines.  Hypertensive crises may occur in patients with pheochromocytoma due to induction of catecholamine release from the tumor.', '3', 'Abe M, Orita Y, Nakashima Y, Nakamura M "Hypertensive crisis induced by metoclopramide in patient with pheochromocytoma." Angiology 35 (1984):  122-8|Filibeck DJ, Grimm D, Forman WB, Leidner BA "Metoclopramide-induced hypertensive crisis." Clin Pharm 3 (1984):  548-9|Agabiti-Rosei E, Aliccandri CL, Corea L "Hyperstensive crisis in patients with phaeochromocytoma given metoclopramide." Lancet 1 (1977):  600|Plouin PF, Menard J, Corval P "Hypertensive crisis in patient with phaeochromocytoma given metoclopramide." Lancet 2 (1976):  1357-8|"Product Information. Reglan (metoclopramide)." Wyeth-Ayerst Laboratories  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7544, 25001, 'Metoclopramide', 'Pheochromocytoma', 'The use of metoclopramide is contraindicated in patients with pheochromocytoma.  In a study involving patients with essential hypertension, intravenously administered metoclopramide was shown to induce the release of catecholamines.  Hypertensive crises may occur in patients with pheochromocytoma due to induction of catecholamine release from the tumor.', '3', 'Abe M, Orita Y, Nakashima Y, Nakamura M "Hypertensive crisis induced by metoclopramide in patient with pheochromocytoma." Angiology 35 (1984):  122-8|Filibeck DJ, Grimm D, Forman WB, Leidner BA "Metoclopramide-induced hypertensive crisis." Clin Pharm 3 (1984):  548-9|Agabiti-Rosei E, Aliccandri CL, Corea L "Hyperstensive crisis in patients with phaeochromocytoma given metoclopramide." Lancet 1 (1977):  600|Plouin PF, Menard J, Corval P "Hypertensive crisis in patient with phaeochromocytoma given metoclopramide." Lancet 2 (1976):  1357-8|"Product Information. Reglan (metoclopramide)." Wyeth-Ayerst Laboratories  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7545, 25002, 'Metoclopramide', 'Pheochromocytoma', 'The use of metoclopramide is contraindicated in patients with pheochromocytoma.  In a study involving patients with essential hypertension, intravenously administered metoclopramide was shown to induce the release of catecholamines.  Hypertensive crises may occur in patients with pheochromocytoma due to induction of catecholamine release from the tumor.', '3', 'Abe M, Orita Y, Nakashima Y, Nakamura M "Hypertensive crisis induced by metoclopramide in patient with pheochromocytoma." Angiology 35 (1984):  122-8|Filibeck DJ, Grimm D, Forman WB, Leidner BA "Metoclopramide-induced hypertensive crisis." Clin Pharm 3 (1984):  548-9|Agabiti-Rosei E, Aliccandri CL, Corea L "Hyperstensive crisis in patients with phaeochromocytoma given metoclopramide." Lancet 1 (1977):  600|Plouin PF, Menard J, Corval P "Hypertensive crisis in patient with phaeochromocytoma given metoclopramide." Lancet 2 (1976):  1357-8|"Product Information. Reglan (metoclopramide)." Wyeth-Ayerst Laboratories  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7546, 25257, 'Metoclopramide', 'Pheochromocytoma', 'The use of metoclopramide is contraindicated in patients with pheochromocytoma.  In a study involving patients with essential hypertension, intravenously administered metoclopramide was shown to induce the release of catecholamines.  Hypertensive crises may occur in patients with pheochromocytoma due to induction of catecholamine release from the tumor.', '3', 'Abe M, Orita Y, Nakashima Y, Nakamura M "Hypertensive crisis induced by metoclopramide in patient with pheochromocytoma." Angiology 35 (1984):  122-8|Filibeck DJ, Grimm D, Forman WB, Leidner BA "Metoclopramide-induced hypertensive crisis." Clin Pharm 3 (1984):  548-9|Agabiti-Rosei E, Aliccandri CL, Corea L "Hyperstensive crisis in patients with phaeochromocytoma given metoclopramide." Lancet 1 (1977):  600|Plouin PF, Menard J, Corval P "Hypertensive crisis in patient with phaeochromocytoma given metoclopramide." Lancet 2 (1976):  1357-8|"Product Information. Reglan (metoclopramide)." Wyeth-Ayerst Laboratories  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7547, 25259, 'Metoclopramide', 'Pheochromocytoma', 'The use of metoclopramide is contraindicated in patients with pheochromocytoma.  In a study involving patients with essential hypertension, intravenously administered metoclopramide was shown to induce the release of catecholamines.  Hypertensive crises may occur in patients with pheochromocytoma due to induction of catecholamine release from the tumor.', '3', 'Abe M, Orita Y, Nakashima Y, Nakamura M "Hypertensive crisis induced by metoclopramide in patient with pheochromocytoma." Angiology 35 (1984):  122-8|Filibeck DJ, Grimm D, Forman WB, Leidner BA "Metoclopramide-induced hypertensive crisis." Clin Pharm 3 (1984):  548-9|Agabiti-Rosei E, Aliccandri CL, Corea L "Hyperstensive crisis in patients with phaeochromocytoma given metoclopramide." Lancet 1 (1977):  600|Plouin PF, Menard J, Corval P "Hypertensive crisis in patient with phaeochromocytoma given metoclopramide." Lancet 2 (1976):  1357-8|"Product Information. Reglan (metoclopramide)." Wyeth-Ayerst Laboratories  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7548, 25261, 'Metoclopramide', 'Pheochromocytoma', 'The use of metoclopramide is contraindicated in patients with pheochromocytoma.  In a study involving patients with essential hypertension, intravenously administered metoclopramide was shown to induce the release of catecholamines.  Hypertensive crises may occur in patients with pheochromocytoma due to induction of catecholamine release from the tumor.', '3', 'Abe M, Orita Y, Nakashima Y, Nakamura M "Hypertensive crisis induced by metoclopramide in patient with pheochromocytoma." Angiology 35 (1984):  122-8|Filibeck DJ, Grimm D, Forman WB, Leidner BA "Metoclopramide-induced hypertensive crisis." Clin Pharm 3 (1984):  548-9|Agabiti-Rosei E, Aliccandri CL, Corea L "Hyperstensive crisis in patients with phaeochromocytoma given metoclopramide." Lancet 1 (1977):  600|Plouin PF, Menard J, Corval P "Hypertensive crisis in patient with phaeochromocytoma given metoclopramide." Lancet 2 (1976):  1357-8|"Product Information. Reglan (metoclopramide)." Wyeth-Ayerst Laboratories  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7549, 27683, 'Metoclopramide', 'Pheochromocytoma', 'The use of metoclopramide is contraindicated in patients with pheochromocytoma.  In a study involving patients with essential hypertension, intravenously administered metoclopramide was shown to induce the release of catecholamines.  Hypertensive crises may occur in patients with pheochromocytoma due to induction of catecholamine release from the tumor.', '3', 'Abe M, Orita Y, Nakashima Y, Nakamura M "Hypertensive crisis induced by metoclopramide in patient with pheochromocytoma." Angiology 35 (1984):  122-8|Filibeck DJ, Grimm D, Forman WB, Leidner BA "Metoclopramide-induced hypertensive crisis." Clin Pharm 3 (1984):  548-9|Agabiti-Rosei E, Aliccandri CL, Corea L "Hyperstensive crisis in patients with phaeochromocytoma given metoclopramide." Lancet 1 (1977):  600|Plouin PF, Menard J, Corval P "Hypertensive crisis in patient with phaeochromocytoma given metoclopramide." Lancet 2 (1976):  1357-8|"Product Information. Reglan (metoclopramide)." Wyeth-Ayerst Laboratories  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7550, 29582, 'Metoclopramide', 'Pheochromocytoma', 'The use of metoclopramide is contraindicated in patients with pheochromocytoma.  In a study involving patients with essential hypertension, intravenously administered metoclopramide was shown to induce the release of catecholamines.  Hypertensive crises may occur in patients with pheochromocytoma due to induction of catecholamine release from the tumor.', '3', 'Abe M, Orita Y, Nakashima Y, Nakamura M "Hypertensive crisis induced by metoclopramide in patient with pheochromocytoma." Angiology 35 (1984):  122-8|Filibeck DJ, Grimm D, Forman WB, Leidner BA "Metoclopramide-induced hypertensive crisis." Clin Pharm 3 (1984):  548-9|Agabiti-Rosei E, Aliccandri CL, Corea L "Hyperstensive crisis in patients with phaeochromocytoma given metoclopramide." Lancet 1 (1977):  600|Plouin PF, Menard J, Corval P "Hypertensive crisis in patient with phaeochromocytoma given metoclopramide." Lancet 2 (1976):  1357-8|"Product Information. Reglan (metoclopramide)." Wyeth-Ayerst Laboratories  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7551, 29583, 'Metoclopramide', 'Pheochromocytoma', 'The use of metoclopramide is contraindicated in patients with pheochromocytoma.  In a study involving patients with essential hypertension, intravenously administered metoclopramide was shown to induce the release of catecholamines.  Hypertensive crises may occur in patients with pheochromocytoma due to induction of catecholamine release from the tumor.', '3', 'Abe M, Orita Y, Nakashima Y, Nakamura M "Hypertensive crisis induced by metoclopramide in patient with pheochromocytoma." Angiology 35 (1984):  122-8|Filibeck DJ, Grimm D, Forman WB, Leidner BA "Metoclopramide-induced hypertensive crisis." Clin Pharm 3 (1984):  548-9|Agabiti-Rosei E, Aliccandri CL, Corea L "Hyperstensive crisis in patients with phaeochromocytoma given metoclopramide." Lancet 1 (1977):  600|Plouin PF, Menard J, Corval P "Hypertensive crisis in patient with phaeochromocytoma given metoclopramide." Lancet 2 (1976):  1357-8|"Product Information. Reglan (metoclopramide)." Wyeth-Ayerst Laboratories  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7552, 516, 'Metoclopramide', 'Seizures', 'The use of metoclopramide is contraindicated in patients with seizure disorders.  Metoclopramide may increase the frequency and severity of seizures.', '3', '"Product Information. Reglan (metoclopramide)." Wyeth-Ayerst Laboratories  (2001):|Desmond PV, Watson KJ "Metoclopramide--a review." Med J Aust 144 (1986):  366-9', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7553, 2797, 'Metoclopramide', 'Seizures', 'The use of metoclopramide is contraindicated in patients with seizure disorders.  Metoclopramide may increase the frequency and severity of seizures.', '3', '"Product Information. Reglan (metoclopramide)." Wyeth-Ayerst Laboratories  (2001):|Desmond PV, Watson KJ "Metoclopramide--a review." Med J Aust 144 (1986):  366-9', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7554, 7824, 'Metoclopramide', 'Seizures', 'The use of metoclopramide is contraindicated in patients with seizure disorders.  Metoclopramide may increase the frequency and severity of seizures.', '3', '"Product Information. Reglan (metoclopramide)." Wyeth-Ayerst Laboratories  (2001):|Desmond PV, Watson KJ "Metoclopramide--a review." Med J Aust 144 (1986):  366-9', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7555, 7825, 'Metoclopramide', 'Seizures', 'The use of metoclopramide is contraindicated in patients with seizure disorders.  Metoclopramide may increase the frequency and severity of seizures.', '3', '"Product Information. Reglan (metoclopramide)." Wyeth-Ayerst Laboratories  (2001):|Desmond PV, Watson KJ "Metoclopramide--a review." Med J Aust 144 (1986):  366-9', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7556, 7826, 'Metoclopramide', 'Seizures', 'The use of metoclopramide is contraindicated in patients with seizure disorders.  Metoclopramide may increase the frequency and severity of seizures.', '3', '"Product Information. Reglan (metoclopramide)." Wyeth-Ayerst Laboratories  (2001):|Desmond PV, Watson KJ "Metoclopramide--a review." Med J Aust 144 (1986):  366-9', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7557, 7827, 'Metoclopramide', 'Seizures', 'The use of metoclopramide is contraindicated in patients with seizure disorders.  Metoclopramide may increase the frequency and severity of seizures.', '3', '"Product Information. Reglan (metoclopramide)." Wyeth-Ayerst Laboratories  (2001):|Desmond PV, Watson KJ "Metoclopramide--a review." Med J Aust 144 (1986):  366-9', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7558, 7828, 'Metoclopramide', 'Seizures', 'The use of metoclopramide is contraindicated in patients with seizure disorders.  Metoclopramide may increase the frequency and severity of seizures.', '3', '"Product Information. Reglan (metoclopramide)." Wyeth-Ayerst Laboratories  (2001):|Desmond PV, Watson KJ "Metoclopramide--a review." Med J Aust 144 (1986):  366-9', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7559, 8097, 'Metoclopramide', 'Seizures', 'The use of metoclopramide is contraindicated in patients with seizure disorders.  Metoclopramide may increase the frequency and severity of seizures.', '3', '"Product Information. Reglan (metoclopramide)." Wyeth-Ayerst Laboratories  (2001):|Desmond PV, Watson KJ "Metoclopramide--a review." Med J Aust 144 (1986):  366-9', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7560, 25000, 'Metoclopramide', 'Seizures', 'The use of metoclopramide is contraindicated in patients with seizure disorders.  Metoclopramide may increase the frequency and severity of seizures.', '3', '"Product Information. Reglan (metoclopramide)." Wyeth-Ayerst Laboratories  (2001):|Desmond PV, Watson KJ "Metoclopramide--a review." Med J Aust 144 (1986):  366-9', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7561, 25001, 'Metoclopramide', 'Seizures', 'The use of metoclopramide is contraindicated in patients with seizure disorders.  Metoclopramide may increase the frequency and severity of seizures.', '3', '"Product Information. Reglan (metoclopramide)." Wyeth-Ayerst Laboratories  (2001):|Desmond PV, Watson KJ "Metoclopramide--a review." Med J Aust 144 (1986):  366-9', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7562, 25002, 'Metoclopramide', 'Seizures', 'The use of metoclopramide is contraindicated in patients with seizure disorders.  Metoclopramide may increase the frequency and severity of seizures.', '3', '"Product Information. Reglan (metoclopramide)." Wyeth-Ayerst Laboratories  (2001):|Desmond PV, Watson KJ "Metoclopramide--a review." Med J Aust 144 (1986):  366-9', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7563, 25257, 'Metoclopramide', 'Seizures', 'The use of metoclopramide is contraindicated in patients with seizure disorders.  Metoclopramide may increase the frequency and severity of seizures.', '3', '"Product Information. Reglan (metoclopramide)." Wyeth-Ayerst Laboratories  (2001):|Desmond PV, Watson KJ "Metoclopramide--a review." Med J Aust 144 (1986):  366-9', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7564, 25259, 'Metoclopramide', 'Seizures', 'The use of metoclopramide is contraindicated in patients with seizure disorders.  Metoclopramide may increase the frequency and severity of seizures.', '3', '"Product Information. Reglan (metoclopramide)." Wyeth-Ayerst Laboratories  (2001):|Desmond PV, Watson KJ "Metoclopramide--a review." Med J Aust 144 (1986):  366-9', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7565, 25261, 'Metoclopramide', 'Seizures', 'The use of metoclopramide is contraindicated in patients with seizure disorders.  Metoclopramide may increase the frequency and severity of seizures.', '3', '"Product Information. Reglan (metoclopramide)." Wyeth-Ayerst Laboratories  (2001):|Desmond PV, Watson KJ "Metoclopramide--a review." Med J Aust 144 (1986):  366-9', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7566, 27683, 'Metoclopramide', 'Seizures', 'The use of metoclopramide is contraindicated in patients with seizure disorders.  Metoclopramide may increase the frequency and severity of seizures.', '3', '"Product Information. Reglan (metoclopramide)." Wyeth-Ayerst Laboratories  (2001):|Desmond PV, Watson KJ "Metoclopramide--a review." Med J Aust 144 (1986):  366-9', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7567, 29582, 'Metoclopramide', 'Seizures', 'The use of metoclopramide is contraindicated in patients with seizure disorders.  Metoclopramide may increase the frequency and severity of seizures.', '3', '"Product Information. Reglan (metoclopramide)." Wyeth-Ayerst Laboratories  (2001):|Desmond PV, Watson KJ "Metoclopramide--a review." Med J Aust 144 (1986):  366-9', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7568, 29583, 'Metoclopramide', 'Seizures', 'The use of metoclopramide is contraindicated in patients with seizure disorders.  Metoclopramide may increase the frequency and severity of seizures.', '3', '"Product Information. Reglan (metoclopramide)." Wyeth-Ayerst Laboratories  (2001):|Desmond PV, Watson KJ "Metoclopramide--a review." Med J Aust 144 (1986):  366-9', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7569, 516, 'Metoclopramide', 'Tardive Dyskinesia', 'Metoclopramide may precipitate symptoms of tardive dyskinesia (TD) following chronic administration.  Elderly patients, particularly women, are most susceptible.  Both the risk of developing TD and the likelihood that it will become irreversible increase with the duration and total cumulative dose of metoclopramide or other antidopaminergic therapy administered.  Metoclopramide therapy should be discontinued in patients who develop signs or symptoms of tardive dyskinesia.  There is no known treatment for tardive dyskinesia.  In some patients, symptoms may lessen or resolve after metoclopramide treatment is stopped.  Treatment with metoclopramide for longer than 12 weeks should be avoided in all but rare cases where therapeutic benefit is thought to outweigh the risk of developing tardive dyskinesia.  In patients with preexisting drug-induced TD, initiating or increasing the dosage of metoclopramide therapy may temporarily mask the symptoms of TD but may eventually worsen the condition.', '3', 'Miller LG, Jankovic J "Metoclopramide-induced movement disorders. Clinical findings with a review of the literature." Arch Intern Med 149 (1989):  2486-92|Ganzini L, Casey DE, Hoffman WF, McCall AL "The prevalence of metoclopramide-induced tardive dyskinesia and acute extrapyramidal movement disorders." Arch Intern Med 153 (1993):  1469-75|Pall HS, Williams AC "Extrapyramidal disturbances caused by inappropriate prescribing." Br Med J (Clin Res Ed) 295 (1987):  30-1|Grimes JD "Parkinsonism and tardive dyskinesia associated with long-term metoclopramide therapy." N Engl J Med 305 (1981):  1417|Lavy S, Melamed E, Penchas S "Tardive dyskinesia associated with metoclopramide." Br Med J 1 (1978):  77-8|"Product Information. Reglan (metoclopramide)." Wyeth-Ayerst Laboratories  (2001):|Sewell DD, Kodsi AB, Caligiuri MP, Jeste DV "Metoclopramide and tardive dyskinesia." Biol Psychiatry 36 (1994):  630-2|Bateman DN, Rawlins MD, Simpson JM "Extrapyramidal reactions with metoclopramide." Br Med J (Clin Res Ed) 291 (1985):  930-2|Putnam PE, Orenstein SR, Wessel HB, Stowe RM "Tardive dyskinesia associated with use of metoclopramide in a child." J Pediatr 121 (1992):  983-5|JimenezJimenez FJ, GarciaRuiz PJ, Molina JA "Drug-induced movement disorders." Drug Saf 16 (1997):  180-204', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7570, 2797, 'Metoclopramide', 'Tardive Dyskinesia', 'Metoclopramide may precipitate symptoms of tardive dyskinesia (TD) following chronic administration.  Elderly patients, particularly women, are most susceptible.  Both the risk of developing TD and the likelihood that it will become irreversible increase with the duration and total cumulative dose of metoclopramide or other antidopaminergic therapy administered.  Metoclopramide therapy should be discontinued in patients who develop signs or symptoms of tardive dyskinesia.  There is no known treatment for tardive dyskinesia.  In some patients, symptoms may lessen or resolve after metoclopramide treatment is stopped.  Treatment with metoclopramide for longer than 12 weeks should be avoided in all but rare cases where therapeutic benefit is thought to outweigh the risk of developing tardive dyskinesia.  In patients with preexisting drug-induced TD, initiating or increasing the dosage of metoclopramide therapy may temporarily mask the symptoms of TD but may eventually worsen the condition.', '3', 'Miller LG, Jankovic J "Metoclopramide-induced movement disorders. Clinical findings with a review of the literature." Arch Intern Med 149 (1989):  2486-92|Ganzini L, Casey DE, Hoffman WF, McCall AL "The prevalence of metoclopramide-induced tardive dyskinesia and acute extrapyramidal movement disorders." Arch Intern Med 153 (1993):  1469-75|Pall HS, Williams AC "Extrapyramidal disturbances caused by inappropriate prescribing." Br Med J (Clin Res Ed) 295 (1987):  30-1|Grimes JD "Parkinsonism and tardive dyskinesia associated with long-term metoclopramide therapy." N Engl J Med 305 (1981):  1417|Lavy S, Melamed E, Penchas S "Tardive dyskinesia associated with metoclopramide." Br Med J 1 (1978):  77-8|"Product Information. Reglan (metoclopramide)." Wyeth-Ayerst Laboratories  (2001):|Sewell DD, Kodsi AB, Caligiuri MP, Jeste DV "Metoclopramide and tardive dyskinesia." Biol Psychiatry 36 (1994):  630-2|Bateman DN, Rawlins MD, Simpson JM "Extrapyramidal reactions with metoclopramide." Br Med J (Clin Res Ed) 291 (1985):  930-2|Putnam PE, Orenstein SR, Wessel HB, Stowe RM "Tardive dyskinesia associated with use of metoclopramide in a child." J Pediatr 121 (1992):  983-5|JimenezJimenez FJ, GarciaRuiz PJ, Molina JA "Drug-induced movement disorders." Drug Saf 16 (1997):  180-204', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7571, 7824, 'Metoclopramide', 'Tardive Dyskinesia', 'Metoclopramide may precipitate symptoms of tardive dyskinesia (TD) following chronic administration.  Elderly patients, particularly women, are most susceptible.  Both the risk of developing TD and the likelihood that it will become irreversible increase with the duration and total cumulative dose of metoclopramide or other antidopaminergic therapy administered.  Metoclopramide therapy should be discontinued in patients who develop signs or symptoms of tardive dyskinesia.  There is no known treatment for tardive dyskinesia.  In some patients, symptoms may lessen or resolve after metoclopramide treatment is stopped.  Treatment with metoclopramide for longer than 12 weeks should be avoided in all but rare cases where therapeutic benefit is thought to outweigh the risk of developing tardive dyskinesia.  In patients with preexisting drug-induced TD, initiating or increasing the dosage of metoclopramide therapy may temporarily mask the symptoms of TD but may eventually worsen the condition.', '3', 'Miller LG, Jankovic J "Metoclopramide-induced movement disorders. Clinical findings with a review of the literature." Arch Intern Med 149 (1989):  2486-92|Ganzini L, Casey DE, Hoffman WF, McCall AL "The prevalence of metoclopramide-induced tardive dyskinesia and acute extrapyramidal movement disorders." Arch Intern Med 153 (1993):  1469-75|Pall HS, Williams AC "Extrapyramidal disturbances caused by inappropriate prescribing." Br Med J (Clin Res Ed) 295 (1987):  30-1|Grimes JD "Parkinsonism and tardive dyskinesia associated with long-term metoclopramide therapy." N Engl J Med 305 (1981):  1417|Lavy S, Melamed E, Penchas S "Tardive dyskinesia associated with metoclopramide." Br Med J 1 (1978):  77-8|"Product Information. Reglan (metoclopramide)." Wyeth-Ayerst Laboratories  (2001):|Sewell DD, Kodsi AB, Caligiuri MP, Jeste DV "Metoclopramide and tardive dyskinesia." Biol Psychiatry 36 (1994):  630-2|Bateman DN, Rawlins MD, Simpson JM "Extrapyramidal reactions with metoclopramide." Br Med J (Clin Res Ed) 291 (1985):  930-2|Putnam PE, Orenstein SR, Wessel HB, Stowe RM "Tardive dyskinesia associated with use of metoclopramide in a child." J Pediatr 121 (1992):  983-5|JimenezJimenez FJ, GarciaRuiz PJ, Molina JA "Drug-induced movement disorders." Drug Saf 16 (1997):  180-204', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7572, 7825, 'Metoclopramide', 'Tardive Dyskinesia', 'Metoclopramide may precipitate symptoms of tardive dyskinesia (TD) following chronic administration.  Elderly patients, particularly women, are most susceptible.  Both the risk of developing TD and the likelihood that it will become irreversible increase with the duration and total cumulative dose of metoclopramide or other antidopaminergic therapy administered.  Metoclopramide therapy should be discontinued in patients who develop signs or symptoms of tardive dyskinesia.  There is no known treatment for tardive dyskinesia.  In some patients, symptoms may lessen or resolve after metoclopramide treatment is stopped.  Treatment with metoclopramide for longer than 12 weeks should be avoided in all but rare cases where therapeutic benefit is thought to outweigh the risk of developing tardive dyskinesia.  In patients with preexisting drug-induced TD, initiating or increasing the dosage of metoclopramide therapy may temporarily mask the symptoms of TD but may eventually worsen the condition.', '3', 'Miller LG, Jankovic J "Metoclopramide-induced movement disorders. Clinical findings with a review of the literature." Arch Intern Med 149 (1989):  2486-92|Ganzini L, Casey DE, Hoffman WF, McCall AL "The prevalence of metoclopramide-induced tardive dyskinesia and acute extrapyramidal movement disorders." Arch Intern Med 153 (1993):  1469-75|Pall HS, Williams AC "Extrapyramidal disturbances caused by inappropriate prescribing." Br Med J (Clin Res Ed) 295 (1987):  30-1|Grimes JD "Parkinsonism and tardive dyskinesia associated with long-term metoclopramide therapy." N Engl J Med 305 (1981):  1417|Lavy S, Melamed E, Penchas S "Tardive dyskinesia associated with metoclopramide." Br Med J 1 (1978):  77-8|"Product Information. Reglan (metoclopramide)." Wyeth-Ayerst Laboratories  (2001):|Sewell DD, Kodsi AB, Caligiuri MP, Jeste DV "Metoclopramide and tardive dyskinesia." Biol Psychiatry 36 (1994):  630-2|Bateman DN, Rawlins MD, Simpson JM "Extrapyramidal reactions with metoclopramide." Br Med J (Clin Res Ed) 291 (1985):  930-2|Putnam PE, Orenstein SR, Wessel HB, Stowe RM "Tardive dyskinesia associated with use of metoclopramide in a child." J Pediatr 121 (1992):  983-5|JimenezJimenez FJ, GarciaRuiz PJ, Molina JA "Drug-induced movement disorders." Drug Saf 16 (1997):  180-204', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7573, 7826, 'Metoclopramide', 'Tardive Dyskinesia', 'Metoclopramide may precipitate symptoms of tardive dyskinesia (TD) following chronic administration.  Elderly patients, particularly women, are most susceptible.  Both the risk of developing TD and the likelihood that it will become irreversible increase with the duration and total cumulative dose of metoclopramide or other antidopaminergic therapy administered.  Metoclopramide therapy should be discontinued in patients who develop signs or symptoms of tardive dyskinesia.  There is no known treatment for tardive dyskinesia.  In some patients, symptoms may lessen or resolve after metoclopramide treatment is stopped.  Treatment with metoclopramide for longer than 12 weeks should be avoided in all but rare cases where therapeutic benefit is thought to outweigh the risk of developing tardive dyskinesia.  In patients with preexisting drug-induced TD, initiating or increasing the dosage of metoclopramide therapy may temporarily mask the symptoms of TD but may eventually worsen the condition.', '3', 'Miller LG, Jankovic J "Metoclopramide-induced movement disorders. Clinical findings with a review of the literature." Arch Intern Med 149 (1989):  2486-92|Ganzini L, Casey DE, Hoffman WF, McCall AL "The prevalence of metoclopramide-induced tardive dyskinesia and acute extrapyramidal movement disorders." Arch Intern Med 153 (1993):  1469-75|Pall HS, Williams AC "Extrapyramidal disturbances caused by inappropriate prescribing." Br Med J (Clin Res Ed) 295 (1987):  30-1|Grimes JD "Parkinsonism and tardive dyskinesia associated with long-term metoclopramide therapy." N Engl J Med 305 (1981):  1417|Lavy S, Melamed E, Penchas S "Tardive dyskinesia associated with metoclopramide." Br Med J 1 (1978):  77-8|"Product Information. Reglan (metoclopramide)." Wyeth-Ayerst Laboratories  (2001):|Sewell DD, Kodsi AB, Caligiuri MP, Jeste DV "Metoclopramide and tardive dyskinesia." Biol Psychiatry 36 (1994):  630-2|Bateman DN, Rawlins MD, Simpson JM "Extrapyramidal reactions with metoclopramide." Br Med J (Clin Res Ed) 291 (1985):  930-2|Putnam PE, Orenstein SR, Wessel HB, Stowe RM "Tardive dyskinesia associated with use of metoclopramide in a child." J Pediatr 121 (1992):  983-5|JimenezJimenez FJ, GarciaRuiz PJ, Molina JA "Drug-induced movement disorders." Drug Saf 16 (1997):  180-204', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7574, 7827, 'Metoclopramide', 'Tardive Dyskinesia', 'Metoclopramide may precipitate symptoms of tardive dyskinesia (TD) following chronic administration.  Elderly patients, particularly women, are most susceptible.  Both the risk of developing TD and the likelihood that it will become irreversible increase with the duration and total cumulative dose of metoclopramide or other antidopaminergic therapy administered.  Metoclopramide therapy should be discontinued in patients who develop signs or symptoms of tardive dyskinesia.  There is no known treatment for tardive dyskinesia.  In some patients, symptoms may lessen or resolve after metoclopramide treatment is stopped.  Treatment with metoclopramide for longer than 12 weeks should be avoided in all but rare cases where therapeutic benefit is thought to outweigh the risk of developing tardive dyskinesia.  In patients with preexisting drug-induced TD, initiating or increasing the dosage of metoclopramide therapy may temporarily mask the symptoms of TD but may eventually worsen the condition.', '3', 'Miller LG, Jankovic J "Metoclopramide-induced movement disorders. Clinical findings with a review of the literature." Arch Intern Med 149 (1989):  2486-92|Ganzini L, Casey DE, Hoffman WF, McCall AL "The prevalence of metoclopramide-induced tardive dyskinesia and acute extrapyramidal movement disorders." Arch Intern Med 153 (1993):  1469-75|Pall HS, Williams AC "Extrapyramidal disturbances caused by inappropriate prescribing." Br Med J (Clin Res Ed) 295 (1987):  30-1|Grimes JD "Parkinsonism and tardive dyskinesia associated with long-term metoclopramide therapy." N Engl J Med 305 (1981):  1417|Lavy S, Melamed E, Penchas S "Tardive dyskinesia associated with metoclopramide." Br Med J 1 (1978):  77-8|"Product Information. Reglan (metoclopramide)." Wyeth-Ayerst Laboratories  (2001):|Sewell DD, Kodsi AB, Caligiuri MP, Jeste DV "Metoclopramide and tardive dyskinesia." Biol Psychiatry 36 (1994):  630-2|Bateman DN, Rawlins MD, Simpson JM "Extrapyramidal reactions with metoclopramide." Br Med J (Clin Res Ed) 291 (1985):  930-2|Putnam PE, Orenstein SR, Wessel HB, Stowe RM "Tardive dyskinesia associated with use of metoclopramide in a child." J Pediatr 121 (1992):  983-5|JimenezJimenez FJ, GarciaRuiz PJ, Molina JA "Drug-induced movement disorders." Drug Saf 16 (1997):  180-204', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7575, 7828, 'Metoclopramide', 'Tardive Dyskinesia', 'Metoclopramide may precipitate symptoms of tardive dyskinesia (TD) following chronic administration.  Elderly patients, particularly women, are most susceptible.  Both the risk of developing TD and the likelihood that it will become irreversible increase with the duration and total cumulative dose of metoclopramide or other antidopaminergic therapy administered.  Metoclopramide therapy should be discontinued in patients who develop signs or symptoms of tardive dyskinesia.  There is no known treatment for tardive dyskinesia.  In some patients, symptoms may lessen or resolve after metoclopramide treatment is stopped.  Treatment with metoclopramide for longer than 12 weeks should be avoided in all but rare cases where therapeutic benefit is thought to outweigh the risk of developing tardive dyskinesia.  In patients with preexisting drug-induced TD, initiating or increasing the dosage of metoclopramide therapy may temporarily mask the symptoms of TD but may eventually worsen the condition.', '3', 'Miller LG, Jankovic J "Metoclopramide-induced movement disorders. Clinical findings with a review of the literature." Arch Intern Med 149 (1989):  2486-92|Ganzini L, Casey DE, Hoffman WF, McCall AL "The prevalence of metoclopramide-induced tardive dyskinesia and acute extrapyramidal movement disorders." Arch Intern Med 153 (1993):  1469-75|Pall HS, Williams AC "Extrapyramidal disturbances caused by inappropriate prescribing." Br Med J (Clin Res Ed) 295 (1987):  30-1|Grimes JD "Parkinsonism and tardive dyskinesia associated with long-term metoclopramide therapy." N Engl J Med 305 (1981):  1417|Lavy S, Melamed E, Penchas S "Tardive dyskinesia associated with metoclopramide." Br Med J 1 (1978):  77-8|"Product Information. Reglan (metoclopramide)." Wyeth-Ayerst Laboratories  (2001):|Sewell DD, Kodsi AB, Caligiuri MP, Jeste DV "Metoclopramide and tardive dyskinesia." Biol Psychiatry 36 (1994):  630-2|Bateman DN, Rawlins MD, Simpson JM "Extrapyramidal reactions with metoclopramide." Br Med J (Clin Res Ed) 291 (1985):  930-2|Putnam PE, Orenstein SR, Wessel HB, Stowe RM "Tardive dyskinesia associated with use of metoclopramide in a child." J Pediatr 121 (1992):  983-5|JimenezJimenez FJ, GarciaRuiz PJ, Molina JA "Drug-induced movement disorders." Drug Saf 16 (1997):  180-204', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7576, 8097, 'Metoclopramide', 'Tardive Dyskinesia', 'Metoclopramide may precipitate symptoms of tardive dyskinesia (TD) following chronic administration.  Elderly patients, particularly women, are most susceptible.  Both the risk of developing TD and the likelihood that it will become irreversible increase with the duration and total cumulative dose of metoclopramide or other antidopaminergic therapy administered.  Metoclopramide therapy should be discontinued in patients who develop signs or symptoms of tardive dyskinesia.  There is no known treatment for tardive dyskinesia.  In some patients, symptoms may lessen or resolve after metoclopramide treatment is stopped.  Treatment with metoclopramide for longer than 12 weeks should be avoided in all but rare cases where therapeutic benefit is thought to outweigh the risk of developing tardive dyskinesia.  In patients with preexisting drug-induced TD, initiating or increasing the dosage of metoclopramide therapy may temporarily mask the symptoms of TD but may eventually worsen the condition.', '3', 'Miller LG, Jankovic J "Metoclopramide-induced movement disorders. Clinical findings with a review of the literature." Arch Intern Med 149 (1989):  2486-92|Ganzini L, Casey DE, Hoffman WF, McCall AL "The prevalence of metoclopramide-induced tardive dyskinesia and acute extrapyramidal movement disorders." Arch Intern Med 153 (1993):  1469-75|Pall HS, Williams AC "Extrapyramidal disturbances caused by inappropriate prescribing." Br Med J (Clin Res Ed) 295 (1987):  30-1|Grimes JD "Parkinsonism and tardive dyskinesia associated with long-term metoclopramide therapy." N Engl J Med 305 (1981):  1417|Lavy S, Melamed E, Penchas S "Tardive dyskinesia associated with metoclopramide." Br Med J 1 (1978):  77-8|"Product Information. Reglan (metoclopramide)." Wyeth-Ayerst Laboratories  (2001):|Sewell DD, Kodsi AB, Caligiuri MP, Jeste DV "Metoclopramide and tardive dyskinesia." Biol Psychiatry 36 (1994):  630-2|Bateman DN, Rawlins MD, Simpson JM "Extrapyramidal reactions with metoclopramide." Br Med J (Clin Res Ed) 291 (1985):  930-2|Putnam PE, Orenstein SR, Wessel HB, Stowe RM "Tardive dyskinesia associated with use of metoclopramide in a child." J Pediatr 121 (1992):  983-5|JimenezJimenez FJ, GarciaRuiz PJ, Molina JA "Drug-induced movement disorders." Drug Saf 16 (1997):  180-204', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7577, 25000, 'Metoclopramide', 'Tardive Dyskinesia', 'Metoclopramide may precipitate symptoms of tardive dyskinesia (TD) following chronic administration.  Elderly patients, particularly women, are most susceptible.  Both the risk of developing TD and the likelihood that it will become irreversible increase with the duration and total cumulative dose of metoclopramide or other antidopaminergic therapy administered.  Metoclopramide therapy should be discontinued in patients who develop signs or symptoms of tardive dyskinesia.  There is no known treatment for tardive dyskinesia.  In some patients, symptoms may lessen or resolve after metoclopramide treatment is stopped.  Treatment with metoclopramide for longer than 12 weeks should be avoided in all but rare cases where therapeutic benefit is thought to outweigh the risk of developing tardive dyskinesia.  In patients with preexisting drug-induced TD, initiating or increasing the dosage of metoclopramide therapy may temporarily mask the symptoms of TD but may eventually worsen the condition.', '3', 'Miller LG, Jankovic J "Metoclopramide-induced movement disorders. Clinical findings with a review of the literature." Arch Intern Med 149 (1989):  2486-92|Ganzini L, Casey DE, Hoffman WF, McCall AL "The prevalence of metoclopramide-induced tardive dyskinesia and acute extrapyramidal movement disorders." Arch Intern Med 153 (1993):  1469-75|Pall HS, Williams AC "Extrapyramidal disturbances caused by inappropriate prescribing." Br Med J (Clin Res Ed) 295 (1987):  30-1|Grimes JD "Parkinsonism and tardive dyskinesia associated with long-term metoclopramide therapy." N Engl J Med 305 (1981):  1417|Lavy S, Melamed E, Penchas S "Tardive dyskinesia associated with metoclopramide." Br Med J 1 (1978):  77-8|"Product Information. Reglan (metoclopramide)." Wyeth-Ayerst Laboratories  (2001):|Sewell DD, Kodsi AB, Caligiuri MP, Jeste DV "Metoclopramide and tardive dyskinesia." Biol Psychiatry 36 (1994):  630-2|Bateman DN, Rawlins MD, Simpson JM "Extrapyramidal reactions with metoclopramide." Br Med J (Clin Res Ed) 291 (1985):  930-2|Putnam PE, Orenstein SR, Wessel HB, Stowe RM "Tardive dyskinesia associated with use of metoclopramide in a child." J Pediatr 121 (1992):  983-5|JimenezJimenez FJ, GarciaRuiz PJ, Molina JA "Drug-induced movement disorders." Drug Saf 16 (1997):  180-204', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7578, 25001, 'Metoclopramide', 'Tardive Dyskinesia', 'Metoclopramide may precipitate symptoms of tardive dyskinesia (TD) following chronic administration.  Elderly patients, particularly women, are most susceptible.  Both the risk of developing TD and the likelihood that it will become irreversible increase with the duration and total cumulative dose of metoclopramide or other antidopaminergic therapy administered.  Metoclopramide therapy should be discontinued in patients who develop signs or symptoms of tardive dyskinesia.  There is no known treatment for tardive dyskinesia.  In some patients, symptoms may lessen or resolve after metoclopramide treatment is stopped.  Treatment with metoclopramide for longer than 12 weeks should be avoided in all but rare cases where therapeutic benefit is thought to outweigh the risk of developing tardive dyskinesia.  In patients with preexisting drug-induced TD, initiating or increasing the dosage of metoclopramide therapy may temporarily mask the symptoms of TD but may eventually worsen the condition.', '3', 'Miller LG, Jankovic J "Metoclopramide-induced movement disorders. Clinical findings with a review of the literature." Arch Intern Med 149 (1989):  2486-92|Ganzini L, Casey DE, Hoffman WF, McCall AL "The prevalence of metoclopramide-induced tardive dyskinesia and acute extrapyramidal movement disorders." Arch Intern Med 153 (1993):  1469-75|Pall HS, Williams AC "Extrapyramidal disturbances caused by inappropriate prescribing." Br Med J (Clin Res Ed) 295 (1987):  30-1|Grimes JD "Parkinsonism and tardive dyskinesia associated with long-term metoclopramide therapy." N Engl J Med 305 (1981):  1417|Lavy S, Melamed E, Penchas S "Tardive dyskinesia associated with metoclopramide." Br Med J 1 (1978):  77-8|"Product Information. Reglan (metoclopramide)." Wyeth-Ayerst Laboratories  (2001):|Sewell DD, Kodsi AB, Caligiuri MP, Jeste DV "Metoclopramide and tardive dyskinesia." Biol Psychiatry 36 (1994):  630-2|Bateman DN, Rawlins MD, Simpson JM "Extrapyramidal reactions with metoclopramide." Br Med J (Clin Res Ed) 291 (1985):  930-2|Putnam PE, Orenstein SR, Wessel HB, Stowe RM "Tardive dyskinesia associated with use of metoclopramide in a child." J Pediatr 121 (1992):  983-5|JimenezJimenez FJ, GarciaRuiz PJ, Molina JA "Drug-induced movement disorders." Drug Saf 16 (1997):  180-204', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7579, 25002, 'Metoclopramide', 'Tardive Dyskinesia', 'Metoclopramide may precipitate symptoms of tardive dyskinesia (TD) following chronic administration.  Elderly patients, particularly women, are most susceptible.  Both the risk of developing TD and the likelihood that it will become irreversible increase with the duration and total cumulative dose of metoclopramide or other antidopaminergic therapy administered.  Metoclopramide therapy should be discontinued in patients who develop signs or symptoms of tardive dyskinesia.  There is no known treatment for tardive dyskinesia.  In some patients, symptoms may lessen or resolve after metoclopramide treatment is stopped.  Treatment with metoclopramide for longer than 12 weeks should be avoided in all but rare cases where therapeutic benefit is thought to outweigh the risk of developing tardive dyskinesia.  In patients with preexisting drug-induced TD, initiating or increasing the dosage of metoclopramide therapy may temporarily mask the symptoms of TD but may eventually worsen the condition.', '3', 'Miller LG, Jankovic J "Metoclopramide-induced movement disorders. Clinical findings with a review of the literature." Arch Intern Med 149 (1989):  2486-92|Ganzini L, Casey DE, Hoffman WF, McCall AL "The prevalence of metoclopramide-induced tardive dyskinesia and acute extrapyramidal movement disorders." Arch Intern Med 153 (1993):  1469-75|Pall HS, Williams AC "Extrapyramidal disturbances caused by inappropriate prescribing." Br Med J (Clin Res Ed) 295 (1987):  30-1|Grimes JD "Parkinsonism and tardive dyskinesia associated with long-term metoclopramide therapy." N Engl J Med 305 (1981):  1417|Lavy S, Melamed E, Penchas S "Tardive dyskinesia associated with metoclopramide." Br Med J 1 (1978):  77-8|"Product Information. Reglan (metoclopramide)." Wyeth-Ayerst Laboratories  (2001):|Sewell DD, Kodsi AB, Caligiuri MP, Jeste DV "Metoclopramide and tardive dyskinesia." Biol Psychiatry 36 (1994):  630-2|Bateman DN, Rawlins MD, Simpson JM "Extrapyramidal reactions with metoclopramide." Br Med J (Clin Res Ed) 291 (1985):  930-2|Putnam PE, Orenstein SR, Wessel HB, Stowe RM "Tardive dyskinesia associated with use of metoclopramide in a child." J Pediatr 121 (1992):  983-5|JimenezJimenez FJ, GarciaRuiz PJ, Molina JA "Drug-induced movement disorders." Drug Saf 16 (1997):  180-204', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7580, 25257, 'Metoclopramide', 'Tardive Dyskinesia', 'Metoclopramide may precipitate symptoms of tardive dyskinesia (TD) following chronic administration.  Elderly patients, particularly women, are most susceptible.  Both the risk of developing TD and the likelihood that it will become irreversible increase with the duration and total cumulative dose of metoclopramide or other antidopaminergic therapy administered.  Metoclopramide therapy should be discontinued in patients who develop signs or symptoms of tardive dyskinesia.  There is no known treatment for tardive dyskinesia.  In some patients, symptoms may lessen or resolve after metoclopramide treatment is stopped.  Treatment with metoclopramide for longer than 12 weeks should be avoided in all but rare cases where therapeutic benefit is thought to outweigh the risk of developing tardive dyskinesia.  In patients with preexisting drug-induced TD, initiating or increasing the dosage of metoclopramide therapy may temporarily mask the symptoms of TD but may eventually worsen the condition.', '3', 'Miller LG, Jankovic J "Metoclopramide-induced movement disorders. Clinical findings with a review of the literature." Arch Intern Med 149 (1989):  2486-92|Ganzini L, Casey DE, Hoffman WF, McCall AL "The prevalence of metoclopramide-induced tardive dyskinesia and acute extrapyramidal movement disorders." Arch Intern Med 153 (1993):  1469-75|Pall HS, Williams AC "Extrapyramidal disturbances caused by inappropriate prescribing." Br Med J (Clin Res Ed) 295 (1987):  30-1|Grimes JD "Parkinsonism and tardive dyskinesia associated with long-term metoclopramide therapy." N Engl J Med 305 (1981):  1417|Lavy S, Melamed E, Penchas S "Tardive dyskinesia associated with metoclopramide." Br Med J 1 (1978):  77-8|"Product Information. Reglan (metoclopramide)." Wyeth-Ayerst Laboratories  (2001):|Sewell DD, Kodsi AB, Caligiuri MP, Jeste DV "Metoclopramide and tardive dyskinesia." Biol Psychiatry 36 (1994):  630-2|Bateman DN, Rawlins MD, Simpson JM "Extrapyramidal reactions with metoclopramide." Br Med J (Clin Res Ed) 291 (1985):  930-2|Putnam PE, Orenstein SR, Wessel HB, Stowe RM "Tardive dyskinesia associated with use of metoclopramide in a child." J Pediatr 121 (1992):  983-5|JimenezJimenez FJ, GarciaRuiz PJ, Molina JA "Drug-induced movement disorders." Drug Saf 16 (1997):  180-204', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7581, 25259, 'Metoclopramide', 'Tardive Dyskinesia', 'Metoclopramide may precipitate symptoms of tardive dyskinesia (TD) following chronic administration.  Elderly patients, particularly women, are most susceptible.  Both the risk of developing TD and the likelihood that it will become irreversible increase with the duration and total cumulative dose of metoclopramide or other antidopaminergic therapy administered.  Metoclopramide therapy should be discontinued in patients who develop signs or symptoms of tardive dyskinesia.  There is no known treatment for tardive dyskinesia.  In some patients, symptoms may lessen or resolve after metoclopramide treatment is stopped.  Treatment with metoclopramide for longer than 12 weeks should be avoided in all but rare cases where therapeutic benefit is thought to outweigh the risk of developing tardive dyskinesia.  In patients with preexisting drug-induced TD, initiating or increasing the dosage of metoclopramide therapy may temporarily mask the symptoms of TD but may eventually worsen the condition.', '3', 'Miller LG, Jankovic J "Metoclopramide-induced movement disorders. Clinical findings with a review of the literature." Arch Intern Med 149 (1989):  2486-92|Ganzini L, Casey DE, Hoffman WF, McCall AL "The prevalence of metoclopramide-induced tardive dyskinesia and acute extrapyramidal movement disorders." Arch Intern Med 153 (1993):  1469-75|Pall HS, Williams AC "Extrapyramidal disturbances caused by inappropriate prescribing." Br Med J (Clin Res Ed) 295 (1987):  30-1|Grimes JD "Parkinsonism and tardive dyskinesia associated with long-term metoclopramide therapy." N Engl J Med 305 (1981):  1417|Lavy S, Melamed E, Penchas S "Tardive dyskinesia associated with metoclopramide." Br Med J 1 (1978):  77-8|"Product Information. Reglan (metoclopramide)." Wyeth-Ayerst Laboratories  (2001):|Sewell DD, Kodsi AB, Caligiuri MP, Jeste DV "Metoclopramide and tardive dyskinesia." Biol Psychiatry 36 (1994):  630-2|Bateman DN, Rawlins MD, Simpson JM "Extrapyramidal reactions with metoclopramide." Br Med J (Clin Res Ed) 291 (1985):  930-2|Putnam PE, Orenstein SR, Wessel HB, Stowe RM "Tardive dyskinesia associated with use of metoclopramide in a child." J Pediatr 121 (1992):  983-5|JimenezJimenez FJ, GarciaRuiz PJ, Molina JA "Drug-induced movement disorders." Drug Saf 16 (1997):  180-204', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7582, 25261, 'Metoclopramide', 'Tardive Dyskinesia', 'Metoclopramide may precipitate symptoms of tardive dyskinesia (TD) following chronic administration.  Elderly patients, particularly women, are most susceptible.  Both the risk of developing TD and the likelihood that it will become irreversible increase with the duration and total cumulative dose of metoclopramide or other antidopaminergic therapy administered.  Metoclopramide therapy should be discontinued in patients who develop signs or symptoms of tardive dyskinesia.  There is no known treatment for tardive dyskinesia.  In some patients, symptoms may lessen or resolve after metoclopramide treatment is stopped.  Treatment with metoclopramide for longer than 12 weeks should be avoided in all but rare cases where therapeutic benefit is thought to outweigh the risk of developing tardive dyskinesia.  In patients with preexisting drug-induced TD, initiating or increasing the dosage of metoclopramide therapy may temporarily mask the symptoms of TD but may eventually worsen the condition.', '3', 'Miller LG, Jankovic J "Metoclopramide-induced movement disorders. Clinical findings with a review of the literature." Arch Intern Med 149 (1989):  2486-92|Ganzini L, Casey DE, Hoffman WF, McCall AL "The prevalence of metoclopramide-induced tardive dyskinesia and acute extrapyramidal movement disorders." Arch Intern Med 153 (1993):  1469-75|Pall HS, Williams AC "Extrapyramidal disturbances caused by inappropriate prescribing." Br Med J (Clin Res Ed) 295 (1987):  30-1|Grimes JD "Parkinsonism and tardive dyskinesia associated with long-term metoclopramide therapy." N Engl J Med 305 (1981):  1417|Lavy S, Melamed E, Penchas S "Tardive dyskinesia associated with metoclopramide." Br Med J 1 (1978):  77-8|"Product Information. Reglan (metoclopramide)." Wyeth-Ayerst Laboratories  (2001):|Sewell DD, Kodsi AB, Caligiuri MP, Jeste DV "Metoclopramide and tardive dyskinesia." Biol Psychiatry 36 (1994):  630-2|Bateman DN, Rawlins MD, Simpson JM "Extrapyramidal reactions with metoclopramide." Br Med J (Clin Res Ed) 291 (1985):  930-2|Putnam PE, Orenstein SR, Wessel HB, Stowe RM "Tardive dyskinesia associated with use of metoclopramide in a child." J Pediatr 121 (1992):  983-5|JimenezJimenez FJ, GarciaRuiz PJ, Molina JA "Drug-induced movement disorders." Drug Saf 16 (1997):  180-204', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7583, 27683, 'Metoclopramide', 'Tardive Dyskinesia', 'Metoclopramide may precipitate symptoms of tardive dyskinesia (TD) following chronic administration.  Elderly patients, particularly women, are most susceptible.  Both the risk of developing TD and the likelihood that it will become irreversible increase with the duration and total cumulative dose of metoclopramide or other antidopaminergic therapy administered.  Metoclopramide therapy should be discontinued in patients who develop signs or symptoms of tardive dyskinesia.  There is no known treatment for tardive dyskinesia.  In some patients, symptoms may lessen or resolve after metoclopramide treatment is stopped.  Treatment with metoclopramide for longer than 12 weeks should be avoided in all but rare cases where therapeutic benefit is thought to outweigh the risk of developing tardive dyskinesia.  In patients with preexisting drug-induced TD, initiating or increasing the dosage of metoclopramide therapy may temporarily mask the symptoms of TD but may eventually worsen the condition.', '3', 'Miller LG, Jankovic J "Metoclopramide-induced movement disorders. Clinical findings with a review of the literature." Arch Intern Med 149 (1989):  2486-92|Ganzini L, Casey DE, Hoffman WF, McCall AL "The prevalence of metoclopramide-induced tardive dyskinesia and acute extrapyramidal movement disorders." Arch Intern Med 153 (1993):  1469-75|Pall HS, Williams AC "Extrapyramidal disturbances caused by inappropriate prescribing." Br Med J (Clin Res Ed) 295 (1987):  30-1|Grimes JD "Parkinsonism and tardive dyskinesia associated with long-term metoclopramide therapy." N Engl J Med 305 (1981):  1417|Lavy S, Melamed E, Penchas S "Tardive dyskinesia associated with metoclopramide." Br Med J 1 (1978):  77-8|"Product Information. Reglan (metoclopramide)." Wyeth-Ayerst Laboratories  (2001):|Sewell DD, Kodsi AB, Caligiuri MP, Jeste DV "Metoclopramide and tardive dyskinesia." Biol Psychiatry 36 (1994):  630-2|Bateman DN, Rawlins MD, Simpson JM "Extrapyramidal reactions with metoclopramide." Br Med J (Clin Res Ed) 291 (1985):  930-2|Putnam PE, Orenstein SR, Wessel HB, Stowe RM "Tardive dyskinesia associated with use of metoclopramide in a child." J Pediatr 121 (1992):  983-5|JimenezJimenez FJ, GarciaRuiz PJ, Molina JA "Drug-induced movement disorders." Drug Saf 16 (1997):  180-204', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7584, 29582, 'Metoclopramide', 'Tardive Dyskinesia', 'Metoclopramide may precipitate symptoms of tardive dyskinesia (TD) following chronic administration.  Elderly patients, particularly women, are most susceptible.  Both the risk of developing TD and the likelihood that it will become irreversible increase with the duration and total cumulative dose of metoclopramide or other antidopaminergic therapy administered.  Metoclopramide therapy should be discontinued in patients who develop signs or symptoms of tardive dyskinesia.  There is no known treatment for tardive dyskinesia.  In some patients, symptoms may lessen or resolve after metoclopramide treatment is stopped.  Treatment with metoclopramide for longer than 12 weeks should be avoided in all but rare cases where therapeutic benefit is thought to outweigh the risk of developing tardive dyskinesia.  In patients with preexisting drug-induced TD, initiating or increasing the dosage of metoclopramide therapy may temporarily mask the symptoms of TD but may eventually worsen the condition.', '3', 'Miller LG, Jankovic J "Metoclopramide-induced movement disorders. Clinical findings with a review of the literature." Arch Intern Med 149 (1989):  2486-92|Ganzini L, Casey DE, Hoffman WF, McCall AL "The prevalence of metoclopramide-induced tardive dyskinesia and acute extrapyramidal movement disorders." Arch Intern Med 153 (1993):  1469-75|Pall HS, Williams AC "Extrapyramidal disturbances caused by inappropriate prescribing." Br Med J (Clin Res Ed) 295 (1987):  30-1|Grimes JD "Parkinsonism and tardive dyskinesia associated with long-term metoclopramide therapy." N Engl J Med 305 (1981):  1417|Lavy S, Melamed E, Penchas S "Tardive dyskinesia associated with metoclopramide." Br Med J 1 (1978):  77-8|"Product Information. Reglan (metoclopramide)." Wyeth-Ayerst Laboratories  (2001):|Sewell DD, Kodsi AB, Caligiuri MP, Jeste DV "Metoclopramide and tardive dyskinesia." Biol Psychiatry 36 (1994):  630-2|Bateman DN, Rawlins MD, Simpson JM "Extrapyramidal reactions with metoclopramide." Br Med J (Clin Res Ed) 291 (1985):  930-2|Putnam PE, Orenstein SR, Wessel HB, Stowe RM "Tardive dyskinesia associated with use of metoclopramide in a child." J Pediatr 121 (1992):  983-5|JimenezJimenez FJ, GarciaRuiz PJ, Molina JA "Drug-induced movement disorders." Drug Saf 16 (1997):  180-204', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7585, 29583, 'Metoclopramide', 'Tardive Dyskinesia', 'Metoclopramide may precipitate symptoms of tardive dyskinesia (TD) following chronic administration.  Elderly patients, particularly women, are most susceptible.  Both the risk of developing TD and the likelihood that it will become irreversible increase with the duration and total cumulative dose of metoclopramide or other antidopaminergic therapy administered.  Metoclopramide therapy should be discontinued in patients who develop signs or symptoms of tardive dyskinesia.  There is no known treatment for tardive dyskinesia.  In some patients, symptoms may lessen or resolve after metoclopramide treatment is stopped.  Treatment with metoclopramide for longer than 12 weeks should be avoided in all but rare cases where therapeutic benefit is thought to outweigh the risk of developing tardive dyskinesia.  In patients with preexisting drug-induced TD, initiating or increasing the dosage of metoclopramide therapy may temporarily mask the symptoms of TD but may eventually worsen the condition.', '3', 'Miller LG, Jankovic J "Metoclopramide-induced movement disorders. Clinical findings with a review of the literature." Arch Intern Med 149 (1989):  2486-92|Ganzini L, Casey DE, Hoffman WF, McCall AL "The prevalence of metoclopramide-induced tardive dyskinesia and acute extrapyramidal movement disorders." Arch Intern Med 153 (1993):  1469-75|Pall HS, Williams AC "Extrapyramidal disturbances caused by inappropriate prescribing." Br Med J (Clin Res Ed) 295 (1987):  30-1|Grimes JD "Parkinsonism and tardive dyskinesia associated with long-term metoclopramide therapy." N Engl J Med 305 (1981):  1417|Lavy S, Melamed E, Penchas S "Tardive dyskinesia associated with metoclopramide." Br Med J 1 (1978):  77-8|"Product Information. Reglan (metoclopramide)." Wyeth-Ayerst Laboratories  (2001):|Sewell DD, Kodsi AB, Caligiuri MP, Jeste DV "Metoclopramide and tardive dyskinesia." Biol Psychiatry 36 (1994):  630-2|Bateman DN, Rawlins MD, Simpson JM "Extrapyramidal reactions with metoclopramide." Br Med J (Clin Res Ed) 291 (1985):  930-2|Putnam PE, Orenstein SR, Wessel HB, Stowe RM "Tardive dyskinesia associated with use of metoclopramide in a child." J Pediatr 121 (1992):  983-5|JimenezJimenez FJ, GarciaRuiz PJ, Molina JA "Drug-induced movement disorders." Drug Saf 16 (1997):  180-204', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7586, 516, 'Metoclopramide', 'Water-Electrolyte Imbalance', 'Metoclopramide produces a transient increase in plasma aldosterone and may cause fluid retention and volume overload in susceptible patients.  Therapy with metoclopramide should be administered cautiously in patients with or at risk for fluid overload (e.g., cirrhosis, congestive heart failure).  If these side effects occur at any time during metoclopramide therapy, the drug should be discontinued.', '2', 'Ahmad S "Metoclopramide-induced acute congestive heart failure." South Med J 84 (1991):  283-4|"Product Information. Reglan (metoclopramide)." Wyeth-Ayerst Laboratories  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7587, 2797, 'Metoclopramide', 'Water-Electrolyte Imbalance', 'Metoclopramide produces a transient increase in plasma aldosterone and may cause fluid retention and volume overload in susceptible patients.  Therapy with metoclopramide should be administered cautiously in patients with or at risk for fluid overload (e.g., cirrhosis, congestive heart failure).  If these side effects occur at any time during metoclopramide therapy, the drug should be discontinued.', '2', 'Ahmad S "Metoclopramide-induced acute congestive heart failure." South Med J 84 (1991):  283-4|"Product Information. Reglan (metoclopramide)." Wyeth-Ayerst Laboratories  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7588, 7824, 'Metoclopramide', 'Water-Electrolyte Imbalance', 'Metoclopramide produces a transient increase in plasma aldosterone and may cause fluid retention and volume overload in susceptible patients.  Therapy with metoclopramide should be administered cautiously in patients with or at risk for fluid overload (e.g., cirrhosis, congestive heart failure).  If these side effects occur at any time during metoclopramide therapy, the drug should be discontinued.', '2', 'Ahmad S "Metoclopramide-induced acute congestive heart failure." South Med J 84 (1991):  283-4|"Product Information. Reglan (metoclopramide)." Wyeth-Ayerst Laboratories  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7589, 7825, 'Metoclopramide', 'Water-Electrolyte Imbalance', 'Metoclopramide produces a transient increase in plasma aldosterone and may cause fluid retention and volume overload in susceptible patients.  Therapy with metoclopramide should be administered cautiously in patients with or at risk for fluid overload (e.g., cirrhosis, congestive heart failure).  If these side effects occur at any time during metoclopramide therapy, the drug should be discontinued.', '2', 'Ahmad S "Metoclopramide-induced acute congestive heart failure." South Med J 84 (1991):  283-4|"Product Information. Reglan (metoclopramide)." Wyeth-Ayerst Laboratories  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7590, 7826, 'Metoclopramide', 'Water-Electrolyte Imbalance', 'Metoclopramide produces a transient increase in plasma aldosterone and may cause fluid retention and volume overload in susceptible patients.  Therapy with metoclopramide should be administered cautiously in patients with or at risk for fluid overload (e.g., cirrhosis, congestive heart failure).  If these side effects occur at any time during metoclopramide therapy, the drug should be discontinued.', '2', 'Ahmad S "Metoclopramide-induced acute congestive heart failure." South Med J 84 (1991):  283-4|"Product Information. Reglan (metoclopramide)." Wyeth-Ayerst Laboratories  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7591, 7827, 'Metoclopramide', 'Water-Electrolyte Imbalance', 'Metoclopramide produces a transient increase in plasma aldosterone and may cause fluid retention and volume overload in susceptible patients.  Therapy with metoclopramide should be administered cautiously in patients with or at risk for fluid overload (e.g., cirrhosis, congestive heart failure).  If these side effects occur at any time during metoclopramide therapy, the drug should be discontinued.', '2', 'Ahmad S "Metoclopramide-induced acute congestive heart failure." South Med J 84 (1991):  283-4|"Product Information. Reglan (metoclopramide)." Wyeth-Ayerst Laboratories  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7592, 7828, 'Metoclopramide', 'Water-Electrolyte Imbalance', 'Metoclopramide produces a transient increase in plasma aldosterone and may cause fluid retention and volume overload in susceptible patients.  Therapy with metoclopramide should be administered cautiously in patients with or at risk for fluid overload (e.g., cirrhosis, congestive heart failure).  If these side effects occur at any time during metoclopramide therapy, the drug should be discontinued.', '2', 'Ahmad S "Metoclopramide-induced acute congestive heart failure." South Med J 84 (1991):  283-4|"Product Information. Reglan (metoclopramide)." Wyeth-Ayerst Laboratories  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7593, 8097, 'Metoclopramide', 'Water-Electrolyte Imbalance', 'Metoclopramide produces a transient increase in plasma aldosterone and may cause fluid retention and volume overload in susceptible patients.  Therapy with metoclopramide should be administered cautiously in patients with or at risk for fluid overload (e.g., cirrhosis, congestive heart failure).  If these side effects occur at any time during metoclopramide therapy, the drug should be discontinued.', '2', 'Ahmad S "Metoclopramide-induced acute congestive heart failure." South Med J 84 (1991):  283-4|"Product Information. Reglan (metoclopramide)." Wyeth-Ayerst Laboratories  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7594, 25000, 'Metoclopramide', 'Water-Electrolyte Imbalance', 'Metoclopramide produces a transient increase in plasma aldosterone and may cause fluid retention and volume overload in susceptible patients.  Therapy with metoclopramide should be administered cautiously in patients with or at risk for fluid overload (e.g., cirrhosis, congestive heart failure).  If these side effects occur at any time during metoclopramide therapy, the drug should be discontinued.', '2', 'Ahmad S "Metoclopramide-induced acute congestive heart failure." South Med J 84 (1991):  283-4|"Product Information. Reglan (metoclopramide)." Wyeth-Ayerst Laboratories  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7595, 25001, 'Metoclopramide', 'Water-Electrolyte Imbalance', 'Metoclopramide produces a transient increase in plasma aldosterone and may cause fluid retention and volume overload in susceptible patients.  Therapy with metoclopramide should be administered cautiously in patients with or at risk for fluid overload (e.g., cirrhosis, congestive heart failure).  If these side effects occur at any time during metoclopramide therapy, the drug should be discontinued.', '2', 'Ahmad S "Metoclopramide-induced acute congestive heart failure." South Med J 84 (1991):  283-4|"Product Information. Reglan (metoclopramide)." Wyeth-Ayerst Laboratories  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7596, 25002, 'Metoclopramide', 'Water-Electrolyte Imbalance', 'Metoclopramide produces a transient increase in plasma aldosterone and may cause fluid retention and volume overload in susceptible patients.  Therapy with metoclopramide should be administered cautiously in patients with or at risk for fluid overload (e.g., cirrhosis, congestive heart failure).  If these side effects occur at any time during metoclopramide therapy, the drug should be discontinued.', '2', 'Ahmad S "Metoclopramide-induced acute congestive heart failure." South Med J 84 (1991):  283-4|"Product Information. Reglan (metoclopramide)." Wyeth-Ayerst Laboratories  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7597, 25257, 'Metoclopramide', 'Water-Electrolyte Imbalance', 'Metoclopramide produces a transient increase in plasma aldosterone and may cause fluid retention and volume overload in susceptible patients.  Therapy with metoclopramide should be administered cautiously in patients with or at risk for fluid overload (e.g., cirrhosis, congestive heart failure).  If these side effects occur at any time during metoclopramide therapy, the drug should be discontinued.', '2', 'Ahmad S "Metoclopramide-induced acute congestive heart failure." South Med J 84 (1991):  283-4|"Product Information. Reglan (metoclopramide)." Wyeth-Ayerst Laboratories  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7598, 25259, 'Metoclopramide', 'Water-Electrolyte Imbalance', 'Metoclopramide produces a transient increase in plasma aldosterone and may cause fluid retention and volume overload in susceptible patients.  Therapy with metoclopramide should be administered cautiously in patients with or at risk for fluid overload (e.g., cirrhosis, congestive heart failure).  If these side effects occur at any time during metoclopramide therapy, the drug should be discontinued.', '2', 'Ahmad S "Metoclopramide-induced acute congestive heart failure." South Med J 84 (1991):  283-4|"Product Information. Reglan (metoclopramide)." Wyeth-Ayerst Laboratories  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7599, 25261, 'Metoclopramide', 'Water-Electrolyte Imbalance', 'Metoclopramide produces a transient increase in plasma aldosterone and may cause fluid retention and volume overload in susceptible patients.  Therapy with metoclopramide should be administered cautiously in patients with or at risk for fluid overload (e.g., cirrhosis, congestive heart failure).  If these side effects occur at any time during metoclopramide therapy, the drug should be discontinued.', '2', 'Ahmad S "Metoclopramide-induced acute congestive heart failure." South Med J 84 (1991):  283-4|"Product Information. Reglan (metoclopramide)." Wyeth-Ayerst Laboratories  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7600, 27683, 'Metoclopramide', 'Water-Electrolyte Imbalance', 'Metoclopramide produces a transient increase in plasma aldosterone and may cause fluid retention and volume overload in susceptible patients.  Therapy with metoclopramide should be administered cautiously in patients with or at risk for fluid overload (e.g., cirrhosis, congestive heart failure).  If these side effects occur at any time during metoclopramide therapy, the drug should be discontinued.', '2', 'Ahmad S "Metoclopramide-induced acute congestive heart failure." South Med J 84 (1991):  283-4|"Product Information. Reglan (metoclopramide)." Wyeth-Ayerst Laboratories  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7601, 29582, 'Metoclopramide', 'Water-Electrolyte Imbalance', 'Metoclopramide produces a transient increase in plasma aldosterone and may cause fluid retention and volume overload in susceptible patients.  Therapy with metoclopramide should be administered cautiously in patients with or at risk for fluid overload (e.g., cirrhosis, congestive heart failure).  If these side effects occur at any time during metoclopramide therapy, the drug should be discontinued.', '2', 'Ahmad S "Metoclopramide-induced acute congestive heart failure." South Med J 84 (1991):  283-4|"Product Information. Reglan (metoclopramide)." Wyeth-Ayerst Laboratories  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7602, 29583, 'Metoclopramide', 'Water-Electrolyte Imbalance', 'Metoclopramide produces a transient increase in plasma aldosterone and may cause fluid retention and volume overload in susceptible patients.  Therapy with metoclopramide should be administered cautiously in patients with or at risk for fluid overload (e.g., cirrhosis, congestive heart failure).  If these side effects occur at any time during metoclopramide therapy, the drug should be discontinued.', '2', 'Ahmad S "Metoclopramide-induced acute congestive heart failure." South Med J 84 (1991):  283-4|"Product Information. Reglan (metoclopramide)." Wyeth-Ayerst Laboratories  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7603, 516, 'Metoclopramide', 'Hypertension', 'In a study involving patients with essential hypertension, intravenously administered metoclopramide was shown to induce the release of catecholamines.  Therapy with metoclopramide should be administered cautiously in patients with hypertension because of potential increases in blood pressure.', '2', 'Filibeck DJ, Grimm D, Forman WB, Leidner BA "Metoclopramide-induced hypertensive crisis." Clin Pharm 3 (1984):  548-9|"Product Information. Reglan (metoclopramide)." Wyeth-Ayerst Laboratories  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7604, 2797, 'Metoclopramide', 'Hypertension', 'In a study involving patients with essential hypertension, intravenously administered metoclopramide was shown to induce the release of catecholamines.  Therapy with metoclopramide should be administered cautiously in patients with hypertension because of potential increases in blood pressure.', '2', 'Filibeck DJ, Grimm D, Forman WB, Leidner BA "Metoclopramide-induced hypertensive crisis." Clin Pharm 3 (1984):  548-9|"Product Information. Reglan (metoclopramide)." Wyeth-Ayerst Laboratories  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7605, 7824, 'Metoclopramide', 'Hypertension', 'In a study involving patients with essential hypertension, intravenously administered metoclopramide was shown to induce the release of catecholamines.  Therapy with metoclopramide should be administered cautiously in patients with hypertension because of potential increases in blood pressure.', '2', 'Filibeck DJ, Grimm D, Forman WB, Leidner BA "Metoclopramide-induced hypertensive crisis." Clin Pharm 3 (1984):  548-9|"Product Information. Reglan (metoclopramide)." Wyeth-Ayerst Laboratories  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7606, 7825, 'Metoclopramide', 'Hypertension', 'In a study involving patients with essential hypertension, intravenously administered metoclopramide was shown to induce the release of catecholamines.  Therapy with metoclopramide should be administered cautiously in patients with hypertension because of potential increases in blood pressure.', '2', 'Filibeck DJ, Grimm D, Forman WB, Leidner BA "Metoclopramide-induced hypertensive crisis." Clin Pharm 3 (1984):  548-9|"Product Information. Reglan (metoclopramide)." Wyeth-Ayerst Laboratories  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7607, 7826, 'Metoclopramide', 'Hypertension', 'In a study involving patients with essential hypertension, intravenously administered metoclopramide was shown to induce the release of catecholamines.  Therapy with metoclopramide should be administered cautiously in patients with hypertension because of potential increases in blood pressure.', '2', 'Filibeck DJ, Grimm D, Forman WB, Leidner BA "Metoclopramide-induced hypertensive crisis." Clin Pharm 3 (1984):  548-9|"Product Information. Reglan (metoclopramide)." Wyeth-Ayerst Laboratories  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7608, 7827, 'Metoclopramide', 'Hypertension', 'In a study involving patients with essential hypertension, intravenously administered metoclopramide was shown to induce the release of catecholamines.  Therapy with metoclopramide should be administered cautiously in patients with hypertension because of potential increases in blood pressure.', '2', 'Filibeck DJ, Grimm D, Forman WB, Leidner BA "Metoclopramide-induced hypertensive crisis." Clin Pharm 3 (1984):  548-9|"Product Information. Reglan (metoclopramide)." Wyeth-Ayerst Laboratories  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7609, 7828, 'Metoclopramide', 'Hypertension', 'In a study involving patients with essential hypertension, intravenously administered metoclopramide was shown to induce the release of catecholamines.  Therapy with metoclopramide should be administered cautiously in patients with hypertension because of potential increases in blood pressure.', '2', 'Filibeck DJ, Grimm D, Forman WB, Leidner BA "Metoclopramide-induced hypertensive crisis." Clin Pharm 3 (1984):  548-9|"Product Information. Reglan (metoclopramide)." Wyeth-Ayerst Laboratories  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7610, 8097, 'Metoclopramide', 'Hypertension', 'In a study involving patients with essential hypertension, intravenously administered metoclopramide was shown to induce the release of catecholamines.  Therapy with metoclopramide should be administered cautiously in patients with hypertension because of potential increases in blood pressure.', '2', 'Filibeck DJ, Grimm D, Forman WB, Leidner BA "Metoclopramide-induced hypertensive crisis." Clin Pharm 3 (1984):  548-9|"Product Information. Reglan (metoclopramide)." Wyeth-Ayerst Laboratories  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7611, 25000, 'Metoclopramide', 'Hypertension', 'In a study involving patients with essential hypertension, intravenously administered metoclopramide was shown to induce the release of catecholamines.  Therapy with metoclopramide should be administered cautiously in patients with hypertension because of potential increases in blood pressure.', '2', 'Filibeck DJ, Grimm D, Forman WB, Leidner BA "Metoclopramide-induced hypertensive crisis." Clin Pharm 3 (1984):  548-9|"Product Information. Reglan (metoclopramide)." Wyeth-Ayerst Laboratories  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7612, 25001, 'Metoclopramide', 'Hypertension', 'In a study involving patients with essential hypertension, intravenously administered metoclopramide was shown to induce the release of catecholamines.  Therapy with metoclopramide should be administered cautiously in patients with hypertension because of potential increases in blood pressure.', '2', 'Filibeck DJ, Grimm D, Forman WB, Leidner BA "Metoclopramide-induced hypertensive crisis." Clin Pharm 3 (1984):  548-9|"Product Information. Reglan (metoclopramide)." Wyeth-Ayerst Laboratories  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7613, 25002, 'Metoclopramide', 'Hypertension', 'In a study involving patients with essential hypertension, intravenously administered metoclopramide was shown to induce the release of catecholamines.  Therapy with metoclopramide should be administered cautiously in patients with hypertension because of potential increases in blood pressure.', '2', 'Filibeck DJ, Grimm D, Forman WB, Leidner BA "Metoclopramide-induced hypertensive crisis." Clin Pharm 3 (1984):  548-9|"Product Information. Reglan (metoclopramide)." Wyeth-Ayerst Laboratories  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7614, 25257, 'Metoclopramide', 'Hypertension', 'In a study involving patients with essential hypertension, intravenously administered metoclopramide was shown to induce the release of catecholamines.  Therapy with metoclopramide should be administered cautiously in patients with hypertension because of potential increases in blood pressure.', '2', 'Filibeck DJ, Grimm D, Forman WB, Leidner BA "Metoclopramide-induced hypertensive crisis." Clin Pharm 3 (1984):  548-9|"Product Information. Reglan (metoclopramide)." Wyeth-Ayerst Laboratories  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7615, 25259, 'Metoclopramide', 'Hypertension', 'In a study involving patients with essential hypertension, intravenously administered metoclopramide was shown to induce the release of catecholamines.  Therapy with metoclopramide should be administered cautiously in patients with hypertension because of potential increases in blood pressure.', '2', 'Filibeck DJ, Grimm D, Forman WB, Leidner BA "Metoclopramide-induced hypertensive crisis." Clin Pharm 3 (1984):  548-9|"Product Information. Reglan (metoclopramide)." Wyeth-Ayerst Laboratories  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7616, 25261, 'Metoclopramide', 'Hypertension', 'In a study involving patients with essential hypertension, intravenously administered metoclopramide was shown to induce the release of catecholamines.  Therapy with metoclopramide should be administered cautiously in patients with hypertension because of potential increases in blood pressure.', '2', 'Filibeck DJ, Grimm D, Forman WB, Leidner BA "Metoclopramide-induced hypertensive crisis." Clin Pharm 3 (1984):  548-9|"Product Information. Reglan (metoclopramide)." Wyeth-Ayerst Laboratories  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7617, 27683, 'Metoclopramide', 'Hypertension', 'In a study involving patients with essential hypertension, intravenously administered metoclopramide was shown to induce the release of catecholamines.  Therapy with metoclopramide should be administered cautiously in patients with hypertension because of potential increases in blood pressure.', '2', 'Filibeck DJ, Grimm D, Forman WB, Leidner BA "Metoclopramide-induced hypertensive crisis." Clin Pharm 3 (1984):  548-9|"Product Information. Reglan (metoclopramide)." Wyeth-Ayerst Laboratories  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7618, 29582, 'Metoclopramide', 'Hypertension', 'In a study involving patients with essential hypertension, intravenously administered metoclopramide was shown to induce the release of catecholamines.  Therapy with metoclopramide should be administered cautiously in patients with hypertension because of potential increases in blood pressure.', '2', 'Filibeck DJ, Grimm D, Forman WB, Leidner BA "Metoclopramide-induced hypertensive crisis." Clin Pharm 3 (1984):  548-9|"Product Information. Reglan (metoclopramide)." Wyeth-Ayerst Laboratories  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7619, 29583, 'Metoclopramide', 'Hypertension', 'In a study involving patients with essential hypertension, intravenously administered metoclopramide was shown to induce the release of catecholamines.  Therapy with metoclopramide should be administered cautiously in patients with hypertension because of potential increases in blood pressure.', '2', 'Filibeck DJ, Grimm D, Forman WB, Leidner BA "Metoclopramide-induced hypertensive crisis." Clin Pharm 3 (1984):  548-9|"Product Information. Reglan (metoclopramide)." Wyeth-Ayerst Laboratories  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7620, 516, 'Metoclopramide', 'Parkinsonian Disorders', 'Metoclopramide has antidopaminergic effects and may cause parkinsonian-like symptoms such as akinesia, bradykinesia, tremors, pill-rolling motion, cogwheel rigidity, and postural abnormalities including stooped posture and shuffling gait.  The onset is usually within the first six months following initiation of therapy but occasionally after longer periods.  Symptoms generally subside within 2 to 3 months after drug discontinuation.  Therapy with metoclopramide should be administered cautiously, if at all, in patients with Parkinson''s disease or parkinsonian symptoms.', '2', 'Sirota RA, Kimmel PL, Trichtinger MD, Diamond BF, Stein HD, Yudis M "Metoclopramide-induced parkinsonism in hemodialysis patients. Report of two cases." Arch Intern Med 146 (1986):  2070-1|Miller LG, Jankovic J "Metoclopramide-induced movement disorders. Clinical findings with a review of the literature." Arch Intern Med 149 (1989):  2486-92|Ganzini L, Casey DE, Hoffman WF, McCall AL "The prevalence of metoclopramide-induced tardive dyskinesia and acute extrapyramidal movement disorders." Arch Intern Med 153 (1993):  1469-75|Grimes JD "Parkinsonism and tardive dyskinesia associated with long-term metoclopramide therapy." N Engl J Med 305 (1981):  1417|"Product Information. Reglan (metoclopramide)." Wyeth-Ayerst Laboratories  (2001):|Bateman DN, Rawlins MD, Simpson JM "Extrapyramidal reactions with metoclopramide." Br Med J (Clin Res Ed) 291 (1985):  930-2|JimenezJimenez FJ, GarciaRuiz PJ, Molina JA "Drug-induced movement disorders." Drug Saf 16 (1997):  180-204', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7621, 2797, 'Metoclopramide', 'Parkinsonian Disorders', 'Metoclopramide has antidopaminergic effects and may cause parkinsonian-like symptoms such as akinesia, bradykinesia, tremors, pill-rolling motion, cogwheel rigidity, and postural abnormalities including stooped posture and shuffling gait.  The onset is usually within the first six months following initiation of therapy but occasionally after longer periods.  Symptoms generally subside within 2 to 3 months after drug discontinuation.  Therapy with metoclopramide should be administered cautiously, if at all, in patients with Parkinson''s disease or parkinsonian symptoms.', '2', 'Sirota RA, Kimmel PL, Trichtinger MD, Diamond BF, Stein HD, Yudis M "Metoclopramide-induced parkinsonism in hemodialysis patients. Report of two cases." Arch Intern Med 146 (1986):  2070-1|Miller LG, Jankovic J "Metoclopramide-induced movement disorders. Clinical findings with a review of the literature." Arch Intern Med 149 (1989):  2486-92|Ganzini L, Casey DE, Hoffman WF, McCall AL "The prevalence of metoclopramide-induced tardive dyskinesia and acute extrapyramidal movement disorders." Arch Intern Med 153 (1993):  1469-75|Grimes JD "Parkinsonism and tardive dyskinesia associated with long-term metoclopramide therapy." N Engl J Med 305 (1981):  1417|"Product Information. Reglan (metoclopramide)." Wyeth-Ayerst Laboratories  (2001):|Bateman DN, Rawlins MD, Simpson JM "Extrapyramidal reactions with metoclopramide." Br Med J (Clin Res Ed) 291 (1985):  930-2|JimenezJimenez FJ, GarciaRuiz PJ, Molina JA "Drug-induced movement disorders." Drug Saf 16 (1997):  180-204', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7622, 7824, 'Metoclopramide', 'Parkinsonian Disorders', 'Metoclopramide has antidopaminergic effects and may cause parkinsonian-like symptoms such as akinesia, bradykinesia, tremors, pill-rolling motion, cogwheel rigidity, and postural abnormalities including stooped posture and shuffling gait.  The onset is usually within the first six months following initiation of therapy but occasionally after longer periods.  Symptoms generally subside within 2 to 3 months after drug discontinuation.  Therapy with metoclopramide should be administered cautiously, if at all, in patients with Parkinson''s disease or parkinsonian symptoms.', '2', 'Sirota RA, Kimmel PL, Trichtinger MD, Diamond BF, Stein HD, Yudis M "Metoclopramide-induced parkinsonism in hemodialysis patients. Report of two cases." Arch Intern Med 146 (1986):  2070-1|Miller LG, Jankovic J "Metoclopramide-induced movement disorders. Clinical findings with a review of the literature." Arch Intern Med 149 (1989):  2486-92|Ganzini L, Casey DE, Hoffman WF, McCall AL "The prevalence of metoclopramide-induced tardive dyskinesia and acute extrapyramidal movement disorders." Arch Intern Med 153 (1993):  1469-75|Grimes JD "Parkinsonism and tardive dyskinesia associated with long-term metoclopramide therapy." N Engl J Med 305 (1981):  1417|"Product Information. Reglan (metoclopramide)." Wyeth-Ayerst Laboratories  (2001):|Bateman DN, Rawlins MD, Simpson JM "Extrapyramidal reactions with metoclopramide." Br Med J (Clin Res Ed) 291 (1985):  930-2|JimenezJimenez FJ, GarciaRuiz PJ, Molina JA "Drug-induced movement disorders." Drug Saf 16 (1997):  180-204', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7623, 7825, 'Metoclopramide', 'Parkinsonian Disorders', 'Metoclopramide has antidopaminergic effects and may cause parkinsonian-like symptoms such as akinesia, bradykinesia, tremors, pill-rolling motion, cogwheel rigidity, and postural abnormalities including stooped posture and shuffling gait.  The onset is usually within the first six months following initiation of therapy but occasionally after longer periods.  Symptoms generally subside within 2 to 3 months after drug discontinuation.  Therapy with metoclopramide should be administered cautiously, if at all, in patients with Parkinson''s disease or parkinsonian symptoms.', '2', 'Sirota RA, Kimmel PL, Trichtinger MD, Diamond BF, Stein HD, Yudis M "Metoclopramide-induced parkinsonism in hemodialysis patients. Report of two cases." Arch Intern Med 146 (1986):  2070-1|Miller LG, Jankovic J "Metoclopramide-induced movement disorders. Clinical findings with a review of the literature." Arch Intern Med 149 (1989):  2486-92|Ganzini L, Casey DE, Hoffman WF, McCall AL "The prevalence of metoclopramide-induced tardive dyskinesia and acute extrapyramidal movement disorders." Arch Intern Med 153 (1993):  1469-75|Grimes JD "Parkinsonism and tardive dyskinesia associated with long-term metoclopramide therapy." N Engl J Med 305 (1981):  1417|"Product Information. Reglan (metoclopramide)." Wyeth-Ayerst Laboratories  (2001):|Bateman DN, Rawlins MD, Simpson JM "Extrapyramidal reactions with metoclopramide." Br Med J (Clin Res Ed) 291 (1985):  930-2|JimenezJimenez FJ, GarciaRuiz PJ, Molina JA "Drug-induced movement disorders." Drug Saf 16 (1997):  180-204', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7624, 7826, 'Metoclopramide', 'Parkinsonian Disorders', 'Metoclopramide has antidopaminergic effects and may cause parkinsonian-like symptoms such as akinesia, bradykinesia, tremors, pill-rolling motion, cogwheel rigidity, and postural abnormalities including stooped posture and shuffling gait.  The onset is usually within the first six months following initiation of therapy but occasionally after longer periods.  Symptoms generally subside within 2 to 3 months after drug discontinuation.  Therapy with metoclopramide should be administered cautiously, if at all, in patients with Parkinson''s disease or parkinsonian symptoms.', '2', 'Sirota RA, Kimmel PL, Trichtinger MD, Diamond BF, Stein HD, Yudis M "Metoclopramide-induced parkinsonism in hemodialysis patients. Report of two cases." Arch Intern Med 146 (1986):  2070-1|Miller LG, Jankovic J "Metoclopramide-induced movement disorders. Clinical findings with a review of the literature." Arch Intern Med 149 (1989):  2486-92|Ganzini L, Casey DE, Hoffman WF, McCall AL "The prevalence of metoclopramide-induced tardive dyskinesia and acute extrapyramidal movement disorders." Arch Intern Med 153 (1993):  1469-75|Grimes JD "Parkinsonism and tardive dyskinesia associated with long-term metoclopramide therapy." N Engl J Med 305 (1981):  1417|"Product Information. Reglan (metoclopramide)." Wyeth-Ayerst Laboratories  (2001):|Bateman DN, Rawlins MD, Simpson JM "Extrapyramidal reactions with metoclopramide." Br Med J (Clin Res Ed) 291 (1985):  930-2|JimenezJimenez FJ, GarciaRuiz PJ, Molina JA "Drug-induced movement disorders." Drug Saf 16 (1997):  180-204', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7625, 7827, 'Metoclopramide', 'Parkinsonian Disorders', 'Metoclopramide has antidopaminergic effects and may cause parkinsonian-like symptoms such as akinesia, bradykinesia, tremors, pill-rolling motion, cogwheel rigidity, and postural abnormalities including stooped posture and shuffling gait.  The onset is usually within the first six months following initiation of therapy but occasionally after longer periods.  Symptoms generally subside within 2 to 3 months after drug discontinuation.  Therapy with metoclopramide should be administered cautiously, if at all, in patients with Parkinson''s disease or parkinsonian symptoms.', '2', 'Sirota RA, Kimmel PL, Trichtinger MD, Diamond BF, Stein HD, Yudis M "Metoclopramide-induced parkinsonism in hemodialysis patients. Report of two cases." Arch Intern Med 146 (1986):  2070-1|Miller LG, Jankovic J "Metoclopramide-induced movement disorders. Clinical findings with a review of the literature." Arch Intern Med 149 (1989):  2486-92|Ganzini L, Casey DE, Hoffman WF, McCall AL "The prevalence of metoclopramide-induced tardive dyskinesia and acute extrapyramidal movement disorders." Arch Intern Med 153 (1993):  1469-75|Grimes JD "Parkinsonism and tardive dyskinesia associated with long-term metoclopramide therapy." N Engl J Med 305 (1981):  1417|"Product Information. Reglan (metoclopramide)." Wyeth-Ayerst Laboratories  (2001):|Bateman DN, Rawlins MD, Simpson JM "Extrapyramidal reactions with metoclopramide." Br Med J (Clin Res Ed) 291 (1985):  930-2|JimenezJimenez FJ, GarciaRuiz PJ, Molina JA "Drug-induced movement disorders." Drug Saf 16 (1997):  180-204', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7626, 7828, 'Metoclopramide', 'Parkinsonian Disorders', 'Metoclopramide has antidopaminergic effects and may cause parkinsonian-like symptoms such as akinesia, bradykinesia, tremors, pill-rolling motion, cogwheel rigidity, and postural abnormalities including stooped posture and shuffling gait.  The onset is usually within the first six months following initiation of therapy but occasionally after longer periods.  Symptoms generally subside within 2 to 3 months after drug discontinuation.  Therapy with metoclopramide should be administered cautiously, if at all, in patients with Parkinson''s disease or parkinsonian symptoms.', '2', 'Sirota RA, Kimmel PL, Trichtinger MD, Diamond BF, Stein HD, Yudis M "Metoclopramide-induced parkinsonism in hemodialysis patients. Report of two cases." Arch Intern Med 146 (1986):  2070-1|Miller LG, Jankovic J "Metoclopramide-induced movement disorders. Clinical findings with a review of the literature." Arch Intern Med 149 (1989):  2486-92|Ganzini L, Casey DE, Hoffman WF, McCall AL "The prevalence of metoclopramide-induced tardive dyskinesia and acute extrapyramidal movement disorders." Arch Intern Med 153 (1993):  1469-75|Grimes JD "Parkinsonism and tardive dyskinesia associated with long-term metoclopramide therapy." N Engl J Med 305 (1981):  1417|"Product Information. Reglan (metoclopramide)." Wyeth-Ayerst Laboratories  (2001):|Bateman DN, Rawlins MD, Simpson JM "Extrapyramidal reactions with metoclopramide." Br Med J (Clin Res Ed) 291 (1985):  930-2|JimenezJimenez FJ, GarciaRuiz PJ, Molina JA "Drug-induced movement disorders." Drug Saf 16 (1997):  180-204', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7627, 8097, 'Metoclopramide', 'Parkinsonian Disorders', 'Metoclopramide has antidopaminergic effects and may cause parkinsonian-like symptoms such as akinesia, bradykinesia, tremors, pill-rolling motion, cogwheel rigidity, and postural abnormalities including stooped posture and shuffling gait.  The onset is usually within the first six months following initiation of therapy but occasionally after longer periods.  Symptoms generally subside within 2 to 3 months after drug discontinuation.  Therapy with metoclopramide should be administered cautiously, if at all, in patients with Parkinson''s disease or parkinsonian symptoms.', '2', 'Sirota RA, Kimmel PL, Trichtinger MD, Diamond BF, Stein HD, Yudis M "Metoclopramide-induced parkinsonism in hemodialysis patients. Report of two cases." Arch Intern Med 146 (1986):  2070-1|Miller LG, Jankovic J "Metoclopramide-induced movement disorders. Clinical findings with a review of the literature." Arch Intern Med 149 (1989):  2486-92|Ganzini L, Casey DE, Hoffman WF, McCall AL "The prevalence of metoclopramide-induced tardive dyskinesia and acute extrapyramidal movement disorders." Arch Intern Med 153 (1993):  1469-75|Grimes JD "Parkinsonism and tardive dyskinesia associated with long-term metoclopramide therapy." N Engl J Med 305 (1981):  1417|"Product Information. Reglan (metoclopramide)." Wyeth-Ayerst Laboratories  (2001):|Bateman DN, Rawlins MD, Simpson JM "Extrapyramidal reactions with metoclopramide." Br Med J (Clin Res Ed) 291 (1985):  930-2|JimenezJimenez FJ, GarciaRuiz PJ, Molina JA "Drug-induced movement disorders." Drug Saf 16 (1997):  180-204', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7628, 25000, 'Metoclopramide', 'Parkinsonian Disorders', 'Metoclopramide has antidopaminergic effects and may cause parkinsonian-like symptoms such as akinesia, bradykinesia, tremors, pill-rolling motion, cogwheel rigidity, and postural abnormalities including stooped posture and shuffling gait.  The onset is usually within the first six months following initiation of therapy but occasionally after longer periods.  Symptoms generally subside within 2 to 3 months after drug discontinuation.  Therapy with metoclopramide should be administered cautiously, if at all, in patients with Parkinson''s disease or parkinsonian symptoms.', '2', 'Sirota RA, Kimmel PL, Trichtinger MD, Diamond BF, Stein HD, Yudis M "Metoclopramide-induced parkinsonism in hemodialysis patients. Report of two cases." Arch Intern Med 146 (1986):  2070-1|Miller LG, Jankovic J "Metoclopramide-induced movement disorders. Clinical findings with a review of the literature." Arch Intern Med 149 (1989):  2486-92|Ganzini L, Casey DE, Hoffman WF, McCall AL "The prevalence of metoclopramide-induced tardive dyskinesia and acute extrapyramidal movement disorders." Arch Intern Med 153 (1993):  1469-75|Grimes JD "Parkinsonism and tardive dyskinesia associated with long-term metoclopramide therapy." N Engl J Med 305 (1981):  1417|"Product Information. Reglan (metoclopramide)." Wyeth-Ayerst Laboratories  (2001):|Bateman DN, Rawlins MD, Simpson JM "Extrapyramidal reactions with metoclopramide." Br Med J (Clin Res Ed) 291 (1985):  930-2|JimenezJimenez FJ, GarciaRuiz PJ, Molina JA "Drug-induced movement disorders." Drug Saf 16 (1997):  180-204', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7629, 25001, 'Metoclopramide', 'Parkinsonian Disorders', 'Metoclopramide has antidopaminergic effects and may cause parkinsonian-like symptoms such as akinesia, bradykinesia, tremors, pill-rolling motion, cogwheel rigidity, and postural abnormalities including stooped posture and shuffling gait.  The onset is usually within the first six months following initiation of therapy but occasionally after longer periods.  Symptoms generally subside within 2 to 3 months after drug discontinuation.  Therapy with metoclopramide should be administered cautiously, if at all, in patients with Parkinson''s disease or parkinsonian symptoms.', '2', 'Sirota RA, Kimmel PL, Trichtinger MD, Diamond BF, Stein HD, Yudis M "Metoclopramide-induced parkinsonism in hemodialysis patients. Report of two cases." Arch Intern Med 146 (1986):  2070-1|Miller LG, Jankovic J "Metoclopramide-induced movement disorders. Clinical findings with a review of the literature." Arch Intern Med 149 (1989):  2486-92|Ganzini L, Casey DE, Hoffman WF, McCall AL "The prevalence of metoclopramide-induced tardive dyskinesia and acute extrapyramidal movement disorders." Arch Intern Med 153 (1993):  1469-75|Grimes JD "Parkinsonism and tardive dyskinesia associated with long-term metoclopramide therapy." N Engl J Med 305 (1981):  1417|"Product Information. Reglan (metoclopramide)." Wyeth-Ayerst Laboratories  (2001):|Bateman DN, Rawlins MD, Simpson JM "Extrapyramidal reactions with metoclopramide." Br Med J (Clin Res Ed) 291 (1985):  930-2|JimenezJimenez FJ, GarciaRuiz PJ, Molina JA "Drug-induced movement disorders." Drug Saf 16 (1997):  180-204', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7630, 25002, 'Metoclopramide', 'Parkinsonian Disorders', 'Metoclopramide has antidopaminergic effects and may cause parkinsonian-like symptoms such as akinesia, bradykinesia, tremors, pill-rolling motion, cogwheel rigidity, and postural abnormalities including stooped posture and shuffling gait.  The onset is usually within the first six months following initiation of therapy but occasionally after longer periods.  Symptoms generally subside within 2 to 3 months after drug discontinuation.  Therapy with metoclopramide should be administered cautiously, if at all, in patients with Parkinson''s disease or parkinsonian symptoms.', '2', 'Sirota RA, Kimmel PL, Trichtinger MD, Diamond BF, Stein HD, Yudis M "Metoclopramide-induced parkinsonism in hemodialysis patients. Report of two cases." Arch Intern Med 146 (1986):  2070-1|Miller LG, Jankovic J "Metoclopramide-induced movement disorders. Clinical findings with a review of the literature." Arch Intern Med 149 (1989):  2486-92|Ganzini L, Casey DE, Hoffman WF, McCall AL "The prevalence of metoclopramide-induced tardive dyskinesia and acute extrapyramidal movement disorders." Arch Intern Med 153 (1993):  1469-75|Grimes JD "Parkinsonism and tardive dyskinesia associated with long-term metoclopramide therapy." N Engl J Med 305 (1981):  1417|"Product Information. Reglan (metoclopramide)." Wyeth-Ayerst Laboratories  (2001):|Bateman DN, Rawlins MD, Simpson JM "Extrapyramidal reactions with metoclopramide." Br Med J (Clin Res Ed) 291 (1985):  930-2|JimenezJimenez FJ, GarciaRuiz PJ, Molina JA "Drug-induced movement disorders." Drug Saf 16 (1997):  180-204', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7631, 25257, 'Metoclopramide', 'Parkinsonian Disorders', 'Metoclopramide has antidopaminergic effects and may cause parkinsonian-like symptoms such as akinesia, bradykinesia, tremors, pill-rolling motion, cogwheel rigidity, and postural abnormalities including stooped posture and shuffling gait.  The onset is usually within the first six months following initiation of therapy but occasionally after longer periods.  Symptoms generally subside within 2 to 3 months after drug discontinuation.  Therapy with metoclopramide should be administered cautiously, if at all, in patients with Parkinson''s disease or parkinsonian symptoms.', '2', 'Sirota RA, Kimmel PL, Trichtinger MD, Diamond BF, Stein HD, Yudis M "Metoclopramide-induced parkinsonism in hemodialysis patients. Report of two cases." Arch Intern Med 146 (1986):  2070-1|Miller LG, Jankovic J "Metoclopramide-induced movement disorders. Clinical findings with a review of the literature." Arch Intern Med 149 (1989):  2486-92|Ganzini L, Casey DE, Hoffman WF, McCall AL "The prevalence of metoclopramide-induced tardive dyskinesia and acute extrapyramidal movement disorders." Arch Intern Med 153 (1993):  1469-75|Grimes JD "Parkinsonism and tardive dyskinesia associated with long-term metoclopramide therapy." N Engl J Med 305 (1981):  1417|"Product Information. Reglan (metoclopramide)." Wyeth-Ayerst Laboratories  (2001):|Bateman DN, Rawlins MD, Simpson JM "Extrapyramidal reactions with metoclopramide." Br Med J (Clin Res Ed) 291 (1985):  930-2|JimenezJimenez FJ, GarciaRuiz PJ, Molina JA "Drug-induced movement disorders." Drug Saf 16 (1997):  180-204', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7632, 25259, 'Metoclopramide', 'Parkinsonian Disorders', 'Metoclopramide has antidopaminergic effects and may cause parkinsonian-like symptoms such as akinesia, bradykinesia, tremors, pill-rolling motion, cogwheel rigidity, and postural abnormalities including stooped posture and shuffling gait.  The onset is usually within the first six months following initiation of therapy but occasionally after longer periods.  Symptoms generally subside within 2 to 3 months after drug discontinuation.  Therapy with metoclopramide should be administered cautiously, if at all, in patients with Parkinson''s disease or parkinsonian symptoms.', '2', 'Sirota RA, Kimmel PL, Trichtinger MD, Diamond BF, Stein HD, Yudis M "Metoclopramide-induced parkinsonism in hemodialysis patients. Report of two cases." Arch Intern Med 146 (1986):  2070-1|Miller LG, Jankovic J "Metoclopramide-induced movement disorders. Clinical findings with a review of the literature." Arch Intern Med 149 (1989):  2486-92|Ganzini L, Casey DE, Hoffman WF, McCall AL "The prevalence of metoclopramide-induced tardive dyskinesia and acute extrapyramidal movement disorders." Arch Intern Med 153 (1993):  1469-75|Grimes JD "Parkinsonism and tardive dyskinesia associated with long-term metoclopramide therapy." N Engl J Med 305 (1981):  1417|"Product Information. Reglan (metoclopramide)." Wyeth-Ayerst Laboratories  (2001):|Bateman DN, Rawlins MD, Simpson JM "Extrapyramidal reactions with metoclopramide." Br Med J (Clin Res Ed) 291 (1985):  930-2|JimenezJimenez FJ, GarciaRuiz PJ, Molina JA "Drug-induced movement disorders." Drug Saf 16 (1997):  180-204', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7633, 25261, 'Metoclopramide', 'Parkinsonian Disorders', 'Metoclopramide has antidopaminergic effects and may cause parkinsonian-like symptoms such as akinesia, bradykinesia, tremors, pill-rolling motion, cogwheel rigidity, and postural abnormalities including stooped posture and shuffling gait.  The onset is usually within the first six months following initiation of therapy but occasionally after longer periods.  Symptoms generally subside within 2 to 3 months after drug discontinuation.  Therapy with metoclopramide should be administered cautiously, if at all, in patients with Parkinson''s disease or parkinsonian symptoms.', '2', 'Sirota RA, Kimmel PL, Trichtinger MD, Diamond BF, Stein HD, Yudis M "Metoclopramide-induced parkinsonism in hemodialysis patients. Report of two cases." Arch Intern Med 146 (1986):  2070-1|Miller LG, Jankovic J "Metoclopramide-induced movement disorders. Clinical findings with a review of the literature." Arch Intern Med 149 (1989):  2486-92|Ganzini L, Casey DE, Hoffman WF, McCall AL "The prevalence of metoclopramide-induced tardive dyskinesia and acute extrapyramidal movement disorders." Arch Intern Med 153 (1993):  1469-75|Grimes JD "Parkinsonism and tardive dyskinesia associated with long-term metoclopramide therapy." N Engl J Med 305 (1981):  1417|"Product Information. Reglan (metoclopramide)." Wyeth-Ayerst Laboratories  (2001):|Bateman DN, Rawlins MD, Simpson JM "Extrapyramidal reactions with metoclopramide." Br Med J (Clin Res Ed) 291 (1985):  930-2|JimenezJimenez FJ, GarciaRuiz PJ, Molina JA "Drug-induced movement disorders." Drug Saf 16 (1997):  180-204', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7634, 27683, 'Metoclopramide', 'Parkinsonian Disorders', 'Metoclopramide has antidopaminergic effects and may cause parkinsonian-like symptoms such as akinesia, bradykinesia, tremors, pill-rolling motion, cogwheel rigidity, and postural abnormalities including stooped posture and shuffling gait.  The onset is usually within the first six months following initiation of therapy but occasionally after longer periods.  Symptoms generally subside within 2 to 3 months after drug discontinuation.  Therapy with metoclopramide should be administered cautiously, if at all, in patients with Parkinson''s disease or parkinsonian symptoms.', '2', 'Sirota RA, Kimmel PL, Trichtinger MD, Diamond BF, Stein HD, Yudis M "Metoclopramide-induced parkinsonism in hemodialysis patients. Report of two cases." Arch Intern Med 146 (1986):  2070-1|Miller LG, Jankovic J "Metoclopramide-induced movement disorders. Clinical findings with a review of the literature." Arch Intern Med 149 (1989):  2486-92|Ganzini L, Casey DE, Hoffman WF, McCall AL "The prevalence of metoclopramide-induced tardive dyskinesia and acute extrapyramidal movement disorders." Arch Intern Med 153 (1993):  1469-75|Grimes JD "Parkinsonism and tardive dyskinesia associated with long-term metoclopramide therapy." N Engl J Med 305 (1981):  1417|"Product Information. Reglan (metoclopramide)." Wyeth-Ayerst Laboratories  (2001):|Bateman DN, Rawlins MD, Simpson JM "Extrapyramidal reactions with metoclopramide." Br Med J (Clin Res Ed) 291 (1985):  930-2|JimenezJimenez FJ, GarciaRuiz PJ, Molina JA "Drug-induced movement disorders." Drug Saf 16 (1997):  180-204', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7635, 29582, 'Metoclopramide', 'Parkinsonian Disorders', 'Metoclopramide has antidopaminergic effects and may cause parkinsonian-like symptoms such as akinesia, bradykinesia, tremors, pill-rolling motion, cogwheel rigidity, and postural abnormalities including stooped posture and shuffling gait.  The onset is usually within the first six months following initiation of therapy but occasionally after longer periods.  Symptoms generally subside within 2 to 3 months after drug discontinuation.  Therapy with metoclopramide should be administered cautiously, if at all, in patients with Parkinson''s disease or parkinsonian symptoms.', '2', 'Sirota RA, Kimmel PL, Trichtinger MD, Diamond BF, Stein HD, Yudis M "Metoclopramide-induced parkinsonism in hemodialysis patients. Report of two cases." Arch Intern Med 146 (1986):  2070-1|Miller LG, Jankovic J "Metoclopramide-induced movement disorders. Clinical findings with a review of the literature." Arch Intern Med 149 (1989):  2486-92|Ganzini L, Casey DE, Hoffman WF, McCall AL "The prevalence of metoclopramide-induced tardive dyskinesia and acute extrapyramidal movement disorders." Arch Intern Med 153 (1993):  1469-75|Grimes JD "Parkinsonism and tardive dyskinesia associated with long-term metoclopramide therapy." N Engl J Med 305 (1981):  1417|"Product Information. Reglan (metoclopramide)." Wyeth-Ayerst Laboratories  (2001):|Bateman DN, Rawlins MD, Simpson JM "Extrapyramidal reactions with metoclopramide." Br Med J (Clin Res Ed) 291 (1985):  930-2|JimenezJimenez FJ, GarciaRuiz PJ, Molina JA "Drug-induced movement disorders." Drug Saf 16 (1997):  180-204', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7636, 29583, 'Metoclopramide', 'Parkinsonian Disorders', 'Metoclopramide has antidopaminergic effects and may cause parkinsonian-like symptoms such as akinesia, bradykinesia, tremors, pill-rolling motion, cogwheel rigidity, and postural abnormalities including stooped posture and shuffling gait.  The onset is usually within the first six months following initiation of therapy but occasionally after longer periods.  Symptoms generally subside within 2 to 3 months after drug discontinuation.  Therapy with metoclopramide should be administered cautiously, if at all, in patients with Parkinson''s disease or parkinsonian symptoms.', '2', 'Sirota RA, Kimmel PL, Trichtinger MD, Diamond BF, Stein HD, Yudis M "Metoclopramide-induced parkinsonism in hemodialysis patients. Report of two cases." Arch Intern Med 146 (1986):  2070-1|Miller LG, Jankovic J "Metoclopramide-induced movement disorders. Clinical findings with a review of the literature." Arch Intern Med 149 (1989):  2486-92|Ganzini L, Casey DE, Hoffman WF, McCall AL "The prevalence of metoclopramide-induced tardive dyskinesia and acute extrapyramidal movement disorders." Arch Intern Med 153 (1993):  1469-75|Grimes JD "Parkinsonism and tardive dyskinesia associated with long-term metoclopramide therapy." N Engl J Med 305 (1981):  1417|"Product Information. Reglan (metoclopramide)." Wyeth-Ayerst Laboratories  (2001):|Bateman DN, Rawlins MD, Simpson JM "Extrapyramidal reactions with metoclopramide." Br Med J (Clin Res Ed) 291 (1985):  930-2|JimenezJimenez FJ, GarciaRuiz PJ, Molina JA "Drug-induced movement disorders." Drug Saf 16 (1997):  180-204', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7637, 516, 'Metoclopramide', 'Kidney Diseases', 'Renal function affects the clearance of metoclopramide.  In patients with varying degrees of renal impairment, a reduction in creatinine clearance was correlated with a reduction in plasma clearance, renal clearance, and non-renal clearance, and increase in elimination half-life of metoclopramide.  Therapy with metoclopramide should be administered cautiously in patients with impaired renal function.  A dosage reduction may be appropriate to avoid drug accumulation.', '2', 'Lehmann CR, Heironimus JD, Collins CB, O''Neil TJ, Pierson WP, Crowe JT, Melikian AP, Wright GJ "Metoclopramide kinetics in patients with impaired renal function and clearance by hemodialysis." Clin Pharmacol Ther 37 (1985):  284-9|Lloveras J, Masramon J, Aubia J, Llorach M "Amiodarone, metoclopramide, and renal failure." Lancet 1 (1979):  981-2|Caralps A "Metoclopramide and renal failure." Lancet 1 (1979):  554|Bateman DN, Gokal R, Dodd TR, Blain PG "The pharmacokinetics of single doses of metoclopramide in renal failure." Eur J Clin Pharmacol 19 (1981):  437-41|"Product Information. Reglan (metoclopramide)." Wyeth-Ayerst Laboratories  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7638, 2797, 'Metoclopramide', 'Kidney Diseases', 'Renal function affects the clearance of metoclopramide.  In patients with varying degrees of renal impairment, a reduction in creatinine clearance was correlated with a reduction in plasma clearance, renal clearance, and non-renal clearance, and increase in elimination half-life of metoclopramide.  Therapy with metoclopramide should be administered cautiously in patients with impaired renal function.  A dosage reduction may be appropriate to avoid drug accumulation.', '2', 'Lehmann CR, Heironimus JD, Collins CB, O''Neil TJ, Pierson WP, Crowe JT, Melikian AP, Wright GJ "Metoclopramide kinetics in patients with impaired renal function and clearance by hemodialysis." Clin Pharmacol Ther 37 (1985):  284-9|Lloveras J, Masramon J, Aubia J, Llorach M "Amiodarone, metoclopramide, and renal failure." Lancet 1 (1979):  981-2|Caralps A "Metoclopramide and renal failure." Lancet 1 (1979):  554|Bateman DN, Gokal R, Dodd TR, Blain PG "The pharmacokinetics of single doses of metoclopramide in renal failure." Eur J Clin Pharmacol 19 (1981):  437-41|"Product Information. Reglan (metoclopramide)." Wyeth-Ayerst Laboratories  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7639, 7824, 'Metoclopramide', 'Kidney Diseases', 'Renal function affects the clearance of metoclopramide.  In patients with varying degrees of renal impairment, a reduction in creatinine clearance was correlated with a reduction in plasma clearance, renal clearance, and non-renal clearance, and increase in elimination half-life of metoclopramide.  Therapy with metoclopramide should be administered cautiously in patients with impaired renal function.  A dosage reduction may be appropriate to avoid drug accumulation.', '2', 'Lehmann CR, Heironimus JD, Collins CB, O''Neil TJ, Pierson WP, Crowe JT, Melikian AP, Wright GJ "Metoclopramide kinetics in patients with impaired renal function and clearance by hemodialysis." Clin Pharmacol Ther 37 (1985):  284-9|Lloveras J, Masramon J, Aubia J, Llorach M "Amiodarone, metoclopramide, and renal failure." Lancet 1 (1979):  981-2|Caralps A "Metoclopramide and renal failure." Lancet 1 (1979):  554|Bateman DN, Gokal R, Dodd TR, Blain PG "The pharmacokinetics of single doses of metoclopramide in renal failure." Eur J Clin Pharmacol 19 (1981):  437-41|"Product Information. Reglan (metoclopramide)." Wyeth-Ayerst Laboratories  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7640, 7825, 'Metoclopramide', 'Kidney Diseases', 'Renal function affects the clearance of metoclopramide.  In patients with varying degrees of renal impairment, a reduction in creatinine clearance was correlated with a reduction in plasma clearance, renal clearance, and non-renal clearance, and increase in elimination half-life of metoclopramide.  Therapy with metoclopramide should be administered cautiously in patients with impaired renal function.  A dosage reduction may be appropriate to avoid drug accumulation.', '2', 'Lehmann CR, Heironimus JD, Collins CB, O''Neil TJ, Pierson WP, Crowe JT, Melikian AP, Wright GJ "Metoclopramide kinetics in patients with impaired renal function and clearance by hemodialysis." Clin Pharmacol Ther 37 (1985):  284-9|Lloveras J, Masramon J, Aubia J, Llorach M "Amiodarone, metoclopramide, and renal failure." Lancet 1 (1979):  981-2|Caralps A "Metoclopramide and renal failure." Lancet 1 (1979):  554|Bateman DN, Gokal R, Dodd TR, Blain PG "The pharmacokinetics of single doses of metoclopramide in renal failure." Eur J Clin Pharmacol 19 (1981):  437-41|"Product Information. Reglan (metoclopramide)." Wyeth-Ayerst Laboratories  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7641, 7826, 'Metoclopramide', 'Kidney Diseases', 'Renal function affects the clearance of metoclopramide.  In patients with varying degrees of renal impairment, a reduction in creatinine clearance was correlated with a reduction in plasma clearance, renal clearance, and non-renal clearance, and increase in elimination half-life of metoclopramide.  Therapy with metoclopramide should be administered cautiously in patients with impaired renal function.  A dosage reduction may be appropriate to avoid drug accumulation.', '2', 'Lehmann CR, Heironimus JD, Collins CB, O''Neil TJ, Pierson WP, Crowe JT, Melikian AP, Wright GJ "Metoclopramide kinetics in patients with impaired renal function and clearance by hemodialysis." Clin Pharmacol Ther 37 (1985):  284-9|Lloveras J, Masramon J, Aubia J, Llorach M "Amiodarone, metoclopramide, and renal failure." Lancet 1 (1979):  981-2|Caralps A "Metoclopramide and renal failure." Lancet 1 (1979):  554|Bateman DN, Gokal R, Dodd TR, Blain PG "The pharmacokinetics of single doses of metoclopramide in renal failure." Eur J Clin Pharmacol 19 (1981):  437-41|"Product Information. Reglan (metoclopramide)." Wyeth-Ayerst Laboratories  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7642, 7827, 'Metoclopramide', 'Kidney Diseases', 'Renal function affects the clearance of metoclopramide.  In patients with varying degrees of renal impairment, a reduction in creatinine clearance was correlated with a reduction in plasma clearance, renal clearance, and non-renal clearance, and increase in elimination half-life of metoclopramide.  Therapy with metoclopramide should be administered cautiously in patients with impaired renal function.  A dosage reduction may be appropriate to avoid drug accumulation.', '2', 'Lehmann CR, Heironimus JD, Collins CB, O''Neil TJ, Pierson WP, Crowe JT, Melikian AP, Wright GJ "Metoclopramide kinetics in patients with impaired renal function and clearance by hemodialysis." Clin Pharmacol Ther 37 (1985):  284-9|Lloveras J, Masramon J, Aubia J, Llorach M "Amiodarone, metoclopramide, and renal failure." Lancet 1 (1979):  981-2|Caralps A "Metoclopramide and renal failure." Lancet 1 (1979):  554|Bateman DN, Gokal R, Dodd TR, Blain PG "The pharmacokinetics of single doses of metoclopramide in renal failure." Eur J Clin Pharmacol 19 (1981):  437-41|"Product Information. Reglan (metoclopramide)." Wyeth-Ayerst Laboratories  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7643, 7828, 'Metoclopramide', 'Kidney Diseases', 'Renal function affects the clearance of metoclopramide.  In patients with varying degrees of renal impairment, a reduction in creatinine clearance was correlated with a reduction in plasma clearance, renal clearance, and non-renal clearance, and increase in elimination half-life of metoclopramide.  Therapy with metoclopramide should be administered cautiously in patients with impaired renal function.  A dosage reduction may be appropriate to avoid drug accumulation.', '2', 'Lehmann CR, Heironimus JD, Collins CB, O''Neil TJ, Pierson WP, Crowe JT, Melikian AP, Wright GJ "Metoclopramide kinetics in patients with impaired renal function and clearance by hemodialysis." Clin Pharmacol Ther 37 (1985):  284-9|Lloveras J, Masramon J, Aubia J, Llorach M "Amiodarone, metoclopramide, and renal failure." Lancet 1 (1979):  981-2|Caralps A "Metoclopramide and renal failure." Lancet 1 (1979):  554|Bateman DN, Gokal R, Dodd TR, Blain PG "The pharmacokinetics of single doses of metoclopramide in renal failure." Eur J Clin Pharmacol 19 (1981):  437-41|"Product Information. Reglan (metoclopramide)." Wyeth-Ayerst Laboratories  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7644, 8097, 'Metoclopramide', 'Kidney Diseases', 'Renal function affects the clearance of metoclopramide.  In patients with varying degrees of renal impairment, a reduction in creatinine clearance was correlated with a reduction in plasma clearance, renal clearance, and non-renal clearance, and increase in elimination half-life of metoclopramide.  Therapy with metoclopramide should be administered cautiously in patients with impaired renal function.  A dosage reduction may be appropriate to avoid drug accumulation.', '2', 'Lehmann CR, Heironimus JD, Collins CB, O''Neil TJ, Pierson WP, Crowe JT, Melikian AP, Wright GJ "Metoclopramide kinetics in patients with impaired renal function and clearance by hemodialysis." Clin Pharmacol Ther 37 (1985):  284-9|Lloveras J, Masramon J, Aubia J, Llorach M "Amiodarone, metoclopramide, and renal failure." Lancet 1 (1979):  981-2|Caralps A "Metoclopramide and renal failure." Lancet 1 (1979):  554|Bateman DN, Gokal R, Dodd TR, Blain PG "The pharmacokinetics of single doses of metoclopramide in renal failure." Eur J Clin Pharmacol 19 (1981):  437-41|"Product Information. Reglan (metoclopramide)." Wyeth-Ayerst Laboratories  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7645, 25000, 'Metoclopramide', 'Kidney Diseases', 'Renal function affects the clearance of metoclopramide.  In patients with varying degrees of renal impairment, a reduction in creatinine clearance was correlated with a reduction in plasma clearance, renal clearance, and non-renal clearance, and increase in elimination half-life of metoclopramide.  Therapy with metoclopramide should be administered cautiously in patients with impaired renal function.  A dosage reduction may be appropriate to avoid drug accumulation.', '2', 'Lehmann CR, Heironimus JD, Collins CB, O''Neil TJ, Pierson WP, Crowe JT, Melikian AP, Wright GJ "Metoclopramide kinetics in patients with impaired renal function and clearance by hemodialysis." Clin Pharmacol Ther 37 (1985):  284-9|Lloveras J, Masramon J, Aubia J, Llorach M "Amiodarone, metoclopramide, and renal failure." Lancet 1 (1979):  981-2|Caralps A "Metoclopramide and renal failure." Lancet 1 (1979):  554|Bateman DN, Gokal R, Dodd TR, Blain PG "The pharmacokinetics of single doses of metoclopramide in renal failure." Eur J Clin Pharmacol 19 (1981):  437-41|"Product Information. Reglan (metoclopramide)." Wyeth-Ayerst Laboratories  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7646, 25001, 'Metoclopramide', 'Kidney Diseases', 'Renal function affects the clearance of metoclopramide.  In patients with varying degrees of renal impairment, a reduction in creatinine clearance was correlated with a reduction in plasma clearance, renal clearance, and non-renal clearance, and increase in elimination half-life of metoclopramide.  Therapy with metoclopramide should be administered cautiously in patients with impaired renal function.  A dosage reduction may be appropriate to avoid drug accumulation.', '2', 'Lehmann CR, Heironimus JD, Collins CB, O''Neil TJ, Pierson WP, Crowe JT, Melikian AP, Wright GJ "Metoclopramide kinetics in patients with impaired renal function and clearance by hemodialysis." Clin Pharmacol Ther 37 (1985):  284-9|Lloveras J, Masramon J, Aubia J, Llorach M "Amiodarone, metoclopramide, and renal failure." Lancet 1 (1979):  981-2|Caralps A "Metoclopramide and renal failure." Lancet 1 (1979):  554|Bateman DN, Gokal R, Dodd TR, Blain PG "The pharmacokinetics of single doses of metoclopramide in renal failure." Eur J Clin Pharmacol 19 (1981):  437-41|"Product Information. Reglan (metoclopramide)." Wyeth-Ayerst Laboratories  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7647, 25002, 'Metoclopramide', 'Kidney Diseases', 'Renal function affects the clearance of metoclopramide.  In patients with varying degrees of renal impairment, a reduction in creatinine clearance was correlated with a reduction in plasma clearance, renal clearance, and non-renal clearance, and increase in elimination half-life of metoclopramide.  Therapy with metoclopramide should be administered cautiously in patients with impaired renal function.  A dosage reduction may be appropriate to avoid drug accumulation.', '2', 'Lehmann CR, Heironimus JD, Collins CB, O''Neil TJ, Pierson WP, Crowe JT, Melikian AP, Wright GJ "Metoclopramide kinetics in patients with impaired renal function and clearance by hemodialysis." Clin Pharmacol Ther 37 (1985):  284-9|Lloveras J, Masramon J, Aubia J, Llorach M "Amiodarone, metoclopramide, and renal failure." Lancet 1 (1979):  981-2|Caralps A "Metoclopramide and renal failure." Lancet 1 (1979):  554|Bateman DN, Gokal R, Dodd TR, Blain PG "The pharmacokinetics of single doses of metoclopramide in renal failure." Eur J Clin Pharmacol 19 (1981):  437-41|"Product Information. Reglan (metoclopramide)." Wyeth-Ayerst Laboratories  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7648, 25257, 'Metoclopramide', 'Kidney Diseases', 'Renal function affects the clearance of metoclopramide.  In patients with varying degrees of renal impairment, a reduction in creatinine clearance was correlated with a reduction in plasma clearance, renal clearance, and non-renal clearance, and increase in elimination half-life of metoclopramide.  Therapy with metoclopramide should be administered cautiously in patients with impaired renal function.  A dosage reduction may be appropriate to avoid drug accumulation.', '2', 'Lehmann CR, Heironimus JD, Collins CB, O''Neil TJ, Pierson WP, Crowe JT, Melikian AP, Wright GJ "Metoclopramide kinetics in patients with impaired renal function and clearance by hemodialysis." Clin Pharmacol Ther 37 (1985):  284-9|Lloveras J, Masramon J, Aubia J, Llorach M "Amiodarone, metoclopramide, and renal failure." Lancet 1 (1979):  981-2|Caralps A "Metoclopramide and renal failure." Lancet 1 (1979):  554|Bateman DN, Gokal R, Dodd TR, Blain PG "The pharmacokinetics of single doses of metoclopramide in renal failure." Eur J Clin Pharmacol 19 (1981):  437-41|"Product Information. Reglan (metoclopramide)." Wyeth-Ayerst Laboratories  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7649, 25259, 'Metoclopramide', 'Kidney Diseases', 'Renal function affects the clearance of metoclopramide.  In patients with varying degrees of renal impairment, a reduction in creatinine clearance was correlated with a reduction in plasma clearance, renal clearance, and non-renal clearance, and increase in elimination half-life of metoclopramide.  Therapy with metoclopramide should be administered cautiously in patients with impaired renal function.  A dosage reduction may be appropriate to avoid drug accumulation.', '2', 'Lehmann CR, Heironimus JD, Collins CB, O''Neil TJ, Pierson WP, Crowe JT, Melikian AP, Wright GJ "Metoclopramide kinetics in patients with impaired renal function and clearance by hemodialysis." Clin Pharmacol Ther 37 (1985):  284-9|Lloveras J, Masramon J, Aubia J, Llorach M "Amiodarone, metoclopramide, and renal failure." Lancet 1 (1979):  981-2|Caralps A "Metoclopramide and renal failure." Lancet 1 (1979):  554|Bateman DN, Gokal R, Dodd TR, Blain PG "The pharmacokinetics of single doses of metoclopramide in renal failure." Eur J Clin Pharmacol 19 (1981):  437-41|"Product Information. Reglan (metoclopramide)." Wyeth-Ayerst Laboratories  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7650, 25261, 'Metoclopramide', 'Kidney Diseases', 'Renal function affects the clearance of metoclopramide.  In patients with varying degrees of renal impairment, a reduction in creatinine clearance was correlated with a reduction in plasma clearance, renal clearance, and non-renal clearance, and increase in elimination half-life of metoclopramide.  Therapy with metoclopramide should be administered cautiously in patients with impaired renal function.  A dosage reduction may be appropriate to avoid drug accumulation.', '2', 'Lehmann CR, Heironimus JD, Collins CB, O''Neil TJ, Pierson WP, Crowe JT, Melikian AP, Wright GJ "Metoclopramide kinetics in patients with impaired renal function and clearance by hemodialysis." Clin Pharmacol Ther 37 (1985):  284-9|Lloveras J, Masramon J, Aubia J, Llorach M "Amiodarone, metoclopramide, and renal failure." Lancet 1 (1979):  981-2|Caralps A "Metoclopramide and renal failure." Lancet 1 (1979):  554|Bateman DN, Gokal R, Dodd TR, Blain PG "The pharmacokinetics of single doses of metoclopramide in renal failure." Eur J Clin Pharmacol 19 (1981):  437-41|"Product Information. Reglan (metoclopramide)." Wyeth-Ayerst Laboratories  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7651, 27683, 'Metoclopramide', 'Kidney Diseases', 'Renal function affects the clearance of metoclopramide.  In patients with varying degrees of renal impairment, a reduction in creatinine clearance was correlated with a reduction in plasma clearance, renal clearance, and non-renal clearance, and increase in elimination half-life of metoclopramide.  Therapy with metoclopramide should be administered cautiously in patients with impaired renal function.  A dosage reduction may be appropriate to avoid drug accumulation.', '2', 'Lehmann CR, Heironimus JD, Collins CB, O''Neil TJ, Pierson WP, Crowe JT, Melikian AP, Wright GJ "Metoclopramide kinetics in patients with impaired renal function and clearance by hemodialysis." Clin Pharmacol Ther 37 (1985):  284-9|Lloveras J, Masramon J, Aubia J, Llorach M "Amiodarone, metoclopramide, and renal failure." Lancet 1 (1979):  981-2|Caralps A "Metoclopramide and renal failure." Lancet 1 (1979):  554|Bateman DN, Gokal R, Dodd TR, Blain PG "The pharmacokinetics of single doses of metoclopramide in renal failure." Eur J Clin Pharmacol 19 (1981):  437-41|"Product Information. Reglan (metoclopramide)." Wyeth-Ayerst Laboratories  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7652, 29582, 'Metoclopramide', 'Kidney Diseases', 'Renal function affects the clearance of metoclopramide.  In patients with varying degrees of renal impairment, a reduction in creatinine clearance was correlated with a reduction in plasma clearance, renal clearance, and non-renal clearance, and increase in elimination half-life of metoclopramide.  Therapy with metoclopramide should be administered cautiously in patients with impaired renal function.  A dosage reduction may be appropriate to avoid drug accumulation.', '2', 'Lehmann CR, Heironimus JD, Collins CB, O''Neil TJ, Pierson WP, Crowe JT, Melikian AP, Wright GJ "Metoclopramide kinetics in patients with impaired renal function and clearance by hemodialysis." Clin Pharmacol Ther 37 (1985):  284-9|Lloveras J, Masramon J, Aubia J, Llorach M "Amiodarone, metoclopramide, and renal failure." Lancet 1 (1979):  981-2|Caralps A "Metoclopramide and renal failure." Lancet 1 (1979):  554|Bateman DN, Gokal R, Dodd TR, Blain PG "The pharmacokinetics of single doses of metoclopramide in renal failure." Eur J Clin Pharmacol 19 (1981):  437-41|"Product Information. Reglan (metoclopramide)." Wyeth-Ayerst Laboratories  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7653, 29583, 'Metoclopramide', 'Kidney Diseases', 'Renal function affects the clearance of metoclopramide.  In patients with varying degrees of renal impairment, a reduction in creatinine clearance was correlated with a reduction in plasma clearance, renal clearance, and non-renal clearance, and increase in elimination half-life of metoclopramide.  Therapy with metoclopramide should be administered cautiously in patients with impaired renal function.  A dosage reduction may be appropriate to avoid drug accumulation.', '2', 'Lehmann CR, Heironimus JD, Collins CB, O''Neil TJ, Pierson WP, Crowe JT, Melikian AP, Wright GJ "Metoclopramide kinetics in patients with impaired renal function and clearance by hemodialysis." Clin Pharmacol Ther 37 (1985):  284-9|Lloveras J, Masramon J, Aubia J, Llorach M "Amiodarone, metoclopramide, and renal failure." Lancet 1 (1979):  981-2|Caralps A "Metoclopramide and renal failure." Lancet 1 (1979):  554|Bateman DN, Gokal R, Dodd TR, Blain PG "The pharmacokinetics of single doses of metoclopramide in renal failure." Eur J Clin Pharmacol 19 (1981):  437-41|"Product Information. Reglan (metoclopramide)." Wyeth-Ayerst Laboratories  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7654, 8083, 'Methylergometrine', 'Cardiotoxicity', 'The amine ergot alkaloids, ergonovine and methylergonovine, can cause serious cardiovascular complications because of their vasospastic effects.  Hypertension (more often with ergonovine) has been most commonly reported, particularly when administered IV undiluted or at an excessive rate or when used in conjunction with regional anesthesia or vasoconstrictors.  Headaches, seizures, cerebrovascular accidents and death have been associated with the hypertensive episodes.  Other, less common adverse effects include acute myocardial infarction, transient chest pains, thrombophlebitis, tachycardia and palpitations.  Therapy with ergot alkaloids should generally be avoided, except under special circumstances, in patients with chronic hypertension, preeclampsia or eclampsia, cardiovascular disease, cerebrovascular disease, or peripheral vascular disease.  Caution is advised when these agents are administered to patients with venoatrial shunts, mitral valve stenosis, or sepsis.  Close monitoring of cardiovascular status is highly recommended during therapy.', '3', 'American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|"Product Information. Ergotrate Maleate (ergonovine)." Bedford Laboratories  (2001):|"Product Information. Methergine (methylergonovine)." Novartis Pharmaceuticals  (2010):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7655, 8084, 'Methylergometrine', 'Cardiotoxicity', 'The amine ergot alkaloids, ergonovine and methylergonovine, can cause serious cardiovascular complications because of their vasospastic effects.  Hypertension (more often with ergonovine) has been most commonly reported, particularly when administered IV undiluted or at an excessive rate or when used in conjunction with regional anesthesia or vasoconstrictors.  Headaches, seizures, cerebrovascular accidents and death have been associated with the hypertensive episodes.  Other, less common adverse effects include acute myocardial infarction, transient chest pains, thrombophlebitis, tachycardia and palpitations.  Therapy with ergot alkaloids should generally be avoided, except under special circumstances, in patients with chronic hypertension, preeclampsia or eclampsia, cardiovascular disease, cerebrovascular disease, or peripheral vascular disease.  Caution is advised when these agents are administered to patients with venoatrial shunts, mitral valve stenosis, or sepsis.  Close monitoring of cardiovascular status is highly recommended during therapy.', '3', 'American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|"Product Information. Ergotrate Maleate (ergonovine)." Bedford Laboratories  (2001):|"Product Information. Methergine (methylergonovine)." Novartis Pharmaceuticals  (2010):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7656, 31431, 'Methylergometrine', 'Cardiotoxicity', 'The amine ergot alkaloids, ergonovine and methylergonovine, can cause serious cardiovascular complications because of their vasospastic effects.  Hypertension (more often with ergonovine) has been most commonly reported, particularly when administered IV undiluted or at an excessive rate or when used in conjunction with regional anesthesia or vasoconstrictors.  Headaches, seizures, cerebrovascular accidents and death have been associated with the hypertensive episodes.  Other, less common adverse effects include acute myocardial infarction, transient chest pains, thrombophlebitis, tachycardia and palpitations.  Therapy with ergot alkaloids should generally be avoided, except under special circumstances, in patients with chronic hypertension, preeclampsia or eclampsia, cardiovascular disease, cerebrovascular disease, or peripheral vascular disease.  Caution is advised when these agents are administered to patients with venoatrial shunts, mitral valve stenosis, or sepsis.  Close monitoring of cardiovascular status is highly recommended during therapy.', '3', 'American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|"Product Information. Ergotrate Maleate (ergonovine)." Bedford Laboratories  (2001):|"Product Information. Methergine (methylergonovine)." Novartis Pharmaceuticals  (2010):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7657, 8083, 'Methylergometrine', 'Hypertension', 'The use of the amine ergot alkaloids, ergonovine and methylergonovine, is considered by some clinicians to be contraindicated in patients with hypertension.  These agents can cause hypertension, particularly when administered IV undiluted or at an excessive rate or when used in conjunction with regional anesthesia or vasoconstrictors.  Headaches, seizures, cerebrovascular accidents and death have been associated with the hypertensive episodes.  Patients with chronic hypertension or preeclampsia may be at increased risk for these complications.  Of the two agents, methylergonovine has less tendency to cause hypertension, although preferably neither agent should be administered to at- risk patients.', '3', 'American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|"Product Information. Ergotrate Maleate (ergonovine)." Bedford Laboratories  (2001):|"Product Information. Methergine (methylergonovine)." Novartis Pharmaceuticals  (2010):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7658, 8084, 'Methylergometrine', 'Hypertension', 'The use of the amine ergot alkaloids, ergonovine and methylergonovine, is considered by some clinicians to be contraindicated in patients with hypertension.  These agents can cause hypertension, particularly when administered IV undiluted or at an excessive rate or when used in conjunction with regional anesthesia or vasoconstrictors.  Headaches, seizures, cerebrovascular accidents and death have been associated with the hypertensive episodes.  Patients with chronic hypertension or preeclampsia may be at increased risk for these complications.  Of the two agents, methylergonovine has less tendency to cause hypertension, although preferably neither agent should be administered to at- risk patients.', '3', 'American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|"Product Information. Ergotrate Maleate (ergonovine)." Bedford Laboratories  (2001):|"Product Information. Methergine (methylergonovine)." Novartis Pharmaceuticals  (2010):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7659, 31431, 'Methylergometrine', 'Hypertension', 'The use of the amine ergot alkaloids, ergonovine and methylergonovine, is considered by some clinicians to be contraindicated in patients with hypertension.  These agents can cause hypertension, particularly when administered IV undiluted or at an excessive rate or when used in conjunction with regional anesthesia or vasoconstrictors.  Headaches, seizures, cerebrovascular accidents and death have been associated with the hypertensive episodes.  Patients with chronic hypertension or preeclampsia may be at increased risk for these complications.  Of the two agents, methylergonovine has less tendency to cause hypertension, although preferably neither agent should be administered to at- risk patients.', '3', 'American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|"Product Information. Ergotrate Maleate (ergonovine)." Bedford Laboratories  (2001):|"Product Information. Methergine (methylergonovine)." Novartis Pharmaceuticals  (2010):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7660, 8083, 'Methylergometrine', 'Liver Diseases', 'The amine ergot alkaloids, ergonovine and methylergonovine, appear to be eliminated by both renal and hepatic routes.  Patients with renal and/or liver disease may be at greater risk for adverse effects from these agents due to decreased drug clearance.  Caution is advised if these agents are used.  Dosage adjustments may be necessary.', '2', '"Product Information. Ergotrate Maleate (ergonovine)." Bedford Laboratories  (2001):|"Product Information. Methergine (methylergonovine)." Novartis Pharmaceuticals  (2010):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7661, 8084, 'Methylergometrine', 'Liver Diseases', 'The amine ergot alkaloids, ergonovine and methylergonovine, appear to be eliminated by both renal and hepatic routes.  Patients with renal and/or liver disease may be at greater risk for adverse effects from these agents due to decreased drug clearance.  Caution is advised if these agents are used.  Dosage adjustments may be necessary.', '2', '"Product Information. Ergotrate Maleate (ergonovine)." Bedford Laboratories  (2001):|"Product Information. Methergine (methylergonovine)." Novartis Pharmaceuticals  (2010):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7662, 31431, 'Methylergometrine', 'Liver Diseases', 'The amine ergot alkaloids, ergonovine and methylergonovine, appear to be eliminated by both renal and hepatic routes.  Patients with renal and/or liver disease may be at greater risk for adverse effects from these agents due to decreased drug clearance.  Caution is advised if these agents are used.  Dosage adjustments may be necessary.', '2', '"Product Information. Ergotrate Maleate (ergonovine)." Bedford Laboratories  (2001):|"Product Information. Methergine (methylergonovine)." Novartis Pharmaceuticals  (2010):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7663, 721, 'Methylnaltrexone', 'Intestinal Obstruction', 'Peripheral opioid receptor antagonists are contraindicated in patients with known or suspected gastrointestinal obstruction, and in patients at increased risk of recurrent obstruction, due to the potential for gastrointestinal perforation.  Cases of gastrointestinal perforation have been reported in patients with opioid-induced constipation and advanced illness with conditions that may be associated with localized or diffuse reduction of structure integrity in the wall of the GI tract such as peptic ulcer, diverticular disease, Crohn''s disease, infiltrative GI tract malignancies or peritoneal metastases.  It is recommended to monitor for the development of severe, persistent, or worsening abdominal pain and to discontinue treatment in patients who develop symptoms.  The overall risk- benefit profile should be carefully evaluated before using these agents in patients with these conditions.', '3', '"Product Information. Relistor (methylnaltrexone)." Wyeth Laboratories  (2008):|"Product Information. Movantik (naloxegol)." Astra-Zeneca Pharmaceuticals  (2014):|"Product Information. Symproic (naldemedine)." Shionogi USA Inc  (2017):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7664, 3401, 'Methylnaltrexone', 'Intestinal Obstruction', 'Peripheral opioid receptor antagonists are contraindicated in patients with known or suspected gastrointestinal obstruction, and in patients at increased risk of recurrent obstruction, due to the potential for gastrointestinal perforation.  Cases of gastrointestinal perforation have been reported in patients with opioid-induced constipation and advanced illness with conditions that may be associated with localized or diffuse reduction of structure integrity in the wall of the GI tract such as peptic ulcer, diverticular disease, Crohn''s disease, infiltrative GI tract malignancies or peritoneal metastases.  It is recommended to monitor for the development of severe, persistent, or worsening abdominal pain and to discontinue treatment in patients who develop symptoms.  The overall risk- benefit profile should be carefully evaluated before using these agents in patients with these conditions.', '3', '"Product Information. Relistor (methylnaltrexone)." Wyeth Laboratories  (2008):|"Product Information. Movantik (naloxegol)." Astra-Zeneca Pharmaceuticals  (2014):|"Product Information. Symproic (naldemedine)." Shionogi USA Inc  (2017):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7665, 6738, 'Methylnaltrexone', 'Intestinal Obstruction', 'Peripheral opioid receptor antagonists are contraindicated in patients with known or suspected gastrointestinal obstruction, and in patients at increased risk of recurrent obstruction, due to the potential for gastrointestinal perforation.  Cases of gastrointestinal perforation have been reported in patients with opioid-induced constipation and advanced illness with conditions that may be associated with localized or diffuse reduction of structure integrity in the wall of the GI tract such as peptic ulcer, diverticular disease, Crohn''s disease, infiltrative GI tract malignancies or peritoneal metastases.  It is recommended to monitor for the development of severe, persistent, or worsening abdominal pain and to discontinue treatment in patients who develop symptoms.  The overall risk- benefit profile should be carefully evaluated before using these agents in patients with these conditions.', '3', '"Product Information. Relistor (methylnaltrexone)." Wyeth Laboratories  (2008):|"Product Information. Movantik (naloxegol)." Astra-Zeneca Pharmaceuticals  (2014):|"Product Information. Symproic (naldemedine)." Shionogi USA Inc  (2017):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7666, 6993, 'Methylnaltrexone', 'Intestinal Obstruction', 'Peripheral opioid receptor antagonists are contraindicated in patients with known or suspected gastrointestinal obstruction, and in patients at increased risk of recurrent obstruction, due to the potential for gastrointestinal perforation.  Cases of gastrointestinal perforation have been reported in patients with opioid-induced constipation and advanced illness with conditions that may be associated with localized or diffuse reduction of structure integrity in the wall of the GI tract such as peptic ulcer, diverticular disease, Crohn''s disease, infiltrative GI tract malignancies or peritoneal metastases.  It is recommended to monitor for the development of severe, persistent, or worsening abdominal pain and to discontinue treatment in patients who develop symptoms.  The overall risk- benefit profile should be carefully evaluated before using these agents in patients with these conditions.', '3', '"Product Information. Relistor (methylnaltrexone)." Wyeth Laboratories  (2008):|"Product Information. Movantik (naloxegol)." Astra-Zeneca Pharmaceuticals  (2014):|"Product Information. Symproic (naldemedine)." Shionogi USA Inc  (2017):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7667, 17233, 'Methylnaltrexone', 'Intestinal Obstruction', 'Peripheral opioid receptor antagonists are contraindicated in patients with known or suspected gastrointestinal obstruction, and in patients at increased risk of recurrent obstruction, due to the potential for gastrointestinal perforation.  Cases of gastrointestinal perforation have been reported in patients with opioid-induced constipation and advanced illness with conditions that may be associated with localized or diffuse reduction of structure integrity in the wall of the GI tract such as peptic ulcer, diverticular disease, Crohn''s disease, infiltrative GI tract malignancies or peritoneal metastases.  It is recommended to monitor for the development of severe, persistent, or worsening abdominal pain and to discontinue treatment in patients who develop symptoms.  The overall risk- benefit profile should be carefully evaluated before using these agents in patients with these conditions.', '3', '"Product Information. Relistor (methylnaltrexone)." Wyeth Laboratories  (2008):|"Product Information. Movantik (naloxegol)." Astra-Zeneca Pharmaceuticals  (2014):|"Product Information. Symproic (naldemedine)." Shionogi USA Inc  (2017):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7668, 25953, 'Methylnaltrexone', 'Intestinal Obstruction', 'Peripheral opioid receptor antagonists are contraindicated in patients with known or suspected gastrointestinal obstruction, and in patients at increased risk of recurrent obstruction, due to the potential for gastrointestinal perforation.  Cases of gastrointestinal perforation have been reported in patients with opioid-induced constipation and advanced illness with conditions that may be associated with localized or diffuse reduction of structure integrity in the wall of the GI tract such as peptic ulcer, diverticular disease, Crohn''s disease, infiltrative GI tract malignancies or peritoneal metastases.  It is recommended to monitor for the development of severe, persistent, or worsening abdominal pain and to discontinue treatment in patients who develop symptoms.  The overall risk- benefit profile should be carefully evaluated before using these agents in patients with these conditions.', '3', '"Product Information. Relistor (methylnaltrexone)." Wyeth Laboratories  (2008):|"Product Information. Movantik (naloxegol)." Astra-Zeneca Pharmaceuticals  (2014):|"Product Information. Symproic (naldemedine)." Shionogi USA Inc  (2017):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7669, 721, 'Methylnaltrexone', 'Hepatic Insufficiency', 'Studies have shown a significant increase in systemic exposure of methylnaltrexone in patients with moderate and severe hepatic impairment, compared to subjects with normal hepatic function.  A dosage reduction is recommended in these patients.  No dose adjustment is needed in patients with mild hepatic impairment.', '2', '"Product Information. Relistor (methylnaltrexone)." Wyeth Laboratories  (2008):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7670, 3401, 'Methylnaltrexone', 'Hepatic Insufficiency', 'Studies have shown a significant increase in systemic exposure of methylnaltrexone in patients with moderate and severe hepatic impairment, compared to subjects with normal hepatic function.  A dosage reduction is recommended in these patients.  No dose adjustment is needed in patients with mild hepatic impairment.', '2', '"Product Information. Relistor (methylnaltrexone)." Wyeth Laboratories  (2008):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7671, 6738, 'Methylnaltrexone', 'Hepatic Insufficiency', 'Studies have shown a significant increase in systemic exposure of methylnaltrexone in patients with moderate and severe hepatic impairment, compared to subjects with normal hepatic function.  A dosage reduction is recommended in these patients.  No dose adjustment is needed in patients with mild hepatic impairment.', '2', '"Product Information. Relistor (methylnaltrexone)." Wyeth Laboratories  (2008):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7672, 6993, 'Methylnaltrexone', 'Hepatic Insufficiency', 'Studies have shown a significant increase in systemic exposure of methylnaltrexone in patients with moderate and severe hepatic impairment, compared to subjects with normal hepatic function.  A dosage reduction is recommended in these patients.  No dose adjustment is needed in patients with mild hepatic impairment.', '2', '"Product Information. Relistor (methylnaltrexone)." Wyeth Laboratories  (2008):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7673, 17233, 'Methylnaltrexone', 'Hepatic Insufficiency', 'Studies have shown a significant increase in systemic exposure of methylnaltrexone in patients with moderate and severe hepatic impairment, compared to subjects with normal hepatic function.  A dosage reduction is recommended in these patients.  No dose adjustment is needed in patients with mild hepatic impairment.', '2', '"Product Information. Relistor (methylnaltrexone)." Wyeth Laboratories  (2008):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7674, 25953, 'Methylnaltrexone', 'Hepatic Insufficiency', 'Studies have shown a significant increase in systemic exposure of methylnaltrexone in patients with moderate and severe hepatic impairment, compared to subjects with normal hepatic function.  A dosage reduction is recommended in these patients.  No dose adjustment is needed in patients with mild hepatic impairment.', '2', '"Product Information. Relistor (methylnaltrexone)." Wyeth Laboratories  (2008):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7675, 721, 'Methylnaltrexone', 'Kidney Diseases', 'Patients with moderate, severe and end-stage renal disease have shown to exhibit markedly higher systemic exposure to peripheral opioid receptor antagonists such as methylnaltrexone and naloxegol, compared to subjects with normal renal function.  A dose reduction is recommended for these patients.  No dosage adjustment is needed in patients with mild renal impairment.', '2', '"Product Information. Relistor (methylnaltrexone)." Wyeth Laboratories  (2008):|"Product Information. Movantik (naloxegol)." Astra-Zeneca Pharmaceuticals  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7676, 3401, 'Methylnaltrexone', 'Kidney Diseases', 'Patients with moderate, severe and end-stage renal disease have shown to exhibit markedly higher systemic exposure to peripheral opioid receptor antagonists such as methylnaltrexone and naloxegol, compared to subjects with normal renal function.  A dose reduction is recommended for these patients.  No dosage adjustment is needed in patients with mild renal impairment.', '2', '"Product Information. Relistor (methylnaltrexone)." Wyeth Laboratories  (2008):|"Product Information. Movantik (naloxegol)." Astra-Zeneca Pharmaceuticals  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7677, 6738, 'Methylnaltrexone', 'Kidney Diseases', 'Patients with moderate, severe and end-stage renal disease have shown to exhibit markedly higher systemic exposure to peripheral opioid receptor antagonists such as methylnaltrexone and naloxegol, compared to subjects with normal renal function.  A dose reduction is recommended for these patients.  No dosage adjustment is needed in patients with mild renal impairment.', '2', '"Product Information. Relistor (methylnaltrexone)." Wyeth Laboratories  (2008):|"Product Information. Movantik (naloxegol)." Astra-Zeneca Pharmaceuticals  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7678, 6993, 'Methylnaltrexone', 'Kidney Diseases', 'Patients with moderate, severe and end-stage renal disease have shown to exhibit markedly higher systemic exposure to peripheral opioid receptor antagonists such as methylnaltrexone and naloxegol, compared to subjects with normal renal function.  A dose reduction is recommended for these patients.  No dosage adjustment is needed in patients with mild renal impairment.', '2', '"Product Information. Relistor (methylnaltrexone)." Wyeth Laboratories  (2008):|"Product Information. Movantik (naloxegol)." Astra-Zeneca Pharmaceuticals  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7679, 17233, 'Methylnaltrexone', 'Kidney Diseases', 'Patients with moderate, severe and end-stage renal disease have shown to exhibit markedly higher systemic exposure to peripheral opioid receptor antagonists such as methylnaltrexone and naloxegol, compared to subjects with normal renal function.  A dose reduction is recommended for these patients.  No dosage adjustment is needed in patients with mild renal impairment.', '2', '"Product Information. Relistor (methylnaltrexone)." Wyeth Laboratories  (2008):|"Product Information. Movantik (naloxegol)." Astra-Zeneca Pharmaceuticals  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7680, 25953, 'Methylnaltrexone', 'Kidney Diseases', 'Patients with moderate, severe and end-stage renal disease have shown to exhibit markedly higher systemic exposure to peripheral opioid receptor antagonists such as methylnaltrexone and naloxegol, compared to subjects with normal renal function.  A dose reduction is recommended for these patients.  No dosage adjustment is needed in patients with mild renal impairment.', '2', '"Product Information. Relistor (methylnaltrexone)." Wyeth Laboratories  (2008):|"Product Information. Movantik (naloxegol)." Astra-Zeneca Pharmaceuticals  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7681, 17239, 'Metolazone', 'Anuria', 'The use of thiazide diuretics is contraindicated in patients with anuria.', '3', '"Product Information. HydroDIURIL (hydrochlorothiazide)." Merck & Co., Inc  (2002):|"Product Information. Lozol (indapamide)." Rhone Poulenc Rorer  (2002):|"Product Information. Zaroxolyn (metolazone)." Rhone Poulenc Rorer  (2001):|"Product Information. Thalitone (chlorthalidone)." Monarch Pharmaceuticals Inc  (2001):|"Product Information. Diuril (chlorothiazide)." Merck & Co., Inc  (2001):|"Product Information. Enduron (methyclothiazide)." Abbott Pharmaceutical  (2001):|"Product Information. Metahydrin (trichlormethiazide)." Hoechst Marion Roussel  (2001):|"Product Information. Diucardin (hydroflumethiazide)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Renese-R (reserpine-polythiazide)." Pfizer US Pharmaceuticals, New York, NY.', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7682, 18087, 'Metolazone', 'Anuria', 'The use of thiazide diuretics is contraindicated in patients with anuria.', '3', '"Product Information. HydroDIURIL (hydrochlorothiazide)." Merck & Co., Inc  (2002):|"Product Information. Lozol (indapamide)." Rhone Poulenc Rorer  (2002):|"Product Information. Zaroxolyn (metolazone)." Rhone Poulenc Rorer  (2001):|"Product Information. Thalitone (chlorthalidone)." Monarch Pharmaceuticals Inc  (2001):|"Product Information. Diuril (chlorothiazide)." Merck & Co., Inc  (2001):|"Product Information. Enduron (methyclothiazide)." Abbott Pharmaceutical  (2001):|"Product Information. Metahydrin (trichlormethiazide)." Hoechst Marion Roussel  (2001):|"Product Information. Diucardin (hydroflumethiazide)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Renese-R (reserpine-polythiazide)." Pfizer US Pharmaceuticals, New York, NY.', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7683, 22666, 'Metolazone', 'Anuria', 'The use of thiazide diuretics is contraindicated in patients with anuria.', '3', '"Product Information. HydroDIURIL (hydrochlorothiazide)." Merck & Co., Inc  (2002):|"Product Information. Lozol (indapamide)." Rhone Poulenc Rorer  (2002):|"Product Information. Zaroxolyn (metolazone)." Rhone Poulenc Rorer  (2001):|"Product Information. Thalitone (chlorthalidone)." Monarch Pharmaceuticals Inc  (2001):|"Product Information. Diuril (chlorothiazide)." Merck & Co., Inc  (2001):|"Product Information. Enduron (methyclothiazide)." Abbott Pharmaceutical  (2001):|"Product Information. Metahydrin (trichlormethiazide)." Hoechst Marion Roussel  (2001):|"Product Information. Diucardin (hydroflumethiazide)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Renese-R (reserpine-polythiazide)." Pfizer US Pharmaceuticals, New York, NY.', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7684, 26084, 'Metolazone', 'Anuria', 'The use of thiazide diuretics is contraindicated in patients with anuria.', '3', '"Product Information. HydroDIURIL (hydrochlorothiazide)." Merck & Co., Inc  (2002):|"Product Information. Lozol (indapamide)." Rhone Poulenc Rorer  (2002):|"Product Information. Zaroxolyn (metolazone)." Rhone Poulenc Rorer  (2001):|"Product Information. Thalitone (chlorthalidone)." Monarch Pharmaceuticals Inc  (2001):|"Product Information. Diuril (chlorothiazide)." Merck & Co., Inc  (2001):|"Product Information. Enduron (methyclothiazide)." Abbott Pharmaceutical  (2001):|"Product Information. Metahydrin (trichlormethiazide)." Hoechst Marion Roussel  (2001):|"Product Information. Diucardin (hydroflumethiazide)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Renese-R (reserpine-polythiazide)." Pfizer US Pharmaceuticals, New York, NY.', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7685, 17239, 'Metolazone', 'Water-Electrolyte Imbalance', 'The use of thiazide diuretics is commonly associated with loss of electrolytes, most significantly potassium but also sodium, chloride, bicarbonate, and magnesium.  The loss of other electrolytes such as phosphate, bromide and iodide is usually slight.  Potassium and magnesium depletion may lead to cardiac arrhythmias and cardiac arrest.  Other electrolyte-related complications include metabolic alkalosis and hyponatremia, which are rarely life-threatening.  Therapy with thiazide diuretics should be administered cautiously in patients with or predisposed to fluid and electrolyte depletion, including patients with primary or secondary aldosteronism (may have low potassium levels); those with severe or prolonged diarrhea or vomiting; and those with poor nutritional status.  Fluid and electrolyte abnormalities should be corrected prior to initiating therapy, and blood pressure as well as serum electrolyte concentrations monitored periodically and maintained at normal ranges during therapy.  Patients should be advised to immediately report signs and symptoms of fluid or electrolyte imbalance, including dry mouth, thirst, weakness, lethargy, drowsiness, restlessness, muscle pains or cramps, muscular fatigue, hypotension, oliguria, tachycardia, arrhythmia, or gastrointestinal disturbances such as nausea and vomiting.  Digitalized patients and patients with a history of ventricular arrhythmias should be monitored carefully, since development of hypokalemia may be particularly dangerous in these patients.  The risk of hypokalemia may be minimized by slow diuresis, a lower thiazide dosage, potassium supplementation, or combined use with a potassium-sparing diuretic.', '3', 'Lindy S, Tarssanen L "Serum calcium and phosphorus in patients treated with thiazides and furosemide." Acta Med Scand 194 (1973):  319-22|Leigh H "Letter: Factitious hypokalemia." Ann Intern Med 80 (1974):  111-2|Moore TD, Bechtel TP "Hyponatremia secondary to tolbutamide and chlorothiazide." Am J Hosp Pharm 36 (1979):  1107-10|Falch DK, Schreiner AM "Changes in urinary electrolytes versus serum electrolytes during treatment of primary hypertension with chlorthalidone alone and in combination with spironolactone." Acta Med Scand 209 (1981):  111-4|Papademetriou V, Fletcher R, Khatri IM, Freis ED "Diuretic-induced hypokalemia in uncomplicated systemic hypertension: effect of plasma potassium correction on cardiac arrhythmias." Am J Cardiol 52 (1983):  1017-22|Kuller L, Farrier N, Caggiula A, Borhani N, Dunkle S "Relationship of diuretic therapy and serum magnesium levels among participants in the Multiple Risk Factor Intervention Trial." Am J Epidemiol 122 (1985):  1045-59|Remenchik AP, Johnston LC "Potassium depletion produced by administration of chlorthalidone to nonedematous patients with arterial hypertensin." Am J Med Sci 252 (1966):  171-6|Katz FH, Eckert RC, Gebott MD "Hypokalemia caused by surreptitious self-administration of diuretics." Ann Intern Med 76 (1972):  85-90|Fichman MP, Vorherr H, Kleeman CR, Telfer N "Diuretic-induced hyponatremia." Ann Intern Med 75 (1971):  853-63|Stewart DE, Ikram H, Espiner EA, Nicholls MG "Arrhythmogenic potential of diuretic induced hypokalaemia in patients with mild hypertension and ischaemic heart disease." Br Heart J 54 (1985):  290-7|Kuller LH, Hulley SB, Cohen JD, Neaton J "Unexpected effects of treating hypertension in men with electrocardiographic abnormalities: a critical analysis." Circulation 73 (1986):  114-23|Landmann-Suter R, Struyvenberg A "Initial potassium loss and hypokalaemia during chlorthalidone administration in patients with essential hypertension: the influence of dietary sodium restriction." Eur J Clin Invest 8 (1978):  155-64|Navarro RP, O''Brien DK, Nuffort P, Spencer DL "Diuretic induced hypokalemia in the elderly." J Fam Pract 14 (1982):  685-9|Oh SJ, Douglas JE, Brown RA "Hypokalemic vacuolar myopathy associated with chlorthalidone treatment." JAMA 216 (1971):  1858-9|Mozes B, Pines A, Werner D, Olchovsky D, Lieberman P, Frankl O "Thiazide-induced hyponatremia: an unusual neurologic course." South Med J 79 (1986):  629-31|Jensen OB, Mosdal C, Reske-Nielsen E "Hypokalemic myopathy during treatment with diuretics." Acta Neurol Scand 55 (1977):  465-82|Cembrowski GS, Huntington RW, 3d "Probable fatal cardiac dysrhythmia secondary to diuretic-induced hypokalemia." Am J Forensic Med Pathol 2 (1981):  243-8|Sumiye L, Vivian AS, Frisof KB, Podany EC "Potassium loss associated with hydrochlorothiazide versus chlorthalidone." Clin Ther 4 (1981):  308-20|Berg KJ, Gisholt K, Wideroe TE "Potassium deficiency in hypertensives treated with diuretics. Analysis of three alternative treatments by an oral test for potassium deficiency." Eur J Clin Pharmacol 7 (1974):  401-5|Chowdhury FR, Bleicher SJ "Chlorthalidone--induced hypokalemia and abnormal carbohydrate metabolism." Horm Metab Res 2 (1970):  13-6|Carney SL, Morgan TO "Diuretic-induced hypokalemia and altered renal function." Int J Clin Pharmacol Ther Toxicol 24 (1986):  665-7|Ragnarsson J, Hardarson T, Snorrason SP "Ventricular dysrhythmias in middle-aged hypertensive men treated either with a diuretic agent or a beta-blocker." Acta Med Scand 221 (1987):  143-8|Hollifield JW, Slaton PE "Thiazide diuretics, hypokalemia and cardiac arrhythmias." Acta Med Scand Suppl 647 (1981):  67-73|Papademetriou V, Price M, Notargiacomo A, Gottdiener J, Fletcher RD, Freis ED "Effect of diuretic therapy on ventricular arrhythmias in hypertensive patients with or without left ventricular hypertrophy." Am Heart J 110 (1985):  595-9|Papademetriou V, Fletcher R, Khatri IM, Freis ED "Diuretic-induced hypokalemia in uncomplicated systemic hypertension: effect of plasma potassium correction on cardiac arrhythmias." Am J Cardiol 52 (1983):  1017-22|Krishna GG, Narins RG "Hemodynamic consequences of diuretic-induced hypokalemia." Am J Kidney Dis 12 (1988):  329-31|Polanska AI, Baron DN "Hyponatraemia associated with hydrochlorothiazide treatment ." Br Med J 1 (1978):  175-6|Pinnock CA "Hyponatraemia associated with hydrochlorothiazide treatment ." Br Med J 1 (1978):  48|Itescu S, Haskell LP, Tannenberg AM "Thiazide-induced clinically significant hypophosphatemia ." Clin Nephrol 27 (1987):  161-2|Byatt CM, Millard PH, Levin GE "Diuretics and electrolyte disturbances in 1000 consecutive geriatric admissions." J R Soc Med 83 (1990):  704-8|Bain PG, Egner W, Walker PR "Thiazide-induced dilutional hyponatraemia masquerading as subarachnoid haemorrhage ." Lancet 2 (1986):  634|Benfield GF, Haffner C, Harris P, Stableforth DE "Dilutional hyponatraemia masquerading as subarachnoid haemorrhage in patient on hydrochlorothiazide/amiloride/timolol combined drug ." Lancet 2 (1986):  341|Gould L, Reddy CV, Zen B, Singh BK "Life-threatening reaction to thiazides." N Y State J Med 80 (1980):  1975-6|Seelig CB "Magnesium deficiency in two hypertensive patient groups." South Med J 83 (1990):  739-42|Peters RW, Hamilton J, Hamilton BP "Incidence of cardiac arrhythmias associated with mild hypokalemia induced by low-dose diuretic therapy for hypertension." South Med J 82 (1989):  966-9,|Kone B, Gimenez L, Watson AJ "Thiazide-induced hyponatremia." South Med J 79 (1986):  1456-7|Holland OB, Kuhnert L, Pollard J, Padia M, Anderson RJ, Blomqvist G "Ventricular ectopic activity with diuretic therapy." Am J Hypertens 1 (1988):  380-5|Mouallem M, Friedman E, Shemesh Y, Mayan H, Pauzner R, Farfel Z "Cardiac conduction defects associated with hyponatremia." Clin Cardiol 14 (1991):  165-8|Kaur J, Wahi PL "Polythiazide as a diuretic. A clinical trial." J Indian Med Assoc 48 (1967):  13-7|Mroczek WJ "Indapamide: clinical pharmacology, therapeutic efficacy in hypertension, and adverse effects." Pharmacotherapy 3 (1983):  61-7|Beling S, Vukovich RA, Neiss ES, Zisblatt M, Webb E, Losi M "Long-term experience with indapamide." Am Heart J 106 (1983):  258-62|Slotkoff L "Clinical efficacy and safety of indapamide in the treatment of edema." Am Heart J 106 (1983):  233-7|"Product Information. HydroDIURIL (hydrochlorothiazide)." Merck & Co., Inc  (2002):|"Product Information. Lozol (indapamide)." Rhone Poulenc Rorer  (2002):|"Product Information. Zaroxolyn (metolazone)." Rhone Poulenc Rorer  (2001):|Stern A "Metolazone, a diuretic agent." Am Heart J 91 (1976):  262-3|Black W, Shiner P, Roman J "Severe electrolyte disturbances associated with metolazone and furosemide." South Med J 71 (1978):  381|"Product Information. Thalitone (chlorthalidone)." Monarch Pharmaceuticals Inc  (2001):|"Product Information. Diuril (chlorothiazide)." Merck & Co., Inc  (2001):|Ghose RR "Letter: Hyponatraemia and diuretics." Lancet 1 (1975):  578-9|Brors O, Enger E, Jacobsen S, Aakvaag A, Foss OP "Effects of hydroflumethiazide in congestive heart failure: renal electrolyte excretion related to urinary thiazide excretion and aldosterone." Acta Pharmacol Toxicol (Copenh) 49 (1981):  399-406|Brors O, Jacobsen S, Foss OP, Aakvaag A "Effect of repeated doses of hydroflumethiazide on renal excretion of electrolytes and uric acid in healthy subjects." Acta Pharmacol Toxicol (Copenh) 48 (1981):  145-50|el-Meheiry MM, Nabih AE, Soliman MD "A clinical study of a new diuretic, Trichlormethiazide." J Trop Med Hyg 69 (1966):  209-14|"Product Information. Enduron (methyclothiazide)." Abbott Pharmaceutical  (2001):|"Product Information. Metahydrin (trichlormethiazide)." Hoechst Marion Roussel  (2001):|"Product Information. Diucardin (hydroflumethiazide)." Wyeth-Ayerst Laboratories  (2001):|Husby S, Marthedal NJ "Hyponatraemia due to a thiazide diuretic. A case report." Acta Med Scand 210 (1981):  523-4|Berglund G, Andersson O, Larsson O, Wilhelmsen L "Antihypertensive effect and side-effects of bendroflumethiazide and propranolol." Acta Med Scand 199 (1976):  499-506|Gudbrandsson T, Hansson L "Combination therapy with saluretics and atenolol in essential hypertension. Effects on blood pressure, electrolytes and uric acid." Acta Med Scand Suppl 625 (1979):  86-91|Elmfeldt D, Berglund G, Wedel H, Wilhelmsen L "Incidence and importance of metabolic side-effects during antihypertensive therapy." Acta Med Scand Suppl 672 (1983):  79-83|Condon JR, Nassim R "Hypophosphataemia and hypokalaemia." Br Med J 1 (1970):  110|Winchester JF, Kellett RJ, Boddy K, Boyle P, Dargie HJ, Mahaffey ME, Ward DM, Kennedy AC "Metolazone and bendroflumethiazide in hypertension: physiologic and metabolic observations." Clin Pharmacol Ther 28 (1980):  611-8|Lee MR, Morgan DB "Familial hyperkalaemia responsive to benzothiadiazine diuretic." Lancet 1 (1980):  879|Hesp R, Wilkinson PR "Potassium supplementation of thiazide therapy." Lancet 2 (1976):  1144|Struthers AD, Whitesmith R, Reid JL "Prior thiazide diuretic treatment increases adrenaline-induced hypokalaemia." Lancet 1 (1983):  1358-61|Petri M, Cumber P, Grimes L, Treby D, Bryant R, Rawlins D, Ising H "The metabolic effects of thiazide therapy in the elderly: a population study." Age Ageing 15 (1986):  151-5|Starr JM, Whalley LJ "Hypertensive Old People in Edinburgh (HOPE) Study: electrocardiographic changes after captopril or bendrofluazide treatment." Age Ageing 22 (1993):  343-8|Toner JM, Ramsay LE "Thiazide-induced hypokalaemia; prevalence higher in women." Br J Clin Pharmacol 18 (1984):  449-52|Jorgensen FS, Brunner S "The long-term effect of bendroflumethiazide on renal calcium and magnesium excretion and stone formation in patients with recurring renal stones." Scand J Urol Nephrol 8 (1974):  128-31|Ljunghall S, Backman U, Danielson BG, Fellstrom B, Johansson G, Wikstrom B "Calcium and magnesium metabolism during long-term treatment with thiazides." Scand J Urol Nephrol 15 (1981):  257-62|Medical Research Council Working Party on Mild to Moderate Hypertension. "Ventricular extrasystoles during thiazide treatment: substudy of MRC mild hypertension trial." Br Med J (Clin Res Ed) 287 (1983):  1249-53|"Product Information. Renese-R (reserpine-polythiazide)." Pfizer US Pharmaceuticals, New York, NY.|Freis ED "The efficacy and safety of diuretics in treating hypertension." Ann Intern Med 122 (1995):  223-6|Read SJ, Trenerry HM, Whiting GF "Hyponatraemia and raised creatine kinase level associated with indapamide." Med J Aust 161 (1994):  607-8|Chan TY "Indapamide-induced severe hyponatremia and hypokalemia." Ann Pharmacother 29 (1995):  1124-8|Simunic M, Rumboldt Z, Ljutic D, Sardelic S "Ramipril decreases chlorthalidone-induced loss of magnesium and potassium in hypertensive patients." J Clin Pharmacol 35 (1995):  1150-5|Brater DC "Drug therapy: Diuretic therapy." N Engl J Med 339 (1998):  387-95|Palmer BF, Gates JR, Lader M "Causes and management of hyponatremia." Ann Pharmacother 37 (2003):  1694-702', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7686, 18087, 'Metolazone', 'Water-Electrolyte Imbalance', 'The use of thiazide diuretics is commonly associated with loss of electrolytes, most significantly potassium but also sodium, chloride, bicarbonate, and magnesium.  The loss of other electrolytes such as phosphate, bromide and iodide is usually slight.  Potassium and magnesium depletion may lead to cardiac arrhythmias and cardiac arrest.  Other electrolyte-related complications include metabolic alkalosis and hyponatremia, which are rarely life-threatening.  Therapy with thiazide diuretics should be administered cautiously in patients with or predisposed to fluid and electrolyte depletion, including patients with primary or secondary aldosteronism (may have low potassium levels); those with severe or prolonged diarrhea or vomiting; and those with poor nutritional status.  Fluid and electrolyte abnormalities should be corrected prior to initiating therapy, and blood pressure as well as serum electrolyte concentrations monitored periodically and maintained at normal ranges during therapy.  Patients should be advised to immediately report signs and symptoms of fluid or electrolyte imbalance, including dry mouth, thirst, weakness, lethargy, drowsiness, restlessness, muscle pains or cramps, muscular fatigue, hypotension, oliguria, tachycardia, arrhythmia, or gastrointestinal disturbances such as nausea and vomiting.  Digitalized patients and patients with a history of ventricular arrhythmias should be monitored carefully, since development of hypokalemia may be particularly dangerous in these patients.  The risk of hypokalemia may be minimized by slow diuresis, a lower thiazide dosage, potassium supplementation, or combined use with a potassium-sparing diuretic.', '3', 'Lindy S, Tarssanen L "Serum calcium and phosphorus in patients treated with thiazides and furosemide." Acta Med Scand 194 (1973):  319-22|Leigh H "Letter: Factitious hypokalemia." Ann Intern Med 80 (1974):  111-2|Moore TD, Bechtel TP "Hyponatremia secondary to tolbutamide and chlorothiazide." Am J Hosp Pharm 36 (1979):  1107-10|Falch DK, Schreiner AM "Changes in urinary electrolytes versus serum electrolytes during treatment of primary hypertension with chlorthalidone alone and in combination with spironolactone." Acta Med Scand 209 (1981):  111-4|Papademetriou V, Fletcher R, Khatri IM, Freis ED "Diuretic-induced hypokalemia in uncomplicated systemic hypertension: effect of plasma potassium correction on cardiac arrhythmias." Am J Cardiol 52 (1983):  1017-22|Kuller L, Farrier N, Caggiula A, Borhani N, Dunkle S "Relationship of diuretic therapy and serum magnesium levels among participants in the Multiple Risk Factor Intervention Trial." Am J Epidemiol 122 (1985):  1045-59|Remenchik AP, Johnston LC "Potassium depletion produced by administration of chlorthalidone to nonedematous patients with arterial hypertensin." Am J Med Sci 252 (1966):  171-6|Katz FH, Eckert RC, Gebott MD "Hypokalemia caused by surreptitious self-administration of diuretics." Ann Intern Med 76 (1972):  85-90|Fichman MP, Vorherr H, Kleeman CR, Telfer N "Diuretic-induced hyponatremia." Ann Intern Med 75 (1971):  853-63|Stewart DE, Ikram H, Espiner EA, Nicholls MG "Arrhythmogenic potential of diuretic induced hypokalaemia in patients with mild hypertension and ischaemic heart disease." Br Heart J 54 (1985):  290-7|Kuller LH, Hulley SB, Cohen JD, Neaton J "Unexpected effects of treating hypertension in men with electrocardiographic abnormalities: a critical analysis." Circulation 73 (1986):  114-23|Landmann-Suter R, Struyvenberg A "Initial potassium loss and hypokalaemia during chlorthalidone administration in patients with essential hypertension: the influence of dietary sodium restriction." Eur J Clin Invest 8 (1978):  155-64|Navarro RP, O''Brien DK, Nuffort P, Spencer DL "Diuretic induced hypokalemia in the elderly." J Fam Pract 14 (1982):  685-9|Oh SJ, Douglas JE, Brown RA "Hypokalemic vacuolar myopathy associated with chlorthalidone treatment." JAMA 216 (1971):  1858-9|Mozes B, Pines A, Werner D, Olchovsky D, Lieberman P, Frankl O "Thiazide-induced hyponatremia: an unusual neurologic course." South Med J 79 (1986):  629-31|Jensen OB, Mosdal C, Reske-Nielsen E "Hypokalemic myopathy during treatment with diuretics." Acta Neurol Scand 55 (1977):  465-82|Cembrowski GS, Huntington RW, 3d "Probable fatal cardiac dysrhythmia secondary to diuretic-induced hypokalemia." Am J Forensic Med Pathol 2 (1981):  243-8|Sumiye L, Vivian AS, Frisof KB, Podany EC "Potassium loss associated with hydrochlorothiazide versus chlorthalidone." Clin Ther 4 (1981):  308-20|Berg KJ, Gisholt K, Wideroe TE "Potassium deficiency in hypertensives treated with diuretics. Analysis of three alternative treatments by an oral test for potassium deficiency." Eur J Clin Pharmacol 7 (1974):  401-5|Chowdhury FR, Bleicher SJ "Chlorthalidone--induced hypokalemia and abnormal carbohydrate metabolism." Horm Metab Res 2 (1970):  13-6|Carney SL, Morgan TO "Diuretic-induced hypokalemia and altered renal function." Int J Clin Pharmacol Ther Toxicol 24 (1986):  665-7|Ragnarsson J, Hardarson T, Snorrason SP "Ventricular dysrhythmias in middle-aged hypertensive men treated either with a diuretic agent or a beta-blocker." Acta Med Scand 221 (1987):  143-8|Hollifield JW, Slaton PE "Thiazide diuretics, hypokalemia and cardiac arrhythmias." Acta Med Scand Suppl 647 (1981):  67-73|Papademetriou V, Price M, Notargiacomo A, Gottdiener J, Fletcher RD, Freis ED "Effect of diuretic therapy on ventricular arrhythmias in hypertensive patients with or without left ventricular hypertrophy." Am Heart J 110 (1985):  595-9|Papademetriou V, Fletcher R, Khatri IM, Freis ED "Diuretic-induced hypokalemia in uncomplicated systemic hypertension: effect of plasma potassium correction on cardiac arrhythmias." Am J Cardiol 52 (1983):  1017-22|Krishna GG, Narins RG "Hemodynamic consequences of diuretic-induced hypokalemia." Am J Kidney Dis 12 (1988):  329-31|Polanska AI, Baron DN "Hyponatraemia associated with hydrochlorothiazide treatment ." Br Med J 1 (1978):  175-6|Pinnock CA "Hyponatraemia associated with hydrochlorothiazide treatment ." Br Med J 1 (1978):  48|Itescu S, Haskell LP, Tannenberg AM "Thiazide-induced clinically significant hypophosphatemia ." Clin Nephrol 27 (1987):  161-2|Byatt CM, Millard PH, Levin GE "Diuretics and electrolyte disturbances in 1000 consecutive geriatric admissions." J R Soc Med 83 (1990):  704-8|Bain PG, Egner W, Walker PR "Thiazide-induced dilutional hyponatraemia masquerading as subarachnoid haemorrhage ." Lancet 2 (1986):  634|Benfield GF, Haffner C, Harris P, Stableforth DE "Dilutional hyponatraemia masquerading as subarachnoid haemorrhage in patient on hydrochlorothiazide/amiloride/timolol combined drug ." Lancet 2 (1986):  341|Gould L, Reddy CV, Zen B, Singh BK "Life-threatening reaction to thiazides." N Y State J Med 80 (1980):  1975-6|Seelig CB "Magnesium deficiency in two hypertensive patient groups." South Med J 83 (1990):  739-42|Peters RW, Hamilton J, Hamilton BP "Incidence of cardiac arrhythmias associated with mild hypokalemia induced by low-dose diuretic therapy for hypertension." South Med J 82 (1989):  966-9,|Kone B, Gimenez L, Watson AJ "Thiazide-induced hyponatremia." South Med J 79 (1986):  1456-7|Holland OB, Kuhnert L, Pollard J, Padia M, Anderson RJ, Blomqvist G "Ventricular ectopic activity with diuretic therapy." Am J Hypertens 1 (1988):  380-5|Mouallem M, Friedman E, Shemesh Y, Mayan H, Pauzner R, Farfel Z "Cardiac conduction defects associated with hyponatremia." Clin Cardiol 14 (1991):  165-8|Kaur J, Wahi PL "Polythiazide as a diuretic. A clinical trial." J Indian Med Assoc 48 (1967):  13-7|Mroczek WJ "Indapamide: clinical pharmacology, therapeutic efficacy in hypertension, and adverse effects." Pharmacotherapy 3 (1983):  61-7|Beling S, Vukovich RA, Neiss ES, Zisblatt M, Webb E, Losi M "Long-term experience with indapamide." Am Heart J 106 (1983):  258-62|Slotkoff L "Clinical efficacy and safety of indapamide in the treatment of edema." Am Heart J 106 (1983):  233-7|"Product Information. HydroDIURIL (hydrochlorothiazide)." Merck & Co., Inc  (2002):|"Product Information. Lozol (indapamide)." Rhone Poulenc Rorer  (2002):|"Product Information. Zaroxolyn (metolazone)." Rhone Poulenc Rorer  (2001):|Stern A "Metolazone, a diuretic agent." Am Heart J 91 (1976):  262-3|Black W, Shiner P, Roman J "Severe electrolyte disturbances associated with metolazone and furosemide." South Med J 71 (1978):  381|"Product Information. Thalitone (chlorthalidone)." Monarch Pharmaceuticals Inc  (2001):|"Product Information. Diuril (chlorothiazide)." Merck & Co., Inc  (2001):|Ghose RR "Letter: Hyponatraemia and diuretics." Lancet 1 (1975):  578-9|Brors O, Enger E, Jacobsen S, Aakvaag A, Foss OP "Effects of hydroflumethiazide in congestive heart failure: renal electrolyte excretion related to urinary thiazide excretion and aldosterone." Acta Pharmacol Toxicol (Copenh) 49 (1981):  399-406|Brors O, Jacobsen S, Foss OP, Aakvaag A "Effect of repeated doses of hydroflumethiazide on renal excretion of electrolytes and uric acid in healthy subjects." Acta Pharmacol Toxicol (Copenh) 48 (1981):  145-50|el-Meheiry MM, Nabih AE, Soliman MD "A clinical study of a new diuretic, Trichlormethiazide." J Trop Med Hyg 69 (1966):  209-14|"Product Information. Enduron (methyclothiazide)." Abbott Pharmaceutical  (2001):|"Product Information. Metahydrin (trichlormethiazide)." Hoechst Marion Roussel  (2001):|"Product Information. Diucardin (hydroflumethiazide)." Wyeth-Ayerst Laboratories  (2001):|Husby S, Marthedal NJ "Hyponatraemia due to a thiazide diuretic. A case report." Acta Med Scand 210 (1981):  523-4|Berglund G, Andersson O, Larsson O, Wilhelmsen L "Antihypertensive effect and side-effects of bendroflumethiazide and propranolol." Acta Med Scand 199 (1976):  499-506|Gudbrandsson T, Hansson L "Combination therapy with saluretics and atenolol in essential hypertension. Effects on blood pressure, electrolytes and uric acid." Acta Med Scand Suppl 625 (1979):  86-91|Elmfeldt D, Berglund G, Wedel H, Wilhelmsen L "Incidence and importance of metabolic side-effects during antihypertensive therapy." Acta Med Scand Suppl 672 (1983):  79-83|Condon JR, Nassim R "Hypophosphataemia and hypokalaemia." Br Med J 1 (1970):  110|Winchester JF, Kellett RJ, Boddy K, Boyle P, Dargie HJ, Mahaffey ME, Ward DM, Kennedy AC "Metolazone and bendroflumethiazide in hypertension: physiologic and metabolic observations." Clin Pharmacol Ther 28 (1980):  611-8|Lee MR, Morgan DB "Familial hyperkalaemia responsive to benzothiadiazine diuretic." Lancet 1 (1980):  879|Hesp R, Wilkinson PR "Potassium supplementation of thiazide therapy." Lancet 2 (1976):  1144|Struthers AD, Whitesmith R, Reid JL "Prior thiazide diuretic treatment increases adrenaline-induced hypokalaemia." Lancet 1 (1983):  1358-61|Petri M, Cumber P, Grimes L, Treby D, Bryant R, Rawlins D, Ising H "The metabolic effects of thiazide therapy in the elderly: a population study." Age Ageing 15 (1986):  151-5|Starr JM, Whalley LJ "Hypertensive Old People in Edinburgh (HOPE) Study: electrocardiographic changes after captopril or bendrofluazide treatment." Age Ageing 22 (1993):  343-8|Toner JM, Ramsay LE "Thiazide-induced hypokalaemia; prevalence higher in women." Br J Clin Pharmacol 18 (1984):  449-52|Jorgensen FS, Brunner S "The long-term effect of bendroflumethiazide on renal calcium and magnesium excretion and stone formation in patients with recurring renal stones." Scand J Urol Nephrol 8 (1974):  128-31|Ljunghall S, Backman U, Danielson BG, Fellstrom B, Johansson G, Wikstrom B "Calcium and magnesium metabolism during long-term treatment with thiazides." Scand J Urol Nephrol 15 (1981):  257-62|Medical Research Council Working Party on Mild to Moderate Hypertension. "Ventricular extrasystoles during thiazide treatment: substudy of MRC mild hypertension trial." Br Med J (Clin Res Ed) 287 (1983):  1249-53|"Product Information. Renese-R (reserpine-polythiazide)." Pfizer US Pharmaceuticals, New York, NY.|Freis ED "The efficacy and safety of diuretics in treating hypertension." Ann Intern Med 122 (1995):  223-6|Read SJ, Trenerry HM, Whiting GF "Hyponatraemia and raised creatine kinase level associated with indapamide." Med J Aust 161 (1994):  607-8|Chan TY "Indapamide-induced severe hyponatremia and hypokalemia." Ann Pharmacother 29 (1995):  1124-8|Simunic M, Rumboldt Z, Ljutic D, Sardelic S "Ramipril decreases chlorthalidone-induced loss of magnesium and potassium in hypertensive patients." J Clin Pharmacol 35 (1995):  1150-5|Brater DC "Drug therapy: Diuretic therapy." N Engl J Med 339 (1998):  387-95|Palmer BF, Gates JR, Lader M "Causes and management of hyponatremia." Ann Pharmacother 37 (2003):  1694-702', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7687, 22666, 'Metolazone', 'Water-Electrolyte Imbalance', 'The use of thiazide diuretics is commonly associated with loss of electrolytes, most significantly potassium but also sodium, chloride, bicarbonate, and magnesium.  The loss of other electrolytes such as phosphate, bromide and iodide is usually slight.  Potassium and magnesium depletion may lead to cardiac arrhythmias and cardiac arrest.  Other electrolyte-related complications include metabolic alkalosis and hyponatremia, which are rarely life-threatening.  Therapy with thiazide diuretics should be administered cautiously in patients with or predisposed to fluid and electrolyte depletion, including patients with primary or secondary aldosteronism (may have low potassium levels); those with severe or prolonged diarrhea or vomiting; and those with poor nutritional status.  Fluid and electrolyte abnormalities should be corrected prior to initiating therapy, and blood pressure as well as serum electrolyte concentrations monitored periodically and maintained at normal ranges during therapy.  Patients should be advised to immediately report signs and symptoms of fluid or electrolyte imbalance, including dry mouth, thirst, weakness, lethargy, drowsiness, restlessness, muscle pains or cramps, muscular fatigue, hypotension, oliguria, tachycardia, arrhythmia, or gastrointestinal disturbances such as nausea and vomiting.  Digitalized patients and patients with a history of ventricular arrhythmias should be monitored carefully, since development of hypokalemia may be particularly dangerous in these patients.  The risk of hypokalemia may be minimized by slow diuresis, a lower thiazide dosage, potassium supplementation, or combined use with a potassium-sparing diuretic.', '3', 'Lindy S, Tarssanen L "Serum calcium and phosphorus in patients treated with thiazides and furosemide." Acta Med Scand 194 (1973):  319-22|Leigh H "Letter: Factitious hypokalemia." Ann Intern Med 80 (1974):  111-2|Moore TD, Bechtel TP "Hyponatremia secondary to tolbutamide and chlorothiazide." Am J Hosp Pharm 36 (1979):  1107-10|Falch DK, Schreiner AM "Changes in urinary electrolytes versus serum electrolytes during treatment of primary hypertension with chlorthalidone alone and in combination with spironolactone." Acta Med Scand 209 (1981):  111-4|Papademetriou V, Fletcher R, Khatri IM, Freis ED "Diuretic-induced hypokalemia in uncomplicated systemic hypertension: effect of plasma potassium correction on cardiac arrhythmias." Am J Cardiol 52 (1983):  1017-22|Kuller L, Farrier N, Caggiula A, Borhani N, Dunkle S "Relationship of diuretic therapy and serum magnesium levels among participants in the Multiple Risk Factor Intervention Trial." Am J Epidemiol 122 (1985):  1045-59|Remenchik AP, Johnston LC "Potassium depletion produced by administration of chlorthalidone to nonedematous patients with arterial hypertensin." Am J Med Sci 252 (1966):  171-6|Katz FH, Eckert RC, Gebott MD "Hypokalemia caused by surreptitious self-administration of diuretics." Ann Intern Med 76 (1972):  85-90|Fichman MP, Vorherr H, Kleeman CR, Telfer N "Diuretic-induced hyponatremia." Ann Intern Med 75 (1971):  853-63|Stewart DE, Ikram H, Espiner EA, Nicholls MG "Arrhythmogenic potential of diuretic induced hypokalaemia in patients with mild hypertension and ischaemic heart disease." Br Heart J 54 (1985):  290-7|Kuller LH, Hulley SB, Cohen JD, Neaton J "Unexpected effects of treating hypertension in men with electrocardiographic abnormalities: a critical analysis." Circulation 73 (1986):  114-23|Landmann-Suter R, Struyvenberg A "Initial potassium loss and hypokalaemia during chlorthalidone administration in patients with essential hypertension: the influence of dietary sodium restriction." Eur J Clin Invest 8 (1978):  155-64|Navarro RP, O''Brien DK, Nuffort P, Spencer DL "Diuretic induced hypokalemia in the elderly." J Fam Pract 14 (1982):  685-9|Oh SJ, Douglas JE, Brown RA "Hypokalemic vacuolar myopathy associated with chlorthalidone treatment." JAMA 216 (1971):  1858-9|Mozes B, Pines A, Werner D, Olchovsky D, Lieberman P, Frankl O "Thiazide-induced hyponatremia: an unusual neurologic course." South Med J 79 (1986):  629-31|Jensen OB, Mosdal C, Reske-Nielsen E "Hypokalemic myopathy during treatment with diuretics." Acta Neurol Scand 55 (1977):  465-82|Cembrowski GS, Huntington RW, 3d "Probable fatal cardiac dysrhythmia secondary to diuretic-induced hypokalemia." Am J Forensic Med Pathol 2 (1981):  243-8|Sumiye L, Vivian AS, Frisof KB, Podany EC "Potassium loss associated with hydrochlorothiazide versus chlorthalidone." Clin Ther 4 (1981):  308-20|Berg KJ, Gisholt K, Wideroe TE "Potassium deficiency in hypertensives treated with diuretics. Analysis of three alternative treatments by an oral test for potassium deficiency." Eur J Clin Pharmacol 7 (1974):  401-5|Chowdhury FR, Bleicher SJ "Chlorthalidone--induced hypokalemia and abnormal carbohydrate metabolism." Horm Metab Res 2 (1970):  13-6|Carney SL, Morgan TO "Diuretic-induced hypokalemia and altered renal function." Int J Clin Pharmacol Ther Toxicol 24 (1986):  665-7|Ragnarsson J, Hardarson T, Snorrason SP "Ventricular dysrhythmias in middle-aged hypertensive men treated either with a diuretic agent or a beta-blocker." Acta Med Scand 221 (1987):  143-8|Hollifield JW, Slaton PE "Thiazide diuretics, hypokalemia and cardiac arrhythmias." Acta Med Scand Suppl 647 (1981):  67-73|Papademetriou V, Price M, Notargiacomo A, Gottdiener J, Fletcher RD, Freis ED "Effect of diuretic therapy on ventricular arrhythmias in hypertensive patients with or without left ventricular hypertrophy." Am Heart J 110 (1985):  595-9|Papademetriou V, Fletcher R, Khatri IM, Freis ED "Diuretic-induced hypokalemia in uncomplicated systemic hypertension: effect of plasma potassium correction on cardiac arrhythmias." Am J Cardiol 52 (1983):  1017-22|Krishna GG, Narins RG "Hemodynamic consequences of diuretic-induced hypokalemia." Am J Kidney Dis 12 (1988):  329-31|Polanska AI, Baron DN "Hyponatraemia associated with hydrochlorothiazide treatment ." Br Med J 1 (1978):  175-6|Pinnock CA "Hyponatraemia associated with hydrochlorothiazide treatment ." Br Med J 1 (1978):  48|Itescu S, Haskell LP, Tannenberg AM "Thiazide-induced clinically significant hypophosphatemia ." Clin Nephrol 27 (1987):  161-2|Byatt CM, Millard PH, Levin GE "Diuretics and electrolyte disturbances in 1000 consecutive geriatric admissions." J R Soc Med 83 (1990):  704-8|Bain PG, Egner W, Walker PR "Thiazide-induced dilutional hyponatraemia masquerading as subarachnoid haemorrhage ." Lancet 2 (1986):  634|Benfield GF, Haffner C, Harris P, Stableforth DE "Dilutional hyponatraemia masquerading as subarachnoid haemorrhage in patient on hydrochlorothiazide/amiloride/timolol combined drug ." Lancet 2 (1986):  341|Gould L, Reddy CV, Zen B, Singh BK "Life-threatening reaction to thiazides." N Y State J Med 80 (1980):  1975-6|Seelig CB "Magnesium deficiency in two hypertensive patient groups." South Med J 83 (1990):  739-42|Peters RW, Hamilton J, Hamilton BP "Incidence of cardiac arrhythmias associated with mild hypokalemia induced by low-dose diuretic therapy for hypertension." South Med J 82 (1989):  966-9,|Kone B, Gimenez L, Watson AJ "Thiazide-induced hyponatremia." South Med J 79 (1986):  1456-7|Holland OB, Kuhnert L, Pollard J, Padia M, Anderson RJ, Blomqvist G "Ventricular ectopic activity with diuretic therapy." Am J Hypertens 1 (1988):  380-5|Mouallem M, Friedman E, Shemesh Y, Mayan H, Pauzner R, Farfel Z "Cardiac conduction defects associated with hyponatremia." Clin Cardiol 14 (1991):  165-8|Kaur J, Wahi PL "Polythiazide as a diuretic. A clinical trial." J Indian Med Assoc 48 (1967):  13-7|Mroczek WJ "Indapamide: clinical pharmacology, therapeutic efficacy in hypertension, and adverse effects." Pharmacotherapy 3 (1983):  61-7|Beling S, Vukovich RA, Neiss ES, Zisblatt M, Webb E, Losi M "Long-term experience with indapamide." Am Heart J 106 (1983):  258-62|Slotkoff L "Clinical efficacy and safety of indapamide in the treatment of edema." Am Heart J 106 (1983):  233-7|"Product Information. HydroDIURIL (hydrochlorothiazide)." Merck & Co., Inc  (2002):|"Product Information. Lozol (indapamide)." Rhone Poulenc Rorer  (2002):|"Product Information. Zaroxolyn (metolazone)." Rhone Poulenc Rorer  (2001):|Stern A "Metolazone, a diuretic agent." Am Heart J 91 (1976):  262-3|Black W, Shiner P, Roman J "Severe electrolyte disturbances associated with metolazone and furosemide." South Med J 71 (1978):  381|"Product Information. Thalitone (chlorthalidone)." Monarch Pharmaceuticals Inc  (2001):|"Product Information. Diuril (chlorothiazide)." Merck & Co., Inc  (2001):|Ghose RR "Letter: Hyponatraemia and diuretics." Lancet 1 (1975):  578-9|Brors O, Enger E, Jacobsen S, Aakvaag A, Foss OP "Effects of hydroflumethiazide in congestive heart failure: renal electrolyte excretion related to urinary thiazide excretion and aldosterone." Acta Pharmacol Toxicol (Copenh) 49 (1981):  399-406|Brors O, Jacobsen S, Foss OP, Aakvaag A "Effect of repeated doses of hydroflumethiazide on renal excretion of electrolytes and uric acid in healthy subjects." Acta Pharmacol Toxicol (Copenh) 48 (1981):  145-50|el-Meheiry MM, Nabih AE, Soliman MD "A clinical study of a new diuretic, Trichlormethiazide." J Trop Med Hyg 69 (1966):  209-14|"Product Information. Enduron (methyclothiazide)." Abbott Pharmaceutical  (2001):|"Product Information. Metahydrin (trichlormethiazide)." Hoechst Marion Roussel  (2001):|"Product Information. Diucardin (hydroflumethiazide)." Wyeth-Ayerst Laboratories  (2001):|Husby S, Marthedal NJ "Hyponatraemia due to a thiazide diuretic. A case report." Acta Med Scand 210 (1981):  523-4|Berglund G, Andersson O, Larsson O, Wilhelmsen L "Antihypertensive effect and side-effects of bendroflumethiazide and propranolol." Acta Med Scand 199 (1976):  499-506|Gudbrandsson T, Hansson L "Combination therapy with saluretics and atenolol in essential hypertension. Effects on blood pressure, electrolytes and uric acid." Acta Med Scand Suppl 625 (1979):  86-91|Elmfeldt D, Berglund G, Wedel H, Wilhelmsen L "Incidence and importance of metabolic side-effects during antihypertensive therapy." Acta Med Scand Suppl 672 (1983):  79-83|Condon JR, Nassim R "Hypophosphataemia and hypokalaemia." Br Med J 1 (1970):  110|Winchester JF, Kellett RJ, Boddy K, Boyle P, Dargie HJ, Mahaffey ME, Ward DM, Kennedy AC "Metolazone and bendroflumethiazide in hypertension: physiologic and metabolic observations." Clin Pharmacol Ther 28 (1980):  611-8|Lee MR, Morgan DB "Familial hyperkalaemia responsive to benzothiadiazine diuretic." Lancet 1 (1980):  879|Hesp R, Wilkinson PR "Potassium supplementation of thiazide therapy." Lancet 2 (1976):  1144|Struthers AD, Whitesmith R, Reid JL "Prior thiazide diuretic treatment increases adrenaline-induced hypokalaemia." Lancet 1 (1983):  1358-61|Petri M, Cumber P, Grimes L, Treby D, Bryant R, Rawlins D, Ising H "The metabolic effects of thiazide therapy in the elderly: a population study." Age Ageing 15 (1986):  151-5|Starr JM, Whalley LJ "Hypertensive Old People in Edinburgh (HOPE) Study: electrocardiographic changes after captopril or bendrofluazide treatment." Age Ageing 22 (1993):  343-8|Toner JM, Ramsay LE "Thiazide-induced hypokalaemia; prevalence higher in women." Br J Clin Pharmacol 18 (1984):  449-52|Jorgensen FS, Brunner S "The long-term effect of bendroflumethiazide on renal calcium and magnesium excretion and stone formation in patients with recurring renal stones." Scand J Urol Nephrol 8 (1974):  128-31|Ljunghall S, Backman U, Danielson BG, Fellstrom B, Johansson G, Wikstrom B "Calcium and magnesium metabolism during long-term treatment with thiazides." Scand J Urol Nephrol 15 (1981):  257-62|Medical Research Council Working Party on Mild to Moderate Hypertension. "Ventricular extrasystoles during thiazide treatment: substudy of MRC mild hypertension trial." Br Med J (Clin Res Ed) 287 (1983):  1249-53|"Product Information. Renese-R (reserpine-polythiazide)." Pfizer US Pharmaceuticals, New York, NY.|Freis ED "The efficacy and safety of diuretics in treating hypertension." Ann Intern Med 122 (1995):  223-6|Read SJ, Trenerry HM, Whiting GF "Hyponatraemia and raised creatine kinase level associated with indapamide." Med J Aust 161 (1994):  607-8|Chan TY "Indapamide-induced severe hyponatremia and hypokalemia." Ann Pharmacother 29 (1995):  1124-8|Simunic M, Rumboldt Z, Ljutic D, Sardelic S "Ramipril decreases chlorthalidone-induced loss of magnesium and potassium in hypertensive patients." J Clin Pharmacol 35 (1995):  1150-5|Brater DC "Drug therapy: Diuretic therapy." N Engl J Med 339 (1998):  387-95|Palmer BF, Gates JR, Lader M "Causes and management of hyponatremia." Ann Pharmacother 37 (2003):  1694-702', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7688, 26084, 'Metolazone', 'Water-Electrolyte Imbalance', 'The use of thiazide diuretics is commonly associated with loss of electrolytes, most significantly potassium but also sodium, chloride, bicarbonate, and magnesium.  The loss of other electrolytes such as phosphate, bromide and iodide is usually slight.  Potassium and magnesium depletion may lead to cardiac arrhythmias and cardiac arrest.  Other electrolyte-related complications include metabolic alkalosis and hyponatremia, which are rarely life-threatening.  Therapy with thiazide diuretics should be administered cautiously in patients with or predisposed to fluid and electrolyte depletion, including patients with primary or secondary aldosteronism (may have low potassium levels); those with severe or prolonged diarrhea or vomiting; and those with poor nutritional status.  Fluid and electrolyte abnormalities should be corrected prior to initiating therapy, and blood pressure as well as serum electrolyte concentrations monitored periodically and maintained at normal ranges during therapy.  Patients should be advised to immediately report signs and symptoms of fluid or electrolyte imbalance, including dry mouth, thirst, weakness, lethargy, drowsiness, restlessness, muscle pains or cramps, muscular fatigue, hypotension, oliguria, tachycardia, arrhythmia, or gastrointestinal disturbances such as nausea and vomiting.  Digitalized patients and patients with a history of ventricular arrhythmias should be monitored carefully, since development of hypokalemia may be particularly dangerous in these patients.  The risk of hypokalemia may be minimized by slow diuresis, a lower thiazide dosage, potassium supplementation, or combined use with a potassium-sparing diuretic.', '3', 'Lindy S, Tarssanen L "Serum calcium and phosphorus in patients treated with thiazides and furosemide." Acta Med Scand 194 (1973):  319-22|Leigh H "Letter: Factitious hypokalemia." Ann Intern Med 80 (1974):  111-2|Moore TD, Bechtel TP "Hyponatremia secondary to tolbutamide and chlorothiazide." Am J Hosp Pharm 36 (1979):  1107-10|Falch DK, Schreiner AM "Changes in urinary electrolytes versus serum electrolytes during treatment of primary hypertension with chlorthalidone alone and in combination with spironolactone." Acta Med Scand 209 (1981):  111-4|Papademetriou V, Fletcher R, Khatri IM, Freis ED "Diuretic-induced hypokalemia in uncomplicated systemic hypertension: effect of plasma potassium correction on cardiac arrhythmias." Am J Cardiol 52 (1983):  1017-22|Kuller L, Farrier N, Caggiula A, Borhani N, Dunkle S "Relationship of diuretic therapy and serum magnesium levels among participants in the Multiple Risk Factor Intervention Trial." Am J Epidemiol 122 (1985):  1045-59|Remenchik AP, Johnston LC "Potassium depletion produced by administration of chlorthalidone to nonedematous patients with arterial hypertensin." Am J Med Sci 252 (1966):  171-6|Katz FH, Eckert RC, Gebott MD "Hypokalemia caused by surreptitious self-administration of diuretics." Ann Intern Med 76 (1972):  85-90|Fichman MP, Vorherr H, Kleeman CR, Telfer N "Diuretic-induced hyponatremia." Ann Intern Med 75 (1971):  853-63|Stewart DE, Ikram H, Espiner EA, Nicholls MG "Arrhythmogenic potential of diuretic induced hypokalaemia in patients with mild hypertension and ischaemic heart disease." Br Heart J 54 (1985):  290-7|Kuller LH, Hulley SB, Cohen JD, Neaton J "Unexpected effects of treating hypertension in men with electrocardiographic abnormalities: a critical analysis." Circulation 73 (1986):  114-23|Landmann-Suter R, Struyvenberg A "Initial potassium loss and hypokalaemia during chlorthalidone administration in patients with essential hypertension: the influence of dietary sodium restriction." Eur J Clin Invest 8 (1978):  155-64|Navarro RP, O''Brien DK, Nuffort P, Spencer DL "Diuretic induced hypokalemia in the elderly." J Fam Pract 14 (1982):  685-9|Oh SJ, Douglas JE, Brown RA "Hypokalemic vacuolar myopathy associated with chlorthalidone treatment." JAMA 216 (1971):  1858-9|Mozes B, Pines A, Werner D, Olchovsky D, Lieberman P, Frankl O "Thiazide-induced hyponatremia: an unusual neurologic course." South Med J 79 (1986):  629-31|Jensen OB, Mosdal C, Reske-Nielsen E "Hypokalemic myopathy during treatment with diuretics." Acta Neurol Scand 55 (1977):  465-82|Cembrowski GS, Huntington RW, 3d "Probable fatal cardiac dysrhythmia secondary to diuretic-induced hypokalemia." Am J Forensic Med Pathol 2 (1981):  243-8|Sumiye L, Vivian AS, Frisof KB, Podany EC "Potassium loss associated with hydrochlorothiazide versus chlorthalidone." Clin Ther 4 (1981):  308-20|Berg KJ, Gisholt K, Wideroe TE "Potassium deficiency in hypertensives treated with diuretics. Analysis of three alternative treatments by an oral test for potassium deficiency." Eur J Clin Pharmacol 7 (1974):  401-5|Chowdhury FR, Bleicher SJ "Chlorthalidone--induced hypokalemia and abnormal carbohydrate metabolism." Horm Metab Res 2 (1970):  13-6|Carney SL, Morgan TO "Diuretic-induced hypokalemia and altered renal function." Int J Clin Pharmacol Ther Toxicol 24 (1986):  665-7|Ragnarsson J, Hardarson T, Snorrason SP "Ventricular dysrhythmias in middle-aged hypertensive men treated either with a diuretic agent or a beta-blocker." Acta Med Scand 221 (1987):  143-8|Hollifield JW, Slaton PE "Thiazide diuretics, hypokalemia and cardiac arrhythmias." Acta Med Scand Suppl 647 (1981):  67-73|Papademetriou V, Price M, Notargiacomo A, Gottdiener J, Fletcher RD, Freis ED "Effect of diuretic therapy on ventricular arrhythmias in hypertensive patients with or without left ventricular hypertrophy." Am Heart J 110 (1985):  595-9|Papademetriou V, Fletcher R, Khatri IM, Freis ED "Diuretic-induced hypokalemia in uncomplicated systemic hypertension: effect of plasma potassium correction on cardiac arrhythmias." Am J Cardiol 52 (1983):  1017-22|Krishna GG, Narins RG "Hemodynamic consequences of diuretic-induced hypokalemia." Am J Kidney Dis 12 (1988):  329-31|Polanska AI, Baron DN "Hyponatraemia associated with hydrochlorothiazide treatment ." Br Med J 1 (1978):  175-6|Pinnock CA "Hyponatraemia associated with hydrochlorothiazide treatment ." Br Med J 1 (1978):  48|Itescu S, Haskell LP, Tannenberg AM "Thiazide-induced clinically significant hypophosphatemia ." Clin Nephrol 27 (1987):  161-2|Byatt CM, Millard PH, Levin GE "Diuretics and electrolyte disturbances in 1000 consecutive geriatric admissions." J R Soc Med 83 (1990):  704-8|Bain PG, Egner W, Walker PR "Thiazide-induced dilutional hyponatraemia masquerading as subarachnoid haemorrhage ." Lancet 2 (1986):  634|Benfield GF, Haffner C, Harris P, Stableforth DE "Dilutional hyponatraemia masquerading as subarachnoid haemorrhage in patient on hydrochlorothiazide/amiloride/timolol combined drug ." Lancet 2 (1986):  341|Gould L, Reddy CV, Zen B, Singh BK "Life-threatening reaction to thiazides." N Y State J Med 80 (1980):  1975-6|Seelig CB "Magnesium deficiency in two hypertensive patient groups." South Med J 83 (1990):  739-42|Peters RW, Hamilton J, Hamilton BP "Incidence of cardiac arrhythmias associated with mild hypokalemia induced by low-dose diuretic therapy for hypertension." South Med J 82 (1989):  966-9,|Kone B, Gimenez L, Watson AJ "Thiazide-induced hyponatremia." South Med J 79 (1986):  1456-7|Holland OB, Kuhnert L, Pollard J, Padia M, Anderson RJ, Blomqvist G "Ventricular ectopic activity with diuretic therapy." Am J Hypertens 1 (1988):  380-5|Mouallem M, Friedman E, Shemesh Y, Mayan H, Pauzner R, Farfel Z "Cardiac conduction defects associated with hyponatremia." Clin Cardiol 14 (1991):  165-8|Kaur J, Wahi PL "Polythiazide as a diuretic. A clinical trial." J Indian Med Assoc 48 (1967):  13-7|Mroczek WJ "Indapamide: clinical pharmacology, therapeutic efficacy in hypertension, and adverse effects." Pharmacotherapy 3 (1983):  61-7|Beling S, Vukovich RA, Neiss ES, Zisblatt M, Webb E, Losi M "Long-term experience with indapamide." Am Heart J 106 (1983):  258-62|Slotkoff L "Clinical efficacy and safety of indapamide in the treatment of edema." Am Heart J 106 (1983):  233-7|"Product Information. HydroDIURIL (hydrochlorothiazide)." Merck & Co., Inc  (2002):|"Product Information. Lozol (indapamide)." Rhone Poulenc Rorer  (2002):|"Product Information. Zaroxolyn (metolazone)." Rhone Poulenc Rorer  (2001):|Stern A "Metolazone, a diuretic agent." Am Heart J 91 (1976):  262-3|Black W, Shiner P, Roman J "Severe electrolyte disturbances associated with metolazone and furosemide." South Med J 71 (1978):  381|"Product Information. Thalitone (chlorthalidone)." Monarch Pharmaceuticals Inc  (2001):|"Product Information. Diuril (chlorothiazide)." Merck & Co., Inc  (2001):|Ghose RR "Letter: Hyponatraemia and diuretics." Lancet 1 (1975):  578-9|Brors O, Enger E, Jacobsen S, Aakvaag A, Foss OP "Effects of hydroflumethiazide in congestive heart failure: renal electrolyte excretion related to urinary thiazide excretion and aldosterone." Acta Pharmacol Toxicol (Copenh) 49 (1981):  399-406|Brors O, Jacobsen S, Foss OP, Aakvaag A "Effect of repeated doses of hydroflumethiazide on renal excretion of electrolytes and uric acid in healthy subjects." Acta Pharmacol Toxicol (Copenh) 48 (1981):  145-50|el-Meheiry MM, Nabih AE, Soliman MD "A clinical study of a new diuretic, Trichlormethiazide." J Trop Med Hyg 69 (1966):  209-14|"Product Information. Enduron (methyclothiazide)." Abbott Pharmaceutical  (2001):|"Product Information. Metahydrin (trichlormethiazide)." Hoechst Marion Roussel  (2001):|"Product Information. Diucardin (hydroflumethiazide)." Wyeth-Ayerst Laboratories  (2001):|Husby S, Marthedal NJ "Hyponatraemia due to a thiazide diuretic. A case report." Acta Med Scand 210 (1981):  523-4|Berglund G, Andersson O, Larsson O, Wilhelmsen L "Antihypertensive effect and side-effects of bendroflumethiazide and propranolol." Acta Med Scand 199 (1976):  499-506|Gudbrandsson T, Hansson L "Combination therapy with saluretics and atenolol in essential hypertension. Effects on blood pressure, electrolytes and uric acid." Acta Med Scand Suppl 625 (1979):  86-91|Elmfeldt D, Berglund G, Wedel H, Wilhelmsen L "Incidence and importance of metabolic side-effects during antihypertensive therapy." Acta Med Scand Suppl 672 (1983):  79-83|Condon JR, Nassim R "Hypophosphataemia and hypokalaemia." Br Med J 1 (1970):  110|Winchester JF, Kellett RJ, Boddy K, Boyle P, Dargie HJ, Mahaffey ME, Ward DM, Kennedy AC "Metolazone and bendroflumethiazide in hypertension: physiologic and metabolic observations." Clin Pharmacol Ther 28 (1980):  611-8|Lee MR, Morgan DB "Familial hyperkalaemia responsive to benzothiadiazine diuretic." Lancet 1 (1980):  879|Hesp R, Wilkinson PR "Potassium supplementation of thiazide therapy." Lancet 2 (1976):  1144|Struthers AD, Whitesmith R, Reid JL "Prior thiazide diuretic treatment increases adrenaline-induced hypokalaemia." Lancet 1 (1983):  1358-61|Petri M, Cumber P, Grimes L, Treby D, Bryant R, Rawlins D, Ising H "The metabolic effects of thiazide therapy in the elderly: a population study." Age Ageing 15 (1986):  151-5|Starr JM, Whalley LJ "Hypertensive Old People in Edinburgh (HOPE) Study: electrocardiographic changes after captopril or bendrofluazide treatment." Age Ageing 22 (1993):  343-8|Toner JM, Ramsay LE "Thiazide-induced hypokalaemia; prevalence higher in women." Br J Clin Pharmacol 18 (1984):  449-52|Jorgensen FS, Brunner S "The long-term effect of bendroflumethiazide on renal calcium and magnesium excretion and stone formation in patients with recurring renal stones." Scand J Urol Nephrol 8 (1974):  128-31|Ljunghall S, Backman U, Danielson BG, Fellstrom B, Johansson G, Wikstrom B "Calcium and magnesium metabolism during long-term treatment with thiazides." Scand J Urol Nephrol 15 (1981):  257-62|Medical Research Council Working Party on Mild to Moderate Hypertension. "Ventricular extrasystoles during thiazide treatment: substudy of MRC mild hypertension trial." Br Med J (Clin Res Ed) 287 (1983):  1249-53|"Product Information. Renese-R (reserpine-polythiazide)." Pfizer US Pharmaceuticals, New York, NY.|Freis ED "The efficacy and safety of diuretics in treating hypertension." Ann Intern Med 122 (1995):  223-6|Read SJ, Trenerry HM, Whiting GF "Hyponatraemia and raised creatine kinase level associated with indapamide." Med J Aust 161 (1994):  607-8|Chan TY "Indapamide-induced severe hyponatremia and hypokalemia." Ann Pharmacother 29 (1995):  1124-8|Simunic M, Rumboldt Z, Ljutic D, Sardelic S "Ramipril decreases chlorthalidone-induced loss of magnesium and potassium in hypertensive patients." J Clin Pharmacol 35 (1995):  1150-5|Brater DC "Drug therapy: Diuretic therapy." N Engl J Med 339 (1998):  387-95|Palmer BF, Gates JR, Lader M "Causes and management of hyponatremia." Ann Pharmacother 37 (2003):  1694-702', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7689, 17239, 'Metolazone', 'Liver Diseases', 'Patients with severe liver disease or cirrhosis are very susceptible to thiazide-induced hypokalemic hypochloremic alkalosis.  Blood ammonia concentrations may be further increased in patients with previously elevated concentrations.  Hepatic encephalopathy and death have occurred secondary to the electrolyte alterations accompanying diuretic use.  Therapy with thiazide diuretics should be administered cautiously in patients with impaired hepatic function or progressive liver disease, and discontinued promptly if signs of impending hepatic coma appear (e.g., tremors, confusion, and increased jaundice).', '3', 'Aneckstein AG, Weingold AB "Chlorothiazide-induced hepatic coma in pregnancy." Am J Obstet Gynecol 95 (1966):  136-7|Sherlock S, Senewiratne B, Scott A, Walker JG "Complications of diuretic therapy in hepatic cirrhosis." Lancet 1 (1966):  1049-52|Sherlock S, Walker JG, Senewiratne B, Scott A "The complications of diuretic therapy in patients with cirrhosis." Ann N Y Acad Sci 139 (1966):  497-505|"Product Information. HydroDIURIL (hydrochlorothiazide)." Merck & Co., Inc  (2002):|"Product Information. Lozol (indapamide)." Rhone Poulenc Rorer  (2002):|"Product Information. Zaroxolyn (metolazone)." Rhone Poulenc Rorer  (2001):|"Product Information. Thalitone (chlorthalidone)." Monarch Pharmaceuticals Inc  (2001):|"Product Information. Diuril (chlorothiazide)." Merck & Co., Inc  (2001):|"Product Information. Enduron (methyclothiazide)." Abbott Pharmaceutical  (2001):|"Product Information. Metahydrin (trichlormethiazide)." Hoechst Marion Roussel  (2001):|"Product Information. Diucardin (hydroflumethiazide)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Renese-R (reserpine-polythiazide)." Pfizer US Pharmaceuticals, New York, NY.', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7690, 18087, 'Metolazone', 'Liver Diseases', 'Patients with severe liver disease or cirrhosis are very susceptible to thiazide-induced hypokalemic hypochloremic alkalosis.  Blood ammonia concentrations may be further increased in patients with previously elevated concentrations.  Hepatic encephalopathy and death have occurred secondary to the electrolyte alterations accompanying diuretic use.  Therapy with thiazide diuretics should be administered cautiously in patients with impaired hepatic function or progressive liver disease, and discontinued promptly if signs of impending hepatic coma appear (e.g., tremors, confusion, and increased jaundice).', '3', 'Aneckstein AG, Weingold AB "Chlorothiazide-induced hepatic coma in pregnancy." Am J Obstet Gynecol 95 (1966):  136-7|Sherlock S, Senewiratne B, Scott A, Walker JG "Complications of diuretic therapy in hepatic cirrhosis." Lancet 1 (1966):  1049-52|Sherlock S, Walker JG, Senewiratne B, Scott A "The complications of diuretic therapy in patients with cirrhosis." Ann N Y Acad Sci 139 (1966):  497-505|"Product Information. HydroDIURIL (hydrochlorothiazide)." Merck & Co., Inc  (2002):|"Product Information. Lozol (indapamide)." Rhone Poulenc Rorer  (2002):|"Product Information. Zaroxolyn (metolazone)." Rhone Poulenc Rorer  (2001):|"Product Information. Thalitone (chlorthalidone)." Monarch Pharmaceuticals Inc  (2001):|"Product Information. Diuril (chlorothiazide)." Merck & Co., Inc  (2001):|"Product Information. Enduron (methyclothiazide)." Abbott Pharmaceutical  (2001):|"Product Information. Metahydrin (trichlormethiazide)." Hoechst Marion Roussel  (2001):|"Product Information. Diucardin (hydroflumethiazide)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Renese-R (reserpine-polythiazide)." Pfizer US Pharmaceuticals, New York, NY.', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7691, 22666, 'Metolazone', 'Liver Diseases', 'Patients with severe liver disease or cirrhosis are very susceptible to thiazide-induced hypokalemic hypochloremic alkalosis.  Blood ammonia concentrations may be further increased in patients with previously elevated concentrations.  Hepatic encephalopathy and death have occurred secondary to the electrolyte alterations accompanying diuretic use.  Therapy with thiazide diuretics should be administered cautiously in patients with impaired hepatic function or progressive liver disease, and discontinued promptly if signs of impending hepatic coma appear (e.g., tremors, confusion, and increased jaundice).', '3', 'Aneckstein AG, Weingold AB "Chlorothiazide-induced hepatic coma in pregnancy." Am J Obstet Gynecol 95 (1966):  136-7|Sherlock S, Senewiratne B, Scott A, Walker JG "Complications of diuretic therapy in hepatic cirrhosis." Lancet 1 (1966):  1049-52|Sherlock S, Walker JG, Senewiratne B, Scott A "The complications of diuretic therapy in patients with cirrhosis." Ann N Y Acad Sci 139 (1966):  497-505|"Product Information. HydroDIURIL (hydrochlorothiazide)." Merck & Co., Inc  (2002):|"Product Information. Lozol (indapamide)." Rhone Poulenc Rorer  (2002):|"Product Information. Zaroxolyn (metolazone)." Rhone Poulenc Rorer  (2001):|"Product Information. Thalitone (chlorthalidone)." Monarch Pharmaceuticals Inc  (2001):|"Product Information. Diuril (chlorothiazide)." Merck & Co., Inc  (2001):|"Product Information. Enduron (methyclothiazide)." Abbott Pharmaceutical  (2001):|"Product Information. Metahydrin (trichlormethiazide)." Hoechst Marion Roussel  (2001):|"Product Information. Diucardin (hydroflumethiazide)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Renese-R (reserpine-polythiazide)." Pfizer US Pharmaceuticals, New York, NY.', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7692, 26084, 'Metolazone', 'Liver Diseases', 'Patients with severe liver disease or cirrhosis are very susceptible to thiazide-induced hypokalemic hypochloremic alkalosis.  Blood ammonia concentrations may be further increased in patients with previously elevated concentrations.  Hepatic encephalopathy and death have occurred secondary to the electrolyte alterations accompanying diuretic use.  Therapy with thiazide diuretics should be administered cautiously in patients with impaired hepatic function or progressive liver disease, and discontinued promptly if signs of impending hepatic coma appear (e.g., tremors, confusion, and increased jaundice).', '3', 'Aneckstein AG, Weingold AB "Chlorothiazide-induced hepatic coma in pregnancy." Am J Obstet Gynecol 95 (1966):  136-7|Sherlock S, Senewiratne B, Scott A, Walker JG "Complications of diuretic therapy in hepatic cirrhosis." Lancet 1 (1966):  1049-52|Sherlock S, Walker JG, Senewiratne B, Scott A "The complications of diuretic therapy in patients with cirrhosis." Ann N Y Acad Sci 139 (1966):  497-505|"Product Information. HydroDIURIL (hydrochlorothiazide)." Merck & Co., Inc  (2002):|"Product Information. Lozol (indapamide)." Rhone Poulenc Rorer  (2002):|"Product Information. Zaroxolyn (metolazone)." Rhone Poulenc Rorer  (2001):|"Product Information. Thalitone (chlorthalidone)." Monarch Pharmaceuticals Inc  (2001):|"Product Information. Diuril (chlorothiazide)." Merck & Co., Inc  (2001):|"Product Information. Enduron (methyclothiazide)." Abbott Pharmaceutical  (2001):|"Product Information. Metahydrin (trichlormethiazide)." Hoechst Marion Roussel  (2001):|"Product Information. Diucardin (hydroflumethiazide)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Renese-R (reserpine-polythiazide)." Pfizer US Pharmaceuticals, New York, NY.', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7693, 17239, 'Metolazone', 'Lupus Erythematosus, Systemic', 'The use of thiazide diuretics has been reported to possibly exacerbate or activate systemic lupus erythematosus.  Reported cases have generally been associated with chlorothiazide and hydrochlorothiazide.  Therapy with thiazide diuretics should be administered cautiously in patients with a history or risk of SLE.', '3', 'Reed BR, Huff JC, Jones SK, Orton PW, Lee LA, Norris DA "Subacute cutaneous lupus erythematosus associated with hydrochlorothiazide therapy." Ann Intern Med 103 (1985):  49-51|Parodi A, Romagnoli M, Rebora A "Subacute cutaneous lupus erythematosus-like eruption caused by hydrochlorothiazide." Photodermatol 6 (1989):  100-2|"Product Information. HydroDIURIL (hydrochlorothiazide)." Merck & Co., Inc  (2002):|"Product Information. Lozol (indapamide)." Rhone Poulenc Rorer  (2002):|Goodrich AL, Kohn SR "Hydrochlorothiazide-induced lupus erythematosus: a new variant?" J Am Acad Dermatol 28 (1993):  1001-2|"Product Information. Zaroxolyn (metolazone)." Rhone Poulenc Rorer  (2001):|"Product Information. Thalitone (chlorthalidone)." Monarch Pharmaceuticals Inc  (2001):|"Product Information. Diuril (chlorothiazide)." Merck & Co., Inc  (2001):|"Product Information. Enduron (methyclothiazide)." Abbott Pharmaceutical  (2001):|"Product Information. Metahydrin (trichlormethiazide)." Hoechst Marion Roussel  (2001):|"Product Information. Diucardin (hydroflumethiazide)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Renese-R (reserpine-polythiazide)." Pfizer US Pharmaceuticals, New York, NY.|Rich MW, Eckman JM "Can hydrochlorothiazide cause lupus?" J Rheumatol 22 (1995):  1001|Brown CW, Deng JS "Thiazide diuretics induce cutaneous lupus-like adverse reaction." J Toxicol Clin Toxicol 33 (1995):  729-33', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7694, 18087, 'Metolazone', 'Lupus Erythematosus, Systemic', 'The use of thiazide diuretics has been reported to possibly exacerbate or activate systemic lupus erythematosus.  Reported cases have generally been associated with chlorothiazide and hydrochlorothiazide.  Therapy with thiazide diuretics should be administered cautiously in patients with a history or risk of SLE.', '3', 'Reed BR, Huff JC, Jones SK, Orton PW, Lee LA, Norris DA "Subacute cutaneous lupus erythematosus associated with hydrochlorothiazide therapy." Ann Intern Med 103 (1985):  49-51|Parodi A, Romagnoli M, Rebora A "Subacute cutaneous lupus erythematosus-like eruption caused by hydrochlorothiazide." Photodermatol 6 (1989):  100-2|"Product Information. HydroDIURIL (hydrochlorothiazide)." Merck & Co., Inc  (2002):|"Product Information. Lozol (indapamide)." Rhone Poulenc Rorer  (2002):|Goodrich AL, Kohn SR "Hydrochlorothiazide-induced lupus erythematosus: a new variant?" J Am Acad Dermatol 28 (1993):  1001-2|"Product Information. Zaroxolyn (metolazone)." Rhone Poulenc Rorer  (2001):|"Product Information. Thalitone (chlorthalidone)." Monarch Pharmaceuticals Inc  (2001):|"Product Information. Diuril (chlorothiazide)." Merck & Co., Inc  (2001):|"Product Information. Enduron (methyclothiazide)." Abbott Pharmaceutical  (2001):|"Product Information. Metahydrin (trichlormethiazide)." Hoechst Marion Roussel  (2001):|"Product Information. Diucardin (hydroflumethiazide)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Renese-R (reserpine-polythiazide)." Pfizer US Pharmaceuticals, New York, NY.|Rich MW, Eckman JM "Can hydrochlorothiazide cause lupus?" J Rheumatol 22 (1995):  1001|Brown CW, Deng JS "Thiazide diuretics induce cutaneous lupus-like adverse reaction." J Toxicol Clin Toxicol 33 (1995):  729-33', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7695, 22666, 'Metolazone', 'Lupus Erythematosus, Systemic', 'The use of thiazide diuretics has been reported to possibly exacerbate or activate systemic lupus erythematosus.  Reported cases have generally been associated with chlorothiazide and hydrochlorothiazide.  Therapy with thiazide diuretics should be administered cautiously in patients with a history or risk of SLE.', '3', 'Reed BR, Huff JC, Jones SK, Orton PW, Lee LA, Norris DA "Subacute cutaneous lupus erythematosus associated with hydrochlorothiazide therapy." Ann Intern Med 103 (1985):  49-51|Parodi A, Romagnoli M, Rebora A "Subacute cutaneous lupus erythematosus-like eruption caused by hydrochlorothiazide." Photodermatol 6 (1989):  100-2|"Product Information. HydroDIURIL (hydrochlorothiazide)." Merck & Co., Inc  (2002):|"Product Information. Lozol (indapamide)." Rhone Poulenc Rorer  (2002):|Goodrich AL, Kohn SR "Hydrochlorothiazide-induced lupus erythematosus: a new variant?" J Am Acad Dermatol 28 (1993):  1001-2|"Product Information. Zaroxolyn (metolazone)." Rhone Poulenc Rorer  (2001):|"Product Information. Thalitone (chlorthalidone)." Monarch Pharmaceuticals Inc  (2001):|"Product Information. Diuril (chlorothiazide)." Merck & Co., Inc  (2001):|"Product Information. Enduron (methyclothiazide)." Abbott Pharmaceutical  (2001):|"Product Information. Metahydrin (trichlormethiazide)." Hoechst Marion Roussel  (2001):|"Product Information. Diucardin (hydroflumethiazide)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Renese-R (reserpine-polythiazide)." Pfizer US Pharmaceuticals, New York, NY.|Rich MW, Eckman JM "Can hydrochlorothiazide cause lupus?" J Rheumatol 22 (1995):  1001|Brown CW, Deng JS "Thiazide diuretics induce cutaneous lupus-like adverse reaction." J Toxicol Clin Toxicol 33 (1995):  729-33', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7696, 26084, 'Metolazone', 'Lupus Erythematosus, Systemic', 'The use of thiazide diuretics has been reported to possibly exacerbate or activate systemic lupus erythematosus.  Reported cases have generally been associated with chlorothiazide and hydrochlorothiazide.  Therapy with thiazide diuretics should be administered cautiously in patients with a history or risk of SLE.', '3', 'Reed BR, Huff JC, Jones SK, Orton PW, Lee LA, Norris DA "Subacute cutaneous lupus erythematosus associated with hydrochlorothiazide therapy." Ann Intern Med 103 (1985):  49-51|Parodi A, Romagnoli M, Rebora A "Subacute cutaneous lupus erythematosus-like eruption caused by hydrochlorothiazide." Photodermatol 6 (1989):  100-2|"Product Information. HydroDIURIL (hydrochlorothiazide)." Merck & Co., Inc  (2002):|"Product Information. Lozol (indapamide)." Rhone Poulenc Rorer  (2002):|Goodrich AL, Kohn SR "Hydrochlorothiazide-induced lupus erythematosus: a new variant?" J Am Acad Dermatol 28 (1993):  1001-2|"Product Information. Zaroxolyn (metolazone)." Rhone Poulenc Rorer  (2001):|"Product Information. Thalitone (chlorthalidone)." Monarch Pharmaceuticals Inc  (2001):|"Product Information. Diuril (chlorothiazide)." Merck & Co., Inc  (2001):|"Product Information. Enduron (methyclothiazide)." Abbott Pharmaceutical  (2001):|"Product Information. Metahydrin (trichlormethiazide)." Hoechst Marion Roussel  (2001):|"Product Information. Diucardin (hydroflumethiazide)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Renese-R (reserpine-polythiazide)." Pfizer US Pharmaceuticals, New York, NY.|Rich MW, Eckman JM "Can hydrochlorothiazide cause lupus?" J Rheumatol 22 (1995):  1001|Brown CW, Deng JS "Thiazide diuretics induce cutaneous lupus-like adverse reaction." J Toxicol Clin Toxicol 33 (1995):  729-33', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7697, 17239, 'Metolazone', 'Kidney Failure, Chronic', 'Thiazide diuretics may be ineffective when the glomerular filtration rate is low (GFR < 25 mL/min) because they are not expected to be filtered into the renal tubule, their site of action.  In addition, thiazide diuretics decrease the GFR and may precipitate azotemia in renal disease.  Cumulative effects may also develop because most of these drugs are excreted unchanged in the urine by glomerular filtration and active tubular secretion.  Therapy with thiazide diuretics should be administered cautiously at reduced dosages in patients with renal impairment.  If renal function becomes progressively worse, as indicated by rising BUN or serum creatinine levels, an interruption or discontinuation of thiazide therapy should be considered.', '3', 'Fleuren HLJ, Verwey-van Wissen C, van Rossum JM "Dose-dependent urinary excretion of chlorthalidone." Clin Pharmacol Ther 25 (1979):  806-12|Beermann B, Groschinsky-Grind M, Rosen A "Absorption, metabolism, and excretion of hydrochlorothiazide." Clin Pharmacol Ther 19 (1975):  531-7|Niemeyer C, Hasenfub G, Wais U, et al. "Pharmacokinetics of hydrochlorothiazide in relation to renal function." Eur J Clin Pharmacol 24 (1983):  661-5|Gehr TW, Sica DA, Brater DC, et al. "Metolazone pharmacokinetics and pharmacodynamics in renal transplantation." Int J Clin Pharmacol Ther Toxicol 29 (1991):  116-23|Jones B, Nanra RS "Double-blind trial of antihypertensive effect of chlorothiazide in severe renal failure." Lancet 2 (1979):  1258-60|Carney SL, Morgan TO "Diuretic-induced hypokalemia and altered renal function." Int J Clin Pharmacol Ther Toxicol 24 (1986):  665-7|Magil AB, Ballon HS, Cameron EC, Rae A "Acute interstitial nephritis associated with thiazide diuretics. Clinical and pathologic observations in three cases." Am J Med 69 (1980):  939-43|Magil AB "Drug-induced acute interstitial nephritis with granulomas." Hum Pathol 14 (1983):  36-41|Delevett AF, Recalde M "Diuretic-induced renal colic." JAMA 225 (1973):  992|Riess W, Dubach UC, Burckhardt D, Theobald W, Vuillard P, Zimmerli M "Pharmacokinetic studies with chlorthalidone (Hygroton) in man." Eur J Clin Pharmacol 12 (1977):  375-82|Tilstone WJ, Dargie H, Dargie EN, Morgan HG, Kennedy AC "Pharmacokinetics of metolazone in normal subjects and in patients with cardiac or renal failure." Clin Pharmacol Ther 16 (1974):  322-9|Bennett WM, Porter GA "Efficacy and safety of metolazone in renal failure and the nephrotic syndrome." J Clin Pharmacol 13 (1973):  357-64|Craswell PW, Ezzat E, Kopstein J, Varghese Z, Moorhead JF "Use of metolazone, a new diuretic, in patients with renal disease." Nephron 12 (1974):  63-73|Acchiardo SR, Skoutakis VA "Clinical efficacy, safety, and pharmacokinetics of indapamide in renal impairment." Am Heart J 106 (1983):  237-44|Brennan L, Wu MJ, Laquer UJ "A multicenter study of indapamide in hypertensive patients with impaired renal function." Clin Ther 5 (1982):  121-8|Klunk LJ, Ringel S, Neiss ES "The disposition of 14C-indapamide in man." J Clin Pharmacol 23 (1983):  377-84|Newstead CG, Moore RH, Barnes AJ "Interstitial nephritis associated with indapamide." BMJ 300 (1990):  1344|"Product Information. HydroDIURIL (hydrochlorothiazide)." Merck & Co., Inc  (2002):|"Product Information. Lozol (indapamide)." Rhone Poulenc Rorer  (2002):|"Product Information. Zaroxolyn (metolazone)." Rhone Poulenc Rorer  (2001):|Gilman AG, eds., Nies AS, Rall TW, Taylor P "Goodman and Gilman''s the Pharmacological Basis of Therapeutics." New York, NY: Pergamon Press Inc.  (1990):|Seyffart, G "Drug Dosage in Renal Insufficiency." Dordrecht, The Netherlands:  Kluwer Academic Publishers 1 (1991):  227-8|"Product Information. Thalitone (chlorthalidone)." Monarch Pharmaceuticals Inc  (2001):|"Product Information. Diuril (chlorothiazide)." Merck & Co., Inc  (2001):|Hobbs DC, Twomey TM "Kinetics of polythiazide." Clin Pharmacol Ther 23 (1978):  241-6|Lant AF, Baba WI, Wilson GM "Localization of the site of action of oral diuretics in the human kidney." Clin Sci 33 (1967):  11-27|Brors O, Jacobsen S "Distribution of elimination of hydroflumethiazide in man." Eur J Clin Pharmacol 16 (1979):  125-31|Brors O, Haffner JF, Jacobsen S "Excretion of hydroflumethiazide in bile and urine of man." Eur J Clin Pharmacol 15 (1979):  287-9|Yakatan GJ, Smith RB, Frome EL, Doluisio JT "Pharmacokinetics of orally administered hydroflumethiazide in man." J Clin Pharmacol 17 (1977):  37-47|el-Meheiry MM, Nabih AE, Soliman MD "A clinical study of a new diuretic, Trichlormethiazide." J Trop Med Hyg 69 (1966):  209-14|Sketris IS, Skoutakis VA, Acchiardo SR, Meyer MC "The pharmacokinetics of trichlormethiazide in hypertensive patients with normal and compromised renal function." Eur J Clin Pharmacol 20 (1981):  453-7|"Product Information. Enduron (methyclothiazide)." Abbott Pharmaceutical  (2001):|"Product Information. Metahydrin (trichlormethiazide)." Hoechst Marion Roussel  (2001):|"Product Information. Diucardin (hydroflumethiazide)." Wyeth-Ayerst Laboratories  (2001):|Larsson GB, Langer L, Nassberger L "Thiazide-induced kidney damage with circulating antibodies against myeloperoxidase and cardiolipin." J Intern Med 233 (1993):  493-4|Beermann B, Groschinsky-Grind M, Lindstrom B "Pharmacokinetics of bendroflumethiazide." Clin Pharmacol Ther 22 (1977):  385-8|Beermann B, Groschinsky-Grind M, Lindstrom B, Wikland B "Pharmacokinetics of bendroflumenthiazide in hypertensive patients." Eur J Clin Pharmacol 13 (1978):  119-24|"Product Information. Renese-R (reserpine-polythiazide)." Pfizer US Pharmaceuticals, New York, NY.|Read SJ, Trenerry HM, Whiting GF "Hyponatraemia and raised creatine kinase level associated with indapamide." Med J Aust 161 (1994):  607-8|Madkour H, Gadallah M, Plante GE, Massry SG "Comparison between the effects of indapamide and hydrochlorothiazide on creatinine clearance in patients with impaired renal function and hypertension." Am J Nephrol 15 (1995):  251-5|Brater DC "Drug therapy: Diuretic therapy." N Engl J Med 339 (1998):  387-95', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7698, 18087, 'Metolazone', 'Kidney Failure, Chronic', 'Thiazide diuretics may be ineffective when the glomerular filtration rate is low (GFR < 25 mL/min) because they are not expected to be filtered into the renal tubule, their site of action.  In addition, thiazide diuretics decrease the GFR and may precipitate azotemia in renal disease.  Cumulative effects may also develop because most of these drugs are excreted unchanged in the urine by glomerular filtration and active tubular secretion.  Therapy with thiazide diuretics should be administered cautiously at reduced dosages in patients with renal impairment.  If renal function becomes progressively worse, as indicated by rising BUN or serum creatinine levels, an interruption or discontinuation of thiazide therapy should be considered.', '3', 'Fleuren HLJ, Verwey-van Wissen C, van Rossum JM "Dose-dependent urinary excretion of chlorthalidone." Clin Pharmacol Ther 25 (1979):  806-12|Beermann B, Groschinsky-Grind M, Rosen A "Absorption, metabolism, and excretion of hydrochlorothiazide." Clin Pharmacol Ther 19 (1975):  531-7|Niemeyer C, Hasenfub G, Wais U, et al. "Pharmacokinetics of hydrochlorothiazide in relation to renal function." Eur J Clin Pharmacol 24 (1983):  661-5|Gehr TW, Sica DA, Brater DC, et al. "Metolazone pharmacokinetics and pharmacodynamics in renal transplantation." Int J Clin Pharmacol Ther Toxicol 29 (1991):  116-23|Jones B, Nanra RS "Double-blind trial of antihypertensive effect of chlorothiazide in severe renal failure." Lancet 2 (1979):  1258-60|Carney SL, Morgan TO "Diuretic-induced hypokalemia and altered renal function." Int J Clin Pharmacol Ther Toxicol 24 (1986):  665-7|Magil AB, Ballon HS, Cameron EC, Rae A "Acute interstitial nephritis associated with thiazide diuretics. Clinical and pathologic observations in three cases." Am J Med 69 (1980):  939-43|Magil AB "Drug-induced acute interstitial nephritis with granulomas." Hum Pathol 14 (1983):  36-41|Delevett AF, Recalde M "Diuretic-induced renal colic." JAMA 225 (1973):  992|Riess W, Dubach UC, Burckhardt D, Theobald W, Vuillard P, Zimmerli M "Pharmacokinetic studies with chlorthalidone (Hygroton) in man." Eur J Clin Pharmacol 12 (1977):  375-82|Tilstone WJ, Dargie H, Dargie EN, Morgan HG, Kennedy AC "Pharmacokinetics of metolazone in normal subjects and in patients with cardiac or renal failure." Clin Pharmacol Ther 16 (1974):  322-9|Bennett WM, Porter GA "Efficacy and safety of metolazone in renal failure and the nephrotic syndrome." J Clin Pharmacol 13 (1973):  357-64|Craswell PW, Ezzat E, Kopstein J, Varghese Z, Moorhead JF "Use of metolazone, a new diuretic, in patients with renal disease." Nephron 12 (1974):  63-73|Acchiardo SR, Skoutakis VA "Clinical efficacy, safety, and pharmacokinetics of indapamide in renal impairment." Am Heart J 106 (1983):  237-44|Brennan L, Wu MJ, Laquer UJ "A multicenter study of indapamide in hypertensive patients with impaired renal function." Clin Ther 5 (1982):  121-8|Klunk LJ, Ringel S, Neiss ES "The disposition of 14C-indapamide in man." J Clin Pharmacol 23 (1983):  377-84|Newstead CG, Moore RH, Barnes AJ "Interstitial nephritis associated with indapamide." BMJ 300 (1990):  1344|"Product Information. HydroDIURIL (hydrochlorothiazide)." Merck & Co., Inc  (2002):|"Product Information. Lozol (indapamide)." Rhone Poulenc Rorer  (2002):|"Product Information. Zaroxolyn (metolazone)." Rhone Poulenc Rorer  (2001):|Gilman AG, eds., Nies AS, Rall TW, Taylor P "Goodman and Gilman''s the Pharmacological Basis of Therapeutics." New York, NY: Pergamon Press Inc.  (1990):|Seyffart, G "Drug Dosage in Renal Insufficiency." Dordrecht, The Netherlands:  Kluwer Academic Publishers 1 (1991):  227-8|"Product Information. Thalitone (chlorthalidone)." Monarch Pharmaceuticals Inc  (2001):|"Product Information. Diuril (chlorothiazide)." Merck & Co., Inc  (2001):|Hobbs DC, Twomey TM "Kinetics of polythiazide." Clin Pharmacol Ther 23 (1978):  241-6|Lant AF, Baba WI, Wilson GM "Localization of the site of action of oral diuretics in the human kidney." Clin Sci 33 (1967):  11-27|Brors O, Jacobsen S "Distribution of elimination of hydroflumethiazide in man." Eur J Clin Pharmacol 16 (1979):  125-31|Brors O, Haffner JF, Jacobsen S "Excretion of hydroflumethiazide in bile and urine of man." Eur J Clin Pharmacol 15 (1979):  287-9|Yakatan GJ, Smith RB, Frome EL, Doluisio JT "Pharmacokinetics of orally administered hydroflumethiazide in man." J Clin Pharmacol 17 (1977):  37-47|el-Meheiry MM, Nabih AE, Soliman MD "A clinical study of a new diuretic, Trichlormethiazide." J Trop Med Hyg 69 (1966):  209-14|Sketris IS, Skoutakis VA, Acchiardo SR, Meyer MC "The pharmacokinetics of trichlormethiazide in hypertensive patients with normal and compromised renal function." Eur J Clin Pharmacol 20 (1981):  453-7|"Product Information. Enduron (methyclothiazide)." Abbott Pharmaceutical  (2001):|"Product Information. Metahydrin (trichlormethiazide)." Hoechst Marion Roussel  (2001):|"Product Information. Diucardin (hydroflumethiazide)." Wyeth-Ayerst Laboratories  (2001):|Larsson GB, Langer L, Nassberger L "Thiazide-induced kidney damage with circulating antibodies against myeloperoxidase and cardiolipin." J Intern Med 233 (1993):  493-4|Beermann B, Groschinsky-Grind M, Lindstrom B "Pharmacokinetics of bendroflumethiazide." Clin Pharmacol Ther 22 (1977):  385-8|Beermann B, Groschinsky-Grind M, Lindstrom B, Wikland B "Pharmacokinetics of bendroflumenthiazide in hypertensive patients." Eur J Clin Pharmacol 13 (1978):  119-24|"Product Information. Renese-R (reserpine-polythiazide)." Pfizer US Pharmaceuticals, New York, NY.|Read SJ, Trenerry HM, Whiting GF "Hyponatraemia and raised creatine kinase level associated with indapamide." Med J Aust 161 (1994):  607-8|Madkour H, Gadallah M, Plante GE, Massry SG "Comparison between the effects of indapamide and hydrochlorothiazide on creatinine clearance in patients with impaired renal function and hypertension." Am J Nephrol 15 (1995):  251-5|Brater DC "Drug therapy: Diuretic therapy." N Engl J Med 339 (1998):  387-95', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7699, 22666, 'Metolazone', 'Kidney Failure, Chronic', 'Thiazide diuretics may be ineffective when the glomerular filtration rate is low (GFR < 25 mL/min) because they are not expected to be filtered into the renal tubule, their site of action.  In addition, thiazide diuretics decrease the GFR and may precipitate azotemia in renal disease.  Cumulative effects may also develop because most of these drugs are excreted unchanged in the urine by glomerular filtration and active tubular secretion.  Therapy with thiazide diuretics should be administered cautiously at reduced dosages in patients with renal impairment.  If renal function becomes progressively worse, as indicated by rising BUN or serum creatinine levels, an interruption or discontinuation of thiazide therapy should be considered.', '3', 'Fleuren HLJ, Verwey-van Wissen C, van Rossum JM "Dose-dependent urinary excretion of chlorthalidone." Clin Pharmacol Ther 25 (1979):  806-12|Beermann B, Groschinsky-Grind M, Rosen A "Absorption, metabolism, and excretion of hydrochlorothiazide." Clin Pharmacol Ther 19 (1975):  531-7|Niemeyer C, Hasenfub G, Wais U, et al. "Pharmacokinetics of hydrochlorothiazide in relation to renal function." Eur J Clin Pharmacol 24 (1983):  661-5|Gehr TW, Sica DA, Brater DC, et al. "Metolazone pharmacokinetics and pharmacodynamics in renal transplantation." Int J Clin Pharmacol Ther Toxicol 29 (1991):  116-23|Jones B, Nanra RS "Double-blind trial of antihypertensive effect of chlorothiazide in severe renal failure." Lancet 2 (1979):  1258-60|Carney SL, Morgan TO "Diuretic-induced hypokalemia and altered renal function." Int J Clin Pharmacol Ther Toxicol 24 (1986):  665-7|Magil AB, Ballon HS, Cameron EC, Rae A "Acute interstitial nephritis associated with thiazide diuretics. Clinical and pathologic observations in three cases." Am J Med 69 (1980):  939-43|Magil AB "Drug-induced acute interstitial nephritis with granulomas." Hum Pathol 14 (1983):  36-41|Delevett AF, Recalde M "Diuretic-induced renal colic." JAMA 225 (1973):  992|Riess W, Dubach UC, Burckhardt D, Theobald W, Vuillard P, Zimmerli M "Pharmacokinetic studies with chlorthalidone (Hygroton) in man." Eur J Clin Pharmacol 12 (1977):  375-82|Tilstone WJ, Dargie H, Dargie EN, Morgan HG, Kennedy AC "Pharmacokinetics of metolazone in normal subjects and in patients with cardiac or renal failure." Clin Pharmacol Ther 16 (1974):  322-9|Bennett WM, Porter GA "Efficacy and safety of metolazone in renal failure and the nephrotic syndrome." J Clin Pharmacol 13 (1973):  357-64|Craswell PW, Ezzat E, Kopstein J, Varghese Z, Moorhead JF "Use of metolazone, a new diuretic, in patients with renal disease." Nephron 12 (1974):  63-73|Acchiardo SR, Skoutakis VA "Clinical efficacy, safety, and pharmacokinetics of indapamide in renal impairment." Am Heart J 106 (1983):  237-44|Brennan L, Wu MJ, Laquer UJ "A multicenter study of indapamide in hypertensive patients with impaired renal function." Clin Ther 5 (1982):  121-8|Klunk LJ, Ringel S, Neiss ES "The disposition of 14C-indapamide in man." J Clin Pharmacol 23 (1983):  377-84|Newstead CG, Moore RH, Barnes AJ "Interstitial nephritis associated with indapamide." BMJ 300 (1990):  1344|"Product Information. HydroDIURIL (hydrochlorothiazide)." Merck & Co., Inc  (2002):|"Product Information. Lozol (indapamide)." Rhone Poulenc Rorer  (2002):|"Product Information. Zaroxolyn (metolazone)." Rhone Poulenc Rorer  (2001):|Gilman AG, eds., Nies AS, Rall TW, Taylor P "Goodman and Gilman''s the Pharmacological Basis of Therapeutics." New York, NY: Pergamon Press Inc.  (1990):|Seyffart, G "Drug Dosage in Renal Insufficiency." Dordrecht, The Netherlands:  Kluwer Academic Publishers 1 (1991):  227-8|"Product Information. Thalitone (chlorthalidone)." Monarch Pharmaceuticals Inc  (2001):|"Product Information. Diuril (chlorothiazide)." Merck & Co., Inc  (2001):|Hobbs DC, Twomey TM "Kinetics of polythiazide." Clin Pharmacol Ther 23 (1978):  241-6|Lant AF, Baba WI, Wilson GM "Localization of the site of action of oral diuretics in the human kidney." Clin Sci 33 (1967):  11-27|Brors O, Jacobsen S "Distribution of elimination of hydroflumethiazide in man." Eur J Clin Pharmacol 16 (1979):  125-31|Brors O, Haffner JF, Jacobsen S "Excretion of hydroflumethiazide in bile and urine of man." Eur J Clin Pharmacol 15 (1979):  287-9|Yakatan GJ, Smith RB, Frome EL, Doluisio JT "Pharmacokinetics of orally administered hydroflumethiazide in man." J Clin Pharmacol 17 (1977):  37-47|el-Meheiry MM, Nabih AE, Soliman MD "A clinical study of a new diuretic, Trichlormethiazide." J Trop Med Hyg 69 (1966):  209-14|Sketris IS, Skoutakis VA, Acchiardo SR, Meyer MC "The pharmacokinetics of trichlormethiazide in hypertensive patients with normal and compromised renal function." Eur J Clin Pharmacol 20 (1981):  453-7|"Product Information. Enduron (methyclothiazide)." Abbott Pharmaceutical  (2001):|"Product Information. Metahydrin (trichlormethiazide)." Hoechst Marion Roussel  (2001):|"Product Information. Diucardin (hydroflumethiazide)." Wyeth-Ayerst Laboratories  (2001):|Larsson GB, Langer L, Nassberger L "Thiazide-induced kidney damage with circulating antibodies against myeloperoxidase and cardiolipin." J Intern Med 233 (1993):  493-4|Beermann B, Groschinsky-Grind M, Lindstrom B "Pharmacokinetics of bendroflumethiazide." Clin Pharmacol Ther 22 (1977):  385-8|Beermann B, Groschinsky-Grind M, Lindstrom B, Wikland B "Pharmacokinetics of bendroflumenthiazide in hypertensive patients." Eur J Clin Pharmacol 13 (1978):  119-24|"Product Information. Renese-R (reserpine-polythiazide)." Pfizer US Pharmaceuticals, New York, NY.|Read SJ, Trenerry HM, Whiting GF "Hyponatraemia and raised creatine kinase level associated with indapamide." Med J Aust 161 (1994):  607-8|Madkour H, Gadallah M, Plante GE, Massry SG "Comparison between the effects of indapamide and hydrochlorothiazide on creatinine clearance in patients with impaired renal function and hypertension." Am J Nephrol 15 (1995):  251-5|Brater DC "Drug therapy: Diuretic therapy." N Engl J Med 339 (1998):  387-95', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7700, 26084, 'Metolazone', 'Kidney Failure, Chronic', 'Thiazide diuretics may be ineffective when the glomerular filtration rate is low (GFR < 25 mL/min) because they are not expected to be filtered into the renal tubule, their site of action.  In addition, thiazide diuretics decrease the GFR and may precipitate azotemia in renal disease.  Cumulative effects may also develop because most of these drugs are excreted unchanged in the urine by glomerular filtration and active tubular secretion.  Therapy with thiazide diuretics should be administered cautiously at reduced dosages in patients with renal impairment.  If renal function becomes progressively worse, as indicated by rising BUN or serum creatinine levels, an interruption or discontinuation of thiazide therapy should be considered.', '3', 'Fleuren HLJ, Verwey-van Wissen C, van Rossum JM "Dose-dependent urinary excretion of chlorthalidone." Clin Pharmacol Ther 25 (1979):  806-12|Beermann B, Groschinsky-Grind M, Rosen A "Absorption, metabolism, and excretion of hydrochlorothiazide." Clin Pharmacol Ther 19 (1975):  531-7|Niemeyer C, Hasenfub G, Wais U, et al. "Pharmacokinetics of hydrochlorothiazide in relation to renal function." Eur J Clin Pharmacol 24 (1983):  661-5|Gehr TW, Sica DA, Brater DC, et al. "Metolazone pharmacokinetics and pharmacodynamics in renal transplantation." Int J Clin Pharmacol Ther Toxicol 29 (1991):  116-23|Jones B, Nanra RS "Double-blind trial of antihypertensive effect of chlorothiazide in severe renal failure." Lancet 2 (1979):  1258-60|Carney SL, Morgan TO "Diuretic-induced hypokalemia and altered renal function." Int J Clin Pharmacol Ther Toxicol 24 (1986):  665-7|Magil AB, Ballon HS, Cameron EC, Rae A "Acute interstitial nephritis associated with thiazide diuretics. Clinical and pathologic observations in three cases." Am J Med 69 (1980):  939-43|Magil AB "Drug-induced acute interstitial nephritis with granulomas." Hum Pathol 14 (1983):  36-41|Delevett AF, Recalde M "Diuretic-induced renal colic." JAMA 225 (1973):  992|Riess W, Dubach UC, Burckhardt D, Theobald W, Vuillard P, Zimmerli M "Pharmacokinetic studies with chlorthalidone (Hygroton) in man." Eur J Clin Pharmacol 12 (1977):  375-82|Tilstone WJ, Dargie H, Dargie EN, Morgan HG, Kennedy AC "Pharmacokinetics of metolazone in normal subjects and in patients with cardiac or renal failure." Clin Pharmacol Ther 16 (1974):  322-9|Bennett WM, Porter GA "Efficacy and safety of metolazone in renal failure and the nephrotic syndrome." J Clin Pharmacol 13 (1973):  357-64|Craswell PW, Ezzat E, Kopstein J, Varghese Z, Moorhead JF "Use of metolazone, a new diuretic, in patients with renal disease." Nephron 12 (1974):  63-73|Acchiardo SR, Skoutakis VA "Clinical efficacy, safety, and pharmacokinetics of indapamide in renal impairment." Am Heart J 106 (1983):  237-44|Brennan L, Wu MJ, Laquer UJ "A multicenter study of indapamide in hypertensive patients with impaired renal function." Clin Ther 5 (1982):  121-8|Klunk LJ, Ringel S, Neiss ES "The disposition of 14C-indapamide in man." J Clin Pharmacol 23 (1983):  377-84|Newstead CG, Moore RH, Barnes AJ "Interstitial nephritis associated with indapamide." BMJ 300 (1990):  1344|"Product Information. HydroDIURIL (hydrochlorothiazide)." Merck & Co., Inc  (2002):|"Product Information. Lozol (indapamide)." Rhone Poulenc Rorer  (2002):|"Product Information. Zaroxolyn (metolazone)." Rhone Poulenc Rorer  (2001):|Gilman AG, eds., Nies AS, Rall TW, Taylor P "Goodman and Gilman''s the Pharmacological Basis of Therapeutics." New York, NY: Pergamon Press Inc.  (1990):|Seyffart, G "Drug Dosage in Renal Insufficiency." Dordrecht, The Netherlands:  Kluwer Academic Publishers 1 (1991):  227-8|"Product Information. Thalitone (chlorthalidone)." Monarch Pharmaceuticals Inc  (2001):|"Product Information. Diuril (chlorothiazide)." Merck & Co., Inc  (2001):|Hobbs DC, Twomey TM "Kinetics of polythiazide." Clin Pharmacol Ther 23 (1978):  241-6|Lant AF, Baba WI, Wilson GM "Localization of the site of action of oral diuretics in the human kidney." Clin Sci 33 (1967):  11-27|Brors O, Jacobsen S "Distribution of elimination of hydroflumethiazide in man." Eur J Clin Pharmacol 16 (1979):  125-31|Brors O, Haffner JF, Jacobsen S "Excretion of hydroflumethiazide in bile and urine of man." Eur J Clin Pharmacol 15 (1979):  287-9|Yakatan GJ, Smith RB, Frome EL, Doluisio JT "Pharmacokinetics of orally administered hydroflumethiazide in man." J Clin Pharmacol 17 (1977):  37-47|el-Meheiry MM, Nabih AE, Soliman MD "A clinical study of a new diuretic, Trichlormethiazide." J Trop Med Hyg 69 (1966):  209-14|Sketris IS, Skoutakis VA, Acchiardo SR, Meyer MC "The pharmacokinetics of trichlormethiazide in hypertensive patients with normal and compromised renal function." Eur J Clin Pharmacol 20 (1981):  453-7|"Product Information. Enduron (methyclothiazide)." Abbott Pharmaceutical  (2001):|"Product Information. Metahydrin (trichlormethiazide)." Hoechst Marion Roussel  (2001):|"Product Information. Diucardin (hydroflumethiazide)." Wyeth-Ayerst Laboratories  (2001):|Larsson GB, Langer L, Nassberger L "Thiazide-induced kidney damage with circulating antibodies against myeloperoxidase and cardiolipin." J Intern Med 233 (1993):  493-4|Beermann B, Groschinsky-Grind M, Lindstrom B "Pharmacokinetics of bendroflumethiazide." Clin Pharmacol Ther 22 (1977):  385-8|Beermann B, Groschinsky-Grind M, Lindstrom B, Wikland B "Pharmacokinetics of bendroflumenthiazide in hypertensive patients." Eur J Clin Pharmacol 13 (1978):  119-24|"Product Information. Renese-R (reserpine-polythiazide)." Pfizer US Pharmaceuticals, New York, NY.|Read SJ, Trenerry HM, Whiting GF "Hyponatraemia and raised creatine kinase level associated with indapamide." Med J Aust 161 (1994):  607-8|Madkour H, Gadallah M, Plante GE, Massry SG "Comparison between the effects of indapamide and hydrochlorothiazide on creatinine clearance in patients with impaired renal function and hypertension." Am J Nephrol 15 (1995):  251-5|Brater DC "Drug therapy: Diuretic therapy." N Engl J Med 339 (1998):  387-95', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7701, 17239, 'Metolazone', 'Asthma', 'Thiazide diuretics should be used with caution in patients with history of bronchial asthma as sensitivity reactions may occur.', '2', '"Product Information. HydroDIURIL (hydrochlorothiazide)." Merck & Co., Inc  (2002):|"Product Information. Lozol (indapamide)." Rhone Poulenc Rorer  (2002):|"Product Information. Zaroxolyn (metolazone)." Rhone Poulenc Rorer  (2001):|"Product Information. Thalitone (chlorthalidone)." Monarch Pharmaceuticals Inc  (2001):|"Product Information. Diuril (chlorothiazide)." Merck & Co., Inc  (2001):|"Product Information. Enduron (methyclothiazide)." Abbott Pharmaceutical  (2001):|"Product Information. Metahydrin (trichlormethiazide)." Hoechst Marion Roussel  (2001):|"Product Information. Diucardin (hydroflumethiazide)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Renese-R (reserpine-polythiazide)." Pfizer US Pharmaceuticals, New York, NY.', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7702, 18087, 'Metolazone', 'Asthma', 'Thiazide diuretics should be used with caution in patients with history of bronchial asthma as sensitivity reactions may occur.', '2', '"Product Information. HydroDIURIL (hydrochlorothiazide)." Merck & Co., Inc  (2002):|"Product Information. Lozol (indapamide)." Rhone Poulenc Rorer  (2002):|"Product Information. Zaroxolyn (metolazone)." Rhone Poulenc Rorer  (2001):|"Product Information. Thalitone (chlorthalidone)." Monarch Pharmaceuticals Inc  (2001):|"Product Information. Diuril (chlorothiazide)." Merck & Co., Inc  (2001):|"Product Information. Enduron (methyclothiazide)." Abbott Pharmaceutical  (2001):|"Product Information. Metahydrin (trichlormethiazide)." Hoechst Marion Roussel  (2001):|"Product Information. Diucardin (hydroflumethiazide)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Renese-R (reserpine-polythiazide)." Pfizer US Pharmaceuticals, New York, NY.', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7703, 22666, 'Metolazone', 'Asthma', 'Thiazide diuretics should be used with caution in patients with history of bronchial asthma as sensitivity reactions may occur.', '2', '"Product Information. HydroDIURIL (hydrochlorothiazide)." Merck & Co., Inc  (2002):|"Product Information. Lozol (indapamide)." Rhone Poulenc Rorer  (2002):|"Product Information. Zaroxolyn (metolazone)." Rhone Poulenc Rorer  (2001):|"Product Information. Thalitone (chlorthalidone)." Monarch Pharmaceuticals Inc  (2001):|"Product Information. Diuril (chlorothiazide)." Merck & Co., Inc  (2001):|"Product Information. Enduron (methyclothiazide)." Abbott Pharmaceutical  (2001):|"Product Information. Metahydrin (trichlormethiazide)." Hoechst Marion Roussel  (2001):|"Product Information. Diucardin (hydroflumethiazide)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Renese-R (reserpine-polythiazide)." Pfizer US Pharmaceuticals, New York, NY.', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7704, 26084, 'Metolazone', 'Asthma', 'Thiazide diuretics should be used with caution in patients with history of bronchial asthma as sensitivity reactions may occur.', '2', '"Product Information. HydroDIURIL (hydrochlorothiazide)." Merck & Co., Inc  (2002):|"Product Information. Lozol (indapamide)." Rhone Poulenc Rorer  (2002):|"Product Information. Zaroxolyn (metolazone)." Rhone Poulenc Rorer  (2001):|"Product Information. Thalitone (chlorthalidone)." Monarch Pharmaceuticals Inc  (2001):|"Product Information. Diuril (chlorothiazide)." Merck & Co., Inc  (2001):|"Product Information. Enduron (methyclothiazide)." Abbott Pharmaceutical  (2001):|"Product Information. Metahydrin (trichlormethiazide)." Hoechst Marion Roussel  (2001):|"Product Information. Diucardin (hydroflumethiazide)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Renese-R (reserpine-polythiazide)." Pfizer US Pharmaceuticals, New York, NY.', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7705, 17239, 'Metolazone', 'Diabetes Mellitus', 'Thiazide diuretics may cause hyperglycemia and glycosuria in patients with diabetes.  They may also precipitate diabetes in prediabetic patients.  These effects are usually reversible following discontinuation of the drugs.  Therapy with thiazide diuretics should be administered cautiously in patients with diabetes mellitus, glucose intolerance, or a predisposition to hyperglycemia.  Patients with diabetes mellitus should be monitored more closely during thiazide therapy, and their antidiabetic regimen adjusted accordingly.', '2', 'Pollare T, Lithell H, Berne C "A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension." N Engl J Med 321 (1989):  868-73|Goldman JA, Neri A, Ovadia J, Eckerling B, Vries A, de "Effect of chlorothiazide on intravenous glucose tolerance in pregnancy." Am J Obstet Gynecol 105 (1969):  556-60|Miller NR, Moses H "Transient oculomotor nerve palsy. Association with thiazide-induced glucose intolerance." JAMA 240 (1978):  1887-8|Kansal PC, Buse J, Buse MG "Thiazide diuretics and control of diabetes mellitus." South Med J 62 (1969):  1372-9|Andersen OO, Persson I "Carbohydrate metabolism during treatment with chlorthalidone and ethacrynic acid." Br Med J 2 (1968):  798-801|Curtis J, Horrigan F, Ahearn D, Varney R, Sandler SG "Chlorthalidone-induced hyperosmolar hyperglycemic nonketotic coma." JAMA 220 (1972):  1592-3|Chowdhury FR, Bleicher SJ "Chlorthalidone--induced hypokalemia and abnormal carbohydrate metabolism." Horm Metab Res 2 (1970):  13-6|Diamond MT "Hyperglycemic hyperosmolar coma associated with hydrochlorothiazide and pancreatitis." N Y State J Med 72 (1972):  1741-2|Jones IG, Pickens PT "Diabetes mellitus following oral diuretics." Practitioner 199 (1967):  209-10|Beling S, Vukovich RA, Neiss ES, Zisblatt M, Webb E, Losi M "Long-term experience with indapamide." Am Heart J 106 (1983):  258-62|Slotkoff L "Clinical efficacy and safety of indapamide in the treatment of edema." Am Heart J 106 (1983):  233-7|Murphy MB, Kohner E, Lewis PJ, Schumer B, Dollery CT "Glucose intolerance in hypertensive patients treated with diuretics: a fourteen-year follow-up." Lancet 2 (1982):  1293-5|Seltzer HS, Allen EW "Hyperglycemia and inhibition of insulin secretion during administration of diazoxide and trichlormethiazide in man." Diabetes 18 (1969):  19-28|"Product Information. HydroDIURIL (hydrochlorothiazide)." Merck & Co., Inc  (2002):|"Product Information. Lozol (indapamide)." Rhone Poulenc Rorer  (2002):|Bell DS "Insulin resistance. An often unrecognized problem accompanying chronic medical disorders." Postgrad Med 93 (1993):  99-103,|Berlin I "Prazosin, diuretics, and glucose intolerance." Ann Intern Med 119 (1993):  860|"Product Information. Zaroxolyn (metolazone)." Rhone Poulenc Rorer  (2001):|Rowe P, Mather H "Hyperosmolar non-ketotic diabetes mellitus associated with metolazone." Br Med J 291 (1985):  25-6|Domenet JG "Diabetogenic effect of oral diuretics." Br Med J 3 (1968):  188|"Product Information. Thalitone (chlorthalidone)." Monarch Pharmaceuticals Inc  (2001):|"Product Information. Diuril (chlorothiazide)." Merck & Co., Inc  (2001):|Schmitz O, Hermansen K, Nielsen OH, Christensen CK, Arnfred J, Hansen HE, Mogensen CE, Orskov H, Beck-Nielsen H "Insulin action in insulin-dependent diabetics after short-term thiazide therapy." Diabetes Care 9 (1986):  631-6|Blayac JP, Ribes G, Buys D, Puech R, Loubatieres-Mariani MM "Effects of a new benzothiadiazine derivative, LN 5330, on insulin secretion." Arch Int Pharmacodyn Ther 253 (1981):  154-63|"Product Information. Enduron (methyclothiazide)." Abbott Pharmaceutical  (2001):|"Product Information. Metahydrin (trichlormethiazide)." Hoechst Marion Roussel  (2001):|"Product Information. Diucardin (hydroflumethiazide)." Wyeth-Ayerst Laboratories  (2001):|Berglund G, Andersson O, Widgren B "Low-dose antihypertensive treatment with a thiazide diuretic is not diabetogenic. A 10-year controlled trial with bendroflumethiazide." Acta Med Scand 220 (1986):  419-24|Elmfeldt D, Berglund G, Wedel H, Wilhelmsen L "Incidence and importance of metabolic side-effects during antihypertensive therapy." Acta Med Scand Suppl 672 (1983):  79-83|Winchester JF, Kellett RJ, Boddy K, Boyle P, Dargie HJ, Mahaffey ME, Ward DM, Kennedy AC "Metolazone and bendroflumethiazide in hypertension: physiologic and metabolic observations." Clin Pharmacol Ther 28 (1980):  611-8|Petri M, Cumber P, Grimes L, Treby D, Bryant R, Rawlins D, Ising H "The metabolic effects of thiazide therapy in the elderly: a population study." Age Ageing 15 (1986):  151-5|"Product Information. Renese-R (reserpine-polythiazide)." Pfizer US Pharmaceuticals, New York, NY.|Freis ED "The efficacy and safety of diuretics in treating hypertension." Ann Intern Med 122 (1995):  223-6|Nielsen S, Schmitz A, Knudsen RE, Dollerup J, Mogensen CE "Enalapril versus bendroflumethiazide in type 2 diabetes complicated by hypertension." Q J Med 87 (1994):  747-54|Harper R, Ennis CN, Heaney AP, Sheridan B, Gormley M, Atkinson AB, Johnston GD, Bell PM "A comparison of the effects of low- and conventional-dose thiazide diuretic on insulin action in hypertensive patients with NIDDM." Diabetologia 38 (1995):  853-9|Pickkers P, Schachter M, Hughes AD, Feher MD, Sever PS "Thiazide-induced hyperglycaemia: a role for calcium-activated potassium channels?" Diabetologia 39 (1996):  861-4', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7706, 18087, 'Metolazone', 'Diabetes Mellitus', 'Thiazide diuretics may cause hyperglycemia and glycosuria in patients with diabetes.  They may also precipitate diabetes in prediabetic patients.  These effects are usually reversible following discontinuation of the drugs.  Therapy with thiazide diuretics should be administered cautiously in patients with diabetes mellitus, glucose intolerance, or a predisposition to hyperglycemia.  Patients with diabetes mellitus should be monitored more closely during thiazide therapy, and their antidiabetic regimen adjusted accordingly.', '2', 'Pollare T, Lithell H, Berne C "A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension." N Engl J Med 321 (1989):  868-73|Goldman JA, Neri A, Ovadia J, Eckerling B, Vries A, de "Effect of chlorothiazide on intravenous glucose tolerance in pregnancy." Am J Obstet Gynecol 105 (1969):  556-60|Miller NR, Moses H "Transient oculomotor nerve palsy. Association with thiazide-induced glucose intolerance." JAMA 240 (1978):  1887-8|Kansal PC, Buse J, Buse MG "Thiazide diuretics and control of diabetes mellitus." South Med J 62 (1969):  1372-9|Andersen OO, Persson I "Carbohydrate metabolism during treatment with chlorthalidone and ethacrynic acid." Br Med J 2 (1968):  798-801|Curtis J, Horrigan F, Ahearn D, Varney R, Sandler SG "Chlorthalidone-induced hyperosmolar hyperglycemic nonketotic coma." JAMA 220 (1972):  1592-3|Chowdhury FR, Bleicher SJ "Chlorthalidone--induced hypokalemia and abnormal carbohydrate metabolism." Horm Metab Res 2 (1970):  13-6|Diamond MT "Hyperglycemic hyperosmolar coma associated with hydrochlorothiazide and pancreatitis." N Y State J Med 72 (1972):  1741-2|Jones IG, Pickens PT "Diabetes mellitus following oral diuretics." Practitioner 199 (1967):  209-10|Beling S, Vukovich RA, Neiss ES, Zisblatt M, Webb E, Losi M "Long-term experience with indapamide." Am Heart J 106 (1983):  258-62|Slotkoff L "Clinical efficacy and safety of indapamide in the treatment of edema." Am Heart J 106 (1983):  233-7|Murphy MB, Kohner E, Lewis PJ, Schumer B, Dollery CT "Glucose intolerance in hypertensive patients treated with diuretics: a fourteen-year follow-up." Lancet 2 (1982):  1293-5|Seltzer HS, Allen EW "Hyperglycemia and inhibition of insulin secretion during administration of diazoxide and trichlormethiazide in man." Diabetes 18 (1969):  19-28|"Product Information. HydroDIURIL (hydrochlorothiazide)." Merck & Co., Inc  (2002):|"Product Information. Lozol (indapamide)." Rhone Poulenc Rorer  (2002):|Bell DS "Insulin resistance. An often unrecognized problem accompanying chronic medical disorders." Postgrad Med 93 (1993):  99-103,|Berlin I "Prazosin, diuretics, and glucose intolerance." Ann Intern Med 119 (1993):  860|"Product Information. Zaroxolyn (metolazone)." Rhone Poulenc Rorer  (2001):|Rowe P, Mather H "Hyperosmolar non-ketotic diabetes mellitus associated with metolazone." Br Med J 291 (1985):  25-6|Domenet JG "Diabetogenic effect of oral diuretics." Br Med J 3 (1968):  188|"Product Information. Thalitone (chlorthalidone)." Monarch Pharmaceuticals Inc  (2001):|"Product Information. Diuril (chlorothiazide)." Merck & Co., Inc  (2001):|Schmitz O, Hermansen K, Nielsen OH, Christensen CK, Arnfred J, Hansen HE, Mogensen CE, Orskov H, Beck-Nielsen H "Insulin action in insulin-dependent diabetics after short-term thiazide therapy." Diabetes Care 9 (1986):  631-6|Blayac JP, Ribes G, Buys D, Puech R, Loubatieres-Mariani MM "Effects of a new benzothiadiazine derivative, LN 5330, on insulin secretion." Arch Int Pharmacodyn Ther 253 (1981):  154-63|"Product Information. Enduron (methyclothiazide)." Abbott Pharmaceutical  (2001):|"Product Information. Metahydrin (trichlormethiazide)." Hoechst Marion Roussel  (2001):|"Product Information. Diucardin (hydroflumethiazide)." Wyeth-Ayerst Laboratories  (2001):|Berglund G, Andersson O, Widgren B "Low-dose antihypertensive treatment with a thiazide diuretic is not diabetogenic. A 10-year controlled trial with bendroflumethiazide." Acta Med Scand 220 (1986):  419-24|Elmfeldt D, Berglund G, Wedel H, Wilhelmsen L "Incidence and importance of metabolic side-effects during antihypertensive therapy." Acta Med Scand Suppl 672 (1983):  79-83|Winchester JF, Kellett RJ, Boddy K, Boyle P, Dargie HJ, Mahaffey ME, Ward DM, Kennedy AC "Metolazone and bendroflumethiazide in hypertension: physiologic and metabolic observations." Clin Pharmacol Ther 28 (1980):  611-8|Petri M, Cumber P, Grimes L, Treby D, Bryant R, Rawlins D, Ising H "The metabolic effects of thiazide therapy in the elderly: a population study." Age Ageing 15 (1986):  151-5|"Product Information. Renese-R (reserpine-polythiazide)." Pfizer US Pharmaceuticals, New York, NY.|Freis ED "The efficacy and safety of diuretics in treating hypertension." Ann Intern Med 122 (1995):  223-6|Nielsen S, Schmitz A, Knudsen RE, Dollerup J, Mogensen CE "Enalapril versus bendroflumethiazide in type 2 diabetes complicated by hypertension." Q J Med 87 (1994):  747-54|Harper R, Ennis CN, Heaney AP, Sheridan B, Gormley M, Atkinson AB, Johnston GD, Bell PM "A comparison of the effects of low- and conventional-dose thiazide diuretic on insulin action in hypertensive patients with NIDDM." Diabetologia 38 (1995):  853-9|Pickkers P, Schachter M, Hughes AD, Feher MD, Sever PS "Thiazide-induced hyperglycaemia: a role for calcium-activated potassium channels?" Diabetologia 39 (1996):  861-4', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7707, 22666, 'Metolazone', 'Diabetes Mellitus', 'Thiazide diuretics may cause hyperglycemia and glycosuria in patients with diabetes.  They may also precipitate diabetes in prediabetic patients.  These effects are usually reversible following discontinuation of the drugs.  Therapy with thiazide diuretics should be administered cautiously in patients with diabetes mellitus, glucose intolerance, or a predisposition to hyperglycemia.  Patients with diabetes mellitus should be monitored more closely during thiazide therapy, and their antidiabetic regimen adjusted accordingly.', '2', 'Pollare T, Lithell H, Berne C "A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension." N Engl J Med 321 (1989):  868-73|Goldman JA, Neri A, Ovadia J, Eckerling B, Vries A, de "Effect of chlorothiazide on intravenous glucose tolerance in pregnancy." Am J Obstet Gynecol 105 (1969):  556-60|Miller NR, Moses H "Transient oculomotor nerve palsy. Association with thiazide-induced glucose intolerance." JAMA 240 (1978):  1887-8|Kansal PC, Buse J, Buse MG "Thiazide diuretics and control of diabetes mellitus." South Med J 62 (1969):  1372-9|Andersen OO, Persson I "Carbohydrate metabolism during treatment with chlorthalidone and ethacrynic acid." Br Med J 2 (1968):  798-801|Curtis J, Horrigan F, Ahearn D, Varney R, Sandler SG "Chlorthalidone-induced hyperosmolar hyperglycemic nonketotic coma." JAMA 220 (1972):  1592-3|Chowdhury FR, Bleicher SJ "Chlorthalidone--induced hypokalemia and abnormal carbohydrate metabolism." Horm Metab Res 2 (1970):  13-6|Diamond MT "Hyperglycemic hyperosmolar coma associated with hydrochlorothiazide and pancreatitis." N Y State J Med 72 (1972):  1741-2|Jones IG, Pickens PT "Diabetes mellitus following oral diuretics." Practitioner 199 (1967):  209-10|Beling S, Vukovich RA, Neiss ES, Zisblatt M, Webb E, Losi M "Long-term experience with indapamide." Am Heart J 106 (1983):  258-62|Slotkoff L "Clinical efficacy and safety of indapamide in the treatment of edema." Am Heart J 106 (1983):  233-7|Murphy MB, Kohner E, Lewis PJ, Schumer B, Dollery CT "Glucose intolerance in hypertensive patients treated with diuretics: a fourteen-year follow-up." Lancet 2 (1982):  1293-5|Seltzer HS, Allen EW "Hyperglycemia and inhibition of insulin secretion during administration of diazoxide and trichlormethiazide in man." Diabetes 18 (1969):  19-28|"Product Information. HydroDIURIL (hydrochlorothiazide)." Merck & Co., Inc  (2002):|"Product Information. Lozol (indapamide)." Rhone Poulenc Rorer  (2002):|Bell DS "Insulin resistance. An often unrecognized problem accompanying chronic medical disorders." Postgrad Med 93 (1993):  99-103,|Berlin I "Prazosin, diuretics, and glucose intolerance." Ann Intern Med 119 (1993):  860|"Product Information. Zaroxolyn (metolazone)." Rhone Poulenc Rorer  (2001):|Rowe P, Mather H "Hyperosmolar non-ketotic diabetes mellitus associated with metolazone." Br Med J 291 (1985):  25-6|Domenet JG "Diabetogenic effect of oral diuretics." Br Med J 3 (1968):  188|"Product Information. Thalitone (chlorthalidone)." Monarch Pharmaceuticals Inc  (2001):|"Product Information. Diuril (chlorothiazide)." Merck & Co., Inc  (2001):|Schmitz O, Hermansen K, Nielsen OH, Christensen CK, Arnfred J, Hansen HE, Mogensen CE, Orskov H, Beck-Nielsen H "Insulin action in insulin-dependent diabetics after short-term thiazide therapy." Diabetes Care 9 (1986):  631-6|Blayac JP, Ribes G, Buys D, Puech R, Loubatieres-Mariani MM "Effects of a new benzothiadiazine derivative, LN 5330, on insulin secretion." Arch Int Pharmacodyn Ther 253 (1981):  154-63|"Product Information. Enduron (methyclothiazide)." Abbott Pharmaceutical  (2001):|"Product Information. Metahydrin (trichlormethiazide)." Hoechst Marion Roussel  (2001):|"Product Information. Diucardin (hydroflumethiazide)." Wyeth-Ayerst Laboratories  (2001):|Berglund G, Andersson O, Widgren B "Low-dose antihypertensive treatment with a thiazide diuretic is not diabetogenic. A 10-year controlled trial with bendroflumethiazide." Acta Med Scand 220 (1986):  419-24|Elmfeldt D, Berglund G, Wedel H, Wilhelmsen L "Incidence and importance of metabolic side-effects during antihypertensive therapy." Acta Med Scand Suppl 672 (1983):  79-83|Winchester JF, Kellett RJ, Boddy K, Boyle P, Dargie HJ, Mahaffey ME, Ward DM, Kennedy AC "Metolazone and bendroflumethiazide in hypertension: physiologic and metabolic observations." Clin Pharmacol Ther 28 (1980):  611-8|Petri M, Cumber P, Grimes L, Treby D, Bryant R, Rawlins D, Ising H "The metabolic effects of thiazide therapy in the elderly: a population study." Age Ageing 15 (1986):  151-5|"Product Information. Renese-R (reserpine-polythiazide)." Pfizer US Pharmaceuticals, New York, NY.|Freis ED "The efficacy and safety of diuretics in treating hypertension." Ann Intern Med 122 (1995):  223-6|Nielsen S, Schmitz A, Knudsen RE, Dollerup J, Mogensen CE "Enalapril versus bendroflumethiazide in type 2 diabetes complicated by hypertension." Q J Med 87 (1994):  747-54|Harper R, Ennis CN, Heaney AP, Sheridan B, Gormley M, Atkinson AB, Johnston GD, Bell PM "A comparison of the effects of low- and conventional-dose thiazide diuretic on insulin action in hypertensive patients with NIDDM." Diabetologia 38 (1995):  853-9|Pickkers P, Schachter M, Hughes AD, Feher MD, Sever PS "Thiazide-induced hyperglycaemia: a role for calcium-activated potassium channels?" Diabetologia 39 (1996):  861-4', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7708, 26084, 'Metolazone', 'Diabetes Mellitus', 'Thiazide diuretics may cause hyperglycemia and glycosuria in patients with diabetes.  They may also precipitate diabetes in prediabetic patients.  These effects are usually reversible following discontinuation of the drugs.  Therapy with thiazide diuretics should be administered cautiously in patients with diabetes mellitus, glucose intolerance, or a predisposition to hyperglycemia.  Patients with diabetes mellitus should be monitored more closely during thiazide therapy, and their antidiabetic regimen adjusted accordingly.', '2', 'Pollare T, Lithell H, Berne C "A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension." N Engl J Med 321 (1989):  868-73|Goldman JA, Neri A, Ovadia J, Eckerling B, Vries A, de "Effect of chlorothiazide on intravenous glucose tolerance in pregnancy." Am J Obstet Gynecol 105 (1969):  556-60|Miller NR, Moses H "Transient oculomotor nerve palsy. Association with thiazide-induced glucose intolerance." JAMA 240 (1978):  1887-8|Kansal PC, Buse J, Buse MG "Thiazide diuretics and control of diabetes mellitus." South Med J 62 (1969):  1372-9|Andersen OO, Persson I "Carbohydrate metabolism during treatment with chlorthalidone and ethacrynic acid." Br Med J 2 (1968):  798-801|Curtis J, Horrigan F, Ahearn D, Varney R, Sandler SG "Chlorthalidone-induced hyperosmolar hyperglycemic nonketotic coma." JAMA 220 (1972):  1592-3|Chowdhury FR, Bleicher SJ "Chlorthalidone--induced hypokalemia and abnormal carbohydrate metabolism." Horm Metab Res 2 (1970):  13-6|Diamond MT "Hyperglycemic hyperosmolar coma associated with hydrochlorothiazide and pancreatitis." N Y State J Med 72 (1972):  1741-2|Jones IG, Pickens PT "Diabetes mellitus following oral diuretics." Practitioner 199 (1967):  209-10|Beling S, Vukovich RA, Neiss ES, Zisblatt M, Webb E, Losi M "Long-term experience with indapamide." Am Heart J 106 (1983):  258-62|Slotkoff L "Clinical efficacy and safety of indapamide in the treatment of edema." Am Heart J 106 (1983):  233-7|Murphy MB, Kohner E, Lewis PJ, Schumer B, Dollery CT "Glucose intolerance in hypertensive patients treated with diuretics: a fourteen-year follow-up." Lancet 2 (1982):  1293-5|Seltzer HS, Allen EW "Hyperglycemia and inhibition of insulin secretion during administration of diazoxide and trichlormethiazide in man." Diabetes 18 (1969):  19-28|"Product Information. HydroDIURIL (hydrochlorothiazide)." Merck & Co., Inc  (2002):|"Product Information. Lozol (indapamide)." Rhone Poulenc Rorer  (2002):|Bell DS "Insulin resistance. An often unrecognized problem accompanying chronic medical disorders." Postgrad Med 93 (1993):  99-103,|Berlin I "Prazosin, diuretics, and glucose intolerance." Ann Intern Med 119 (1993):  860|"Product Information. Zaroxolyn (metolazone)." Rhone Poulenc Rorer  (2001):|Rowe P, Mather H "Hyperosmolar non-ketotic diabetes mellitus associated with metolazone." Br Med J 291 (1985):  25-6|Domenet JG "Diabetogenic effect of oral diuretics." Br Med J 3 (1968):  188|"Product Information. Thalitone (chlorthalidone)." Monarch Pharmaceuticals Inc  (2001):|"Product Information. Diuril (chlorothiazide)." Merck & Co., Inc  (2001):|Schmitz O, Hermansen K, Nielsen OH, Christensen CK, Arnfred J, Hansen HE, Mogensen CE, Orskov H, Beck-Nielsen H "Insulin action in insulin-dependent diabetics after short-term thiazide therapy." Diabetes Care 9 (1986):  631-6|Blayac JP, Ribes G, Buys D, Puech R, Loubatieres-Mariani MM "Effects of a new benzothiadiazine derivative, LN 5330, on insulin secretion." Arch Int Pharmacodyn Ther 253 (1981):  154-63|"Product Information. Enduron (methyclothiazide)." Abbott Pharmaceutical  (2001):|"Product Information. Metahydrin (trichlormethiazide)." Hoechst Marion Roussel  (2001):|"Product Information. Diucardin (hydroflumethiazide)." Wyeth-Ayerst Laboratories  (2001):|Berglund G, Andersson O, Widgren B "Low-dose antihypertensive treatment with a thiazide diuretic is not diabetogenic. A 10-year controlled trial with bendroflumethiazide." Acta Med Scand 220 (1986):  419-24|Elmfeldt D, Berglund G, Wedel H, Wilhelmsen L "Incidence and importance of metabolic side-effects during antihypertensive therapy." Acta Med Scand Suppl 672 (1983):  79-83|Winchester JF, Kellett RJ, Boddy K, Boyle P, Dargie HJ, Mahaffey ME, Ward DM, Kennedy AC "Metolazone and bendroflumethiazide in hypertension: physiologic and metabolic observations." Clin Pharmacol Ther 28 (1980):  611-8|Petri M, Cumber P, Grimes L, Treby D, Bryant R, Rawlins D, Ising H "The metabolic effects of thiazide therapy in the elderly: a population study." Age Ageing 15 (1986):  151-5|"Product Information. Renese-R (reserpine-polythiazide)." Pfizer US Pharmaceuticals, New York, NY.|Freis ED "The efficacy and safety of diuretics in treating hypertension." Ann Intern Med 122 (1995):  223-6|Nielsen S, Schmitz A, Knudsen RE, Dollerup J, Mogensen CE "Enalapril versus bendroflumethiazide in type 2 diabetes complicated by hypertension." Q J Med 87 (1994):  747-54|Harper R, Ennis CN, Heaney AP, Sheridan B, Gormley M, Atkinson AB, Johnston GD, Bell PM "A comparison of the effects of low- and conventional-dose thiazide diuretic on insulin action in hypertensive patients with NIDDM." Diabetologia 38 (1995):  853-9|Pickkers P, Schachter M, Hughes AD, Feher MD, Sever PS "Thiazide-induced hyperglycaemia: a role for calcium-activated potassium channels?" Diabetologia 39 (1996):  861-4', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7709, 17239, 'Metolazone', 'Hyperlipidemias', 'Thiazide diuretics may increase serum triglyceride and cholesterol levels, primarily LDL and VLDL.  Whether these effects are dose-related and sustained during chronic therapy are unknown.  Patients with preexisting hyperlipidemia may require closer monitoring during thiazide therapy, and adjustments made accordingly in their lipid-lowering regimen', '2', 'Pollare T, Lithell H, Berne C "A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension." N Engl J Med 321 (1989):  868-73|Ames RP, Hill P "Increase in serum-lipids during treatment of hypertension with chlorthalidone." Lancet 1 (1976):  721-3|Pollare T, Lithell H, Berne C "A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension." N Engl J Med 321 (1989):  868-73|Fager G, Berglund G, Bondjers G, Elmfeldt D, Lager I, Olofsson SO, Smith U, Wiklund O "Effects of anti-hypertensive therapy on serum lipoproteins. Treatment with metoprolol, propranolol and hydrochlorothiazide." Artery 11 (1983):  283-96|Beling S, Vukovich RA, Neiss ES, Zisblatt M, Webb E, Losi M "Long-term experience with indapamide." Am Heart J 106 (1983):  258-62|Slotkoff L "Clinical efficacy and safety of indapamide in the treatment of edema." Am Heart J 106 (1983):  233-7|"Product Information. HydroDIURIL (hydrochlorothiazide)." Merck & Co., Inc  (2002):|"Product Information. Lozol (indapamide)." Rhone Poulenc Rorer  (2002):|Luther RR, Glassman HN, Estep CB, Maurath CJ, Jordan DC "The effects of terazosin and methyclothiazide on blood pressure and serum lipids." Am Heart J 117 (1989):  842-7|"Product Information. Zaroxolyn (metolazone)." Rhone Poulenc Rorer  (2001):|"Product Information. Thalitone (chlorthalidone)." Monarch Pharmaceuticals Inc  (2001):|"Product Information. Diuril (chlorothiazide)." Merck & Co., Inc  (2001):|Smith WM "Diuretics and cholesterol elevation." JAMA 242 (1979):  1612|"Product Information. Enduron (methyclothiazide)." Abbott Pharmaceutical  (2001):|"Product Information. Metahydrin (trichlormethiazide)." Hoechst Marion Roussel  (2001):|"Product Information. Diucardin (hydroflumethiazide)." Wyeth-Ayerst Laboratories  (2001):|Elmfeldt D, Berglund G, Wedel H, Wilhelmsen L "Incidence and importance of metabolic side-effects during antihypertensive therapy." Acta Med Scand Suppl 672 (1983):  79-83|Winchester JF, Kellett RJ, Boddy K, Boyle P, Dargie HJ, Mahaffey ME, Ward DM, Kennedy AC "Metolazone and bendroflumethiazide in hypertension: physiologic and metabolic observations." Clin Pharmacol Ther 28 (1980):  611-8|Petri M, Cumber P, Grimes L, Treby D, Bryant R, Rawlins D, Ising H "The metabolic effects of thiazide therapy in the elderly: a population study." Age Ageing 15 (1986):  151-5|"Product Information. Renese-R (reserpine-polythiazide)." Pfizer US Pharmaceuticals, New York, NY.|Kasiske BL, Ma JZ, Kalil RS, Louis TA "Effects of antihypertensive therapy on serum lipids." Ann Intern Med 122 (1995):  133-41|Freis ED "The efficacy and safety of diuretics in treating hypertension." Ann Intern Med 122 (1995):  223-6|Ames RP "A comparison of blood lipid and blood pressure responses during the treatment of systemic hypertension with indapamide and with thiazides." Am J Cardiol 77 (1996):  b12-6', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7710, 18087, 'Metolazone', 'Hyperlipidemias', 'Thiazide diuretics may increase serum triglyceride and cholesterol levels, primarily LDL and VLDL.  Whether these effects are dose-related and sustained during chronic therapy are unknown.  Patients with preexisting hyperlipidemia may require closer monitoring during thiazide therapy, and adjustments made accordingly in their lipid-lowering regimen', '2', 'Pollare T, Lithell H, Berne C "A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension." N Engl J Med 321 (1989):  868-73|Ames RP, Hill P "Increase in serum-lipids during treatment of hypertension with chlorthalidone." Lancet 1 (1976):  721-3|Pollare T, Lithell H, Berne C "A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension." N Engl J Med 321 (1989):  868-73|Fager G, Berglund G, Bondjers G, Elmfeldt D, Lager I, Olofsson SO, Smith U, Wiklund O "Effects of anti-hypertensive therapy on serum lipoproteins. Treatment with metoprolol, propranolol and hydrochlorothiazide." Artery 11 (1983):  283-96|Beling S, Vukovich RA, Neiss ES, Zisblatt M, Webb E, Losi M "Long-term experience with indapamide." Am Heart J 106 (1983):  258-62|Slotkoff L "Clinical efficacy and safety of indapamide in the treatment of edema." Am Heart J 106 (1983):  233-7|"Product Information. HydroDIURIL (hydrochlorothiazide)." Merck & Co., Inc  (2002):|"Product Information. Lozol (indapamide)." Rhone Poulenc Rorer  (2002):|Luther RR, Glassman HN, Estep CB, Maurath CJ, Jordan DC "The effects of terazosin and methyclothiazide on blood pressure and serum lipids." Am Heart J 117 (1989):  842-7|"Product Information. Zaroxolyn (metolazone)." Rhone Poulenc Rorer  (2001):|"Product Information. Thalitone (chlorthalidone)." Monarch Pharmaceuticals Inc  (2001):|"Product Information. Diuril (chlorothiazide)." Merck & Co., Inc  (2001):|Smith WM "Diuretics and cholesterol elevation." JAMA 242 (1979):  1612|"Product Information. Enduron (methyclothiazide)." Abbott Pharmaceutical  (2001):|"Product Information. Metahydrin (trichlormethiazide)." Hoechst Marion Roussel  (2001):|"Product Information. Diucardin (hydroflumethiazide)." Wyeth-Ayerst Laboratories  (2001):|Elmfeldt D, Berglund G, Wedel H, Wilhelmsen L "Incidence and importance of metabolic side-effects during antihypertensive therapy." Acta Med Scand Suppl 672 (1983):  79-83|Winchester JF, Kellett RJ, Boddy K, Boyle P, Dargie HJ, Mahaffey ME, Ward DM, Kennedy AC "Metolazone and bendroflumethiazide in hypertension: physiologic and metabolic observations." Clin Pharmacol Ther 28 (1980):  611-8|Petri M, Cumber P, Grimes L, Treby D, Bryant R, Rawlins D, Ising H "The metabolic effects of thiazide therapy in the elderly: a population study." Age Ageing 15 (1986):  151-5|"Product Information. Renese-R (reserpine-polythiazide)." Pfizer US Pharmaceuticals, New York, NY.|Kasiske BL, Ma JZ, Kalil RS, Louis TA "Effects of antihypertensive therapy on serum lipids." Ann Intern Med 122 (1995):  133-41|Freis ED "The efficacy and safety of diuretics in treating hypertension." Ann Intern Med 122 (1995):  223-6|Ames RP "A comparison of blood lipid and blood pressure responses during the treatment of systemic hypertension with indapamide and with thiazides." Am J Cardiol 77 (1996):  b12-6', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7711, 22666, 'Metolazone', 'Hyperlipidemias', 'Thiazide diuretics may increase serum triglyceride and cholesterol levels, primarily LDL and VLDL.  Whether these effects are dose-related and sustained during chronic therapy are unknown.  Patients with preexisting hyperlipidemia may require closer monitoring during thiazide therapy, and adjustments made accordingly in their lipid-lowering regimen', '2', 'Pollare T, Lithell H, Berne C "A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension." N Engl J Med 321 (1989):  868-73|Ames RP, Hill P "Increase in serum-lipids during treatment of hypertension with chlorthalidone." Lancet 1 (1976):  721-3|Pollare T, Lithell H, Berne C "A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension." N Engl J Med 321 (1989):  868-73|Fager G, Berglund G, Bondjers G, Elmfeldt D, Lager I, Olofsson SO, Smith U, Wiklund O "Effects of anti-hypertensive therapy on serum lipoproteins. Treatment with metoprolol, propranolol and hydrochlorothiazide." Artery 11 (1983):  283-96|Beling S, Vukovich RA, Neiss ES, Zisblatt M, Webb E, Losi M "Long-term experience with indapamide." Am Heart J 106 (1983):  258-62|Slotkoff L "Clinical efficacy and safety of indapamide in the treatment of edema." Am Heart J 106 (1983):  233-7|"Product Information. HydroDIURIL (hydrochlorothiazide)." Merck & Co., Inc  (2002):|"Product Information. Lozol (indapamide)." Rhone Poulenc Rorer  (2002):|Luther RR, Glassman HN, Estep CB, Maurath CJ, Jordan DC "The effects of terazosin and methyclothiazide on blood pressure and serum lipids." Am Heart J 117 (1989):  842-7|"Product Information. Zaroxolyn (metolazone)." Rhone Poulenc Rorer  (2001):|"Product Information. Thalitone (chlorthalidone)." Monarch Pharmaceuticals Inc  (2001):|"Product Information. Diuril (chlorothiazide)." Merck & Co., Inc  (2001):|Smith WM "Diuretics and cholesterol elevation." JAMA 242 (1979):  1612|"Product Information. Enduron (methyclothiazide)." Abbott Pharmaceutical  (2001):|"Product Information. Metahydrin (trichlormethiazide)." Hoechst Marion Roussel  (2001):|"Product Information. Diucardin (hydroflumethiazide)." Wyeth-Ayerst Laboratories  (2001):|Elmfeldt D, Berglund G, Wedel H, Wilhelmsen L "Incidence and importance of metabolic side-effects during antihypertensive therapy." Acta Med Scand Suppl 672 (1983):  79-83|Winchester JF, Kellett RJ, Boddy K, Boyle P, Dargie HJ, Mahaffey ME, Ward DM, Kennedy AC "Metolazone and bendroflumethiazide in hypertension: physiologic and metabolic observations." Clin Pharmacol Ther 28 (1980):  611-8|Petri M, Cumber P, Grimes L, Treby D, Bryant R, Rawlins D, Ising H "The metabolic effects of thiazide therapy in the elderly: a population study." Age Ageing 15 (1986):  151-5|"Product Information. Renese-R (reserpine-polythiazide)." Pfizer US Pharmaceuticals, New York, NY.|Kasiske BL, Ma JZ, Kalil RS, Louis TA "Effects of antihypertensive therapy on serum lipids." Ann Intern Med 122 (1995):  133-41|Freis ED "The efficacy and safety of diuretics in treating hypertension." Ann Intern Med 122 (1995):  223-6|Ames RP "A comparison of blood lipid and blood pressure responses during the treatment of systemic hypertension with indapamide and with thiazides." Am J Cardiol 77 (1996):  b12-6', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7712, 26084, 'Metolazone', 'Hyperlipidemias', 'Thiazide diuretics may increase serum triglyceride and cholesterol levels, primarily LDL and VLDL.  Whether these effects are dose-related and sustained during chronic therapy are unknown.  Patients with preexisting hyperlipidemia may require closer monitoring during thiazide therapy, and adjustments made accordingly in their lipid-lowering regimen', '2', 'Pollare T, Lithell H, Berne C "A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension." N Engl J Med 321 (1989):  868-73|Ames RP, Hill P "Increase in serum-lipids during treatment of hypertension with chlorthalidone." Lancet 1 (1976):  721-3|Pollare T, Lithell H, Berne C "A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension." N Engl J Med 321 (1989):  868-73|Fager G, Berglund G, Bondjers G, Elmfeldt D, Lager I, Olofsson SO, Smith U, Wiklund O "Effects of anti-hypertensive therapy on serum lipoproteins. Treatment with metoprolol, propranolol and hydrochlorothiazide." Artery 11 (1983):  283-96|Beling S, Vukovich RA, Neiss ES, Zisblatt M, Webb E, Losi M "Long-term experience with indapamide." Am Heart J 106 (1983):  258-62|Slotkoff L "Clinical efficacy and safety of indapamide in the treatment of edema." Am Heart J 106 (1983):  233-7|"Product Information. HydroDIURIL (hydrochlorothiazide)." Merck & Co., Inc  (2002):|"Product Information. Lozol (indapamide)." Rhone Poulenc Rorer  (2002):|Luther RR, Glassman HN, Estep CB, Maurath CJ, Jordan DC "The effects of terazosin and methyclothiazide on blood pressure and serum lipids." Am Heart J 117 (1989):  842-7|"Product Information. Zaroxolyn (metolazone)." Rhone Poulenc Rorer  (2001):|"Product Information. Thalitone (chlorthalidone)." Monarch Pharmaceuticals Inc  (2001):|"Product Information. Diuril (chlorothiazide)." Merck & Co., Inc  (2001):|Smith WM "Diuretics and cholesterol elevation." JAMA 242 (1979):  1612|"Product Information. Enduron (methyclothiazide)." Abbott Pharmaceutical  (2001):|"Product Information. Metahydrin (trichlormethiazide)." Hoechst Marion Roussel  (2001):|"Product Information. Diucardin (hydroflumethiazide)." Wyeth-Ayerst Laboratories  (2001):|Elmfeldt D, Berglund G, Wedel H, Wilhelmsen L "Incidence and importance of metabolic side-effects during antihypertensive therapy." Acta Med Scand Suppl 672 (1983):  79-83|Winchester JF, Kellett RJ, Boddy K, Boyle P, Dargie HJ, Mahaffey ME, Ward DM, Kennedy AC "Metolazone and bendroflumethiazide in hypertension: physiologic and metabolic observations." Clin Pharmacol Ther 28 (1980):  611-8|Petri M, Cumber P, Grimes L, Treby D, Bryant R, Rawlins D, Ising H "The metabolic effects of thiazide therapy in the elderly: a population study." Age Ageing 15 (1986):  151-5|"Product Information. Renese-R (reserpine-polythiazide)." Pfizer US Pharmaceuticals, New York, NY.|Kasiske BL, Ma JZ, Kalil RS, Louis TA "Effects of antihypertensive therapy on serum lipids." Ann Intern Med 122 (1995):  133-41|Freis ED "The efficacy and safety of diuretics in treating hypertension." Ann Intern Med 122 (1995):  223-6|Ames RP "A comparison of blood lipid and blood pressure responses during the treatment of systemic hypertension with indapamide and with thiazides." Am J Cardiol 77 (1996):  b12-6', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7713, 17239, 'Metolazone', 'Hyperparathyroidism', 'Urinary calcium excretion is decreased by thiazide diuretics during chronic administration.  Pathologic changes in the parathyroid gland with hypercalcemia and hypophosphatemia have been reported during prolonged therapy.  However, the common complications of hyperparathyroidism such as renal lithiasis, bone resorption, and peptic ulceration have not been seen.  Clinicians should be cognizant of these effects when prescribing or administering thiazide therapy to patients with hyperparathyroidism.  These drugs should be discontinued before carrying out tests for parathyroid function.', '2', 'Anderson PE, Ellis GG, Austin SM "Case report: metolazone-associated hypercalcemia and acute pancreatitis." Am J Med Sci 302 (1991):  235-7|Lindy S, Tarssanen L "Serum calcium and phosphorus in patients treated with thiazides and furosemide." Acta Med Scand 194 (1973):  319-22|Gammon GD, Docherty JP "Thiazide-induced hypercalcemia in a manic-depressive patient." Am J Psychiatry 137 (1980):  1453-5|Parfitt AM "Thiazide-induced hypercalcemia in vitamin D-treated hypoparathyroidism." Ann Intern Med 77 (1972):  557-63|Popovtzer MM, Subryan VL, Alfrey AC, Reeve EB, Schrier RW "The acute effect of chlorothiazide on serum-ionized calcium. Evidence for a parathyroid hormone-dependent mechanism." J Clin Invest 55 (1975):  1295-302|Paloyan E, Farland M, Pickleman JR "Hyperparathyroidism coexisting with hypertension and prolonged thiazide administration." JAMA 210 (1969):  1243-5|Parfitt AM "Chlorothiazide-induced hypercalcemia in juvenile osteoporosis and hyperparathyroidism." N Engl J Med 281 (1969):  55-9|Palmer FJ "Letter: Chlorthalidone-induced hypercalcemia." JAMA 229 (1974):  267|Hakim R, Tolis G, Goltzman D, Meltzer S, Friedman R "Severe hypercalcemia associated with hydrochlorothiazide and calcium carbonate therapy." Can Med Assoc J 121 (1979):  591-4|Itescu S, Haskell LP, Tannenberg AM "Thiazide-induced clinically significant hypophosphatemia ." Clin Nephrol 27 (1987):  161-2|Byatt CM, Millard PH, Levin GE "Diuretics and electrolyte disturbances in 1000 consecutive geriatric admissions." J R Soc Med 83 (1990):  704-8|Balizet L "Recurrent parathyroid adenoma. Association with prolonged thiazide administration." JAMA 225 (1973):  1238-9|Paloyan E, Farland M, Pickleman JR "Hyperparathyroidism coexisting with hypertension and prolonged thiazide administration." JAMA 210 (1969):  1243-5|Duarte CG, Winnacker JL, Becker KL, Pace A "Thiazide-induced hypercalcemia." N Engl J Med 284 (1971):  828-30|Klimiuk PS, Davies M, Adams PH "Primary hyperparathyroidism and thiazide diuretics." Postgrad Med J 57 (1981):  80-3|"Product Information. HydroDIURIL (hydrochlorothiazide)." Merck & Co., Inc  (2002):|"Product Information. Lozol (indapamide)." Rhone Poulenc Rorer  (2002):|"Product Information. Zaroxolyn (metolazone)." Rhone Poulenc Rorer  (2001):|"Product Information. Thalitone (chlorthalidone)." Monarch Pharmaceuticals Inc  (2001):|"Product Information. Diuril (chlorothiazide)." Merck & Co., Inc  (2001):|"Product Information. Enduron (methyclothiazide)." Abbott Pharmaceutical  (2001):|"Product Information. Metahydrin (trichlormethiazide)." Hoechst Marion Roussel  (2001):|"Product Information. Diucardin (hydroflumethiazide)." Wyeth-Ayerst Laboratories  (2001):|Hilker RR "Reversible hypercalcemia associated with prolonged thiazide administration to control hypertension." J Occup Med 12 (1970):  444-5|Jorgensen FS, Brunner S "The long-term effect of bendroflumethiazide on renal calcium and magnesium excretion and stone formation in patients with recurring renal stones." Scand J Urol Nephrol 8 (1974):  128-31|Ljunghall S, Backman U, Danielson BG, Fellstrom B, Johansson G, Wikstrom B "Calcium and magnesium metabolism during long-term treatment with thiazides." Scand J Urol Nephrol 15 (1981):  257-62|"Product Information. Renese-R (reserpine-polythiazide)." Pfizer US Pharmaceuticals, New York, NY.', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7714, 18087, 'Metolazone', 'Hyperparathyroidism', 'Urinary calcium excretion is decreased by thiazide diuretics during chronic administration.  Pathologic changes in the parathyroid gland with hypercalcemia and hypophosphatemia have been reported during prolonged therapy.  However, the common complications of hyperparathyroidism such as renal lithiasis, bone resorption, and peptic ulceration have not been seen.  Clinicians should be cognizant of these effects when prescribing or administering thiazide therapy to patients with hyperparathyroidism.  These drugs should be discontinued before carrying out tests for parathyroid function.', '2', 'Anderson PE, Ellis GG, Austin SM "Case report: metolazone-associated hypercalcemia and acute pancreatitis." Am J Med Sci 302 (1991):  235-7|Lindy S, Tarssanen L "Serum calcium and phosphorus in patients treated with thiazides and furosemide." Acta Med Scand 194 (1973):  319-22|Gammon GD, Docherty JP "Thiazide-induced hypercalcemia in a manic-depressive patient." Am J Psychiatry 137 (1980):  1453-5|Parfitt AM "Thiazide-induced hypercalcemia in vitamin D-treated hypoparathyroidism." Ann Intern Med 77 (1972):  557-63|Popovtzer MM, Subryan VL, Alfrey AC, Reeve EB, Schrier RW "The acute effect of chlorothiazide on serum-ionized calcium. Evidence for a parathyroid hormone-dependent mechanism." J Clin Invest 55 (1975):  1295-302|Paloyan E, Farland M, Pickleman JR "Hyperparathyroidism coexisting with hypertension and prolonged thiazide administration." JAMA 210 (1969):  1243-5|Parfitt AM "Chlorothiazide-induced hypercalcemia in juvenile osteoporosis and hyperparathyroidism." N Engl J Med 281 (1969):  55-9|Palmer FJ "Letter: Chlorthalidone-induced hypercalcemia." JAMA 229 (1974):  267|Hakim R, Tolis G, Goltzman D, Meltzer S, Friedman R "Severe hypercalcemia associated with hydrochlorothiazide and calcium carbonate therapy." Can Med Assoc J 121 (1979):  591-4|Itescu S, Haskell LP, Tannenberg AM "Thiazide-induced clinically significant hypophosphatemia ." Clin Nephrol 27 (1987):  161-2|Byatt CM, Millard PH, Levin GE "Diuretics and electrolyte disturbances in 1000 consecutive geriatric admissions." J R Soc Med 83 (1990):  704-8|Balizet L "Recurrent parathyroid adenoma. Association with prolonged thiazide administration." JAMA 225 (1973):  1238-9|Paloyan E, Farland M, Pickleman JR "Hyperparathyroidism coexisting with hypertension and prolonged thiazide administration." JAMA 210 (1969):  1243-5|Duarte CG, Winnacker JL, Becker KL, Pace A "Thiazide-induced hypercalcemia." N Engl J Med 284 (1971):  828-30|Klimiuk PS, Davies M, Adams PH "Primary hyperparathyroidism and thiazide diuretics." Postgrad Med J 57 (1981):  80-3|"Product Information. HydroDIURIL (hydrochlorothiazide)." Merck & Co., Inc  (2002):|"Product Information. Lozol (indapamide)." Rhone Poulenc Rorer  (2002):|"Product Information. Zaroxolyn (metolazone)." Rhone Poulenc Rorer  (2001):|"Product Information. Thalitone (chlorthalidone)." Monarch Pharmaceuticals Inc  (2001):|"Product Information. Diuril (chlorothiazide)." Merck & Co., Inc  (2001):|"Product Information. Enduron (methyclothiazide)." Abbott Pharmaceutical  (2001):|"Product Information. Metahydrin (trichlormethiazide)." Hoechst Marion Roussel  (2001):|"Product Information. Diucardin (hydroflumethiazide)." Wyeth-Ayerst Laboratories  (2001):|Hilker RR "Reversible hypercalcemia associated with prolonged thiazide administration to control hypertension." J Occup Med 12 (1970):  444-5|Jorgensen FS, Brunner S "The long-term effect of bendroflumethiazide on renal calcium and magnesium excretion and stone formation in patients with recurring renal stones." Scand J Urol Nephrol 8 (1974):  128-31|Ljunghall S, Backman U, Danielson BG, Fellstrom B, Johansson G, Wikstrom B "Calcium and magnesium metabolism during long-term treatment with thiazides." Scand J Urol Nephrol 15 (1981):  257-62|"Product Information. Renese-R (reserpine-polythiazide)." Pfizer US Pharmaceuticals, New York, NY.', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7715, 22666, 'Metolazone', 'Hyperparathyroidism', 'Urinary calcium excretion is decreased by thiazide diuretics during chronic administration.  Pathologic changes in the parathyroid gland with hypercalcemia and hypophosphatemia have been reported during prolonged therapy.  However, the common complications of hyperparathyroidism such as renal lithiasis, bone resorption, and peptic ulceration have not been seen.  Clinicians should be cognizant of these effects when prescribing or administering thiazide therapy to patients with hyperparathyroidism.  These drugs should be discontinued before carrying out tests for parathyroid function.', '2', 'Anderson PE, Ellis GG, Austin SM "Case report: metolazone-associated hypercalcemia and acute pancreatitis." Am J Med Sci 302 (1991):  235-7|Lindy S, Tarssanen L "Serum calcium and phosphorus in patients treated with thiazides and furosemide." Acta Med Scand 194 (1973):  319-22|Gammon GD, Docherty JP "Thiazide-induced hypercalcemia in a manic-depressive patient." Am J Psychiatry 137 (1980):  1453-5|Parfitt AM "Thiazide-induced hypercalcemia in vitamin D-treated hypoparathyroidism." Ann Intern Med 77 (1972):  557-63|Popovtzer MM, Subryan VL, Alfrey AC, Reeve EB, Schrier RW "The acute effect of chlorothiazide on serum-ionized calcium. Evidence for a parathyroid hormone-dependent mechanism." J Clin Invest 55 (1975):  1295-302|Paloyan E, Farland M, Pickleman JR "Hyperparathyroidism coexisting with hypertension and prolonged thiazide administration." JAMA 210 (1969):  1243-5|Parfitt AM "Chlorothiazide-induced hypercalcemia in juvenile osteoporosis and hyperparathyroidism." N Engl J Med 281 (1969):  55-9|Palmer FJ "Letter: Chlorthalidone-induced hypercalcemia." JAMA 229 (1974):  267|Hakim R, Tolis G, Goltzman D, Meltzer S, Friedman R "Severe hypercalcemia associated with hydrochlorothiazide and calcium carbonate therapy." Can Med Assoc J 121 (1979):  591-4|Itescu S, Haskell LP, Tannenberg AM "Thiazide-induced clinically significant hypophosphatemia ." Clin Nephrol 27 (1987):  161-2|Byatt CM, Millard PH, Levin GE "Diuretics and electrolyte disturbances in 1000 consecutive geriatric admissions." J R Soc Med 83 (1990):  704-8|Balizet L "Recurrent parathyroid adenoma. Association with prolonged thiazide administration." JAMA 225 (1973):  1238-9|Paloyan E, Farland M, Pickleman JR "Hyperparathyroidism coexisting with hypertension and prolonged thiazide administration." JAMA 210 (1969):  1243-5|Duarte CG, Winnacker JL, Becker KL, Pace A "Thiazide-induced hypercalcemia." N Engl J Med 284 (1971):  828-30|Klimiuk PS, Davies M, Adams PH "Primary hyperparathyroidism and thiazide diuretics." Postgrad Med J 57 (1981):  80-3|"Product Information. HydroDIURIL (hydrochlorothiazide)." Merck & Co., Inc  (2002):|"Product Information. Lozol (indapamide)." Rhone Poulenc Rorer  (2002):|"Product Information. Zaroxolyn (metolazone)." Rhone Poulenc Rorer  (2001):|"Product Information. Thalitone (chlorthalidone)." Monarch Pharmaceuticals Inc  (2001):|"Product Information. Diuril (chlorothiazide)." Merck & Co., Inc  (2001):|"Product Information. Enduron (methyclothiazide)." Abbott Pharmaceutical  (2001):|"Product Information. Metahydrin (trichlormethiazide)." Hoechst Marion Roussel  (2001):|"Product Information. Diucardin (hydroflumethiazide)." Wyeth-Ayerst Laboratories  (2001):|Hilker RR "Reversible hypercalcemia associated with prolonged thiazide administration to control hypertension." J Occup Med 12 (1970):  444-5|Jorgensen FS, Brunner S "The long-term effect of bendroflumethiazide on renal calcium and magnesium excretion and stone formation in patients with recurring renal stones." Scand J Urol Nephrol 8 (1974):  128-31|Ljunghall S, Backman U, Danielson BG, Fellstrom B, Johansson G, Wikstrom B "Calcium and magnesium metabolism during long-term treatment with thiazides." Scand J Urol Nephrol 15 (1981):  257-62|"Product Information. Renese-R (reserpine-polythiazide)." Pfizer US Pharmaceuticals, New York, NY.', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7716, 26084, 'Metolazone', 'Hyperparathyroidism', 'Urinary calcium excretion is decreased by thiazide diuretics during chronic administration.  Pathologic changes in the parathyroid gland with hypercalcemia and hypophosphatemia have been reported during prolonged therapy.  However, the common complications of hyperparathyroidism such as renal lithiasis, bone resorption, and peptic ulceration have not been seen.  Clinicians should be cognizant of these effects when prescribing or administering thiazide therapy to patients with hyperparathyroidism.  These drugs should be discontinued before carrying out tests for parathyroid function.', '2', 'Anderson PE, Ellis GG, Austin SM "Case report: metolazone-associated hypercalcemia and acute pancreatitis." Am J Med Sci 302 (1991):  235-7|Lindy S, Tarssanen L "Serum calcium and phosphorus in patients treated with thiazides and furosemide." Acta Med Scand 194 (1973):  319-22|Gammon GD, Docherty JP "Thiazide-induced hypercalcemia in a manic-depressive patient." Am J Psychiatry 137 (1980):  1453-5|Parfitt AM "Thiazide-induced hypercalcemia in vitamin D-treated hypoparathyroidism." Ann Intern Med 77 (1972):  557-63|Popovtzer MM, Subryan VL, Alfrey AC, Reeve EB, Schrier RW "The acute effect of chlorothiazide on serum-ionized calcium. Evidence for a parathyroid hormone-dependent mechanism." J Clin Invest 55 (1975):  1295-302|Paloyan E, Farland M, Pickleman JR "Hyperparathyroidism coexisting with hypertension and prolonged thiazide administration." JAMA 210 (1969):  1243-5|Parfitt AM "Chlorothiazide-induced hypercalcemia in juvenile osteoporosis and hyperparathyroidism." N Engl J Med 281 (1969):  55-9|Palmer FJ "Letter: Chlorthalidone-induced hypercalcemia." JAMA 229 (1974):  267|Hakim R, Tolis G, Goltzman D, Meltzer S, Friedman R "Severe hypercalcemia associated with hydrochlorothiazide and calcium carbonate therapy." Can Med Assoc J 121 (1979):  591-4|Itescu S, Haskell LP, Tannenberg AM "Thiazide-induced clinically significant hypophosphatemia ." Clin Nephrol 27 (1987):  161-2|Byatt CM, Millard PH, Levin GE "Diuretics and electrolyte disturbances in 1000 consecutive geriatric admissions." J R Soc Med 83 (1990):  704-8|Balizet L "Recurrent parathyroid adenoma. Association with prolonged thiazide administration." JAMA 225 (1973):  1238-9|Paloyan E, Farland M, Pickleman JR "Hyperparathyroidism coexisting with hypertension and prolonged thiazide administration." JAMA 210 (1969):  1243-5|Duarte CG, Winnacker JL, Becker KL, Pace A "Thiazide-induced hypercalcemia." N Engl J Med 284 (1971):  828-30|Klimiuk PS, Davies M, Adams PH "Primary hyperparathyroidism and thiazide diuretics." Postgrad Med J 57 (1981):  80-3|"Product Information. HydroDIURIL (hydrochlorothiazide)." Merck & Co., Inc  (2002):|"Product Information. Lozol (indapamide)." Rhone Poulenc Rorer  (2002):|"Product Information. Zaroxolyn (metolazone)." Rhone Poulenc Rorer  (2001):|"Product Information. Thalitone (chlorthalidone)." Monarch Pharmaceuticals Inc  (2001):|"Product Information. Diuril (chlorothiazide)." Merck & Co., Inc  (2001):|"Product Information. Enduron (methyclothiazide)." Abbott Pharmaceutical  (2001):|"Product Information. Metahydrin (trichlormethiazide)." Hoechst Marion Roussel  (2001):|"Product Information. Diucardin (hydroflumethiazide)." Wyeth-Ayerst Laboratories  (2001):|Hilker RR "Reversible hypercalcemia associated with prolonged thiazide administration to control hypertension." J Occup Med 12 (1970):  444-5|Jorgensen FS, Brunner S "The long-term effect of bendroflumethiazide on renal calcium and magnesium excretion and stone formation in patients with recurring renal stones." Scand J Urol Nephrol 8 (1974):  128-31|Ljunghall S, Backman U, Danielson BG, Fellstrom B, Johansson G, Wikstrom B "Calcium and magnesium metabolism during long-term treatment with thiazides." Scand J Urol Nephrol 15 (1981):  257-62|"Product Information. Renese-R (reserpine-polythiazide)." Pfizer US Pharmaceuticals, New York, NY.', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7717, 17239, 'Metolazone', 'Hyperuricemia', 'Thiazide diuretics decrease the rate of uric acid excretion.  Hyperuricemia occurs frequently but is usually asymptomatic and rarely leads to clinical gout except in patients with a history of gout or chronic renal failure.  Therapy with thiazide diuretics should be administered cautiously in such patients.', '2', 'Lapidus PW, Guidotti FP "Gout in orthopaedic practice: review of 232 cases." Clin Orthop 28 (1963):  97-110|Labeeuw M, Pozet N, Aissa AH, Zech PY, Sassard J, Laville M "Uric acid renal handling: spontaneous changes and influence of a thiazide alone or associated with triamterene." Int J Clin Pharmacol Ther Toxicol 26 (1988):  79-83|Beling S, Vukovich RA, Neiss ES, Zisblatt M, Webb E, Losi M "Long-term experience with indapamide." Am Heart J 106 (1983):  258-62|Slotkoff L "Clinical efficacy and safety of indapamide in the treatment of edema." Am Heart J 106 (1983):  233-7|"Product Information. HydroDIURIL (hydrochlorothiazide)." Merck & Co., Inc  (2002):|"Product Information. Lozol (indapamide)." Rhone Poulenc Rorer  (2002):|"Product Information. Zaroxolyn (metolazone)." Rhone Poulenc Rorer  (2001):|"Product Information. Thalitone (chlorthalidone)." Monarch Pharmaceuticals Inc  (2001):|"Product Information. Diuril (chlorothiazide)." Merck & Co., Inc  (2001):|Brors O, Jacobsen S, Foss OP, Aakvaag A "Effect of repeated doses of hydroflumethiazide on renal excretion of electrolytes and uric acid in healthy subjects." Acta Pharmacol Toxicol (Copenh) 48 (1981):  145-50|"Product Information. Enduron (methyclothiazide)." Abbott Pharmaceutical  (2001):|"Product Information. Metahydrin (trichlormethiazide)." Hoechst Marion Roussel  (2001):|"Product Information. Diucardin (hydroflumethiazide)." Wyeth-Ayerst Laboratories  (2001):|Gudbrandsson T, Hansson L "Combination therapy with saluretics and atenolol in essential hypertension. Effects on blood pressure, electrolytes and uric acid." Acta Med Scand Suppl 625 (1979):  86-91|Elmfeldt D, Berglund G, Wedel H, Wilhelmsen L "Incidence and importance of metabolic side-effects during antihypertensive therapy." Acta Med Scand Suppl 672 (1983):  79-83|Winchester JF, Kellett RJ, Boddy K, Boyle P, Dargie HJ, Mahaffey ME, Ward DM, Kennedy AC "Metolazone and bendroflumethiazide in hypertension: physiologic and metabolic observations." Clin Pharmacol Ther 28 (1980):  611-8|Petri M, Cumber P, Grimes L, Treby D, Bryant R, Rawlins D, Ising H "The metabolic effects of thiazide therapy in the elderly: a population study." Age Ageing 15 (1986):  151-5|Ljunghall S, Backman U, Danielson BG, Fellstrom B, Johansson G, Odlind B, Wikstrom B "Effects of bendroflumethiazide on urate metabolism during treatment of patients with renal stones." J Urol 127 (1982):  1207-10|"Product Information. Renese-R (reserpine-polythiazide)." Pfizer US Pharmaceuticals, New York, NY.|Freis ED "The efficacy and safety of diuretics in treating hypertension." Ann Intern Med 122 (1995):  223-6', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7718, 18087, 'Metolazone', 'Hyperuricemia', 'Thiazide diuretics decrease the rate of uric acid excretion.  Hyperuricemia occurs frequently but is usually asymptomatic and rarely leads to clinical gout except in patients with a history of gout or chronic renal failure.  Therapy with thiazide diuretics should be administered cautiously in such patients.', '2', 'Lapidus PW, Guidotti FP "Gout in orthopaedic practice: review of 232 cases." Clin Orthop 28 (1963):  97-110|Labeeuw M, Pozet N, Aissa AH, Zech PY, Sassard J, Laville M "Uric acid renal handling: spontaneous changes and influence of a thiazide alone or associated with triamterene." Int J Clin Pharmacol Ther Toxicol 26 (1988):  79-83|Beling S, Vukovich RA, Neiss ES, Zisblatt M, Webb E, Losi M "Long-term experience with indapamide." Am Heart J 106 (1983):  258-62|Slotkoff L "Clinical efficacy and safety of indapamide in the treatment of edema." Am Heart J 106 (1983):  233-7|"Product Information. HydroDIURIL (hydrochlorothiazide)." Merck & Co., Inc  (2002):|"Product Information. Lozol (indapamide)." Rhone Poulenc Rorer  (2002):|"Product Information. Zaroxolyn (metolazone)." Rhone Poulenc Rorer  (2001):|"Product Information. Thalitone (chlorthalidone)." Monarch Pharmaceuticals Inc  (2001):|"Product Information. Diuril (chlorothiazide)." Merck & Co., Inc  (2001):|Brors O, Jacobsen S, Foss OP, Aakvaag A "Effect of repeated doses of hydroflumethiazide on renal excretion of electrolytes and uric acid in healthy subjects." Acta Pharmacol Toxicol (Copenh) 48 (1981):  145-50|"Product Information. Enduron (methyclothiazide)." Abbott Pharmaceutical  (2001):|"Product Information. Metahydrin (trichlormethiazide)." Hoechst Marion Roussel  (2001):|"Product Information. Diucardin (hydroflumethiazide)." Wyeth-Ayerst Laboratories  (2001):|Gudbrandsson T, Hansson L "Combination therapy with saluretics and atenolol in essential hypertension. Effects on blood pressure, electrolytes and uric acid." Acta Med Scand Suppl 625 (1979):  86-91|Elmfeldt D, Berglund G, Wedel H, Wilhelmsen L "Incidence and importance of metabolic side-effects during antihypertensive therapy." Acta Med Scand Suppl 672 (1983):  79-83|Winchester JF, Kellett RJ, Boddy K, Boyle P, Dargie HJ, Mahaffey ME, Ward DM, Kennedy AC "Metolazone and bendroflumethiazide in hypertension: physiologic and metabolic observations." Clin Pharmacol Ther 28 (1980):  611-8|Petri M, Cumber P, Grimes L, Treby D, Bryant R, Rawlins D, Ising H "The metabolic effects of thiazide therapy in the elderly: a population study." Age Ageing 15 (1986):  151-5|Ljunghall S, Backman U, Danielson BG, Fellstrom B, Johansson G, Odlind B, Wikstrom B "Effects of bendroflumethiazide on urate metabolism during treatment of patients with renal stones." J Urol 127 (1982):  1207-10|"Product Information. Renese-R (reserpine-polythiazide)." Pfizer US Pharmaceuticals, New York, NY.|Freis ED "The efficacy and safety of diuretics in treating hypertension." Ann Intern Med 122 (1995):  223-6', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7719, 22666, 'Metolazone', 'Hyperuricemia', 'Thiazide diuretics decrease the rate of uric acid excretion.  Hyperuricemia occurs frequently but is usually asymptomatic and rarely leads to clinical gout except in patients with a history of gout or chronic renal failure.  Therapy with thiazide diuretics should be administered cautiously in such patients.', '2', 'Lapidus PW, Guidotti FP "Gout in orthopaedic practice: review of 232 cases." Clin Orthop 28 (1963):  97-110|Labeeuw M, Pozet N, Aissa AH, Zech PY, Sassard J, Laville M "Uric acid renal handling: spontaneous changes and influence of a thiazide alone or associated with triamterene." Int J Clin Pharmacol Ther Toxicol 26 (1988):  79-83|Beling S, Vukovich RA, Neiss ES, Zisblatt M, Webb E, Losi M "Long-term experience with indapamide." Am Heart J 106 (1983):  258-62|Slotkoff L "Clinical efficacy and safety of indapamide in the treatment of edema." Am Heart J 106 (1983):  233-7|"Product Information. HydroDIURIL (hydrochlorothiazide)." Merck & Co., Inc  (2002):|"Product Information. Lozol (indapamide)." Rhone Poulenc Rorer  (2002):|"Product Information. Zaroxolyn (metolazone)." Rhone Poulenc Rorer  (2001):|"Product Information. Thalitone (chlorthalidone)." Monarch Pharmaceuticals Inc  (2001):|"Product Information. Diuril (chlorothiazide)." Merck & Co., Inc  (2001):|Brors O, Jacobsen S, Foss OP, Aakvaag A "Effect of repeated doses of hydroflumethiazide on renal excretion of electrolytes and uric acid in healthy subjects." Acta Pharmacol Toxicol (Copenh) 48 (1981):  145-50|"Product Information. Enduron (methyclothiazide)." Abbott Pharmaceutical  (2001):|"Product Information. Metahydrin (trichlormethiazide)." Hoechst Marion Roussel  (2001):|"Product Information. Diucardin (hydroflumethiazide)." Wyeth-Ayerst Laboratories  (2001):|Gudbrandsson T, Hansson L "Combination therapy with saluretics and atenolol in essential hypertension. Effects on blood pressure, electrolytes and uric acid." Acta Med Scand Suppl 625 (1979):  86-91|Elmfeldt D, Berglund G, Wedel H, Wilhelmsen L "Incidence and importance of metabolic side-effects during antihypertensive therapy." Acta Med Scand Suppl 672 (1983):  79-83|Winchester JF, Kellett RJ, Boddy K, Boyle P, Dargie HJ, Mahaffey ME, Ward DM, Kennedy AC "Metolazone and bendroflumethiazide in hypertension: physiologic and metabolic observations." Clin Pharmacol Ther 28 (1980):  611-8|Petri M, Cumber P, Grimes L, Treby D, Bryant R, Rawlins D, Ising H "The metabolic effects of thiazide therapy in the elderly: a population study." Age Ageing 15 (1986):  151-5|Ljunghall S, Backman U, Danielson BG, Fellstrom B, Johansson G, Odlind B, Wikstrom B "Effects of bendroflumethiazide on urate metabolism during treatment of patients with renal stones." J Urol 127 (1982):  1207-10|"Product Information. Renese-R (reserpine-polythiazide)." Pfizer US Pharmaceuticals, New York, NY.|Freis ED "The efficacy and safety of diuretics in treating hypertension." Ann Intern Med 122 (1995):  223-6', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7720, 26084, 'Metolazone', 'Hyperuricemia', 'Thiazide diuretics decrease the rate of uric acid excretion.  Hyperuricemia occurs frequently but is usually asymptomatic and rarely leads to clinical gout except in patients with a history of gout or chronic renal failure.  Therapy with thiazide diuretics should be administered cautiously in such patients.', '2', 'Lapidus PW, Guidotti FP "Gout in orthopaedic practice: review of 232 cases." Clin Orthop 28 (1963):  97-110|Labeeuw M, Pozet N, Aissa AH, Zech PY, Sassard J, Laville M "Uric acid renal handling: spontaneous changes and influence of a thiazide alone or associated with triamterene." Int J Clin Pharmacol Ther Toxicol 26 (1988):  79-83|Beling S, Vukovich RA, Neiss ES, Zisblatt M, Webb E, Losi M "Long-term experience with indapamide." Am Heart J 106 (1983):  258-62|Slotkoff L "Clinical efficacy and safety of indapamide in the treatment of edema." Am Heart J 106 (1983):  233-7|"Product Information. HydroDIURIL (hydrochlorothiazide)." Merck & Co., Inc  (2002):|"Product Information. Lozol (indapamide)." Rhone Poulenc Rorer  (2002):|"Product Information. Zaroxolyn (metolazone)." Rhone Poulenc Rorer  (2001):|"Product Information. Thalitone (chlorthalidone)." Monarch Pharmaceuticals Inc  (2001):|"Product Information. Diuril (chlorothiazide)." Merck & Co., Inc  (2001):|Brors O, Jacobsen S, Foss OP, Aakvaag A "Effect of repeated doses of hydroflumethiazide on renal excretion of electrolytes and uric acid in healthy subjects." Acta Pharmacol Toxicol (Copenh) 48 (1981):  145-50|"Product Information. Enduron (methyclothiazide)." Abbott Pharmaceutical  (2001):|"Product Information. Metahydrin (trichlormethiazide)." Hoechst Marion Roussel  (2001):|"Product Information. Diucardin (hydroflumethiazide)." Wyeth-Ayerst Laboratories  (2001):|Gudbrandsson T, Hansson L "Combination therapy with saluretics and atenolol in essential hypertension. Effects on blood pressure, electrolytes and uric acid." Acta Med Scand Suppl 625 (1979):  86-91|Elmfeldt D, Berglund G, Wedel H, Wilhelmsen L "Incidence and importance of metabolic side-effects during antihypertensive therapy." Acta Med Scand Suppl 672 (1983):  79-83|Winchester JF, Kellett RJ, Boddy K, Boyle P, Dargie HJ, Mahaffey ME, Ward DM, Kennedy AC "Metolazone and bendroflumethiazide in hypertension: physiologic and metabolic observations." Clin Pharmacol Ther 28 (1980):  611-8|Petri M, Cumber P, Grimes L, Treby D, Bryant R, Rawlins D, Ising H "The metabolic effects of thiazide therapy in the elderly: a population study." Age Ageing 15 (1986):  151-5|Ljunghall S, Backman U, Danielson BG, Fellstrom B, Johansson G, Odlind B, Wikstrom B "Effects of bendroflumethiazide on urate metabolism during treatment of patients with renal stones." J Urol 127 (1982):  1207-10|"Product Information. Renese-R (reserpine-polythiazide)." Pfizer US Pharmaceuticals, New York, NY.|Freis ED "The efficacy and safety of diuretics in treating hypertension." Ann Intern Med 122 (1995):  223-6', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7721, 17239, 'Metolazone', 'Thyroid Diseases', 'Thiazide diuretics may decrease serum PBI (protein-bound iodine) levels without associated thyroid disturbance.  Clinicians should be cognizant of this effect when prescribing or administering thiazide therapy to patients with thyroid disorders.', '2', 'Bech K, Skovsted L, Siersbaek-Nielsen K, Hansen JM "Influence of thiazides on thyroid parameters in man." Acta Endocrinol (Copenh) 89 (1978):  673-8|"Product Information. HydroDIURIL (hydrochlorothiazide)." Merck & Co., Inc  (2002):|"Product Information. Lozol (indapamide)." Rhone Poulenc Rorer  (2002):|"Product Information. Zaroxolyn (metolazone)." Rhone Poulenc Rorer  (2001):|"Product Information. Thalitone (chlorthalidone)." Monarch Pharmaceuticals Inc  (2001):|"Product Information. Diuril (chlorothiazide)." Merck & Co., Inc  (2001):|"Product Information. Enduron (methyclothiazide)." Abbott Pharmaceutical  (2001):|"Product Information. Metahydrin (trichlormethiazide)." Hoechst Marion Roussel  (2001):|"Product Information. Diucardin (hydroflumethiazide)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Renese-R (reserpine-polythiazide)." Pfizer US Pharmaceuticals, New York, NY.', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7722, 18087, 'Metolazone', 'Thyroid Diseases', 'Thiazide diuretics may decrease serum PBI (protein-bound iodine) levels without associated thyroid disturbance.  Clinicians should be cognizant of this effect when prescribing or administering thiazide therapy to patients with thyroid disorders.', '2', 'Bech K, Skovsted L, Siersbaek-Nielsen K, Hansen JM "Influence of thiazides on thyroid parameters in man." Acta Endocrinol (Copenh) 89 (1978):  673-8|"Product Information. HydroDIURIL (hydrochlorothiazide)." Merck & Co., Inc  (2002):|"Product Information. Lozol (indapamide)." Rhone Poulenc Rorer  (2002):|"Product Information. Zaroxolyn (metolazone)." Rhone Poulenc Rorer  (2001):|"Product Information. Thalitone (chlorthalidone)." Monarch Pharmaceuticals Inc  (2001):|"Product Information. Diuril (chlorothiazide)." Merck & Co., Inc  (2001):|"Product Information. Enduron (methyclothiazide)." Abbott Pharmaceutical  (2001):|"Product Information. Metahydrin (trichlormethiazide)." Hoechst Marion Roussel  (2001):|"Product Information. Diucardin (hydroflumethiazide)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Renese-R (reserpine-polythiazide)." Pfizer US Pharmaceuticals, New York, NY.', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7723, 22666, 'Metolazone', 'Thyroid Diseases', 'Thiazide diuretics may decrease serum PBI (protein-bound iodine) levels without associated thyroid disturbance.  Clinicians should be cognizant of this effect when prescribing or administering thiazide therapy to patients with thyroid disorders.', '2', 'Bech K, Skovsted L, Siersbaek-Nielsen K, Hansen JM "Influence of thiazides on thyroid parameters in man." Acta Endocrinol (Copenh) 89 (1978):  673-8|"Product Information. HydroDIURIL (hydrochlorothiazide)." Merck & Co., Inc  (2002):|"Product Information. Lozol (indapamide)." Rhone Poulenc Rorer  (2002):|"Product Information. Zaroxolyn (metolazone)." Rhone Poulenc Rorer  (2001):|"Product Information. Thalitone (chlorthalidone)." Monarch Pharmaceuticals Inc  (2001):|"Product Information. Diuril (chlorothiazide)." Merck & Co., Inc  (2001):|"Product Information. Enduron (methyclothiazide)." Abbott Pharmaceutical  (2001):|"Product Information. Metahydrin (trichlormethiazide)." Hoechst Marion Roussel  (2001):|"Product Information. Diucardin (hydroflumethiazide)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Renese-R (reserpine-polythiazide)." Pfizer US Pharmaceuticals, New York, NY.', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7724, 26084, 'Metolazone', 'Thyroid Diseases', 'Thiazide diuretics may decrease serum PBI (protein-bound iodine) levels without associated thyroid disturbance.  Clinicians should be cognizant of this effect when prescribing or administering thiazide therapy to patients with thyroid disorders.', '2', 'Bech K, Skovsted L, Siersbaek-Nielsen K, Hansen JM "Influence of thiazides on thyroid parameters in man." Acta Endocrinol (Copenh) 89 (1978):  673-8|"Product Information. HydroDIURIL (hydrochlorothiazide)." Merck & Co., Inc  (2002):|"Product Information. Lozol (indapamide)." Rhone Poulenc Rorer  (2002):|"Product Information. Zaroxolyn (metolazone)." Rhone Poulenc Rorer  (2001):|"Product Information. Thalitone (chlorthalidone)." Monarch Pharmaceuticals Inc  (2001):|"Product Information. Diuril (chlorothiazide)." Merck & Co., Inc  (2001):|"Product Information. Enduron (methyclothiazide)." Abbott Pharmaceutical  (2001):|"Product Information. Metahydrin (trichlormethiazide)." Hoechst Marion Roussel  (2001):|"Product Information. Diucardin (hydroflumethiazide)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Renese-R (reserpine-polythiazide)." Pfizer US Pharmaceuticals, New York, NY.', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7725, 0, 'Acebutolol', 'Diseases requiring hemodialysis', 'Acebutolol is moderately removed by hemodialysis and should be administered after dialysis when the patient is hemodynamically stable to avoid marked falls in blood pressure.  The hemodynamic status should be closely monitored before and after the dose.', '3', 'Roux A, Aubert P, Guedon J, Flouvat B "Study of acebutolol dialysis and pharmacokinetic data in patients with renal insufficiency undergoing hemodialysis." Nouv Presse Med 4 (1975):  3228-33|"Product Information. Sectral (acebutolol)." Wyeth-Ayerst Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7726, 0, 'Acebutolol', 'Kidney Diseases', 'The active metabolite of acebutolol, diacetolol, is eliminated primarily by the kidney.  Patients with renal impairment may be at greater risk for adverse effects due to metabolite accumulation.  Dosage adjustments are recommended for patients with moderate to severe renal dysfunction (CrCl < 50 mL/min).', '3', 'Kirch W, Kohler H, Berggren G, Braun W "The influence of renal function on plasma levels and urinary excretion of acebutolol and its main N-acetyl metabolite." Clin Nephrol 18 (1982):  88-94|Gabriel R "Acebutolol in the management of hypertension in patients with renal disease." Br J Clin Pract 33 (1979):  259-62|Roux A, Aubert P, Guedon J, Flouvat B "Pharmacokinetics of acebutolol in patients with all grades of renal failure." Eur J Clin Pharmacol 17 (1980):  339-48|"Product Information. Sectral (acebutolol)." Wyeth-Ayerst Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7727, 0, 'Acebutolol', 'Atrioventricular Block', 'The use of beta-adrenergic receptor blocking agents (aka beta-blockers) is contraindicated in patients with sinus bradyarrhythmia or heart block greater than the first degree (unless a functioning pacemaker is present).  Due to their negative inotropic and chronotropic effects on the heart, the use of beta-blockers is likely to exacerbate these conditions.', '3', 'Crean PA, Williams DO "Effect of intravenous and oral acebutolol in patients with bundle branch block." Int J Cardiol 10 (1986):  119-26|Mashford ML, Coventry D, Hecker R, et al. "Adverse Drug Reactions Advisory Committee: ADRAC report for 1980." Med J Aust 1 (1982):  416-9|Treseder AS, Thomas TP "Sinus arrest due to timolol eye drops." Br J Clin Pract 40 (1986):  256-8|"Product Information. Sectral (acebutolol)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Tenormin (atenolol)." ICN Pharmaceuticals Inc  (2002):|"Product Information. Normodyne (labetalol)." Schering Corporation  (2002):|"Product Information. Trandate (labetalol)." Glaxo Wellcome  (2002):|"Product Information. Corgard (nadolol)." Bristol-Myers Squibb  (2002):|"Product Information. Inderal (propranolol)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|"Product Information. Brevibloc (esmolol)." DuPont Pharmaceuticals  (2001):|"Product Information. Cartrol (carteolol)." Abbott Pharmaceutical  (2001):|"Product Information. Kerlone (betaxolol)." Searle  (2001):|"Product Information. Lopressor (metoprolol)." Novartis Pharmaceuticals  (2001):|"Product Information. Betapace (sotalol)." Berlex Laboratories  (2001):|"Product Information. Zebeta (bisoprolol)." Lederle Laboratories  (2001):|"Product Information. Visken (pindolol)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Levatol (penbutolol)." Reed and Carnrick  (2001):|"Product Information. Coreg (carvedilol)." SmithKline Beecham  (2001):|Frishman WH "Carvedilol." N Engl J Med 339 (1998):  1759-65|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):|"Product Information. Bystolic (nebivolol)." Forest Pharmaceuticals  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7728, 0, 'Acebutolol', 'Shock, Cardiogenic', 'The use of beta-adrenergic receptor blocking agents (aka beta-blockers) is contraindicated in patients with hypotension or cardiogenic shock.  Due to their negative inotropic and chronotropic effects on the heart, the use of beta-blockers is likely to further depress cardiac output and blood pressure, which can be detrimental in these patients.', '3', 'Kholeif M, Isles C "Profound hypotension after atenolol in severe hypertension." Br Med J 298 (1989):  161-2|Tirlapur VG, Evans PJ, Jones MK "Shock syndrome after acebutolol." Br J Clin Pract 40 (1986):  33-4|"Product Information. Sectral (acebutolol)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Tenormin (atenolol)." ICN Pharmaceuticals Inc  (2002):|"Product Information. Normodyne (labetalol)." Schering Corporation  (2002):|"Product Information. Trandate (labetalol)." Glaxo Wellcome  (2002):|"Product Information. Corgard (nadolol)." Bristol-Myers Squibb  (2002):|"Product Information. Inderal (propranolol)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|"Product Information. Brevibloc (esmolol)." DuPont Pharmaceuticals  (2001):|"Product Information. Cartrol (carteolol)." Abbott Pharmaceutical  (2001):|"Product Information. Kerlone (betaxolol)." Searle  (2001):|"Product Information. Lopressor (metoprolol)." Novartis Pharmaceuticals  (2001):|"Product Information. Betapace (sotalol)." Berlex Laboratories  (2001):|"Product Information. Zebeta (bisoprolol)." Lederle Laboratories  (2001):|"Product Information. Visken (pindolol)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. OptiPranolol (metipranolol ophthalmic)." Bausch and Lomb Americas, Inc.  (2022):|"Product Information. Levatol (penbutolol)." Reed and Carnrick  (2001):|"Product Information. Betagan (levobunolol ophthalmic)." Allergan Inc  (2022):|"Product Information. Coreg (carvedilol)." SmithKline Beecham  (2001):|"Product Information. Acupress (carteolol ophthalmic)." Otsuka American Pharmaceuticals Inc, Rockville, MD.|"Product Information. Betoptic (betaxolol ophthalmic)." Alcon Laboratories Inc  (2001):|Frishman WH "Carvedilol." N Engl J Med 339 (1998):  1759-65|"Product Information. Bystolic (nebivolol)." Forest Pharmaceuticals  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7729, 0, 'Acebutolol', 'Heart Failure', 'Beta-adrenergic receptor blocking agents (aka beta-blockers) in general should not be used in patients with overt congestive heart failure (CHF).  Sympathetic stimulation may be important in maintaining the hemodynamic function in these patients, thus beta-blockade can worsen the heart failure.  However, therapy with beta-blockers may be beneficial and can be administered cautiously in some CHF patients provided they are well compensated and receiving digitalis, diuretics, an ACE inhibitor, and/or nitrates.  Carvedilol, specifically, is indicated for use with these agents in the treatment of mild to severe heart failure of ischemic or cardiomyopathic origin.  There is also increasing evidence that the addition of a beta-blocker to standard therapy can improve morbidity and mortality in patients with advanced heart failure, although it is uncertain whether effectiveness varies significantly with the different agents.  Data from one meta-analysis study suggest a greater reduction of mortality risk for nonselective beta-blockers than for beta-1 selective agents.', '3', 'Michelson EL, Frishman WH, Lewis JE, et al. "Multicenter clinical evaluation of long-term efficacy and safety of labetalol in treatment of hypertension." Am J Med Oct 17 (1983):  68-80|Myers J, Morgan T, Waga S, et al. "Long-term experiences with labetalol." Med J Aust 1 (1980):  665-6|Tcherdakoff P "Side-effects with long-term labetalol: an open study of 251 patients in a single centre." Pharmatherapeutica 3 (1983):  342-8|Altus P "Timolol-induced congestive heart failure." South Med J 74 (1981):  88|Mashford ML, Coventry D, Hecker R, et al. "Adverse Drug Reactions Advisory Committee: ADRAC report for 1980." Med J Aust 1 (1982):  416-9|"Product Information. Sectral (acebutolol)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Tenormin (atenolol)." ICN Pharmaceuticals Inc  (2002):|"Product Information. Normodyne (labetalol)." Schering Corporation  (2002):|"Product Information. Trandate (labetalol)." Glaxo Wellcome  (2002):|"Product Information. Corgard (nadolol)." Bristol-Myers Squibb  (2002):|"Product Information. Inderal (propranolol)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|"Product Information. Brevibloc (esmolol)." DuPont Pharmaceuticals  (2001):|"Product Information. Cartrol (carteolol)." Abbott Pharmaceutical  (2001):|"Product Information. Kerlone (betaxolol)." Searle  (2001):|"Product Information. Lopressor (metoprolol)." Novartis Pharmaceuticals  (2001):|"Product Information. Betapace (sotalol)." Berlex Laboratories  (2001):|"Product Information. Zebeta (bisoprolol)." Lederle Laboratories  (2001):|"Product Information. Visken (pindolol)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Levatol (penbutolol)." Reed and Carnrick  (2001):|Lechat P, Jaillon P, Fontaine ML, Chanton E, Mesenge C, Gagey S, Guillardeau A, Dussous V "A randomized trial of beta-blockade in heart failure - the cardiac insufficiency bisoprolol study (CIBIS)." Circulation 90 (1994):  1765-73|Maisel AS "Beneficial effects of metoprolol treatment in congestive heart failure - reversal of sympathetic-induced alterations of immunologic function." Circulation 90 (1994):  1774-80|Persson H, Rythenalder E, Melcher A, Erhardt L "Effects of beta receptor antagonists in patients with clinical evidence of heart failure after myocardial infarction: double blind comparison of metoprolol and xamoterol." Br Heart J 74 (1995):  140-8|Kelly DT "Carvedilol in heart failure." Cardiology 82 Suppl 3 (1993):  45-9|Olsen SL, Gilbert EM, Renlund DG, Taylor DO, Yanowitz FD, Bristow MR "Carvedilol improves left ventricular function and symptoms in chronic heart failure: a double-blind randomized study." J Am Coll Cardiol 25 (1995):  1225-31|Krum H, Sackner-Bernstein JD, Goldsmith RL, et al. "Double-blind, placebo-controlled study of the long-term efficacy of carvedilol in patients with severe chronic heart failure." Circulation 92 (1995):  1499-506|Australia-New Zealand Heart Failure Research Collaborative Group. "Effects of carvedilol, a vasodilator-B-blocker, in patients with congestive heart failure due to ischemic heart disease." Circulation 92 (1995):  212-8|Kalman J, Buchholz C, Steinmetz M, Courtney M, Gass A, Lansman S, Kukin ML "Safety and efficacy of beta blockade in patients with chronic congestive heart failure awaiting transplantation." J Heart Lung Transplant 14 (1995):  1212-7|Adams KF Jr "Current perspectives on B-receptor antagonists in the treatment of symptomatic ventricular dysfunction." Pharmacotherapy 16(2 Pt 2) (1996):  69-77|Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM, Shusterman NH "The effect of carvedilol on morbidity and mortality in patients with chronic heart failure." N Engl J Med 334 (1996):  1349-55|Persson SV, Erhardt L "Effects of beta receptor antagonists on left ventricular function in patients with clinical evidence of heart failure after myocardial infarction. A double-blind comparison of metoprolol and xamoterol: echocardiographic results from the Metoprolol and..." Eur Heart J 17 (1996):  741-9|Cleland JGF, Swedberg K "Carvedilol for heart failure, with care." Lancet 347 (1996):  1199-201|Moye LA, Abernethy D "Carvedilol in patients with chronic heart failure." N Engl J Med 335 (1996):  1318|Von Olshausen K, Pop T, Berger J "Carvedilol in patients with chronic heart failure." N Engl J Med 335 (1996):  1318-20|Packer M, Cohn JN, Colucci WS "Carvedilol in patients with chronic heart failure." N Engl J Med 335 (1996):  1310-20|Colucci WS, Packer M, Bristow MR, Gilbert EM, Cohn JN, Fowler MB, Krueger SK, Hershberger R, Uretsky BF, Bowers JA, Sackne "Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure." Circulation 94 (1996):  2800-6|Macmahon S, Sharpe N, Doughty R, Krum H, Tonkin A, Trotter A, Burton R, Garrett J, Lane G, Owensby D, Ryan J, Shepherd J, Sing "Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease." Lancet 349 (1997):  375-80|Bristow MR, Gilbert EM, Abraham WT, et al. "Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. MOCHA Investigators." Circulation 94 (1996):  2807-16|Packer M, Colucci WS, Sackner-Bernstein JD, Liang CS, Goldscher DA, Freeman I, Kukin ML, Kinhal V, Udelson JE, Klapholz M, Gottlieb SS, Pearle D "Double-blind, placebo-controlled study of the effects of carvedilol in patients with moderate to severe heart failure. The PRECISE Trial Prospective Randomized Evaluation of Carvedilol on Symptoms an Exercise." Circulation 94 (1996):  2793-9|Doughty RN, Whalley GA, Gamble G, MacMahon S, Sharpe N "Left ventricular remodeling with carvedilol in patients with congestive heart failure due to ischemic heart disease. Australia-Ne Zealand Heart Failure Research Collaborative Group." J Am Coll Cardiol 29 (1997):  1060-6|Lechat P, Packer M, Chalon S, Cucherat M, Arab T, Boissel JP "Clinical effects of beta-adrenergic blockade in chronic heart failure: A meta-analysis of double-blind, placebo-controlled, randomized trials." Circulation 98 (1998):  1184-91|Frishman WH "Carvedilol." N Engl J Med 339 (1998):  1759-65|CIBIS-II Investigators and Committees. "The cardiac insufficiency bisoprolol study II (CIBIS-II): a randomised trial." Lancet 353 (1999):  9-13|Macdonald PS, Keogh AM, Aboyoun CL, Lund M, Amor R, McCaffrey DJ "Tolerability and efficacy of carvedilol in patients with New York Heart Association class IV heart failure." J Am Coll Cardiol 33 (1999):  924-31|Hjalmarson A, Goldstein S, Fagerberg B, et al. "Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF)." JAMA 283 (2000):  1295-302|Phillips KA, Shlipak MG, Coxson P, et al. "Health and economic benefits of increased B-blocker use following myocardial infarction." JAMA 284 (2000):  2748-54|Hart SM "Influence of B-blockers on mortality in chronic heart failure." Ann Pharmacother 34 (2000):  1440-51|"Product Information. Bystolic (nebivolol)." Forest Pharmaceuticals  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7730, 0, 'Acebutolol', 'Diabetes Mellitus', 'Beta-adrenergic receptor blocking agents (aka beta-blockers) may mask symptoms of hypoglycemia such as tremors, tachycardia and blood pressure changes.  In addition, the nonselective beta-blockers (e.g., propranolol, pindolol, timolol) may inhibit catecholamine-mediated glycogenolysis, thereby potentiating insulin-induced hypoglycemia and delaying the recovery of normal blood glucose levels.  Since cardioselectivity is not absolute, larger doses of beta-1 selective agents may demonstrate these effects as well.  Therapy with beta-blockers should be administered cautiously in patients with diabetes or predisposed to spontaneous hypoglycemia.', '3', 'Darga LL, Hakim MJ, Lucas CP, Franklin BA "Comparison of the effects of guanadrel sulfate and propranolol on blood pressure, functional capacity, serum lipoproteins and glucose in systemic hypertension." Am J Cardiol 67 (1991):  590-6|Uusitupa M, Aro A, Pietikainen M "Severe hypoglycaemia caused by physical strain and pindolol therapy." Ann Clin Res 12 (1980):  25-7|Velde TM, Kaiser FE "Ophthalmic timolol treatment causing altered hypoglycemic response in a diabetic patient." Arch Intern Med 143 (1983):  1627|Grimaldi A, Bennett P, Delas B, et al. "Beta-blockers and hypoglycaemia: assessment of cardioselective and intrinsic sympathomimetic properties in relation to severity of hypoglycaemia." Curr Ther Res Clin Exp 36 (1984):  361-73|"Product Information. Sectral (acebutolol)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Tenormin (atenolol)." ICN Pharmaceuticals Inc  (2002):|"Product Information. Normodyne (labetalol)." Schering Corporation  (2002):|"Product Information. Trandate (labetalol)." Glaxo Wellcome  (2002):|"Product Information. Corgard (nadolol)." Bristol-Myers Squibb  (2002):|"Product Information. Inderal (propranolol)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|"Product Information. Brevibloc (esmolol)." DuPont Pharmaceuticals  (2001):|"Product Information. Cartrol (carteolol)." Abbott Pharmaceutical  (2001):|"Product Information. Kerlone (betaxolol)." Searle  (2001):|"Product Information. Lopressor (metoprolol)." Novartis Pharmaceuticals  (2001):|"Product Information. Betapace (sotalol)." Berlex Laboratories  (2001):|"Product Information. Zebeta (bisoprolol)." Lederle Laboratories  (2001):|"Product Information. Visken (pindolol)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Levatol (penbutolol)." Reed and Carnrick  (2001):|Giugliano D, Acampora R, Marfella R, DeRosa N, Ziccardi P, Ragone R, DeAngelis L, DOnofrio F "Metabolic and cardiovascular effects of carvedilol and atenolol in non-insulin-dependent diabetes mellitus and hypertension - A randomized, controlled trial." Ann Intern Med 126 (1997):  955-9|"Product Information. Bystolic (nebivolol)." Forest Pharmaceuticals  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7731, 0, 'Acebutolol', 'Hypersensitivity', 'The use of beta-adrenergic receptor blocking agents (aka beta-blockers) in patients with a history of allergic reactions or anaphylaxis may be associated with heightened reactivity to culprit allergens.  The frequency and/or severity of attacks may be increased during beta-blocker therapy.  In addition, these patients may be refractory to the usual doses of epinephrine used to treat acute hypersensitivity reactions and may require a beta-agonist such as isoproterenol.', '3', '"Product Information. Sectral (acebutolol)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Tenormin (atenolol)." ICN Pharmaceuticals Inc  (2002):|"Product Information. Normodyne (labetalol)." Schering Corporation  (2002):|"Product Information. Trandate (labetalol)." Glaxo Wellcome  (2002):|"Product Information. Corgard (nadolol)." Bristol-Myers Squibb  (2002):|"Product Information. Inderal (propranolol)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|"Product Information. Brevibloc (esmolol)." DuPont Pharmaceuticals  (2001):|"Product Information. Cartrol (carteolol)." Abbott Pharmaceutical  (2001):|"Product Information. Kerlone (betaxolol)." Searle  (2001):|"Product Information. Lopressor (metoprolol)." Novartis Pharmaceuticals  (2001):|"Product Information. Betapace (sotalol)." Berlex Laboratories  (2001):|"Product Information. Zebeta (bisoprolol)." Lederle Laboratories  (2001):|"Product Information. Visken (pindolol)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Levatol (penbutolol)." Reed and Carnrick  (2001):|"Product Information. Coreg (carvedilol)." SmithKline Beecham  (2001):|"Product Information. Bystolic (nebivolol)." Forest Pharmaceuticals  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7732, 0, 'Acebutolol', 'Myocardial Ischemia', 'Heightened sensitivity to catecholamines may occur after prolonged use of beta-adrenergic receptor blocking agents (aka beta-blockers).  Exacerbation of angina, myocardial infarction and ventricular arrhythmias have been reported in patients with coronary artery disease following abrupt withdrawal of therapy.  Cessation of beta-blocker therapy, whenever necessary, should occur gradually with incrementally reduced dosages over a period of 1 to 2 weeks in patients with coronary insufficiency.  Patients should be advised not to discontinue treatment without first consulting with the physician.  In patients who experience an exacerbation of angina following discontinuation of beta-blocker therapy, the medication should generally be reinstituted, at least temporarily, along with other clinically appropriate measures.', '3', 'Miller RR, Olson HG, Amsterdam EA, Mason DT "Propranolol-withdrawal rebound phenomenon: exacerbation of coronary events after abrupt cessation of antianginal therapy." N Engl J Med 293 (1975):  416-8|Rangno RE, Langlois S "Comparison of withdrawal phenomena after propranolol, metoprolol, and pindolol." Am Heart J 104 (1982):  473-8|Szecsi E, Kohlschutter S, Schiess W, Lang E "Abrupt withdrawal of pindolol or metoprolol after chronic therapy." Br J Clin Pharmacol 13 (1982):  s353-7|Walden RJ, Hernandez J, Yu Y, et al. "Withdrawal of beta-blocking drugs." Am Heart J 104 (1982):  515-20|"Product Information. Sectral (acebutolol)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Tenormin (atenolol)." ICN Pharmaceuticals Inc  (2002):|"Product Information. Normodyne (labetalol)." Schering Corporation  (2002):|"Product Information. Trandate (labetalol)." Glaxo Wellcome  (2002):|"Product Information. Corgard (nadolol)." Bristol-Myers Squibb  (2002):|"Product Information. Inderal (propranolol)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|"Product Information. Cartrol (carteolol)." Abbott Pharmaceutical  (2001):|"Product Information. Kerlone (betaxolol)." Searle  (2001):|"Product Information. Lopressor (metoprolol)." Novartis Pharmaceuticals  (2001):|"Product Information. Betapace (sotalol)." Berlex Laboratories  (2001):|"Product Information. Zebeta (bisoprolol)." Lederle Laboratories  (2001):|"Product Information. Visken (pindolol)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Levatol (penbutolol)." Reed and Carnrick  (2001):|"Product Information. Coreg (carvedilol)." SmithKline Beecham  (2001):|"Product Information. Bystolic (nebivolol)." Forest Pharmaceuticals  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7733, 0, 'Acebutolol', 'Peripheral Vascular Diseases', 'Due to their negative inotropic and chronotropic effects on the heart, beta-adrenergic receptor blocking agents (aka beta-blockers) reduce cardiac output and may precipitate or aggravate symptoms of arterial insufficiency in patients with peripheral vascular disease.  In addition, the nonselective beta-blockers (e.g., propranolol, pindolol, timolol) may attenuate catecholamine-mediated vasodilation during exercise by blocking beta-2 receptors in peripheral vessels.  Therapy with beta-blockers should be administered cautiously in patients with peripheral vascular disease.  Close monitoring for progression of arterial obstruction is advised.', '3', 'Michelson EL, Frishman WH, Lewis JE, et al. "Multicenter clinical evaluation of long-term efficacy and safety of labetalol in treatment of hypertension." Am J Med Oct 17 (1983):  68-80|Eliasson K, Danielson M, Hylander B, Lindblad LE "Raynaud''s phenomenon caused by beta-receptor blocking drugs." Acta Med Scand 215 (1984):  333-9|Myers J, Morgan T, Waga S, et al. "Long-term experiences with labetalol." Med J Aust 1 (1980):  665-6|Tcherdakoff P "Side-effects with long-term labetalol: an open study of 251 patients in a single centre." Pharmatherapeutica 3 (1983):  342-8|Eliasson K, Lins L-E, Sundqvist K "Peripheral vasospasm during beta-receptor blockade: a comparison between metoprolol and pindolol." Acta Med Scand 665 (1982):  109-12|Lepantalo M "Beta blockade and intermittent claudication." Acta Med Scand 700 (1985):  1-48|Mashford ML, Coventry D, Hecker R, et al. "Adverse Drug Reactions Advisory Committee: ADRAC report for 1980." Med J Aust 1 (1982):  416-9|Coppeto JR "Transient ischemic attacks and amaurosis fugax from timolol." Ann Ophthalmol 17 (1985):  64-5|"Product Information. Sectral (acebutolol)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Tenormin (atenolol)." ICN Pharmaceuticals Inc  (2002):|"Product Information. Normodyne (labetalol)." Schering Corporation  (2002):|"Product Information. Trandate (labetalol)." Glaxo Wellcome  (2002):|"Product Information. Corgard (nadolol)." Bristol-Myers Squibb  (2002):|"Product Information. Inderal (propranolol)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|"Product Information. Brevibloc (esmolol)." DuPont Pharmaceuticals  (2001):|"Product Information. Cartrol (carteolol)." Abbott Pharmaceutical  (2001):|"Product Information. Kerlone (betaxolol)." Searle  (2001):|"Product Information. Lopressor (metoprolol)." Novartis Pharmaceuticals  (2001):|"Product Information. Betapace (sotalol)." Berlex Laboratories  (2001):|Broeder CE, Thomas EL, Martin NB, Hofman Z, Jesek JK, Scruggs KD, Wambsgans KC, Wilmore JH "Effects of propranolol and pindolol on cardiac output during extended periods of low-intensity physical activity." Am J Cardiol 72 (1993):  1188-95|"Product Information. Zebeta (bisoprolol)." Lederle Laboratories  (2001):|Holti G "A double-blind study of the peripheral vasoconstrictor effects of the beta-blocking drug penbutolol in patients with Raynaud''s phenomenon." Curr Med Res Opin 6 (1979):  267-70|"Product Information. Visken (pindolol)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Levatol (penbutolol)." Reed and Carnrick  (2001):|Breckenridge A, Roberts DH "Antihypertensive treatment in concomitant peripheral vascular disease: current experience and the potential of carvedilol." J Cardiovasc Pharmacol 18 Suppl 4 (1991):  s78-81|"Product Information. Bystolic (nebivolol)." Forest Pharmaceuticals  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7734, 0, 'Acebutolol', 'Hepatic Insufficiency', 'Acebutolol should be used cautiously in patients with impaired hepatic function.', '2', '"Product Information. Sectral (acebutolol)." Wyeth-Ayerst Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7735, 0, 'Acebutolol', 'Cerebrovascular Disorders', 'Beta-adrenergic blocking agents (beta-blockers), should be used with caution in patients with cerebrovascular insufficiency because of their potential effects relative to blood pressure and pulse.  If signs or symptoms suggesting reduced cerebral blood flow are observed, consideration should be given to discontinuing these agents.', '2', '"Product Information. Sectral (acebutolol)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Tenormin (atenolol)." ICN Pharmaceuticals Inc  (2002):|"Product Information. Trandate (labetalol)." Glaxo Wellcome  (2002):|"Product Information. Corgard (nadolol)." Bristol-Myers Squibb  (2002):|"Product Information. Inderal (propranolol)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|"Product Information. Brevibloc (esmolol)." DuPont Pharmaceuticals  (2001):|"Product Information. Cartrol (carteolol)." Abbott Pharmaceutical  (2001):|"Product Information. Kerlone (betaxolol)." Searle  (2001):|"Product Information. Lopressor (metoprolol)." Novartis Pharmaceuticals  (2001):|"Product Information. Betapace (sotalol)." Berlex Laboratories  (2001):|"Product Information. Zebeta (bisoprolol)." Lederle Laboratories  (2001):|"Product Information. Visken (pindolol)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Levatol (penbutolol)." Reed and Carnrick  (2001):|"Product Information. Coreg (carvedilol)." SmithKline Beecham  (2001):|"Product Information. Bystolic (nebivolol)." Forest Pharmaceuticals  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7736, 0, 'Acebutolol', 'Glaucoma', 'Systemic beta-adrenergic receptor blocking agents (aka beta-blockers) may lower intraocular pressure.  Therefore, patients with glaucoma or intraocular hypertension may require adjustments in their ophthalmic regimen following a dosing change or discontinuation of beta-blocker therapy.', '2', '"Product Information. Sectral (acebutolol)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Tenormin (atenolol)." ICN Pharmaceuticals Inc  (2002):|"Product Information. Normodyne (labetalol)." Schering Corporation  (2002):|"Product Information. Trandate (labetalol)." Glaxo Wellcome  (2002):|"Product Information. Corgard (nadolol)." Bristol-Myers Squibb  (2002):|"Product Information. Inderal (propranolol)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|"Product Information. Cartrol (carteolol)." Abbott Pharmaceutical  (2001):|"Product Information. Kerlone (betaxolol)." Searle  (2001):|"Product Information. Lopressor (metoprolol)." Novartis Pharmaceuticals  (2001):|"Product Information. Betapace (sotalol)." Berlex Laboratories  (2001):|"Product Information. Zebeta (bisoprolol)." Lederle Laboratories  (2001):|"Product Information. Visken (pindolol)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Levatol (penbutolol)." Reed and Carnrick  (2001):|"Product Information. Coreg (carvedilol)." SmithKline Beecham  (2001):|"Product Information. Bystolic (nebivolol)." Forest Pharmaceuticals  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7737, 0, 'Acebutolol', 'Hyperlipidemias', 'Beta-adrenergic receptor blocking agents (aka beta-blockers) may alter serum lipid profiles.  Increases in serum VLDL and LDL cholesterol and triglycerides, as well as decreases in HDL cholesterol, have been reported with some beta-blockers.  Patients with preexisting hyperlipidemia may require closer monitoring during beta-blocker therapy, and adjustments made accordingly in their lipid-lowering regimen.', '2', 'Rossner S, Weiner L "Atenolol and metoprolol: comparison of effects on blood pressure and serum lipoproteins, and side effects." Eur J Clin Pharmacol 24 (1983):  573-7|Valimaki M, Maass L, Harno K, Nikkila EA "Lipoprotein lipids and apoproteins during beta-blocker administration: comparison of penbutolol and atenolol." Eur J Clin Pharmacol 30 (1986):  17-20|Disler LJ, Joffe BI, Seftel HC "Massive hypertriglyceridemia associated with atenolol." Am J Med 85 (1988):  586-7|Harvengt C, Heller FR, Martiat P, Nieuwenhuyze YV "Short-term effects of beta blockers atenolol, nadolol, pindolol, and propranolol on lipoprotein metabolism in normolipemic subjects." J Clin Pharmacol 27 (1987):  475-80|Darga LL, Hakim MJ, Lucas CP, Franklin BA "Comparison of the effects of guanadrel sulfate and propranolol on blood pressure, functional capacity, serum lipoproteins and glucose in systemic hypertension." Am J Cardiol 67 (1991):  590-6|Rossner S, Weiner L "Atenolol and metoprolol: comparison of effects on blood pressure and serum lipoproteins, and side effects." Eur J Clin Pharmacol 24 (1983):  573-7|Weiner L, Rossner S "Atenolol 50 mg or metoprolol 200 mg: a comparison of antihypertensive efficacy, side effects and lipoprotein changes." Acta Med Scand 677 (1983):  153-7|Ferrara LA, Marotta T, Scilla A, et al. "Effect of oxprenolol and metoprolol on serum lipid concentration." Eur J Clin Pharmacol 26 (1984):  331-4|Pasotti C, Capra A, Fiorella G, et al. "Effects of pindolol and metoprolol on plasma lipids and lipoproteins." Br J Clin Pharmacol 13 (1982):  s435-9|Carlson LA, Ribacke M, Terent A "A long-term study on the effect of pindolol on serum lipoproteins: a preliminary report." Br J Clin Pharmacol 24 (1987):  s61-2|Samuel P, Chin B, Schoenfeld BH, et al. "Comparison of the effect of pindolol versus propranolol on the lipid profile in patients treated for hypertension." Br J Clin Pharmacol 24 (1987):  s63-4|Terent A, Ribacke M, Carlson LA "Long-term effect of pindolol on lipids and lipoproteins in men with newly diagnosed hypertension." Eur J Clin Pharmacol 36 (1989):  347-50|Sasaki J, Saku K, Ideishi M, et al. "Effects of pindolol on serum lipids, apolipoproteins, and lipoproteins in patients with mild to moderate essential hypertension." Clin Ther 11 (1989):  219-24|Szollar LG, Meszaros I, Tornoci L, et al. "Effect of metoprolol and pindolol monotherapy on plasma lipid- and lipoprotein-cholesterol levels (including the HDL subclasses) in mild hypertensive males and females." J Cardiovasc Pharmacol 15 (1990):  911-7|Leren P, Foss PO, Nordvik B, Fossbakk B "The effect of enalapril and timolol on blood lipids." Acta Med Scand 223 (1988):  321-6|"Product Information. Sectral (acebutolol)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Tenormin (atenolol)." ICN Pharmaceuticals Inc  (2002):|"Product Information. Normodyne (labetalol)." Schering Corporation  (2002):|"Product Information. Trandate (labetalol)." Glaxo Wellcome  (2002):|"Product Information. Corgard (nadolol)." Bristol-Myers Squibb  (2002):|"Product Information. Inderal (propranolol)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|Northcote RJ, Packard CJ, Ballantyne D "The effect of sotalol on plasma lipoproteins and apolipoproteins." Clin Chim Acta 158 (1986):  187-91|Lehtonen A, Hietanen E, Marniemi J, Peltonen P, Nikkila EA "Effect of sotalol withdrawal on serum lipids and lipoprotein lipase activity." Int J Clin Pharmacol Ther Toxicol 21 (1983):  73-6|"Product Information. Cartrol (carteolol)." Abbott Pharmaceutical  (2001):|"Product Information. Kerlone (betaxolol)." Searle  (2001):|"Product Information. Lopressor (metoprolol)." Novartis Pharmaceuticals  (2001):|"Product Information. Betapace (sotalol)." Berlex Laboratories  (2001):|"Product Information. Zebeta (bisoprolol)." Lederle Laboratories  (2001):|Safran AB, Simona F, Sansonetti A, Pometta D, James R "Effects of ocular carteolol and timolol on plasma high-density lipoprotein cholesterol level." Am J Ophthalmol 117 (1994):  683|"Product Information. Visken (pindolol)." Sandoz Pharmaceuticals Corporation  (2001):|Clucas A, Miller N "Effects of acebutolol on the serum lipid profile." Drugs 36 Suppl 2 (1988):  41-50|"Product Information. Levatol (penbutolol)." Reed and Carnrick  (2001):|Kasiske BL, Ma JZ, Kalil RS, Louis TA "Effects of antihypertensive therapy on serum lipids." Ann Intern Med 122 (1995):  133-41|Lind L, Pollare T, Berne C, Lithell H "Long-term metabolic effects of antihypertensive drugs." Am Heart J 128 (1994):  1177-83|Sasaki J, Kajiyama G, Kusukawa R, Mori H, Koga S, Takagi R, Tanaka N, Ogawa N, Arakawa K "Effect of bevantolol and propranolol on serum lipids in patients with essential hypertension." Int J Clin Pharmacol Ther 32 (1994):  660-4|"Product Information. Coreg (carvedilol)." SmithKline Beecham  (2001):|Lithell H, Andersson PE "Metabolic effects of carvedilol in hypertensive patients." Eur J Clin Pharmacol 52 (1997):  13-7|Gordon NF, Scott CB, Duncan JJ "Effects of atenolol versus enalapril on cardiovascular fitness and serum lipids in physically active hypertensive men." Am J Cardiol 79 (1997):  1065-9|"Product Information. Bystolic (nebivolol)." Forest Pharmaceuticals  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7738, 0, 'Acebutolol', 'Hyperthyroidism', 'When beta-adrenergic receptor blocking agents (aka beta-blockers) are used to alleviate symptoms of hyperthyroidism such as tachycardia, anxiety, tremor and heat intolerance, abrupt withdrawal can exacerbate thyrotoxicosis or precipitate a thyroid storm.  To minimize this risk, cessation of beta-blocker therapy, when necessary, should occur gradually with incrementally reduced dosages over a period of 1 to 2 weeks.  Patients should be advised not to discontinue treatment without first consulting with the physician.  Close monitoring is recommended during and after therapy withdrawal.', '2', '"Product Information. Sectral (acebutolol)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Tenormin (atenolol)." ICN Pharmaceuticals Inc  (2002):|"Product Information. Normodyne (labetalol)." Schering Corporation  (2002):|"Product Information. Trandate (labetalol)." Glaxo Wellcome  (2002):|"Product Information. Corgard (nadolol)." Bristol-Myers Squibb  (2002):|"Product Information. Inderal (propranolol)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|"Product Information. Cartrol (carteolol)." Abbott Pharmaceutical  (2001):|"Product Information. Kerlone (betaxolol)." Searle  (2001):|"Product Information. Lopressor (metoprolol)." Novartis Pharmaceuticals  (2001):|"Product Information. Betapace (sotalol)." Berlex Laboratories  (2001):|"Product Information. Zebeta (bisoprolol)." Lederle Laboratories  (2001):|"Product Information. Visken (pindolol)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Levatol (penbutolol)." Reed and Carnrick  (2001):|"Product Information. Coreg (carvedilol)." SmithKline Beecham  (2001):|"Product Information. Bystolic (nebivolol)." Forest Pharmaceuticals  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7739, 0, 'Acebutolol', 'Myasthenia Gravis', 'Beta-adrenergic receptor blocking agents (aka beta-blockers) may potentiate muscle weakness consistent with certain myasthenic symptoms such as diplopia, ptosis, and generalized weakness.  Several beta-blockers have been associated rarely with aggravation of muscle weakness in patients with preexisting myasthenia gravis or myasthenic symptoms.  Use cautiously in patients with myasthenia gravis.', '2', 'Confavreux C, Charles N, Aimard G "Fulminant myasthenia gravis soon after initiation of acebutolol therapy." Eur Neurol 30 (1990):  279-81|Berstein LP, Henkind P "Additional information on adverse reactions to timolol." Am J Ophthalmol 92 (1981):  295-6|Coppeto JR "Timolol-associated myasthenia gravis." Am J Ophthalmol 98 (1984):  244-5|Verkijk A "Worsening of myasthenia gravis with timolol maleate eyedrops." Ann Neurol 17 (1985):  211-2|Herishanu Y, Rosenberg P "Beta-blockers and myasthenia gravis." Ann Intern Med 83 (1975):  834-5|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|Choi KL, Wat MS, Ip TP, Kung AWC, Lam KSL "Phaeochromocytoma associated with myasthenia gravis precipitated by propranolol treatment." Aust N Z J Med 25 (1995):  257', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7740, 0, 'Acebutolol', 'Pheochromocytoma', 'Administration of beta-blockers alone in the setting of pheochromocytoma has been associated with a paradoxical increase in blood pressure due to the attenuation of beta-mediated vasodilatation in skeletal muscle.  In patients with pheochromocytoma, an alpha-blocking agent should be initiated prior to the use of any beta-blocking agent.  Caution should be taken in the administration of these agents to patients suspected of having pheochromocytoma.', '2', '"Product Information. Sectral (acebutolol)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Tenormin (atenolol)." ICN Pharmaceuticals Inc  (2002):|"Product Information. Trandate (labetalol)." Glaxo Wellcome  (2002):|"Product Information. Corgard (nadolol)." Bristol-Myers Squibb  (2002):|"Product Information. Inderal (propranolol)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|"Product Information. Brevibloc (esmolol)." DuPont Pharmaceuticals  (2001):|"Product Information. Cartrol (carteolol)." Abbott Pharmaceutical  (2001):|"Product Information. Kerlone (betaxolol)." Searle  (2001):|"Product Information. Lopressor (metoprolol)." Novartis Pharmaceuticals  (2001):|"Product Information. Betapace (sotalol)." Berlex Laboratories  (2001):|"Product Information. Zebeta (bisoprolol)." Lederle Laboratories  (2001):|"Product Information. Visken (pindolol)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Levatol (penbutolol)." Reed and Carnrick  (2001):|"Product Information. Coreg (carvedilol)." SmithKline Beecham  (2001):|"Product Information. Bystolic (nebivolol)." Forest Pharmaceuticals  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7741, 0, 'Acebutolol', 'Psoriasis', 'The use of beta-blockers in psoriatic patients should be carefully weighed since the use of these agents may cause an aggravation in psoriasis.', '2', '"Product Information. Sectral (acebutolol)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Tenormin (atenolol)." ICN Pharmaceuticals Inc  (2002):|"Product Information. Normodyne (labetalol)." Schering Corporation  (2002):|"Product Information. Trandate (labetalol)." Glaxo Wellcome  (2002):|"Product Information. Corgard (nadolol)." Bristol-Myers Squibb  (2002):|"Product Information. Inderal (propranolol)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|"Product Information. Brevibloc (esmolol)." DuPont Pharmaceuticals  (2001):|"Product Information. Cartrol (carteolol)." Abbott Pharmaceutical  (2001):|"Product Information. Kerlone (betaxolol)." Searle  (2001):|"Product Information. Lopressor (metoprolol)." Novartis Pharmaceuticals  (2001):|"Product Information. Betapace (sotalol)." Berlex Laboratories  (2001):|"Product Information. Zebeta (bisoprolol)." Lederle Laboratories  (2001):|"Product Information. Visken (pindolol)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Levatol (penbutolol)." Reed and Carnrick  (2001):|"Product Information. Bystolic (nebivolol)." Forest Pharmaceuticals  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7742, 0, 'Acebutolol', 'Tachycardia', 'Beta-adrenergic blockade in patients with Wolff-Parkinson-White syndrome and tachycardia has been associated with severe bradycardia requiring treatment with a pacemaker.  In one case, this result was reported after an initial dose of 5 mg propranolol.  The use of beta-adrenergic receptor blocking agents (aka beta-blockers) should be administered cautiously in these patients.', '2', '"Product Information. Sectral (acebutolol)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Tenormin (atenolol)." ICN Pharmaceuticals Inc  (2002):|"Product Information. Normodyne (labetalol)." Schering Corporation  (2002):|"Product Information. Trandate (labetalol)." Glaxo Wellcome  (2002):|"Product Information. Corgard (nadolol)." Bristol-Myers Squibb  (2002):|"Product Information. Inderal (propranolol)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|"Product Information. Brevibloc (esmolol)." DuPont Pharmaceuticals  (2001):|"Product Information. Cartrol (carteolol)." Abbott Pharmaceutical  (2001):|"Product Information. Kerlone (betaxolol)." Searle  (2001):|"Product Information. Lopressor (metoprolol)." Novartis Pharmaceuticals  (2001):|"Product Information. Betapace (sotalol)." Berlex Laboratories  (2001):|"Product Information. Zebeta (bisoprolol)." Lederle Laboratories  (2001):|"Product Information. Visken (pindolol)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Levatol (penbutolol)." Reed and Carnrick  (2001):|"Product Information. Bystolic (nebivolol)." Forest Pharmaceuticals  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7743, 0, 'Acebutolol', 'Asthma', 'Patients with bronchospastic disease, should, in general, not receive beta blockers, including cardioselective beta-blockers.  Because of the relative beta-1 selectivity, cardioselective beta-blockers may be used in patients with bronchospastic disease who do not respond to, or cannot tolerate, other antihypertensive treatment.  Because beta-1 selectivity is not absolute, the lowest possible dose of these agents should be used.  Consider administering in smaller doses to avoid the higher plasma levels associated with the longer dosing intervals.  If dosage must be increased, dividing the dose should be considered to achieve lower peak blood levels.  It is recommended to have bronchodilators, including beta-2 agonists, readily available or administered concomitantly if necessary.', '2', '"Product Information. Sectral (acebutolol)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Tenormin (atenolol)." ICN Pharmaceuticals Inc  (2002):|"Product Information. Brevibloc (esmolol)." DuPont Pharmaceuticals  (2001):|"Product Information. Kerlone (betaxolol)." Searle  (2001):|"Product Information. Lopressor (metoprolol)." Novartis Pharmaceuticals  (2001):|"Product Information. Zebeta (bisoprolol)." Lederle Laboratories  (2001):|"Product Information. Bystolic (nebivolol)." Forest Pharmaceuticals  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7744, 6075, 'Mexiletine', 'Cardiomyopathies', 'Antiarrhythmic agents can induce severe hypotension (particularly with IV administration) or induce or worsen congestive heart failure (CHF).  Patients with primary cardiomyopathy or inadequately compensated CHF are at increased risk.  Antiarrhythmic agents should be administered cautiously and dosage and/or frequency of administration modified in patients with hypotension or adequately compensated CHF.  Alternative therapy should be considered unless these conditions are secondary to cardiac arrhythmia.', '3', 'Halkin H, Meffin P, Melmon KL, Rowland M "Influence of congestive heart failure on blood levels of lidocaine and its active monodeethylated metabolite." Clin Pharmacol Ther 17 (1975):  669-76|Crouthamel WG "The effect of congestive heart failure on quinidine pharmacokinetics." Am Heart J 90 (1975):  335-9|Ravid S, Podrid PJ, Lampert S, Lown B "Congestive heart failure induced by six of the newer antiarrhythmic drugs." J Am Coll Cardiol 14 (1989):  1326-30|Swiryn S, Kim SS "Quinidine-induced syncope." Arch Intern Med 143 (1983):  314-6|Gottlieb SS, Packer M "Deleterious hemodynamic effects of lidocaine in severe congestive heart failure." Am Heart J 118 (1989):  611-2|Ochs HR, Grube E, Greenblatt DJ, Arendt R "Intravenous quinidine in congestive cardiomyopathy." Eur J Clin Pharmacol 19 (1981):  173-6|Prescott LF, Adjepon-Yamoah KK, Talbot RG "Impaired lignocaine metabolism in patients with myocardial infarction and cardiac failure." Br Med J 1 (1976):  939-41|"Product Information. Cordarone (amiodarone)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Xylocaine (lidocaine)." Astra-Zeneca Pharmaceuticals  (2002):|"Product Information. Quinidex Extentabs (quiNIDine)." Wyeth-Ayerst Laboratories|"Product Information. Quiniglute (quinidine)." Berlex, Richmond, CA.|"Product Information. Adenocard (adenosine)." Fujisawa  (2001):|"Product Information. Mexitil (mexiletine)." Boehringer-Ingelheim  (2001):|Thomson P, Melmon K, Richardson J, Cohn K Steinbrunn W, Cudihee R, Rowland M "Lidocaine pharmacokinetics in advanced heart failure, liver disease, and renal failure in humans." Ann Intern Med 78 (1973):  499-508|Singh SN, Fletcher RD, Fisher SG, et al. "Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia." N Engl J Med 333 (1995):  77-82|"Product Information. Cordarone (amiodarone)." Apothecon Inc  (2022):|"Product Information. Corvert (ibutilide)." Pharmacia and Upjohn  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7745, 8112, 'Mexiletine', 'Cardiomyopathies', 'Antiarrhythmic agents can induce severe hypotension (particularly with IV administration) or induce or worsen congestive heart failure (CHF).  Patients with primary cardiomyopathy or inadequately compensated CHF are at increased risk.  Antiarrhythmic agents should be administered cautiously and dosage and/or frequency of administration modified in patients with hypotension or adequately compensated CHF.  Alternative therapy should be considered unless these conditions are secondary to cardiac arrhythmia.', '3', 'Halkin H, Meffin P, Melmon KL, Rowland M "Influence of congestive heart failure on blood levels of lidocaine and its active monodeethylated metabolite." Clin Pharmacol Ther 17 (1975):  669-76|Crouthamel WG "The effect of congestive heart failure on quinidine pharmacokinetics." Am Heart J 90 (1975):  335-9|Ravid S, Podrid PJ, Lampert S, Lown B "Congestive heart failure induced by six of the newer antiarrhythmic drugs." J Am Coll Cardiol 14 (1989):  1326-30|Swiryn S, Kim SS "Quinidine-induced syncope." Arch Intern Med 143 (1983):  314-6|Gottlieb SS, Packer M "Deleterious hemodynamic effects of lidocaine in severe congestive heart failure." Am Heart J 118 (1989):  611-2|Ochs HR, Grube E, Greenblatt DJ, Arendt R "Intravenous quinidine in congestive cardiomyopathy." Eur J Clin Pharmacol 19 (1981):  173-6|Prescott LF, Adjepon-Yamoah KK, Talbot RG "Impaired lignocaine metabolism in patients with myocardial infarction and cardiac failure." Br Med J 1 (1976):  939-41|"Product Information. Cordarone (amiodarone)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Xylocaine (lidocaine)." Astra-Zeneca Pharmaceuticals  (2002):|"Product Information. Quinidex Extentabs (quiNIDine)." Wyeth-Ayerst Laboratories|"Product Information. Quiniglute (quinidine)." Berlex, Richmond, CA.|"Product Information. Adenocard (adenosine)." Fujisawa  (2001):|"Product Information. Mexitil (mexiletine)." Boehringer-Ingelheim  (2001):|Thomson P, Melmon K, Richardson J, Cohn K Steinbrunn W, Cudihee R, Rowland M "Lidocaine pharmacokinetics in advanced heart failure, liver disease, and renal failure in humans." Ann Intern Med 78 (1973):  499-508|Singh SN, Fletcher RD, Fisher SG, et al. "Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia." N Engl J Med 333 (1995):  77-82|"Product Information. Cordarone (amiodarone)." Apothecon Inc  (2022):|"Product Information. Corvert (ibutilide)." Pharmacia and Upjohn  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7746, 6075, 'Mexiletine', 'Arrhythmias, Cardiac', 'Antiarrhythmic agents can induce or worsen ventricular arrhythmias.  Ventricular tachycardia, ventricular fibrillation, and torsades de pointes have occurred in some patients.  Patients with underlying cardiac dysfunction, bradycardia, hypokalemia, hypomagnesemia, or high antiarrhythmic serum concentrations are at increased risk for drug-induced arrhythmias.  Therapy with antiarrhythmics should be used with extreme caution in patients with or predisposed to arrhythmias.  Evidence of improved survival is lacking for use of antiarrhythmic therapy in asymptomatic, non-life-threatening arrhythmias.  Therapy with antiarrhythmic agents should be reserved for patients with life-threatening arrhythmias.', '3', 'Anderson JL, Popat KD "Paradoxical ventricular tachycardia and fibrillation after intravenous bretylium therapy." Arch Intern Med 141 (1981):  801-2|Sclarovsky S, Lewin RF, Kracoff O, Strasberg B, Arditti A, Agmon J "Amiodarone-induced polymorphous ventricular tachycardia." Am Heart J 105 (1983):  6-12|Strasberg B, Sclarovsky S, Erdberg A, et al. "Procainamide-induced polymorphous ventricular tachycardia." Am J Cardiol 47 (1981):  1309-14|Stratmann H, Walter K, Kennedy H "Torsade de pointes associated with elevated N-acetylprocainamide levels." Am Heart J 109 (1985):  375-6|Lo KS, Gantz KB, Stetson PL, et al. "Disopyramide-induced ventricular tachycardia." Arch Intern Med 140 (1980):  413-4|Kinney EL, Field EH, Salmon MP, Zelis R "Cardiac arrhythmias associated with disopyramide." N Engl J Med May (1990):  1146|Chia BL "Disopyramide induced atypical ventricular tachycardia." Aust N Z J Med 10 (1980):  665-8|Tzivoni D, Keren A, Stern S, Gottlieb S "Disopyramide-induced Torsade de pointes." Arch Intern Med 141 (1981):  946-7|Schweitzer P, Mark H "Torsade de pointes caused by disopyramide and hypokalemia." Mt Sinai J Med 49 (1982):  110-4|Riccioni N, Castiglioni M, Bartolomei C "Disopyramide-induced QT prolongation and ventricular tachyarrhythmias." Am Heart J 105 (1983):  870-1|Andrivet P, Beaslay V, Canh VD "Torsades de pointe with flecainide-amiodarone therapy." Intensive Care Med 16 (1990):  342-3|Cocco G, Strozzi C, Chu D, Pansini R "Torsades de pointes as a manifestation of mexiletine toxicity." Am Heart J 100 (1980):  878-80|Nora MO, Chandrasekaran K, Hammill SC, Reeder GS "Prolongation of ventricular depolarization: ECG manifestation of mexiletine toxicity." Chest 95 (1989):  925-8|Morganroth J, Pratt CM "Prevalence and characteristics of proarrhythmia from moricizine (themozine)." Am J Cardiol 63 (1989):  172-6|Damle R, Levine J, Matos J, et al. "Efficacy and risks of moricizine in inducible sustained ventricular tachycardia." Ann Intern Med 116 (1992):  375-81|Nathan AW, Hellestrand KJ, Bexton RS, Camm AJ "Fatal ventricular tachycardia in association with propafenone, a new class IC antiarrhythmic agent." Postgrad Med J 60 (1984):  155-6|Stavens CS, McGovern B, Garan H, Ruskin JN "Aggravation of electrically provoked ventricular tachycardia during treatment with propafenone." Am Heart J 110 (1985):  24-9|Hii JT, Wyse DG, Gillis AM, et al. "Propafenone-induced torsade de pointes: cross-reactivity with quinidine." Pacing Clin Electrophysiol 14 (1991):  1568-70|Cheesman M, Ward DE "Exacerbation of ventricular tachycardia by tocainide." Clin Cardiol 8 (1985):  47-50|Bauman JL, Bauernfeind RA, Hoff JV, et al. "Torsade de pointes due to quinidine: observations in 31 patients." Am Heart J 107 (1984):  425-30|Koenig W, Schinz AM "Spontaneous ventricular flutter and fibrillation during quinidine medication." Am Heart J 105 (1983):  863-5|Morganroth J, Horowitz LN "Incidence of proarrhythmic effects from quinidine in the outpatient treatment of benign or potentially lethal ventricular arrhythmias." Am J Cardiol 56 (1985):  585-7|Au PK, Bhandari AK, Bream R, et al. "Proarrhythmic effects of antiarrhythmic drugs during programmed ventricular stimulation in patients without ventricular tachycardia." J Am Coll Cardiol 9 (1987):  389-97|Engler RL, LeWinter M "Tocainide-induced ventricular fibrillation." Am Heart J 101 (1981):  494-6|Wesley RC Jr, Turnquest P "Torsades de pointe after intravenous adenosine in the presence of prolonged QT syndrome." Am Heart J 123 (1992):  794-6|Orebaugh SL, Handy M "Intravenous adenosine therapy accelerating rate of paroxysmal supraventricular tachycardia." Am J Emerg Med 10 (1992):  326-30|Reed R, Falk JL, O''Brien J "Untoward reaction to adenosine therapy for supraventricular tachycardia." Am J Emerg Med 9 (1991):  566-70|Meurer MK "A 21-year-old woman with rapid atrial fibrillation after adenosine administration." J Emerg Nurs 17 (1991):  135-6|Dougherty AH, Gilman JK, Wiggins S, Jalal S, Naccarelli GV "Provocation of atrioventricular reentry tachycardia: a paradoxical effect of adenosine." Pacing Clin Electrophysiol 16 (1993):  8-12|"Product Information. Tonocard (tocainide)." Merck & Co., Inc  (2002):|"Product Information. Ethmozine (moricizine)." DuPont Pharmaceuticals  (2002):|"Product Information. Cordarone (amiodarone)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Bretylol (bretylium)." DuPont Pharmaceuticals  (2002):|"Product Information. Xylocaine (lidocaine)." Astra-Zeneca Pharmaceuticals  (2002):|"Product Information. Procan SR (procainamide)." Parke-Davis  (2001):|"Product Information. Pronestyl (procainamide)." Apothecon Inc  (2001):|Raehl CL, Patel AK, LeRoy M "Drug-induced torsade de pointes." Clin Pharm 4 (1985):  675-90|Buss J, Neuss H, Bilgin Y, Schlepper M "Malignant ventricular tachyarrhythmias in association with propafenone treatment." Eur Heart J 6 (1985):  424-8|Sulke AN, Holt P, Sowton GE "Acceleration of conduction within an accessory pathway with propafenone." Int J Cardiol 28 (1990):  105-7|"Product Information. Adenocard (adenosine)." Fujisawa  (2001):|"Product Information. Tambocor (flecainide)." 3M Pharmaceuticals  (2001):|"Product Information. Mexitil (mexiletine)." Boehringer-Ingelheim  (2001):|"Product Information. Rythmol (propafenone)." Knoll Pharmaceutical Company|Ben-Sorek ES, Wiesel J "Ventricular fibrillation following adenosine administration. A case report." Arch Intern Med 153 (1993):  2701-2|Said SAM, Somer ST, Luttikhuis HAO "Flecainide-induced JT prolongation, t wave inversion and ventricular tachycardia during treatment for symptomatic atrial fibrillation." Int J Cardiol 44 (1994):  285-7|Makkar RR, Fromm BS, Steinman RT, Meissner MD, Lehmann MH "Female gender as a risk factor for torsades de pointes associated with cardiovascular drugs." JAMA 270 (1993):  2590-7|"Product Information. Norpace (disopyramide)." Searle  (2001):|Oberg KC, Otoole MF, Gallastegui JL, Bauman JL "''''late'''' proarrhythmia due to quinidine." Am J Cardiol 74 (1994):  192-4|Romer M, Candinas R "Adenosine-induced non-sustained polymorphic ventricular tachycardia." Eur Heart J 15 (1994):  281-2|Hohnloser SH, Klingenheben T, Singh BN "Amiodarone-associated proarrhythmic effects - a review with special reference to torsade de pointes tachycardia." Ann Intern Med 121 (1994):  529-35|Celiker A, Tokel K, Cil E, Ozkutlu S, Ozme S "Adenosine induced torsades de pointes in a child with congenital long QT syndrome." Pacing Clin Electrophysiol 17 (1994):  1814-7|Exner DV, Muzyka T, Gillis AM "Proarrhythmia in patients with the Wolff-Parkinson-White Syndrome after standard doses of intravenous adenosine." Ann Intern Med 122 (1995):  351-2|Williamson BD, Hummel J, Niebauer M, Man C, Strickberger SA, Daoud E, Morady F "Bradycardia-facilitated polymorphic ventricular tachycardia caused by amiodarone after radiofrequency modification of atrioventricular conduction." Am Heart J 130 (1995):  399-401|Dhein S, Schott M, Gottwald E, Klaus W "Electrocardiological profile and proarrhythmic effects of quinidine, verapamil and their combination: a mapping study." Naunyn Schmiedebergs Arch Pharmacol 352 (1995):  94-101|"Product Information. Cordarone (amiodarone)." Apothecon Inc  (2022):|Hohnloser SH, Vandeloo A, Baedeker F "Efficacy and proarrhythmic hazards of pharmacologic cardioversion of atrial fibrillation: prospective comparison of sotalol versus quinidine." J Am Coll Cardiol 26 (1995):  852-8|"Product Information. Corvert (ibutilide)." Pharmacia and Upjohn  (2001):|Silverman AJ, Machado C, Baga JJ, Meissner MD, Lehmann MH, Steinman RT "Adenosine-induced atrial fibrillation." Am J Emerg Med 14 (1996):  300-1|Boriani G, Biffi M, Frabetti L, Azzolini U, Sabbatani P, Bronzetti G, Capucci A, Magnani B "Ventricular fibrillation after intravenous amiodarone in wolff-parkinson-white syndrome with atrial fibrillation." Am Heart J 131 (1996):  1214-6|Faggiano P, Gardini A, Daloia A, Benedini G, Giordano A "Torsade de pointes occurring early during oral amiodarone treatment." Int J Cardiol 55 (1996):  205-8|Heisler BE, Ferrier GR "Proarrhythmic actions of flecainide in an isolated tissue model of ischemia and reperfusion." J Pharmacol Exp Ther 279 (1996):  317-24|Strickberger SA, Man KC, Daoud EG, et al. "Adenosine-induced atrial arrhythmia: a prospective analysis." Ann Intern Med 127 (1997):  417-22', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7747, 8112, 'Mexiletine', 'Arrhythmias, Cardiac', 'Antiarrhythmic agents can induce or worsen ventricular arrhythmias.  Ventricular tachycardia, ventricular fibrillation, and torsades de pointes have occurred in some patients.  Patients with underlying cardiac dysfunction, bradycardia, hypokalemia, hypomagnesemia, or high antiarrhythmic serum concentrations are at increased risk for drug-induced arrhythmias.  Therapy with antiarrhythmics should be used with extreme caution in patients with or predisposed to arrhythmias.  Evidence of improved survival is lacking for use of antiarrhythmic therapy in asymptomatic, non-life-threatening arrhythmias.  Therapy with antiarrhythmic agents should be reserved for patients with life-threatening arrhythmias.', '3', 'Anderson JL, Popat KD "Paradoxical ventricular tachycardia and fibrillation after intravenous bretylium therapy." Arch Intern Med 141 (1981):  801-2|Sclarovsky S, Lewin RF, Kracoff O, Strasberg B, Arditti A, Agmon J "Amiodarone-induced polymorphous ventricular tachycardia." Am Heart J 105 (1983):  6-12|Strasberg B, Sclarovsky S, Erdberg A, et al. "Procainamide-induced polymorphous ventricular tachycardia." Am J Cardiol 47 (1981):  1309-14|Stratmann H, Walter K, Kennedy H "Torsade de pointes associated with elevated N-acetylprocainamide levels." Am Heart J 109 (1985):  375-6|Lo KS, Gantz KB, Stetson PL, et al. "Disopyramide-induced ventricular tachycardia." Arch Intern Med 140 (1980):  413-4|Kinney EL, Field EH, Salmon MP, Zelis R "Cardiac arrhythmias associated with disopyramide." N Engl J Med May (1990):  1146|Chia BL "Disopyramide induced atypical ventricular tachycardia." Aust N Z J Med 10 (1980):  665-8|Tzivoni D, Keren A, Stern S, Gottlieb S "Disopyramide-induced Torsade de pointes." Arch Intern Med 141 (1981):  946-7|Schweitzer P, Mark H "Torsade de pointes caused by disopyramide and hypokalemia." Mt Sinai J Med 49 (1982):  110-4|Riccioni N, Castiglioni M, Bartolomei C "Disopyramide-induced QT prolongation and ventricular tachyarrhythmias." Am Heart J 105 (1983):  870-1|Andrivet P, Beaslay V, Canh VD "Torsades de pointe with flecainide-amiodarone therapy." Intensive Care Med 16 (1990):  342-3|Cocco G, Strozzi C, Chu D, Pansini R "Torsades de pointes as a manifestation of mexiletine toxicity." Am Heart J 100 (1980):  878-80|Nora MO, Chandrasekaran K, Hammill SC, Reeder GS "Prolongation of ventricular depolarization: ECG manifestation of mexiletine toxicity." Chest 95 (1989):  925-8|Morganroth J, Pratt CM "Prevalence and characteristics of proarrhythmia from moricizine (themozine)." Am J Cardiol 63 (1989):  172-6|Damle R, Levine J, Matos J, et al. "Efficacy and risks of moricizine in inducible sustained ventricular tachycardia." Ann Intern Med 116 (1992):  375-81|Nathan AW, Hellestrand KJ, Bexton RS, Camm AJ "Fatal ventricular tachycardia in association with propafenone, a new class IC antiarrhythmic agent." Postgrad Med J 60 (1984):  155-6|Stavens CS, McGovern B, Garan H, Ruskin JN "Aggravation of electrically provoked ventricular tachycardia during treatment with propafenone." Am Heart J 110 (1985):  24-9|Hii JT, Wyse DG, Gillis AM, et al. "Propafenone-induced torsade de pointes: cross-reactivity with quinidine." Pacing Clin Electrophysiol 14 (1991):  1568-70|Cheesman M, Ward DE "Exacerbation of ventricular tachycardia by tocainide." Clin Cardiol 8 (1985):  47-50|Bauman JL, Bauernfeind RA, Hoff JV, et al. "Torsade de pointes due to quinidine: observations in 31 patients." Am Heart J 107 (1984):  425-30|Koenig W, Schinz AM "Spontaneous ventricular flutter and fibrillation during quinidine medication." Am Heart J 105 (1983):  863-5|Morganroth J, Horowitz LN "Incidence of proarrhythmic effects from quinidine in the outpatient treatment of benign or potentially lethal ventricular arrhythmias." Am J Cardiol 56 (1985):  585-7|Au PK, Bhandari AK, Bream R, et al. "Proarrhythmic effects of antiarrhythmic drugs during programmed ventricular stimulation in patients without ventricular tachycardia." J Am Coll Cardiol 9 (1987):  389-97|Engler RL, LeWinter M "Tocainide-induced ventricular fibrillation." Am Heart J 101 (1981):  494-6|Wesley RC Jr, Turnquest P "Torsades de pointe after intravenous adenosine in the presence of prolonged QT syndrome." Am Heart J 123 (1992):  794-6|Orebaugh SL, Handy M "Intravenous adenosine therapy accelerating rate of paroxysmal supraventricular tachycardia." Am J Emerg Med 10 (1992):  326-30|Reed R, Falk JL, O''Brien J "Untoward reaction to adenosine therapy for supraventricular tachycardia." Am J Emerg Med 9 (1991):  566-70|Meurer MK "A 21-year-old woman with rapid atrial fibrillation after adenosine administration." J Emerg Nurs 17 (1991):  135-6|Dougherty AH, Gilman JK, Wiggins S, Jalal S, Naccarelli GV "Provocation of atrioventricular reentry tachycardia: a paradoxical effect of adenosine." Pacing Clin Electrophysiol 16 (1993):  8-12|"Product Information. Tonocard (tocainide)." Merck & Co., Inc  (2002):|"Product Information. Ethmozine (moricizine)." DuPont Pharmaceuticals  (2002):|"Product Information. Cordarone (amiodarone)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Bretylol (bretylium)." DuPont Pharmaceuticals  (2002):|"Product Information. Xylocaine (lidocaine)." Astra-Zeneca Pharmaceuticals  (2002):|"Product Information. Procan SR (procainamide)." Parke-Davis  (2001):|"Product Information. Pronestyl (procainamide)." Apothecon Inc  (2001):|Raehl CL, Patel AK, LeRoy M "Drug-induced torsade de pointes." Clin Pharm 4 (1985):  675-90|Buss J, Neuss H, Bilgin Y, Schlepper M "Malignant ventricular tachyarrhythmias in association with propafenone treatment." Eur Heart J 6 (1985):  424-8|Sulke AN, Holt P, Sowton GE "Acceleration of conduction within an accessory pathway with propafenone." Int J Cardiol 28 (1990):  105-7|"Product Information. Adenocard (adenosine)." Fujisawa  (2001):|"Product Information. Tambocor (flecainide)." 3M Pharmaceuticals  (2001):|"Product Information. Mexitil (mexiletine)." Boehringer-Ingelheim  (2001):|"Product Information. Rythmol (propafenone)." Knoll Pharmaceutical Company|Ben-Sorek ES, Wiesel J "Ventricular fibrillation following adenosine administration. A case report." Arch Intern Med 153 (1993):  2701-2|Said SAM, Somer ST, Luttikhuis HAO "Flecainide-induced JT prolongation, t wave inversion and ventricular tachycardia during treatment for symptomatic atrial fibrillation." Int J Cardiol 44 (1994):  285-7|Makkar RR, Fromm BS, Steinman RT, Meissner MD, Lehmann MH "Female gender as a risk factor for torsades de pointes associated with cardiovascular drugs." JAMA 270 (1993):  2590-7|"Product Information. Norpace (disopyramide)." Searle  (2001):|Oberg KC, Otoole MF, Gallastegui JL, Bauman JL "''''late'''' proarrhythmia due to quinidine." Am J Cardiol 74 (1994):  192-4|Romer M, Candinas R "Adenosine-induced non-sustained polymorphic ventricular tachycardia." Eur Heart J 15 (1994):  281-2|Hohnloser SH, Klingenheben T, Singh BN "Amiodarone-associated proarrhythmic effects - a review with special reference to torsade de pointes tachycardia." Ann Intern Med 121 (1994):  529-35|Celiker A, Tokel K, Cil E, Ozkutlu S, Ozme S "Adenosine induced torsades de pointes in a child with congenital long QT syndrome." Pacing Clin Electrophysiol 17 (1994):  1814-7|Exner DV, Muzyka T, Gillis AM "Proarrhythmia in patients with the Wolff-Parkinson-White Syndrome after standard doses of intravenous adenosine." Ann Intern Med 122 (1995):  351-2|Williamson BD, Hummel J, Niebauer M, Man C, Strickberger SA, Daoud E, Morady F "Bradycardia-facilitated polymorphic ventricular tachycardia caused by amiodarone after radiofrequency modification of atrioventricular conduction." Am Heart J 130 (1995):  399-401|Dhein S, Schott M, Gottwald E, Klaus W "Electrocardiological profile and proarrhythmic effects of quinidine, verapamil and their combination: a mapping study." Naunyn Schmiedebergs Arch Pharmacol 352 (1995):  94-101|"Product Information. Cordarone (amiodarone)." Apothecon Inc  (2022):|Hohnloser SH, Vandeloo A, Baedeker F "Efficacy and proarrhythmic hazards of pharmacologic cardioversion of atrial fibrillation: prospective comparison of sotalol versus quinidine." J Am Coll Cardiol 26 (1995):  852-8|"Product Information. Corvert (ibutilide)." Pharmacia and Upjohn  (2001):|Silverman AJ, Machado C, Baga JJ, Meissner MD, Lehmann MH, Steinman RT "Adenosine-induced atrial fibrillation." Am J Emerg Med 14 (1996):  300-1|Boriani G, Biffi M, Frabetti L, Azzolini U, Sabbatani P, Bronzetti G, Capucci A, Magnani B "Ventricular fibrillation after intravenous amiodarone in wolff-parkinson-white syndrome with atrial fibrillation." Am Heart J 131 (1996):  1214-6|Faggiano P, Gardini A, Daloia A, Benedini G, Giordano A "Torsade de pointes occurring early during oral amiodarone treatment." Int J Cardiol 55 (1996):  205-8|Heisler BE, Ferrier GR "Proarrhythmic actions of flecainide in an isolated tissue model of ischemia and reperfusion." J Pharmacol Exp Ther 279 (1996):  317-24|Strickberger SA, Man KC, Daoud EG, et al. "Adenosine-induced atrial arrhythmia: a prospective analysis." Ann Intern Med 127 (1997):  417-22', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7748, 6075, 'Mexiletine', 'Sick Sinus Syndrome', 'The use of mexiletine is contraindicated in patients with cardiogenic shock, second- or third-degree AV block in the absence of a functional artificial pacemaker.', '3', '"Product Information. Mexitil (mexiletine)." Boehringer-Ingelheim  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7749, 8112, 'Mexiletine', 'Sick Sinus Syndrome', 'The use of mexiletine is contraindicated in patients with cardiogenic shock, second- or third-degree AV block in the absence of a functional artificial pacemaker.', '3', '"Product Information. Mexitil (mexiletine)." Boehringer-Ingelheim  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7750, 6075, 'Mexiletine', 'Liver Diseases', 'Mexiletine is extensively metabolized by the liver to minimally active and inactive forms.  The serum concentration of mexiletine is increased and the half-life prolonged in patients with liver impairment.  Elevation of liver enzymes have been reported during the first few weeks of therapy, primarily in patients with congestive heart failure (CHF) or ischemia. Hepatic necrosis, resulting in death, has occurred.   Therapy with mexiletine should be administered cautiously in patients with compromised liver function, CHF or ischemia.  Clinical monitoring of cardiac function (ECG) and liver function is recommended.', '2', 'Pentikainen PJ, Hietakorpi S, Halinen MO, Lampinen LM "Cirrhosis of the liver markedly impairs the elimination of mexiletine." Eur J Clin Pharmacol 30 (1986):  83-8|Nitsch J, Steinbeck G, Luderitz B "Increase of mexiletine plasma levels due to delayed hepatic metabolism in patients with chronic liver disease." Eur Heart J 4 (1983):  810-4|"Product Information. Mexitil (mexiletine)." Boehringer-Ingelheim  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7751, 8112, 'Mexiletine', 'Liver Diseases', 'Mexiletine is extensively metabolized by the liver to minimally active and inactive forms.  The serum concentration of mexiletine is increased and the half-life prolonged in patients with liver impairment.  Elevation of liver enzymes have been reported during the first few weeks of therapy, primarily in patients with congestive heart failure (CHF) or ischemia. Hepatic necrosis, resulting in death, has occurred.   Therapy with mexiletine should be administered cautiously in patients with compromised liver function, CHF or ischemia.  Clinical monitoring of cardiac function (ECG) and liver function is recommended.', '2', 'Pentikainen PJ, Hietakorpi S, Halinen MO, Lampinen LM "Cirrhosis of the liver markedly impairs the elimination of mexiletine." Eur J Clin Pharmacol 30 (1986):  83-8|Nitsch J, Steinbeck G, Luderitz B "Increase of mexiletine plasma levels due to delayed hepatic metabolism in patients with chronic liver disease." Eur Heart J 4 (1983):  810-4|"Product Information. Mexitil (mexiletine)." Boehringer-Ingelheim  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7752, 6075, 'Mexiletine', 'Kidney Diseases', 'Mexiletine is primarily eliminated by the kidney.  Approximately 10% of mexiletine is excreted in the urine unchanged.  Marked changes in urinary pH alter the rate of mexiletine excretion.  Elimination is accelerated with an acidic urinary pH and slowed with an alkaline urinary pH.  Therapy with mexiletine should be administered cautiously in patients with significant renal impairment.  Clinical monitoring of cardiac function (ECG) and renal function is recommended.', '2', 'Wang T, Wuellner D, Woosley RL, Stone WJ "Pharmacokinetics and nondialyzability of mexiletine in renal failure." Clin Pharmacol Ther 37 (1985):  649-53|El Allaf D, Henrard L, Crochelet L, Delapierre D, Carlier J, Dresse A "Pharmacokinetics of mexiletine in renal insufficiency." Br J Clin Pharmacol 14 (1982):  431-5|Guay DR, Meatherall RC, Ferguson I, Smith H, Light B "Mexiletine clearance during peritoneal dialysis ." Br J Clin Pharmacol 19 (1985):  857-8|Jones TE, Reece PA, Fisher GC "Mexiletine removal by peritoneal dialysis." Eur J Clin Pharmacol 25 (1983):  839-40|"Product Information. Mexitil (mexiletine)." Boehringer-Ingelheim  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7753, 8112, 'Mexiletine', 'Kidney Diseases', 'Mexiletine is primarily eliminated by the kidney.  Approximately 10% of mexiletine is excreted in the urine unchanged.  Marked changes in urinary pH alter the rate of mexiletine excretion.  Elimination is accelerated with an acidic urinary pH and slowed with an alkaline urinary pH.  Therapy with mexiletine should be administered cautiously in patients with significant renal impairment.  Clinical monitoring of cardiac function (ECG) and renal function is recommended.', '2', 'Wang T, Wuellner D, Woosley RL, Stone WJ "Pharmacokinetics and nondialyzability of mexiletine in renal failure." Clin Pharmacol Ther 37 (1985):  649-53|El Allaf D, Henrard L, Crochelet L, Delapierre D, Carlier J, Dresse A "Pharmacokinetics of mexiletine in renal insufficiency." Br J Clin Pharmacol 14 (1982):  431-5|Guay DR, Meatherall RC, Ferguson I, Smith H, Light B "Mexiletine clearance during peritoneal dialysis ." Br J Clin Pharmacol 19 (1985):  857-8|Jones TE, Reece PA, Fisher GC "Mexiletine removal by peritoneal dialysis." Eur J Clin Pharmacol 25 (1983):  839-40|"Product Information. Mexitil (mexiletine)." Boehringer-Ingelheim  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7754, 6075, 'Mexiletine', 'Seizures', 'Seizures have been reported rarely during mexiletine therapy in patients with and without a history of seizures.  Therapy with mexiletine should be administered cautiously in patients with or predisposition to seizure disorders.', '2', '"Product Information. Mexitil (mexiletine)." Boehringer-Ingelheim  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7755, 8112, 'Mexiletine', 'Seizures', 'Seizures have been reported rarely during mexiletine therapy in patients with and without a history of seizures.  Therapy with mexiletine should be administered cautiously in patients with or predisposition to seizure disorders.', '2', '"Product Information. Mexitil (mexiletine)." Boehringer-Ingelheim  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7756, 0, 'Metreleptin', 'Lymphoma', 'Cases of T-cell lymphoma have been reported during treatment with metreleptin in patients with acquired generalized lipodystrophy.  Some, but not all, had immunodeficiency and significant hematologic abnormalities including severe bone marrow abnormalities before the initiation of metreleptin therapy.  However, lymphomas and other lymphoproliferative disorders have also been reported in patients with acquired generalized lipodystrophy who did not receive metreleptin, thus a causal relationship with metreleptin has not been established.  Acquired lipodystrophies are associated with autoimmune disorders, and the latter is associated with an increased risk of malignancies including lymphomas.  Until more information is available, the potential benefits and risks of metreleptin treatment should be carefully considered in patients with acquired generalized lipodystrophy and/or those with significant hematologic abnormalities including leukopenia, neutropenia, bone marrow abnormalities, lymphoma, and/or lymphadenopathy.', '3', '"Product Information. Myalept (metreleptin)." Bristol-Myers Squibb  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7757, 0, 'Metreleptin', 'Obesity', 'The use of metreleptin is contraindicated in patients with general obesity not associated with congenital leptin deficiency.  Metreleptin has not been shown to be effective in treating general obesity.  Moreover, development of anti-metreleptin antibodies with neutralizing activity has been reported in obese patients treated with metreleptin, the clinical consequences of which have not been well characterized but could include inhibition of endogenous leptin action and loss of metreleptin efficacy.  Worsening metabolic control and/or severe infection have been reported.', '3', '"Product Information. Myalept (metreleptin)." Bristol-Myers Squibb  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7758, 0, 'Metreleptin', 'Autoimmune Diseases', 'Leptin is involved in immune system homeostasis.  Patients with acquired lipodystrophies and leptin deficiency may have autoimmune disorders including autoimmune hepatitis and membranoproliferative glomerulonephritis.  Progression of autoimmune hepatitis and membranoproliferative glomerulonephritis with massive proteinuria and renal failure has occurred in some patients with acquired generalized lipodystrophy treated with metreleptin, a recombinant analog of human leptin.  A causal relationship between metreleptin treatment and the development and/or progression of autoimmune disease has not been established.  Until more information is available, the potential benefits and risks of metreleptin treatment should be carefully considered in patients with autoimmune diseases.', '2', '"Product Information. Myalept (metreleptin)." Bristol-Myers Squibb  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7759, 0, 'Metreleptin', 'Hypoglycemia', 'Metreleptin can cause hypoglycemia.  Caution is advised in patients that suffer from hypoglycemia or in diabetic patients in treatment with oral hypoglycemic agents or insulin.  A dosage adjustment might be needed.', '2', '"Product Information. Myalept (metreleptin)." Bristol-Myers Squibb  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7760, 0, 'Arsenic trioxide', 'Long QT Syndrome', 'Arsenic trioxide can cause QTc interval prolongation, complete atrioventricular block, and a torsade de pointes- type ventricular arrhythmia, which can be fatal.  Prior to initiating therapy with arsenic trioxide, assess the QTc interval by electrocardiogram, correct pre- existing electrolyte abnormalities, and consider discontinuing drugs known to prolong QTc interval.  Arsenic trioxide should not be administered to patients with ventricular arrhythmia or prolonged QTc interval.', '3', '"Product Information. Trisenox (arsenic trioxide)." Cephalon Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7761, 0, 'Arsenic trioxide', 'Brain Diseases', 'Serious encephalopathy, including Wernicke''s, has occurred in patients treated with arsenic trioxide injection.  Wernicke''s is a neurologic emergency.  Consider testing thiamine levels in patients at risk for thiamine deficiency.  Administer parenteral thiamine in patients with or at risk for thiamine deficiency.  Monitor patients for neurological symptoms and nutritional status while receiving arsenic trioxide injection.  If encephalopathy is suspected, immediately interrupt arsenic trioxide injection and initiate parenteral thiamine.  Monitor until symptoms resolve or improve and thiamine levels normalize.', '3', '"Product Information. Trisenox (arsenic trioxide)." Cephalon Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7762, 690, 'Metronidazole (topical)', 'Alcoholism', 'Metronidazole may be systemically absorbed when applied to the skin or mucosal membranes.  A disulfiram-like reaction has been reported in patients who consume alcohol during treatment with oral metronidazole.  Symptoms include nausea, vomiting, flushing, sweating, headache, abdominal cramps, and hypotension.  Therapy with topical metronidazole should be administered cautiously in patients who might be prone to acute alcohol intake.  Patients should be instructed to avoid alcohol-containing products during therapy and for at least 48 hours after the last dose.', '2', 'Giannini AJ, DeFrance DT "Metronidazole and alcohol: potential for combinative abuse." J Toxicol Clin Toxicol 20 (1983):  509-15|Alexander I "Alcohol-antabuse syndrome in patients receiving metronidazole during gynaecological treatment." Br J Clin Pract 39 (1985):  292-3|Harries DP, Teale KF, Sunderland G "Metronidazole and alcohol: potential problems." Scott Med J 35 (1990):  179-80|"Product Information. MetroGel-Vaginal (metroNIDAZOLE topical)." Curatek Pharmaceuticals Ltd  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7763, 691, 'Metronidazole (topical)', 'Alcoholism', 'Metronidazole may be systemically absorbed when applied to the skin or mucosal membranes.  A disulfiram-like reaction has been reported in patients who consume alcohol during treatment with oral metronidazole.  Symptoms include nausea, vomiting, flushing, sweating, headache, abdominal cramps, and hypotension.  Therapy with topical metronidazole should be administered cautiously in patients who might be prone to acute alcohol intake.  Patients should be instructed to avoid alcohol-containing products during therapy and for at least 48 hours after the last dose.', '2', 'Giannini AJ, DeFrance DT "Metronidazole and alcohol: potential for combinative abuse." J Toxicol Clin Toxicol 20 (1983):  509-15|Alexander I "Alcohol-antabuse syndrome in patients receiving metronidazole during gynaecological treatment." Br J Clin Pract 39 (1985):  292-3|Harries DP, Teale KF, Sunderland G "Metronidazole and alcohol: potential problems." Scott Med J 35 (1990):  179-80|"Product Information. MetroGel-Vaginal (metroNIDAZOLE topical)." Curatek Pharmaceuticals Ltd  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7764, 692, 'Metronidazole (topical)', 'Alcoholism', 'Metronidazole may be systemically absorbed when applied to the skin or mucosal membranes.  A disulfiram-like reaction has been reported in patients who consume alcohol during treatment with oral metronidazole.  Symptoms include nausea, vomiting, flushing, sweating, headache, abdominal cramps, and hypotension.  Therapy with topical metronidazole should be administered cautiously in patients who might be prone to acute alcohol intake.  Patients should be instructed to avoid alcohol-containing products during therapy and for at least 48 hours after the last dose.', '2', 'Giannini AJ, DeFrance DT "Metronidazole and alcohol: potential for combinative abuse." J Toxicol Clin Toxicol 20 (1983):  509-15|Alexander I "Alcohol-antabuse syndrome in patients receiving metronidazole during gynaecological treatment." Br J Clin Pract 39 (1985):  292-3|Harries DP, Teale KF, Sunderland G "Metronidazole and alcohol: potential problems." Scott Med J 35 (1990):  179-80|"Product Information. MetroGel-Vaginal (metroNIDAZOLE topical)." Curatek Pharmaceuticals Ltd  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7765, 4210, 'Metronidazole (topical)', 'Alcoholism', 'Metronidazole may be systemically absorbed when applied to the skin or mucosal membranes.  A disulfiram-like reaction has been reported in patients who consume alcohol during treatment with oral metronidazole.  Symptoms include nausea, vomiting, flushing, sweating, headache, abdominal cramps, and hypotension.  Therapy with topical metronidazole should be administered cautiously in patients who might be prone to acute alcohol intake.  Patients should be instructed to avoid alcohol-containing products during therapy and for at least 48 hours after the last dose.', '2', 'Giannini AJ, DeFrance DT "Metronidazole and alcohol: potential for combinative abuse." J Toxicol Clin Toxicol 20 (1983):  509-15|Alexander I "Alcohol-antabuse syndrome in patients receiving metronidazole during gynaecological treatment." Br J Clin Pract 39 (1985):  292-3|Harries DP, Teale KF, Sunderland G "Metronidazole and alcohol: potential problems." Scott Med J 35 (1990):  179-80|"Product Information. MetroGel-Vaginal (metroNIDAZOLE topical)." Curatek Pharmaceuticals Ltd  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7766, 4325, 'Metronidazole (topical)', 'Alcoholism', 'Metronidazole may be systemically absorbed when applied to the skin or mucosal membranes.  A disulfiram-like reaction has been reported in patients who consume alcohol during treatment with oral metronidazole.  Symptoms include nausea, vomiting, flushing, sweating, headache, abdominal cramps, and hypotension.  Therapy with topical metronidazole should be administered cautiously in patients who might be prone to acute alcohol intake.  Patients should be instructed to avoid alcohol-containing products during therapy and for at least 48 hours after the last dose.', '2', 'Giannini AJ, DeFrance DT "Metronidazole and alcohol: potential for combinative abuse." J Toxicol Clin Toxicol 20 (1983):  509-15|Alexander I "Alcohol-antabuse syndrome in patients receiving metronidazole during gynaecological treatment." Br J Clin Pract 39 (1985):  292-3|Harries DP, Teale KF, Sunderland G "Metronidazole and alcohol: potential problems." Scott Med J 35 (1990):  179-80|"Product Information. MetroGel-Vaginal (metroNIDAZOLE topical)." Curatek Pharmaceuticals Ltd  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7767, 4894, 'Metronidazole (topical)', 'Alcoholism', 'Metronidazole may be systemically absorbed when applied to the skin or mucosal membranes.  A disulfiram-like reaction has been reported in patients who consume alcohol during treatment with oral metronidazole.  Symptoms include nausea, vomiting, flushing, sweating, headache, abdominal cramps, and hypotension.  Therapy with topical metronidazole should be administered cautiously in patients who might be prone to acute alcohol intake.  Patients should be instructed to avoid alcohol-containing products during therapy and for at least 48 hours after the last dose.', '2', 'Giannini AJ, DeFrance DT "Metronidazole and alcohol: potential for combinative abuse." J Toxicol Clin Toxicol 20 (1983):  509-15|Alexander I "Alcohol-antabuse syndrome in patients receiving metronidazole during gynaecological treatment." Br J Clin Pract 39 (1985):  292-3|Harries DP, Teale KF, Sunderland G "Metronidazole and alcohol: potential problems." Scott Med J 35 (1990):  179-80|"Product Information. MetroGel-Vaginal (metroNIDAZOLE topical)." Curatek Pharmaceuticals Ltd  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7768, 4903, 'Metronidazole (topical)', 'Alcoholism', 'Metronidazole may be systemically absorbed when applied to the skin or mucosal membranes.  A disulfiram-like reaction has been reported in patients who consume alcohol during treatment with oral metronidazole.  Symptoms include nausea, vomiting, flushing, sweating, headache, abdominal cramps, and hypotension.  Therapy with topical metronidazole should be administered cautiously in patients who might be prone to acute alcohol intake.  Patients should be instructed to avoid alcohol-containing products during therapy and for at least 48 hours after the last dose.', '2', 'Giannini AJ, DeFrance DT "Metronidazole and alcohol: potential for combinative abuse." J Toxicol Clin Toxicol 20 (1983):  509-15|Alexander I "Alcohol-antabuse syndrome in patients receiving metronidazole during gynaecological treatment." Br J Clin Pract 39 (1985):  292-3|Harries DP, Teale KF, Sunderland G "Metronidazole and alcohol: potential problems." Scott Med J 35 (1990):  179-80|"Product Information. MetroGel-Vaginal (metroNIDAZOLE topical)." Curatek Pharmaceuticals Ltd  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7769, 4904, 'Metronidazole (topical)', 'Alcoholism', 'Metronidazole may be systemically absorbed when applied to the skin or mucosal membranes.  A disulfiram-like reaction has been reported in patients who consume alcohol during treatment with oral metronidazole.  Symptoms include nausea, vomiting, flushing, sweating, headache, abdominal cramps, and hypotension.  Therapy with topical metronidazole should be administered cautiously in patients who might be prone to acute alcohol intake.  Patients should be instructed to avoid alcohol-containing products during therapy and for at least 48 hours after the last dose.', '2', 'Giannini AJ, DeFrance DT "Metronidazole and alcohol: potential for combinative abuse." J Toxicol Clin Toxicol 20 (1983):  509-15|Alexander I "Alcohol-antabuse syndrome in patients receiving metronidazole during gynaecological treatment." Br J Clin Pract 39 (1985):  292-3|Harries DP, Teale KF, Sunderland G "Metronidazole and alcohol: potential problems." Scott Med J 35 (1990):  179-80|"Product Information. MetroGel-Vaginal (metroNIDAZOLE topical)." Curatek Pharmaceuticals Ltd  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7770, 4905, 'Metronidazole (topical)', 'Alcoholism', 'Metronidazole may be systemically absorbed when applied to the skin or mucosal membranes.  A disulfiram-like reaction has been reported in patients who consume alcohol during treatment with oral metronidazole.  Symptoms include nausea, vomiting, flushing, sweating, headache, abdominal cramps, and hypotension.  Therapy with topical metronidazole should be administered cautiously in patients who might be prone to acute alcohol intake.  Patients should be instructed to avoid alcohol-containing products during therapy and for at least 48 hours after the last dose.', '2', 'Giannini AJ, DeFrance DT "Metronidazole and alcohol: potential for combinative abuse." J Toxicol Clin Toxicol 20 (1983):  509-15|Alexander I "Alcohol-antabuse syndrome in patients receiving metronidazole during gynaecological treatment." Br J Clin Pract 39 (1985):  292-3|Harries DP, Teale KF, Sunderland G "Metronidazole and alcohol: potential problems." Scott Med J 35 (1990):  179-80|"Product Information. MetroGel-Vaginal (metroNIDAZOLE topical)." Curatek Pharmaceuticals Ltd  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7771, 4906, 'Metronidazole (topical)', 'Alcoholism', 'Metronidazole may be systemically absorbed when applied to the skin or mucosal membranes.  A disulfiram-like reaction has been reported in patients who consume alcohol during treatment with oral metronidazole.  Symptoms include nausea, vomiting, flushing, sweating, headache, abdominal cramps, and hypotension.  Therapy with topical metronidazole should be administered cautiously in patients who might be prone to acute alcohol intake.  Patients should be instructed to avoid alcohol-containing products during therapy and for at least 48 hours after the last dose.', '2', 'Giannini AJ, DeFrance DT "Metronidazole and alcohol: potential for combinative abuse." J Toxicol Clin Toxicol 20 (1983):  509-15|Alexander I "Alcohol-antabuse syndrome in patients receiving metronidazole during gynaecological treatment." Br J Clin Pract 39 (1985):  292-3|Harries DP, Teale KF, Sunderland G "Metronidazole and alcohol: potential problems." Scott Med J 35 (1990):  179-80|"Product Information. MetroGel-Vaginal (metroNIDAZOLE topical)." Curatek Pharmaceuticals Ltd  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7772, 4930, 'Metronidazole (topical)', 'Alcoholism', 'Metronidazole may be systemically absorbed when applied to the skin or mucosal membranes.  A disulfiram-like reaction has been reported in patients who consume alcohol during treatment with oral metronidazole.  Symptoms include nausea, vomiting, flushing, sweating, headache, abdominal cramps, and hypotension.  Therapy with topical metronidazole should be administered cautiously in patients who might be prone to acute alcohol intake.  Patients should be instructed to avoid alcohol-containing products during therapy and for at least 48 hours after the last dose.', '2', 'Giannini AJ, DeFrance DT "Metronidazole and alcohol: potential for combinative abuse." J Toxicol Clin Toxicol 20 (1983):  509-15|Alexander I "Alcohol-antabuse syndrome in patients receiving metronidazole during gynaecological treatment." Br J Clin Pract 39 (1985):  292-3|Harries DP, Teale KF, Sunderland G "Metronidazole and alcohol: potential problems." Scott Med J 35 (1990):  179-80|"Product Information. MetroGel-Vaginal (metroNIDAZOLE topical)." Curatek Pharmaceuticals Ltd  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7773, 6077, 'Metronidazole (topical)', 'Alcoholism', 'Metronidazole may be systemically absorbed when applied to the skin or mucosal membranes.  A disulfiram-like reaction has been reported in patients who consume alcohol during treatment with oral metronidazole.  Symptoms include nausea, vomiting, flushing, sweating, headache, abdominal cramps, and hypotension.  Therapy with topical metronidazole should be administered cautiously in patients who might be prone to acute alcohol intake.  Patients should be instructed to avoid alcohol-containing products during therapy and for at least 48 hours after the last dose.', '2', 'Giannini AJ, DeFrance DT "Metronidazole and alcohol: potential for combinative abuse." J Toxicol Clin Toxicol 20 (1983):  509-15|Alexander I "Alcohol-antabuse syndrome in patients receiving metronidazole during gynaecological treatment." Br J Clin Pract 39 (1985):  292-3|Harries DP, Teale KF, Sunderland G "Metronidazole and alcohol: potential problems." Scott Med J 35 (1990):  179-80|"Product Information. MetroGel-Vaginal (metroNIDAZOLE topical)." Curatek Pharmaceuticals Ltd  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7774, 8101, 'Metronidazole (topical)', 'Alcoholism', 'Metronidazole may be systemically absorbed when applied to the skin or mucosal membranes.  A disulfiram-like reaction has been reported in patients who consume alcohol during treatment with oral metronidazole.  Symptoms include nausea, vomiting, flushing, sweating, headache, abdominal cramps, and hypotension.  Therapy with topical metronidazole should be administered cautiously in patients who might be prone to acute alcohol intake.  Patients should be instructed to avoid alcohol-containing products during therapy and for at least 48 hours after the last dose.', '2', 'Giannini AJ, DeFrance DT "Metronidazole and alcohol: potential for combinative abuse." J Toxicol Clin Toxicol 20 (1983):  509-15|Alexander I "Alcohol-antabuse syndrome in patients receiving metronidazole during gynaecological treatment." Br J Clin Pract 39 (1985):  292-3|Harries DP, Teale KF, Sunderland G "Metronidazole and alcohol: potential problems." Scott Med J 35 (1990):  179-80|"Product Information. MetroGel-Vaginal (metroNIDAZOLE topical)." Curatek Pharmaceuticals Ltd  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7775, 8102, 'Metronidazole (topical)', 'Alcoholism', 'Metronidazole may be systemically absorbed when applied to the skin or mucosal membranes.  A disulfiram-like reaction has been reported in patients who consume alcohol during treatment with oral metronidazole.  Symptoms include nausea, vomiting, flushing, sweating, headache, abdominal cramps, and hypotension.  Therapy with topical metronidazole should be administered cautiously in patients who might be prone to acute alcohol intake.  Patients should be instructed to avoid alcohol-containing products during therapy and for at least 48 hours after the last dose.', '2', 'Giannini AJ, DeFrance DT "Metronidazole and alcohol: potential for combinative abuse." J Toxicol Clin Toxicol 20 (1983):  509-15|Alexander I "Alcohol-antabuse syndrome in patients receiving metronidazole during gynaecological treatment." Br J Clin Pract 39 (1985):  292-3|Harries DP, Teale KF, Sunderland G "Metronidazole and alcohol: potential problems." Scott Med J 35 (1990):  179-80|"Product Information. MetroGel-Vaginal (metroNIDAZOLE topical)." Curatek Pharmaceuticals Ltd  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7776, 14075, 'Metronidazole (topical)', 'Alcoholism', 'Metronidazole may be systemically absorbed when applied to the skin or mucosal membranes.  A disulfiram-like reaction has been reported in patients who consume alcohol during treatment with oral metronidazole.  Symptoms include nausea, vomiting, flushing, sweating, headache, abdominal cramps, and hypotension.  Therapy with topical metronidazole should be administered cautiously in patients who might be prone to acute alcohol intake.  Patients should be instructed to avoid alcohol-containing products during therapy and for at least 48 hours after the last dose.', '2', 'Giannini AJ, DeFrance DT "Metronidazole and alcohol: potential for combinative abuse." J Toxicol Clin Toxicol 20 (1983):  509-15|Alexander I "Alcohol-antabuse syndrome in patients receiving metronidazole during gynaecological treatment." Br J Clin Pract 39 (1985):  292-3|Harries DP, Teale KF, Sunderland G "Metronidazole and alcohol: potential problems." Scott Med J 35 (1990):  179-80|"Product Information. MetroGel-Vaginal (metroNIDAZOLE topical)." Curatek Pharmaceuticals Ltd  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7777, 14076, 'Metronidazole (topical)', 'Alcoholism', 'Metronidazole may be systemically absorbed when applied to the skin or mucosal membranes.  A disulfiram-like reaction has been reported in patients who consume alcohol during treatment with oral metronidazole.  Symptoms include nausea, vomiting, flushing, sweating, headache, abdominal cramps, and hypotension.  Therapy with topical metronidazole should be administered cautiously in patients who might be prone to acute alcohol intake.  Patients should be instructed to avoid alcohol-containing products during therapy and for at least 48 hours after the last dose.', '2', 'Giannini AJ, DeFrance DT "Metronidazole and alcohol: potential for combinative abuse." J Toxicol Clin Toxicol 20 (1983):  509-15|Alexander I "Alcohol-antabuse syndrome in patients receiving metronidazole during gynaecological treatment." Br J Clin Pract 39 (1985):  292-3|Harries DP, Teale KF, Sunderland G "Metronidazole and alcohol: potential problems." Scott Med J 35 (1990):  179-80|"Product Information. MetroGel-Vaginal (metroNIDAZOLE topical)." Curatek Pharmaceuticals Ltd  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7778, 14080, 'Metronidazole (topical)', 'Alcoholism', 'Metronidazole may be systemically absorbed when applied to the skin or mucosal membranes.  A disulfiram-like reaction has been reported in patients who consume alcohol during treatment with oral metronidazole.  Symptoms include nausea, vomiting, flushing, sweating, headache, abdominal cramps, and hypotension.  Therapy with topical metronidazole should be administered cautiously in patients who might be prone to acute alcohol intake.  Patients should be instructed to avoid alcohol-containing products during therapy and for at least 48 hours after the last dose.', '2', 'Giannini AJ, DeFrance DT "Metronidazole and alcohol: potential for combinative abuse." J Toxicol Clin Toxicol 20 (1983):  509-15|Alexander I "Alcohol-antabuse syndrome in patients receiving metronidazole during gynaecological treatment." Br J Clin Pract 39 (1985):  292-3|Harries DP, Teale KF, Sunderland G "Metronidazole and alcohol: potential problems." Scott Med J 35 (1990):  179-80|"Product Information. MetroGel-Vaginal (metroNIDAZOLE topical)." Curatek Pharmaceuticals Ltd  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7779, 15559, 'Metronidazole (topical)', 'Alcoholism', 'Metronidazole may be systemically absorbed when applied to the skin or mucosal membranes.  A disulfiram-like reaction has been reported in patients who consume alcohol during treatment with oral metronidazole.  Symptoms include nausea, vomiting, flushing, sweating, headache, abdominal cramps, and hypotension.  Therapy with topical metronidazole should be administered cautiously in patients who might be prone to acute alcohol intake.  Patients should be instructed to avoid alcohol-containing products during therapy and for at least 48 hours after the last dose.', '2', 'Giannini AJ, DeFrance DT "Metronidazole and alcohol: potential for combinative abuse." J Toxicol Clin Toxicol 20 (1983):  509-15|Alexander I "Alcohol-antabuse syndrome in patients receiving metronidazole during gynaecological treatment." Br J Clin Pract 39 (1985):  292-3|Harries DP, Teale KF, Sunderland G "Metronidazole and alcohol: potential problems." Scott Med J 35 (1990):  179-80|"Product Information. MetroGel-Vaginal (metroNIDAZOLE topical)." Curatek Pharmaceuticals Ltd  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7780, 16787, 'Metronidazole (topical)', 'Alcoholism', 'Metronidazole may be systemically absorbed when applied to the skin or mucosal membranes.  A disulfiram-like reaction has been reported in patients who consume alcohol during treatment with oral metronidazole.  Symptoms include nausea, vomiting, flushing, sweating, headache, abdominal cramps, and hypotension.  Therapy with topical metronidazole should be administered cautiously in patients who might be prone to acute alcohol intake.  Patients should be instructed to avoid alcohol-containing products during therapy and for at least 48 hours after the last dose.', '2', 'Giannini AJ, DeFrance DT "Metronidazole and alcohol: potential for combinative abuse." J Toxicol Clin Toxicol 20 (1983):  509-15|Alexander I "Alcohol-antabuse syndrome in patients receiving metronidazole during gynaecological treatment." Br J Clin Pract 39 (1985):  292-3|Harries DP, Teale KF, Sunderland G "Metronidazole and alcohol: potential problems." Scott Med J 35 (1990):  179-80|"Product Information. MetroGel-Vaginal (metroNIDAZOLE topical)." Curatek Pharmaceuticals Ltd  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7781, 17956, 'Metronidazole (topical)', 'Alcoholism', 'Metronidazole may be systemically absorbed when applied to the skin or mucosal membranes.  A disulfiram-like reaction has been reported in patients who consume alcohol during treatment with oral metronidazole.  Symptoms include nausea, vomiting, flushing, sweating, headache, abdominal cramps, and hypotension.  Therapy with topical metronidazole should be administered cautiously in patients who might be prone to acute alcohol intake.  Patients should be instructed to avoid alcohol-containing products during therapy and for at least 48 hours after the last dose.', '2', 'Giannini AJ, DeFrance DT "Metronidazole and alcohol: potential for combinative abuse." J Toxicol Clin Toxicol 20 (1983):  509-15|Alexander I "Alcohol-antabuse syndrome in patients receiving metronidazole during gynaecological treatment." Br J Clin Pract 39 (1985):  292-3|Harries DP, Teale KF, Sunderland G "Metronidazole and alcohol: potential problems." Scott Med J 35 (1990):  179-80|"Product Information. MetroGel-Vaginal (metroNIDAZOLE topical)." Curatek Pharmaceuticals Ltd  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7782, 17957, 'Metronidazole (topical)', 'Alcoholism', 'Metronidazole may be systemically absorbed when applied to the skin or mucosal membranes.  A disulfiram-like reaction has been reported in patients who consume alcohol during treatment with oral metronidazole.  Symptoms include nausea, vomiting, flushing, sweating, headache, abdominal cramps, and hypotension.  Therapy with topical metronidazole should be administered cautiously in patients who might be prone to acute alcohol intake.  Patients should be instructed to avoid alcohol-containing products during therapy and for at least 48 hours after the last dose.', '2', 'Giannini AJ, DeFrance DT "Metronidazole and alcohol: potential for combinative abuse." J Toxicol Clin Toxicol 20 (1983):  509-15|Alexander I "Alcohol-antabuse syndrome in patients receiving metronidazole during gynaecological treatment." Br J Clin Pract 39 (1985):  292-3|Harries DP, Teale KF, Sunderland G "Metronidazole and alcohol: potential problems." Scott Med J 35 (1990):  179-80|"Product Information. MetroGel-Vaginal (metroNIDAZOLE topical)." Curatek Pharmaceuticals Ltd  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7783, 18347, 'Metronidazole (topical)', 'Alcoholism', 'Metronidazole may be systemically absorbed when applied to the skin or mucosal membranes.  A disulfiram-like reaction has been reported in patients who consume alcohol during treatment with oral metronidazole.  Symptoms include nausea, vomiting, flushing, sweating, headache, abdominal cramps, and hypotension.  Therapy with topical metronidazole should be administered cautiously in patients who might be prone to acute alcohol intake.  Patients should be instructed to avoid alcohol-containing products during therapy and for at least 48 hours after the last dose.', '2', 'Giannini AJ, DeFrance DT "Metronidazole and alcohol: potential for combinative abuse." J Toxicol Clin Toxicol 20 (1983):  509-15|Alexander I "Alcohol-antabuse syndrome in patients receiving metronidazole during gynaecological treatment." Br J Clin Pract 39 (1985):  292-3|Harries DP, Teale KF, Sunderland G "Metronidazole and alcohol: potential problems." Scott Med J 35 (1990):  179-80|"Product Information. MetroGel-Vaginal (metroNIDAZOLE topical)." Curatek Pharmaceuticals Ltd  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7784, 19075, 'Metronidazole (topical)', 'Alcoholism', 'Metronidazole may be systemically absorbed when applied to the skin or mucosal membranes.  A disulfiram-like reaction has been reported in patients who consume alcohol during treatment with oral metronidazole.  Symptoms include nausea, vomiting, flushing, sweating, headache, abdominal cramps, and hypotension.  Therapy with topical metronidazole should be administered cautiously in patients who might be prone to acute alcohol intake.  Patients should be instructed to avoid alcohol-containing products during therapy and for at least 48 hours after the last dose.', '2', 'Giannini AJ, DeFrance DT "Metronidazole and alcohol: potential for combinative abuse." J Toxicol Clin Toxicol 20 (1983):  509-15|Alexander I "Alcohol-antabuse syndrome in patients receiving metronidazole during gynaecological treatment." Br J Clin Pract 39 (1985):  292-3|Harries DP, Teale KF, Sunderland G "Metronidazole and alcohol: potential problems." Scott Med J 35 (1990):  179-80|"Product Information. MetroGel-Vaginal (metroNIDAZOLE topical)." Curatek Pharmaceuticals Ltd  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7785, 19077, 'Metronidazole (topical)', 'Alcoholism', 'Metronidazole may be systemically absorbed when applied to the skin or mucosal membranes.  A disulfiram-like reaction has been reported in patients who consume alcohol during treatment with oral metronidazole.  Symptoms include nausea, vomiting, flushing, sweating, headache, abdominal cramps, and hypotension.  Therapy with topical metronidazole should be administered cautiously in patients who might be prone to acute alcohol intake.  Patients should be instructed to avoid alcohol-containing products during therapy and for at least 48 hours after the last dose.', '2', 'Giannini AJ, DeFrance DT "Metronidazole and alcohol: potential for combinative abuse." J Toxicol Clin Toxicol 20 (1983):  509-15|Alexander I "Alcohol-antabuse syndrome in patients receiving metronidazole during gynaecological treatment." Br J Clin Pract 39 (1985):  292-3|Harries DP, Teale KF, Sunderland G "Metronidazole and alcohol: potential problems." Scott Med J 35 (1990):  179-80|"Product Information. MetroGel-Vaginal (metroNIDAZOLE topical)." Curatek Pharmaceuticals Ltd  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7786, 19078, 'Metronidazole (topical)', 'Alcoholism', 'Metronidazole may be systemically absorbed when applied to the skin or mucosal membranes.  A disulfiram-like reaction has been reported in patients who consume alcohol during treatment with oral metronidazole.  Symptoms include nausea, vomiting, flushing, sweating, headache, abdominal cramps, and hypotension.  Therapy with topical metronidazole should be administered cautiously in patients who might be prone to acute alcohol intake.  Patients should be instructed to avoid alcohol-containing products during therapy and for at least 48 hours after the last dose.', '2', 'Giannini AJ, DeFrance DT "Metronidazole and alcohol: potential for combinative abuse." J Toxicol Clin Toxicol 20 (1983):  509-15|Alexander I "Alcohol-antabuse syndrome in patients receiving metronidazole during gynaecological treatment." Br J Clin Pract 39 (1985):  292-3|Harries DP, Teale KF, Sunderland G "Metronidazole and alcohol: potential problems." Scott Med J 35 (1990):  179-80|"Product Information. MetroGel-Vaginal (metroNIDAZOLE topical)." Curatek Pharmaceuticals Ltd  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7787, 19079, 'Metronidazole (topical)', 'Alcoholism', 'Metronidazole may be systemically absorbed when applied to the skin or mucosal membranes.  A disulfiram-like reaction has been reported in patients who consume alcohol during treatment with oral metronidazole.  Symptoms include nausea, vomiting, flushing, sweating, headache, abdominal cramps, and hypotension.  Therapy with topical metronidazole should be administered cautiously in patients who might be prone to acute alcohol intake.  Patients should be instructed to avoid alcohol-containing products during therapy and for at least 48 hours after the last dose.', '2', 'Giannini AJ, DeFrance DT "Metronidazole and alcohol: potential for combinative abuse." J Toxicol Clin Toxicol 20 (1983):  509-15|Alexander I "Alcohol-antabuse syndrome in patients receiving metronidazole during gynaecological treatment." Br J Clin Pract 39 (1985):  292-3|Harries DP, Teale KF, Sunderland G "Metronidazole and alcohol: potential problems." Scott Med J 35 (1990):  179-80|"Product Information. MetroGel-Vaginal (metroNIDAZOLE topical)." Curatek Pharmaceuticals Ltd  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7788, 19085, 'Metronidazole (topical)', 'Alcoholism', 'Metronidazole may be systemically absorbed when applied to the skin or mucosal membranes.  A disulfiram-like reaction has been reported in patients who consume alcohol during treatment with oral metronidazole.  Symptoms include nausea, vomiting, flushing, sweating, headache, abdominal cramps, and hypotension.  Therapy with topical metronidazole should be administered cautiously in patients who might be prone to acute alcohol intake.  Patients should be instructed to avoid alcohol-containing products during therapy and for at least 48 hours after the last dose.', '2', 'Giannini AJ, DeFrance DT "Metronidazole and alcohol: potential for combinative abuse." J Toxicol Clin Toxicol 20 (1983):  509-15|Alexander I "Alcohol-antabuse syndrome in patients receiving metronidazole during gynaecological treatment." Br J Clin Pract 39 (1985):  292-3|Harries DP, Teale KF, Sunderland G "Metronidazole and alcohol: potential problems." Scott Med J 35 (1990):  179-80|"Product Information. MetroGel-Vaginal (metroNIDAZOLE topical)." Curatek Pharmaceuticals Ltd  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7789, 19630, 'Metronidazole (topical)', 'Alcoholism', 'Metronidazole may be systemically absorbed when applied to the skin or mucosal membranes.  A disulfiram-like reaction has been reported in patients who consume alcohol during treatment with oral metronidazole.  Symptoms include nausea, vomiting, flushing, sweating, headache, abdominal cramps, and hypotension.  Therapy with topical metronidazole should be administered cautiously in patients who might be prone to acute alcohol intake.  Patients should be instructed to avoid alcohol-containing products during therapy and for at least 48 hours after the last dose.', '2', 'Giannini AJ, DeFrance DT "Metronidazole and alcohol: potential for combinative abuse." J Toxicol Clin Toxicol 20 (1983):  509-15|Alexander I "Alcohol-antabuse syndrome in patients receiving metronidazole during gynaecological treatment." Br J Clin Pract 39 (1985):  292-3|Harries DP, Teale KF, Sunderland G "Metronidazole and alcohol: potential problems." Scott Med J 35 (1990):  179-80|"Product Information. MetroGel-Vaginal (metroNIDAZOLE topical)." Curatek Pharmaceuticals Ltd  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7790, 22672, 'Metronidazole (topical)', 'Alcoholism', 'Metronidazole may be systemically absorbed when applied to the skin or mucosal membranes.  A disulfiram-like reaction has been reported in patients who consume alcohol during treatment with oral metronidazole.  Symptoms include nausea, vomiting, flushing, sweating, headache, abdominal cramps, and hypotension.  Therapy with topical metronidazole should be administered cautiously in patients who might be prone to acute alcohol intake.  Patients should be instructed to avoid alcohol-containing products during therapy and for at least 48 hours after the last dose.', '2', 'Giannini AJ, DeFrance DT "Metronidazole and alcohol: potential for combinative abuse." J Toxicol Clin Toxicol 20 (1983):  509-15|Alexander I "Alcohol-antabuse syndrome in patients receiving metronidazole during gynaecological treatment." Br J Clin Pract 39 (1985):  292-3|Harries DP, Teale KF, Sunderland G "Metronidazole and alcohol: potential problems." Scott Med J 35 (1990):  179-80|"Product Information. MetroGel-Vaginal (metroNIDAZOLE topical)." Curatek Pharmaceuticals Ltd  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7791, 22676, 'Metronidazole (topical)', 'Alcoholism', 'Metronidazole may be systemically absorbed when applied to the skin or mucosal membranes.  A disulfiram-like reaction has been reported in patients who consume alcohol during treatment with oral metronidazole.  Symptoms include nausea, vomiting, flushing, sweating, headache, abdominal cramps, and hypotension.  Therapy with topical metronidazole should be administered cautiously in patients who might be prone to acute alcohol intake.  Patients should be instructed to avoid alcohol-containing products during therapy and for at least 48 hours after the last dose.', '2', 'Giannini AJ, DeFrance DT "Metronidazole and alcohol: potential for combinative abuse." J Toxicol Clin Toxicol 20 (1983):  509-15|Alexander I "Alcohol-antabuse syndrome in patients receiving metronidazole during gynaecological treatment." Br J Clin Pract 39 (1985):  292-3|Harries DP, Teale KF, Sunderland G "Metronidazole and alcohol: potential problems." Scott Med J 35 (1990):  179-80|"Product Information. MetroGel-Vaginal (metroNIDAZOLE topical)." Curatek Pharmaceuticals Ltd  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7792, 22677, 'Metronidazole (topical)', 'Alcoholism', 'Metronidazole may be systemically absorbed when applied to the skin or mucosal membranes.  A disulfiram-like reaction has been reported in patients who consume alcohol during treatment with oral metronidazole.  Symptoms include nausea, vomiting, flushing, sweating, headache, abdominal cramps, and hypotension.  Therapy with topical metronidazole should be administered cautiously in patients who might be prone to acute alcohol intake.  Patients should be instructed to avoid alcohol-containing products during therapy and for at least 48 hours after the last dose.', '2', 'Giannini AJ, DeFrance DT "Metronidazole and alcohol: potential for combinative abuse." J Toxicol Clin Toxicol 20 (1983):  509-15|Alexander I "Alcohol-antabuse syndrome in patients receiving metronidazole during gynaecological treatment." Br J Clin Pract 39 (1985):  292-3|Harries DP, Teale KF, Sunderland G "Metronidazole and alcohol: potential problems." Scott Med J 35 (1990):  179-80|"Product Information. MetroGel-Vaginal (metroNIDAZOLE topical)." Curatek Pharmaceuticals Ltd  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7793, 22679, 'Metronidazole (topical)', 'Alcoholism', 'Metronidazole may be systemically absorbed when applied to the skin or mucosal membranes.  A disulfiram-like reaction has been reported in patients who consume alcohol during treatment with oral metronidazole.  Symptoms include nausea, vomiting, flushing, sweating, headache, abdominal cramps, and hypotension.  Therapy with topical metronidazole should be administered cautiously in patients who might be prone to acute alcohol intake.  Patients should be instructed to avoid alcohol-containing products during therapy and for at least 48 hours after the last dose.', '2', 'Giannini AJ, DeFrance DT "Metronidazole and alcohol: potential for combinative abuse." J Toxicol Clin Toxicol 20 (1983):  509-15|Alexander I "Alcohol-antabuse syndrome in patients receiving metronidazole during gynaecological treatment." Br J Clin Pract 39 (1985):  292-3|Harries DP, Teale KF, Sunderland G "Metronidazole and alcohol: potential problems." Scott Med J 35 (1990):  179-80|"Product Information. MetroGel-Vaginal (metroNIDAZOLE topical)." Curatek Pharmaceuticals Ltd  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7794, 22680, 'Metronidazole (topical)', 'Alcoholism', 'Metronidazole may be systemically absorbed when applied to the skin or mucosal membranes.  A disulfiram-like reaction has been reported in patients who consume alcohol during treatment with oral metronidazole.  Symptoms include nausea, vomiting, flushing, sweating, headache, abdominal cramps, and hypotension.  Therapy with topical metronidazole should be administered cautiously in patients who might be prone to acute alcohol intake.  Patients should be instructed to avoid alcohol-containing products during therapy and for at least 48 hours after the last dose.', '2', 'Giannini AJ, DeFrance DT "Metronidazole and alcohol: potential for combinative abuse." J Toxicol Clin Toxicol 20 (1983):  509-15|Alexander I "Alcohol-antabuse syndrome in patients receiving metronidazole during gynaecological treatment." Br J Clin Pract 39 (1985):  292-3|Harries DP, Teale KF, Sunderland G "Metronidazole and alcohol: potential problems." Scott Med J 35 (1990):  179-80|"Product Information. MetroGel-Vaginal (metroNIDAZOLE topical)." Curatek Pharmaceuticals Ltd  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7795, 26297, 'Metronidazole (topical)', 'Alcoholism', 'Metronidazole may be systemically absorbed when applied to the skin or mucosal membranes.  A disulfiram-like reaction has been reported in patients who consume alcohol during treatment with oral metronidazole.  Symptoms include nausea, vomiting, flushing, sweating, headache, abdominal cramps, and hypotension.  Therapy with topical metronidazole should be administered cautiously in patients who might be prone to acute alcohol intake.  Patients should be instructed to avoid alcohol-containing products during therapy and for at least 48 hours after the last dose.', '2', 'Giannini AJ, DeFrance DT "Metronidazole and alcohol: potential for combinative abuse." J Toxicol Clin Toxicol 20 (1983):  509-15|Alexander I "Alcohol-antabuse syndrome in patients receiving metronidazole during gynaecological treatment." Br J Clin Pract 39 (1985):  292-3|Harries DP, Teale KF, Sunderland G "Metronidazole and alcohol: potential problems." Scott Med J 35 (1990):  179-80|"Product Information. MetroGel-Vaginal (metroNIDAZOLE topical)." Curatek Pharmaceuticals Ltd  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7796, 28488, 'Metronidazole (topical)', 'Alcoholism', 'Metronidazole may be systemically absorbed when applied to the skin or mucosal membranes.  A disulfiram-like reaction has been reported in patients who consume alcohol during treatment with oral metronidazole.  Symptoms include nausea, vomiting, flushing, sweating, headache, abdominal cramps, and hypotension.  Therapy with topical metronidazole should be administered cautiously in patients who might be prone to acute alcohol intake.  Patients should be instructed to avoid alcohol-containing products during therapy and for at least 48 hours after the last dose.', '2', 'Giannini AJ, DeFrance DT "Metronidazole and alcohol: potential for combinative abuse." J Toxicol Clin Toxicol 20 (1983):  509-15|Alexander I "Alcohol-antabuse syndrome in patients receiving metronidazole during gynaecological treatment." Br J Clin Pract 39 (1985):  292-3|Harries DP, Teale KF, Sunderland G "Metronidazole and alcohol: potential problems." Scott Med J 35 (1990):  179-80|"Product Information. MetroGel-Vaginal (metroNIDAZOLE topical)." Curatek Pharmaceuticals Ltd  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7797, 28489, 'Metronidazole (topical)', 'Alcoholism', 'Metronidazole may be systemically absorbed when applied to the skin or mucosal membranes.  A disulfiram-like reaction has been reported in patients who consume alcohol during treatment with oral metronidazole.  Symptoms include nausea, vomiting, flushing, sweating, headache, abdominal cramps, and hypotension.  Therapy with topical metronidazole should be administered cautiously in patients who might be prone to acute alcohol intake.  Patients should be instructed to avoid alcohol-containing products during therapy and for at least 48 hours after the last dose.', '2', 'Giannini AJ, DeFrance DT "Metronidazole and alcohol: potential for combinative abuse." J Toxicol Clin Toxicol 20 (1983):  509-15|Alexander I "Alcohol-antabuse syndrome in patients receiving metronidazole during gynaecological treatment." Br J Clin Pract 39 (1985):  292-3|Harries DP, Teale KF, Sunderland G "Metronidazole and alcohol: potential problems." Scott Med J 35 (1990):  179-80|"Product Information. MetroGel-Vaginal (metroNIDAZOLE topical)." Curatek Pharmaceuticals Ltd  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7798, 28490, 'Metronidazole (topical)', 'Alcoholism', 'Metronidazole may be systemically absorbed when applied to the skin or mucosal membranes.  A disulfiram-like reaction has been reported in patients who consume alcohol during treatment with oral metronidazole.  Symptoms include nausea, vomiting, flushing, sweating, headache, abdominal cramps, and hypotension.  Therapy with topical metronidazole should be administered cautiously in patients who might be prone to acute alcohol intake.  Patients should be instructed to avoid alcohol-containing products during therapy and for at least 48 hours after the last dose.', '2', 'Giannini AJ, DeFrance DT "Metronidazole and alcohol: potential for combinative abuse." J Toxicol Clin Toxicol 20 (1983):  509-15|Alexander I "Alcohol-antabuse syndrome in patients receiving metronidazole during gynaecological treatment." Br J Clin Pract 39 (1985):  292-3|Harries DP, Teale KF, Sunderland G "Metronidazole and alcohol: potential problems." Scott Med J 35 (1990):  179-80|"Product Information. MetroGel-Vaginal (metroNIDAZOLE topical)." Curatek Pharmaceuticals Ltd  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7799, 28491, 'Metronidazole (topical)', 'Alcoholism', 'Metronidazole may be systemically absorbed when applied to the skin or mucosal membranes.  A disulfiram-like reaction has been reported in patients who consume alcohol during treatment with oral metronidazole.  Symptoms include nausea, vomiting, flushing, sweating, headache, abdominal cramps, and hypotension.  Therapy with topical metronidazole should be administered cautiously in patients who might be prone to acute alcohol intake.  Patients should be instructed to avoid alcohol-containing products during therapy and for at least 48 hours after the last dose.', '2', 'Giannini AJ, DeFrance DT "Metronidazole and alcohol: potential for combinative abuse." J Toxicol Clin Toxicol 20 (1983):  509-15|Alexander I "Alcohol-antabuse syndrome in patients receiving metronidazole during gynaecological treatment." Br J Clin Pract 39 (1985):  292-3|Harries DP, Teale KF, Sunderland G "Metronidazole and alcohol: potential problems." Scott Med J 35 (1990):  179-80|"Product Information. MetroGel-Vaginal (metroNIDAZOLE topical)." Curatek Pharmaceuticals Ltd  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7800, 28492, 'Metronidazole (topical)', 'Alcoholism', 'Metronidazole may be systemically absorbed when applied to the skin or mucosal membranes.  A disulfiram-like reaction has been reported in patients who consume alcohol during treatment with oral metronidazole.  Symptoms include nausea, vomiting, flushing, sweating, headache, abdominal cramps, and hypotension.  Therapy with topical metronidazole should be administered cautiously in patients who might be prone to acute alcohol intake.  Patients should be instructed to avoid alcohol-containing products during therapy and for at least 48 hours after the last dose.', '2', 'Giannini AJ, DeFrance DT "Metronidazole and alcohol: potential for combinative abuse." J Toxicol Clin Toxicol 20 (1983):  509-15|Alexander I "Alcohol-antabuse syndrome in patients receiving metronidazole during gynaecological treatment." Br J Clin Pract 39 (1985):  292-3|Harries DP, Teale KF, Sunderland G "Metronidazole and alcohol: potential problems." Scott Med J 35 (1990):  179-80|"Product Information. MetroGel-Vaginal (metroNIDAZOLE topical)." Curatek Pharmaceuticals Ltd  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7801, 30008, 'Metronidazole (topical)', 'Alcoholism', 'Metronidazole may be systemically absorbed when applied to the skin or mucosal membranes.  A disulfiram-like reaction has been reported in patients who consume alcohol during treatment with oral metronidazole.  Symptoms include nausea, vomiting, flushing, sweating, headache, abdominal cramps, and hypotension.  Therapy with topical metronidazole should be administered cautiously in patients who might be prone to acute alcohol intake.  Patients should be instructed to avoid alcohol-containing products during therapy and for at least 48 hours after the last dose.', '2', 'Giannini AJ, DeFrance DT "Metronidazole and alcohol: potential for combinative abuse." J Toxicol Clin Toxicol 20 (1983):  509-15|Alexander I "Alcohol-antabuse syndrome in patients receiving metronidazole during gynaecological treatment." Br J Clin Pract 39 (1985):  292-3|Harries DP, Teale KF, Sunderland G "Metronidazole and alcohol: potential problems." Scott Med J 35 (1990):  179-80|"Product Information. MetroGel-Vaginal (metroNIDAZOLE topical)." Curatek Pharmaceuticals Ltd  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7802, 30543, 'Metronidazole (topical)', 'Alcoholism', 'Metronidazole may be systemically absorbed when applied to the skin or mucosal membranes.  A disulfiram-like reaction has been reported in patients who consume alcohol during treatment with oral metronidazole.  Symptoms include nausea, vomiting, flushing, sweating, headache, abdominal cramps, and hypotension.  Therapy with topical metronidazole should be administered cautiously in patients who might be prone to acute alcohol intake.  Patients should be instructed to avoid alcohol-containing products during therapy and for at least 48 hours after the last dose.', '2', 'Giannini AJ, DeFrance DT "Metronidazole and alcohol: potential for combinative abuse." J Toxicol Clin Toxicol 20 (1983):  509-15|Alexander I "Alcohol-antabuse syndrome in patients receiving metronidazole during gynaecological treatment." Br J Clin Pract 39 (1985):  292-3|Harries DP, Teale KF, Sunderland G "Metronidazole and alcohol: potential problems." Scott Med J 35 (1990):  179-80|"Product Information. MetroGel-Vaginal (metroNIDAZOLE topical)." Curatek Pharmaceuticals Ltd  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7803, 33203, 'Metronidazole (topical)', 'Alcoholism', 'Metronidazole may be systemically absorbed when applied to the skin or mucosal membranes.  A disulfiram-like reaction has been reported in patients who consume alcohol during treatment with oral metronidazole.  Symptoms include nausea, vomiting, flushing, sweating, headache, abdominal cramps, and hypotension.  Therapy with topical metronidazole should be administered cautiously in patients who might be prone to acute alcohol intake.  Patients should be instructed to avoid alcohol-containing products during therapy and for at least 48 hours after the last dose.', '2', 'Giannini AJ, DeFrance DT "Metronidazole and alcohol: potential for combinative abuse." J Toxicol Clin Toxicol 20 (1983):  509-15|Alexander I "Alcohol-antabuse syndrome in patients receiving metronidazole during gynaecological treatment." Br J Clin Pract 39 (1985):  292-3|Harries DP, Teale KF, Sunderland G "Metronidazole and alcohol: potential problems." Scott Med J 35 (1990):  179-80|"Product Information. MetroGel-Vaginal (metroNIDAZOLE topical)." Curatek Pharmaceuticals Ltd  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7804, 690, 'Metronidazole (topical)', 'Hematologic Diseases', 'Metronidazole may be systemically absorbed when applied to the skin or mucosal membranes.  The use of metronidazole has rarely been associated with hematologic adverse effects such as mild, transient leukopenia, thrombocytopenia, and bone marrow aplasia.  The manufacturers recommend that therapy with metronidazole be administered cautiously in patients with evidence of or a history of blood dyscrasias.', '2', 'Smith JA "Neutropenia associated with metronidazole therapy." Can Med Assoc J 123 (1980):  202|White CM, Price JJ, Hunt KM "Bone marrow aplasia associated with metronidazole." Br Med J 280 (1980):  647|"Product Information. MetroGel (metroNIDAZOLE topical)." Galderma Laboratories Inc  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7805, 691, 'Metronidazole (topical)', 'Hematologic Diseases', 'Metronidazole may be systemically absorbed when applied to the skin or mucosal membranes.  The use of metronidazole has rarely been associated with hematologic adverse effects such as mild, transient leukopenia, thrombocytopenia, and bone marrow aplasia.  The manufacturers recommend that therapy with metronidazole be administered cautiously in patients with evidence of or a history of blood dyscrasias.', '2', 'Smith JA "Neutropenia associated with metronidazole therapy." Can Med Assoc J 123 (1980):  202|White CM, Price JJ, Hunt KM "Bone marrow aplasia associated with metronidazole." Br Med J 280 (1980):  647|"Product Information. MetroGel (metroNIDAZOLE topical)." Galderma Laboratories Inc  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7806, 692, 'Metronidazole (topical)', 'Hematologic Diseases', 'Metronidazole may be systemically absorbed when applied to the skin or mucosal membranes.  The use of metronidazole has rarely been associated with hematologic adverse effects such as mild, transient leukopenia, thrombocytopenia, and bone marrow aplasia.  The manufacturers recommend that therapy with metronidazole be administered cautiously in patients with evidence of or a history of blood dyscrasias.', '2', 'Smith JA "Neutropenia associated with metronidazole therapy." Can Med Assoc J 123 (1980):  202|White CM, Price JJ, Hunt KM "Bone marrow aplasia associated with metronidazole." Br Med J 280 (1980):  647|"Product Information. MetroGel (metroNIDAZOLE topical)." Galderma Laboratories Inc  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7807, 4210, 'Metronidazole (topical)', 'Hematologic Diseases', 'Metronidazole may be systemically absorbed when applied to the skin or mucosal membranes.  The use of metronidazole has rarely been associated with hematologic adverse effects such as mild, transient leukopenia, thrombocytopenia, and bone marrow aplasia.  The manufacturers recommend that therapy with metronidazole be administered cautiously in patients with evidence of or a history of blood dyscrasias.', '2', 'Smith JA "Neutropenia associated with metronidazole therapy." Can Med Assoc J 123 (1980):  202|White CM, Price JJ, Hunt KM "Bone marrow aplasia associated with metronidazole." Br Med J 280 (1980):  647|"Product Information. MetroGel (metroNIDAZOLE topical)." Galderma Laboratories Inc  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7808, 4325, 'Metronidazole (topical)', 'Hematologic Diseases', 'Metronidazole may be systemically absorbed when applied to the skin or mucosal membranes.  The use of metronidazole has rarely been associated with hematologic adverse effects such as mild, transient leukopenia, thrombocytopenia, and bone marrow aplasia.  The manufacturers recommend that therapy with metronidazole be administered cautiously in patients with evidence of or a history of blood dyscrasias.', '2', 'Smith JA "Neutropenia associated with metronidazole therapy." Can Med Assoc J 123 (1980):  202|White CM, Price JJ, Hunt KM "Bone marrow aplasia associated with metronidazole." Br Med J 280 (1980):  647|"Product Information. MetroGel (metroNIDAZOLE topical)." Galderma Laboratories Inc  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7809, 4894, 'Metronidazole (topical)', 'Hematologic Diseases', 'Metronidazole may be systemically absorbed when applied to the skin or mucosal membranes.  The use of metronidazole has rarely been associated with hematologic adverse effects such as mild, transient leukopenia, thrombocytopenia, and bone marrow aplasia.  The manufacturers recommend that therapy with metronidazole be administered cautiously in patients with evidence of or a history of blood dyscrasias.', '2', 'Smith JA "Neutropenia associated with metronidazole therapy." Can Med Assoc J 123 (1980):  202|White CM, Price JJ, Hunt KM "Bone marrow aplasia associated with metronidazole." Br Med J 280 (1980):  647|"Product Information. MetroGel (metroNIDAZOLE topical)." Galderma Laboratories Inc  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7810, 4903, 'Metronidazole (topical)', 'Hematologic Diseases', 'Metronidazole may be systemically absorbed when applied to the skin or mucosal membranes.  The use of metronidazole has rarely been associated with hematologic adverse effects such as mild, transient leukopenia, thrombocytopenia, and bone marrow aplasia.  The manufacturers recommend that therapy with metronidazole be administered cautiously in patients with evidence of or a history of blood dyscrasias.', '2', 'Smith JA "Neutropenia associated with metronidazole therapy." Can Med Assoc J 123 (1980):  202|White CM, Price JJ, Hunt KM "Bone marrow aplasia associated with metronidazole." Br Med J 280 (1980):  647|"Product Information. MetroGel (metroNIDAZOLE topical)." Galderma Laboratories Inc  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7811, 4904, 'Metronidazole (topical)', 'Hematologic Diseases', 'Metronidazole may be systemically absorbed when applied to the skin or mucosal membranes.  The use of metronidazole has rarely been associated with hematologic adverse effects such as mild, transient leukopenia, thrombocytopenia, and bone marrow aplasia.  The manufacturers recommend that therapy with metronidazole be administered cautiously in patients with evidence of or a history of blood dyscrasias.', '2', 'Smith JA "Neutropenia associated with metronidazole therapy." Can Med Assoc J 123 (1980):  202|White CM, Price JJ, Hunt KM "Bone marrow aplasia associated with metronidazole." Br Med J 280 (1980):  647|"Product Information. MetroGel (metroNIDAZOLE topical)." Galderma Laboratories Inc  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7812, 4905, 'Metronidazole (topical)', 'Hematologic Diseases', 'Metronidazole may be systemically absorbed when applied to the skin or mucosal membranes.  The use of metronidazole has rarely been associated with hematologic adverse effects such as mild, transient leukopenia, thrombocytopenia, and bone marrow aplasia.  The manufacturers recommend that therapy with metronidazole be administered cautiously in patients with evidence of or a history of blood dyscrasias.', '2', 'Smith JA "Neutropenia associated with metronidazole therapy." Can Med Assoc J 123 (1980):  202|White CM, Price JJ, Hunt KM "Bone marrow aplasia associated with metronidazole." Br Med J 280 (1980):  647|"Product Information. MetroGel (metroNIDAZOLE topical)." Galderma Laboratories Inc  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7813, 4906, 'Metronidazole (topical)', 'Hematologic Diseases', 'Metronidazole may be systemically absorbed when applied to the skin or mucosal membranes.  The use of metronidazole has rarely been associated with hematologic adverse effects such as mild, transient leukopenia, thrombocytopenia, and bone marrow aplasia.  The manufacturers recommend that therapy with metronidazole be administered cautiously in patients with evidence of or a history of blood dyscrasias.', '2', 'Smith JA "Neutropenia associated with metronidazole therapy." Can Med Assoc J 123 (1980):  202|White CM, Price JJ, Hunt KM "Bone marrow aplasia associated with metronidazole." Br Med J 280 (1980):  647|"Product Information. MetroGel (metroNIDAZOLE topical)." Galderma Laboratories Inc  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7814, 4930, 'Metronidazole (topical)', 'Hematologic Diseases', 'Metronidazole may be systemically absorbed when applied to the skin or mucosal membranes.  The use of metronidazole has rarely been associated with hematologic adverse effects such as mild, transient leukopenia, thrombocytopenia, and bone marrow aplasia.  The manufacturers recommend that therapy with metronidazole be administered cautiously in patients with evidence of or a history of blood dyscrasias.', '2', 'Smith JA "Neutropenia associated with metronidazole therapy." Can Med Assoc J 123 (1980):  202|White CM, Price JJ, Hunt KM "Bone marrow aplasia associated with metronidazole." Br Med J 280 (1980):  647|"Product Information. MetroGel (metroNIDAZOLE topical)." Galderma Laboratories Inc  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7815, 6077, 'Metronidazole (topical)', 'Hematologic Diseases', 'Metronidazole may be systemically absorbed when applied to the skin or mucosal membranes.  The use of metronidazole has rarely been associated with hematologic adverse effects such as mild, transient leukopenia, thrombocytopenia, and bone marrow aplasia.  The manufacturers recommend that therapy with metronidazole be administered cautiously in patients with evidence of or a history of blood dyscrasias.', '2', 'Smith JA "Neutropenia associated with metronidazole therapy." Can Med Assoc J 123 (1980):  202|White CM, Price JJ, Hunt KM "Bone marrow aplasia associated with metronidazole." Br Med J 280 (1980):  647|"Product Information. MetroGel (metroNIDAZOLE topical)." Galderma Laboratories Inc  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7816, 8101, 'Metronidazole (topical)', 'Hematologic Diseases', 'Metronidazole may be systemically absorbed when applied to the skin or mucosal membranes.  The use of metronidazole has rarely been associated with hematologic adverse effects such as mild, transient leukopenia, thrombocytopenia, and bone marrow aplasia.  The manufacturers recommend that therapy with metronidazole be administered cautiously in patients with evidence of or a history of blood dyscrasias.', '2', 'Smith JA "Neutropenia associated with metronidazole therapy." Can Med Assoc J 123 (1980):  202|White CM, Price JJ, Hunt KM "Bone marrow aplasia associated with metronidazole." Br Med J 280 (1980):  647|"Product Information. MetroGel (metroNIDAZOLE topical)." Galderma Laboratories Inc  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7817, 8102, 'Metronidazole (topical)', 'Hematologic Diseases', 'Metronidazole may be systemically absorbed when applied to the skin or mucosal membranes.  The use of metronidazole has rarely been associated with hematologic adverse effects such as mild, transient leukopenia, thrombocytopenia, and bone marrow aplasia.  The manufacturers recommend that therapy with metronidazole be administered cautiously in patients with evidence of or a history of blood dyscrasias.', '2', 'Smith JA "Neutropenia associated with metronidazole therapy." Can Med Assoc J 123 (1980):  202|White CM, Price JJ, Hunt KM "Bone marrow aplasia associated with metronidazole." Br Med J 280 (1980):  647|"Product Information. MetroGel (metroNIDAZOLE topical)." Galderma Laboratories Inc  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7818, 14075, 'Metronidazole (topical)', 'Hematologic Diseases', 'Metronidazole may be systemically absorbed when applied to the skin or mucosal membranes.  The use of metronidazole has rarely been associated with hematologic adverse effects such as mild, transient leukopenia, thrombocytopenia, and bone marrow aplasia.  The manufacturers recommend that therapy with metronidazole be administered cautiously in patients with evidence of or a history of blood dyscrasias.', '2', 'Smith JA "Neutropenia associated with metronidazole therapy." Can Med Assoc J 123 (1980):  202|White CM, Price JJ, Hunt KM "Bone marrow aplasia associated with metronidazole." Br Med J 280 (1980):  647|"Product Information. MetroGel (metroNIDAZOLE topical)." Galderma Laboratories Inc  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7819, 14076, 'Metronidazole (topical)', 'Hematologic Diseases', 'Metronidazole may be systemically absorbed when applied to the skin or mucosal membranes.  The use of metronidazole has rarely been associated with hematologic adverse effects such as mild, transient leukopenia, thrombocytopenia, and bone marrow aplasia.  The manufacturers recommend that therapy with metronidazole be administered cautiously in patients with evidence of or a history of blood dyscrasias.', '2', 'Smith JA "Neutropenia associated with metronidazole therapy." Can Med Assoc J 123 (1980):  202|White CM, Price JJ, Hunt KM "Bone marrow aplasia associated with metronidazole." Br Med J 280 (1980):  647|"Product Information. MetroGel (metroNIDAZOLE topical)." Galderma Laboratories Inc  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7820, 14080, 'Metronidazole (topical)', 'Hematologic Diseases', 'Metronidazole may be systemically absorbed when applied to the skin or mucosal membranes.  The use of metronidazole has rarely been associated with hematologic adverse effects such as mild, transient leukopenia, thrombocytopenia, and bone marrow aplasia.  The manufacturers recommend that therapy with metronidazole be administered cautiously in patients with evidence of or a history of blood dyscrasias.', '2', 'Smith JA "Neutropenia associated with metronidazole therapy." Can Med Assoc J 123 (1980):  202|White CM, Price JJ, Hunt KM "Bone marrow aplasia associated with metronidazole." Br Med J 280 (1980):  647|"Product Information. MetroGel (metroNIDAZOLE topical)." Galderma Laboratories Inc  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7821, 15559, 'Metronidazole (topical)', 'Hematologic Diseases', 'Metronidazole may be systemically absorbed when applied to the skin or mucosal membranes.  The use of metronidazole has rarely been associated with hematologic adverse effects such as mild, transient leukopenia, thrombocytopenia, and bone marrow aplasia.  The manufacturers recommend that therapy with metronidazole be administered cautiously in patients with evidence of or a history of blood dyscrasias.', '2', 'Smith JA "Neutropenia associated with metronidazole therapy." Can Med Assoc J 123 (1980):  202|White CM, Price JJ, Hunt KM "Bone marrow aplasia associated with metronidazole." Br Med J 280 (1980):  647|"Product Information. MetroGel (metroNIDAZOLE topical)." Galderma Laboratories Inc  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7822, 16787, 'Metronidazole (topical)', 'Hematologic Diseases', 'Metronidazole may be systemically absorbed when applied to the skin or mucosal membranes.  The use of metronidazole has rarely been associated with hematologic adverse effects such as mild, transient leukopenia, thrombocytopenia, and bone marrow aplasia.  The manufacturers recommend that therapy with metronidazole be administered cautiously in patients with evidence of or a history of blood dyscrasias.', '2', 'Smith JA "Neutropenia associated with metronidazole therapy." Can Med Assoc J 123 (1980):  202|White CM, Price JJ, Hunt KM "Bone marrow aplasia associated with metronidazole." Br Med J 280 (1980):  647|"Product Information. MetroGel (metroNIDAZOLE topical)." Galderma Laboratories Inc  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7823, 17956, 'Metronidazole (topical)', 'Hematologic Diseases', 'Metronidazole may be systemically absorbed when applied to the skin or mucosal membranes.  The use of metronidazole has rarely been associated with hematologic adverse effects such as mild, transient leukopenia, thrombocytopenia, and bone marrow aplasia.  The manufacturers recommend that therapy with metronidazole be administered cautiously in patients with evidence of or a history of blood dyscrasias.', '2', 'Smith JA "Neutropenia associated with metronidazole therapy." Can Med Assoc J 123 (1980):  202|White CM, Price JJ, Hunt KM "Bone marrow aplasia associated with metronidazole." Br Med J 280 (1980):  647|"Product Information. MetroGel (metroNIDAZOLE topical)." Galderma Laboratories Inc  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7824, 17957, 'Metronidazole (topical)', 'Hematologic Diseases', 'Metronidazole may be systemically absorbed when applied to the skin or mucosal membranes.  The use of metronidazole has rarely been associated with hematologic adverse effects such as mild, transient leukopenia, thrombocytopenia, and bone marrow aplasia.  The manufacturers recommend that therapy with metronidazole be administered cautiously in patients with evidence of or a history of blood dyscrasias.', '2', 'Smith JA "Neutropenia associated with metronidazole therapy." Can Med Assoc J 123 (1980):  202|White CM, Price JJ, Hunt KM "Bone marrow aplasia associated with metronidazole." Br Med J 280 (1980):  647|"Product Information. MetroGel (metroNIDAZOLE topical)." Galderma Laboratories Inc  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7825, 18347, 'Metronidazole (topical)', 'Hematologic Diseases', 'Metronidazole may be systemically absorbed when applied to the skin or mucosal membranes.  The use of metronidazole has rarely been associated with hematologic adverse effects such as mild, transient leukopenia, thrombocytopenia, and bone marrow aplasia.  The manufacturers recommend that therapy with metronidazole be administered cautiously in patients with evidence of or a history of blood dyscrasias.', '2', 'Smith JA "Neutropenia associated with metronidazole therapy." Can Med Assoc J 123 (1980):  202|White CM, Price JJ, Hunt KM "Bone marrow aplasia associated with metronidazole." Br Med J 280 (1980):  647|"Product Information. MetroGel (metroNIDAZOLE topical)." Galderma Laboratories Inc  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7826, 19075, 'Metronidazole (topical)', 'Hematologic Diseases', 'Metronidazole may be systemically absorbed when applied to the skin or mucosal membranes.  The use of metronidazole has rarely been associated with hematologic adverse effects such as mild, transient leukopenia, thrombocytopenia, and bone marrow aplasia.  The manufacturers recommend that therapy with metronidazole be administered cautiously in patients with evidence of or a history of blood dyscrasias.', '2', 'Smith JA "Neutropenia associated with metronidazole therapy." Can Med Assoc J 123 (1980):  202|White CM, Price JJ, Hunt KM "Bone marrow aplasia associated with metronidazole." Br Med J 280 (1980):  647|"Product Information. MetroGel (metroNIDAZOLE topical)." Galderma Laboratories Inc  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7827, 19077, 'Metronidazole (topical)', 'Hematologic Diseases', 'Metronidazole may be systemically absorbed when applied to the skin or mucosal membranes.  The use of metronidazole has rarely been associated with hematologic adverse effects such as mild, transient leukopenia, thrombocytopenia, and bone marrow aplasia.  The manufacturers recommend that therapy with metronidazole be administered cautiously in patients with evidence of or a history of blood dyscrasias.', '2', 'Smith JA "Neutropenia associated with metronidazole therapy." Can Med Assoc J 123 (1980):  202|White CM, Price JJ, Hunt KM "Bone marrow aplasia associated with metronidazole." Br Med J 280 (1980):  647|"Product Information. MetroGel (metroNIDAZOLE topical)." Galderma Laboratories Inc  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7828, 19078, 'Metronidazole (topical)', 'Hematologic Diseases', 'Metronidazole may be systemically absorbed when applied to the skin or mucosal membranes.  The use of metronidazole has rarely been associated with hematologic adverse effects such as mild, transient leukopenia, thrombocytopenia, and bone marrow aplasia.  The manufacturers recommend that therapy with metronidazole be administered cautiously in patients with evidence of or a history of blood dyscrasias.', '2', 'Smith JA "Neutropenia associated with metronidazole therapy." Can Med Assoc J 123 (1980):  202|White CM, Price JJ, Hunt KM "Bone marrow aplasia associated with metronidazole." Br Med J 280 (1980):  647|"Product Information. MetroGel (metroNIDAZOLE topical)." Galderma Laboratories Inc  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7829, 19079, 'Metronidazole (topical)', 'Hematologic Diseases', 'Metronidazole may be systemically absorbed when applied to the skin or mucosal membranes.  The use of metronidazole has rarely been associated with hematologic adverse effects such as mild, transient leukopenia, thrombocytopenia, and bone marrow aplasia.  The manufacturers recommend that therapy with metronidazole be administered cautiously in patients with evidence of or a history of blood dyscrasias.', '2', 'Smith JA "Neutropenia associated with metronidazole therapy." Can Med Assoc J 123 (1980):  202|White CM, Price JJ, Hunt KM "Bone marrow aplasia associated with metronidazole." Br Med J 280 (1980):  647|"Product Information. MetroGel (metroNIDAZOLE topical)." Galderma Laboratories Inc  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7830, 19085, 'Metronidazole (topical)', 'Hematologic Diseases', 'Metronidazole may be systemically absorbed when applied to the skin or mucosal membranes.  The use of metronidazole has rarely been associated with hematologic adverse effects such as mild, transient leukopenia, thrombocytopenia, and bone marrow aplasia.  The manufacturers recommend that therapy with metronidazole be administered cautiously in patients with evidence of or a history of blood dyscrasias.', '2', 'Smith JA "Neutropenia associated with metronidazole therapy." Can Med Assoc J 123 (1980):  202|White CM, Price JJ, Hunt KM "Bone marrow aplasia associated with metronidazole." Br Med J 280 (1980):  647|"Product Information. MetroGel (metroNIDAZOLE topical)." Galderma Laboratories Inc  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7831, 19630, 'Metronidazole (topical)', 'Hematologic Diseases', 'Metronidazole may be systemically absorbed when applied to the skin or mucosal membranes.  The use of metronidazole has rarely been associated with hematologic adverse effects such as mild, transient leukopenia, thrombocytopenia, and bone marrow aplasia.  The manufacturers recommend that therapy with metronidazole be administered cautiously in patients with evidence of or a history of blood dyscrasias.', '2', 'Smith JA "Neutropenia associated with metronidazole therapy." Can Med Assoc J 123 (1980):  202|White CM, Price JJ, Hunt KM "Bone marrow aplasia associated with metronidazole." Br Med J 280 (1980):  647|"Product Information. MetroGel (metroNIDAZOLE topical)." Galderma Laboratories Inc  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7832, 22672, 'Metronidazole (topical)', 'Hematologic Diseases', 'Metronidazole may be systemically absorbed when applied to the skin or mucosal membranes.  The use of metronidazole has rarely been associated with hematologic adverse effects such as mild, transient leukopenia, thrombocytopenia, and bone marrow aplasia.  The manufacturers recommend that therapy with metronidazole be administered cautiously in patients with evidence of or a history of blood dyscrasias.', '2', 'Smith JA "Neutropenia associated with metronidazole therapy." Can Med Assoc J 123 (1980):  202|White CM, Price JJ, Hunt KM "Bone marrow aplasia associated with metronidazole." Br Med J 280 (1980):  647|"Product Information. MetroGel (metroNIDAZOLE topical)." Galderma Laboratories Inc  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7833, 22676, 'Metronidazole (topical)', 'Hematologic Diseases', 'Metronidazole may be systemically absorbed when applied to the skin or mucosal membranes.  The use of metronidazole has rarely been associated with hematologic adverse effects such as mild, transient leukopenia, thrombocytopenia, and bone marrow aplasia.  The manufacturers recommend that therapy with metronidazole be administered cautiously in patients with evidence of or a history of blood dyscrasias.', '2', 'Smith JA "Neutropenia associated with metronidazole therapy." Can Med Assoc J 123 (1980):  202|White CM, Price JJ, Hunt KM "Bone marrow aplasia associated with metronidazole." Br Med J 280 (1980):  647|"Product Information. MetroGel (metroNIDAZOLE topical)." Galderma Laboratories Inc  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7834, 22677, 'Metronidazole (topical)', 'Hematologic Diseases', 'Metronidazole may be systemically absorbed when applied to the skin or mucosal membranes.  The use of metronidazole has rarely been associated with hematologic adverse effects such as mild, transient leukopenia, thrombocytopenia, and bone marrow aplasia.  The manufacturers recommend that therapy with metronidazole be administered cautiously in patients with evidence of or a history of blood dyscrasias.', '2', 'Smith JA "Neutropenia associated with metronidazole therapy." Can Med Assoc J 123 (1980):  202|White CM, Price JJ, Hunt KM "Bone marrow aplasia associated with metronidazole." Br Med J 280 (1980):  647|"Product Information. MetroGel (metroNIDAZOLE topical)." Galderma Laboratories Inc  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7835, 22679, 'Metronidazole (topical)', 'Hematologic Diseases', 'Metronidazole may be systemically absorbed when applied to the skin or mucosal membranes.  The use of metronidazole has rarely been associated with hematologic adverse effects such as mild, transient leukopenia, thrombocytopenia, and bone marrow aplasia.  The manufacturers recommend that therapy with metronidazole be administered cautiously in patients with evidence of or a history of blood dyscrasias.', '2', 'Smith JA "Neutropenia associated with metronidazole therapy." Can Med Assoc J 123 (1980):  202|White CM, Price JJ, Hunt KM "Bone marrow aplasia associated with metronidazole." Br Med J 280 (1980):  647|"Product Information. MetroGel (metroNIDAZOLE topical)." Galderma Laboratories Inc  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7836, 22680, 'Metronidazole (topical)', 'Hematologic Diseases', 'Metronidazole may be systemically absorbed when applied to the skin or mucosal membranes.  The use of metronidazole has rarely been associated with hematologic adverse effects such as mild, transient leukopenia, thrombocytopenia, and bone marrow aplasia.  The manufacturers recommend that therapy with metronidazole be administered cautiously in patients with evidence of or a history of blood dyscrasias.', '2', 'Smith JA "Neutropenia associated with metronidazole therapy." Can Med Assoc J 123 (1980):  202|White CM, Price JJ, Hunt KM "Bone marrow aplasia associated with metronidazole." Br Med J 280 (1980):  647|"Product Information. MetroGel (metroNIDAZOLE topical)." Galderma Laboratories Inc  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7837, 26297, 'Metronidazole (topical)', 'Hematologic Diseases', 'Metronidazole may be systemically absorbed when applied to the skin or mucosal membranes.  The use of metronidazole has rarely been associated with hematologic adverse effects such as mild, transient leukopenia, thrombocytopenia, and bone marrow aplasia.  The manufacturers recommend that therapy with metronidazole be administered cautiously in patients with evidence of or a history of blood dyscrasias.', '2', 'Smith JA "Neutropenia associated with metronidazole therapy." Can Med Assoc J 123 (1980):  202|White CM, Price JJ, Hunt KM "Bone marrow aplasia associated with metronidazole." Br Med J 280 (1980):  647|"Product Information. MetroGel (metroNIDAZOLE topical)." Galderma Laboratories Inc  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7838, 28488, 'Metronidazole (topical)', 'Hematologic Diseases', 'Metronidazole may be systemically absorbed when applied to the skin or mucosal membranes.  The use of metronidazole has rarely been associated with hematologic adverse effects such as mild, transient leukopenia, thrombocytopenia, and bone marrow aplasia.  The manufacturers recommend that therapy with metronidazole be administered cautiously in patients with evidence of or a history of blood dyscrasias.', '2', 'Smith JA "Neutropenia associated with metronidazole therapy." Can Med Assoc J 123 (1980):  202|White CM, Price JJ, Hunt KM "Bone marrow aplasia associated with metronidazole." Br Med J 280 (1980):  647|"Product Information. MetroGel (metroNIDAZOLE topical)." Galderma Laboratories Inc  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7839, 28489, 'Metronidazole (topical)', 'Hematologic Diseases', 'Metronidazole may be systemically absorbed when applied to the skin or mucosal membranes.  The use of metronidazole has rarely been associated with hematologic adverse effects such as mild, transient leukopenia, thrombocytopenia, and bone marrow aplasia.  The manufacturers recommend that therapy with metronidazole be administered cautiously in patients with evidence of or a history of blood dyscrasias.', '2', 'Smith JA "Neutropenia associated with metronidazole therapy." Can Med Assoc J 123 (1980):  202|White CM, Price JJ, Hunt KM "Bone marrow aplasia associated with metronidazole." Br Med J 280 (1980):  647|"Product Information. MetroGel (metroNIDAZOLE topical)." Galderma Laboratories Inc  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7840, 28490, 'Metronidazole (topical)', 'Hematologic Diseases', 'Metronidazole may be systemically absorbed when applied to the skin or mucosal membranes.  The use of metronidazole has rarely been associated with hematologic adverse effects such as mild, transient leukopenia, thrombocytopenia, and bone marrow aplasia.  The manufacturers recommend that therapy with metronidazole be administered cautiously in patients with evidence of or a history of blood dyscrasias.', '2', 'Smith JA "Neutropenia associated with metronidazole therapy." Can Med Assoc J 123 (1980):  202|White CM, Price JJ, Hunt KM "Bone marrow aplasia associated with metronidazole." Br Med J 280 (1980):  647|"Product Information. MetroGel (metroNIDAZOLE topical)." Galderma Laboratories Inc  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7841, 28491, 'Metronidazole (topical)', 'Hematologic Diseases', 'Metronidazole may be systemically absorbed when applied to the skin or mucosal membranes.  The use of metronidazole has rarely been associated with hematologic adverse effects such as mild, transient leukopenia, thrombocytopenia, and bone marrow aplasia.  The manufacturers recommend that therapy with metronidazole be administered cautiously in patients with evidence of or a history of blood dyscrasias.', '2', 'Smith JA "Neutropenia associated with metronidazole therapy." Can Med Assoc J 123 (1980):  202|White CM, Price JJ, Hunt KM "Bone marrow aplasia associated with metronidazole." Br Med J 280 (1980):  647|"Product Information. MetroGel (metroNIDAZOLE topical)." Galderma Laboratories Inc  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7842, 28492, 'Metronidazole (topical)', 'Hematologic Diseases', 'Metronidazole may be systemically absorbed when applied to the skin or mucosal membranes.  The use of metronidazole has rarely been associated with hematologic adverse effects such as mild, transient leukopenia, thrombocytopenia, and bone marrow aplasia.  The manufacturers recommend that therapy with metronidazole be administered cautiously in patients with evidence of or a history of blood dyscrasias.', '2', 'Smith JA "Neutropenia associated with metronidazole therapy." Can Med Assoc J 123 (1980):  202|White CM, Price JJ, Hunt KM "Bone marrow aplasia associated with metronidazole." Br Med J 280 (1980):  647|"Product Information. MetroGel (metroNIDAZOLE topical)." Galderma Laboratories Inc  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7843, 30008, 'Metronidazole (topical)', 'Hematologic Diseases', 'Metronidazole may be systemically absorbed when applied to the skin or mucosal membranes.  The use of metronidazole has rarely been associated with hematologic adverse effects such as mild, transient leukopenia, thrombocytopenia, and bone marrow aplasia.  The manufacturers recommend that therapy with metronidazole be administered cautiously in patients with evidence of or a history of blood dyscrasias.', '2', 'Smith JA "Neutropenia associated with metronidazole therapy." Can Med Assoc J 123 (1980):  202|White CM, Price JJ, Hunt KM "Bone marrow aplasia associated with metronidazole." Br Med J 280 (1980):  647|"Product Information. MetroGel (metroNIDAZOLE topical)." Galderma Laboratories Inc  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7844, 30543, 'Metronidazole (topical)', 'Hematologic Diseases', 'Metronidazole may be systemically absorbed when applied to the skin or mucosal membranes.  The use of metronidazole has rarely been associated with hematologic adverse effects such as mild, transient leukopenia, thrombocytopenia, and bone marrow aplasia.  The manufacturers recommend that therapy with metronidazole be administered cautiously in patients with evidence of or a history of blood dyscrasias.', '2', 'Smith JA "Neutropenia associated with metronidazole therapy." Can Med Assoc J 123 (1980):  202|White CM, Price JJ, Hunt KM "Bone marrow aplasia associated with metronidazole." Br Med J 280 (1980):  647|"Product Information. MetroGel (metroNIDAZOLE topical)." Galderma Laboratories Inc  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7845, 33203, 'Metronidazole (topical)', 'Hematologic Diseases', 'Metronidazole may be systemically absorbed when applied to the skin or mucosal membranes.  The use of metronidazole has rarely been associated with hematologic adverse effects such as mild, transient leukopenia, thrombocytopenia, and bone marrow aplasia.  The manufacturers recommend that therapy with metronidazole be administered cautiously in patients with evidence of or a history of blood dyscrasias.', '2', 'Smith JA "Neutropenia associated with metronidazole therapy." Can Med Assoc J 123 (1980):  202|White CM, Price JJ, Hunt KM "Bone marrow aplasia associated with metronidazole." Br Med J 280 (1980):  647|"Product Information. MetroGel (metroNIDAZOLE topical)." Galderma Laboratories Inc  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7846, 690, 'Metronidazole (topical)', 'Liver Diseases', 'Metronidazole may be systemically absorbed when applied to the skin or mucosal membranes.  Once absorbed, metronidazole is extensively metabolized by the liver to both pharmacologically active and inactive compounds.  The plasma clearance of metronidazole may be decreased and the half-life prolonged in patients with impaired hepatic function.  Therapy with topical metronidazole should be administered cautiously in patients with liver disease.', '2', 'Lau AH, Evans R, Chang CW, Seligsohn R "Pharmacokinetics of metronidazole in patients with alcoholic liver disease." Antimicrob Agents Chemother 31 (1987):  1662-4|Jensen JC, Gugler R "Single- and multiple-dose metronidazole kinetics." Clin Pharmacol Ther 34 (1983):  481-7|Farrell G, Baird-Lambert J, Cvejic M, Buchanan N "Disposition and metabolism of metronidazole in patients with liver failure." Hepatology 4 (1984):  772-6|Loft S, Dossing M, Poulsen HE, et al. "Influence of dose and route of administration on disposition of metronidazole and its major metabolites." Eur J Clin Pharmacol 30 (1986):  467-73|Loft S, Sonne J, Dossing M, Andreasen PB "Metronidazole pharmacokinetics in patients with hepatic encephalopathy." Scand J Gastroenterol 22 (1987):  117-23|"Product Information. MetroGel-Vaginal (metroNIDAZOLE topical)." Curatek Pharmaceuticals Ltd  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7847, 691, 'Metronidazole (topical)', 'Liver Diseases', 'Metronidazole may be systemically absorbed when applied to the skin or mucosal membranes.  Once absorbed, metronidazole is extensively metabolized by the liver to both pharmacologically active and inactive compounds.  The plasma clearance of metronidazole may be decreased and the half-life prolonged in patients with impaired hepatic function.  Therapy with topical metronidazole should be administered cautiously in patients with liver disease.', '2', 'Lau AH, Evans R, Chang CW, Seligsohn R "Pharmacokinetics of metronidazole in patients with alcoholic liver disease." Antimicrob Agents Chemother 31 (1987):  1662-4|Jensen JC, Gugler R "Single- and multiple-dose metronidazole kinetics." Clin Pharmacol Ther 34 (1983):  481-7|Farrell G, Baird-Lambert J, Cvejic M, Buchanan N "Disposition and metabolism of metronidazole in patients with liver failure." Hepatology 4 (1984):  772-6|Loft S, Dossing M, Poulsen HE, et al. "Influence of dose and route of administration on disposition of metronidazole and its major metabolites." Eur J Clin Pharmacol 30 (1986):  467-73|Loft S, Sonne J, Dossing M, Andreasen PB "Metronidazole pharmacokinetics in patients with hepatic encephalopathy." Scand J Gastroenterol 22 (1987):  117-23|"Product Information. MetroGel-Vaginal (metroNIDAZOLE topical)." Curatek Pharmaceuticals Ltd  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7848, 692, 'Metronidazole (topical)', 'Liver Diseases', 'Metronidazole may be systemically absorbed when applied to the skin or mucosal membranes.  Once absorbed, metronidazole is extensively metabolized by the liver to both pharmacologically active and inactive compounds.  The plasma clearance of metronidazole may be decreased and the half-life prolonged in patients with impaired hepatic function.  Therapy with topical metronidazole should be administered cautiously in patients with liver disease.', '2', 'Lau AH, Evans R, Chang CW, Seligsohn R "Pharmacokinetics of metronidazole in patients with alcoholic liver disease." Antimicrob Agents Chemother 31 (1987):  1662-4|Jensen JC, Gugler R "Single- and multiple-dose metronidazole kinetics." Clin Pharmacol Ther 34 (1983):  481-7|Farrell G, Baird-Lambert J, Cvejic M, Buchanan N "Disposition and metabolism of metronidazole in patients with liver failure." Hepatology 4 (1984):  772-6|Loft S, Dossing M, Poulsen HE, et al. "Influence of dose and route of administration on disposition of metronidazole and its major metabolites." Eur J Clin Pharmacol 30 (1986):  467-73|Loft S, Sonne J, Dossing M, Andreasen PB "Metronidazole pharmacokinetics in patients with hepatic encephalopathy." Scand J Gastroenterol 22 (1987):  117-23|"Product Information. MetroGel-Vaginal (metroNIDAZOLE topical)." Curatek Pharmaceuticals Ltd  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7849, 4210, 'Metronidazole (topical)', 'Liver Diseases', 'Metronidazole may be systemically absorbed when applied to the skin or mucosal membranes.  Once absorbed, metronidazole is extensively metabolized by the liver to both pharmacologically active and inactive compounds.  The plasma clearance of metronidazole may be decreased and the half-life prolonged in patients with impaired hepatic function.  Therapy with topical metronidazole should be administered cautiously in patients with liver disease.', '2', 'Lau AH, Evans R, Chang CW, Seligsohn R "Pharmacokinetics of metronidazole in patients with alcoholic liver disease." Antimicrob Agents Chemother 31 (1987):  1662-4|Jensen JC, Gugler R "Single- and multiple-dose metronidazole kinetics." Clin Pharmacol Ther 34 (1983):  481-7|Farrell G, Baird-Lambert J, Cvejic M, Buchanan N "Disposition and metabolism of metronidazole in patients with liver failure." Hepatology 4 (1984):  772-6|Loft S, Dossing M, Poulsen HE, et al. "Influence of dose and route of administration on disposition of metronidazole and its major metabolites." Eur J Clin Pharmacol 30 (1986):  467-73|Loft S, Sonne J, Dossing M, Andreasen PB "Metronidazole pharmacokinetics in patients with hepatic encephalopathy." Scand J Gastroenterol 22 (1987):  117-23|"Product Information. MetroGel-Vaginal (metroNIDAZOLE topical)." Curatek Pharmaceuticals Ltd  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7850, 4325, 'Metronidazole (topical)', 'Liver Diseases', 'Metronidazole may be systemically absorbed when applied to the skin or mucosal membranes.  Once absorbed, metronidazole is extensively metabolized by the liver to both pharmacologically active and inactive compounds.  The plasma clearance of metronidazole may be decreased and the half-life prolonged in patients with impaired hepatic function.  Therapy with topical metronidazole should be administered cautiously in patients with liver disease.', '2', 'Lau AH, Evans R, Chang CW, Seligsohn R "Pharmacokinetics of metronidazole in patients with alcoholic liver disease." Antimicrob Agents Chemother 31 (1987):  1662-4|Jensen JC, Gugler R "Single- and multiple-dose metronidazole kinetics." Clin Pharmacol Ther 34 (1983):  481-7|Farrell G, Baird-Lambert J, Cvejic M, Buchanan N "Disposition and metabolism of metronidazole in patients with liver failure." Hepatology 4 (1984):  772-6|Loft S, Dossing M, Poulsen HE, et al. "Influence of dose and route of administration on disposition of metronidazole and its major metabolites." Eur J Clin Pharmacol 30 (1986):  467-73|Loft S, Sonne J, Dossing M, Andreasen PB "Metronidazole pharmacokinetics in patients with hepatic encephalopathy." Scand J Gastroenterol 22 (1987):  117-23|"Product Information. MetroGel-Vaginal (metroNIDAZOLE topical)." Curatek Pharmaceuticals Ltd  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7851, 4894, 'Metronidazole (topical)', 'Liver Diseases', 'Metronidazole may be systemically absorbed when applied to the skin or mucosal membranes.  Once absorbed, metronidazole is extensively metabolized by the liver to both pharmacologically active and inactive compounds.  The plasma clearance of metronidazole may be decreased and the half-life prolonged in patients with impaired hepatic function.  Therapy with topical metronidazole should be administered cautiously in patients with liver disease.', '2', 'Lau AH, Evans R, Chang CW, Seligsohn R "Pharmacokinetics of metronidazole in patients with alcoholic liver disease." Antimicrob Agents Chemother 31 (1987):  1662-4|Jensen JC, Gugler R "Single- and multiple-dose metronidazole kinetics." Clin Pharmacol Ther 34 (1983):  481-7|Farrell G, Baird-Lambert J, Cvejic M, Buchanan N "Disposition and metabolism of metronidazole in patients with liver failure." Hepatology 4 (1984):  772-6|Loft S, Dossing M, Poulsen HE, et al. "Influence of dose and route of administration on disposition of metronidazole and its major metabolites." Eur J Clin Pharmacol 30 (1986):  467-73|Loft S, Sonne J, Dossing M, Andreasen PB "Metronidazole pharmacokinetics in patients with hepatic encephalopathy." Scand J Gastroenterol 22 (1987):  117-23|"Product Information. MetroGel-Vaginal (metroNIDAZOLE topical)." Curatek Pharmaceuticals Ltd  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7852, 4903, 'Metronidazole (topical)', 'Liver Diseases', 'Metronidazole may be systemically absorbed when applied to the skin or mucosal membranes.  Once absorbed, metronidazole is extensively metabolized by the liver to both pharmacologically active and inactive compounds.  The plasma clearance of metronidazole may be decreased and the half-life prolonged in patients with impaired hepatic function.  Therapy with topical metronidazole should be administered cautiously in patients with liver disease.', '2', 'Lau AH, Evans R, Chang CW, Seligsohn R "Pharmacokinetics of metronidazole in patients with alcoholic liver disease." Antimicrob Agents Chemother 31 (1987):  1662-4|Jensen JC, Gugler R "Single- and multiple-dose metronidazole kinetics." Clin Pharmacol Ther 34 (1983):  481-7|Farrell G, Baird-Lambert J, Cvejic M, Buchanan N "Disposition and metabolism of metronidazole in patients with liver failure." Hepatology 4 (1984):  772-6|Loft S, Dossing M, Poulsen HE, et al. "Influence of dose and route of administration on disposition of metronidazole and its major metabolites." Eur J Clin Pharmacol 30 (1986):  467-73|Loft S, Sonne J, Dossing M, Andreasen PB "Metronidazole pharmacokinetics in patients with hepatic encephalopathy." Scand J Gastroenterol 22 (1987):  117-23|"Product Information. MetroGel-Vaginal (metroNIDAZOLE topical)." Curatek Pharmaceuticals Ltd  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7853, 4904, 'Metronidazole (topical)', 'Liver Diseases', 'Metronidazole may be systemically absorbed when applied to the skin or mucosal membranes.  Once absorbed, metronidazole is extensively metabolized by the liver to both pharmacologically active and inactive compounds.  The plasma clearance of metronidazole may be decreased and the half-life prolonged in patients with impaired hepatic function.  Therapy with topical metronidazole should be administered cautiously in patients with liver disease.', '2', 'Lau AH, Evans R, Chang CW, Seligsohn R "Pharmacokinetics of metronidazole in patients with alcoholic liver disease." Antimicrob Agents Chemother 31 (1987):  1662-4|Jensen JC, Gugler R "Single- and multiple-dose metronidazole kinetics." Clin Pharmacol Ther 34 (1983):  481-7|Farrell G, Baird-Lambert J, Cvejic M, Buchanan N "Disposition and metabolism of metronidazole in patients with liver failure." Hepatology 4 (1984):  772-6|Loft S, Dossing M, Poulsen HE, et al. "Influence of dose and route of administration on disposition of metronidazole and its major metabolites." Eur J Clin Pharmacol 30 (1986):  467-73|Loft S, Sonne J, Dossing M, Andreasen PB "Metronidazole pharmacokinetics in patients with hepatic encephalopathy." Scand J Gastroenterol 22 (1987):  117-23|"Product Information. MetroGel-Vaginal (metroNIDAZOLE topical)." Curatek Pharmaceuticals Ltd  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7854, 4905, 'Metronidazole (topical)', 'Liver Diseases', 'Metronidazole may be systemically absorbed when applied to the skin or mucosal membranes.  Once absorbed, metronidazole is extensively metabolized by the liver to both pharmacologically active and inactive compounds.  The plasma clearance of metronidazole may be decreased and the half-life prolonged in patients with impaired hepatic function.  Therapy with topical metronidazole should be administered cautiously in patients with liver disease.', '2', 'Lau AH, Evans R, Chang CW, Seligsohn R "Pharmacokinetics of metronidazole in patients with alcoholic liver disease." Antimicrob Agents Chemother 31 (1987):  1662-4|Jensen JC, Gugler R "Single- and multiple-dose metronidazole kinetics." Clin Pharmacol Ther 34 (1983):  481-7|Farrell G, Baird-Lambert J, Cvejic M, Buchanan N "Disposition and metabolism of metronidazole in patients with liver failure." Hepatology 4 (1984):  772-6|Loft S, Dossing M, Poulsen HE, et al. "Influence of dose and route of administration on disposition of metronidazole and its major metabolites." Eur J Clin Pharmacol 30 (1986):  467-73|Loft S, Sonne J, Dossing M, Andreasen PB "Metronidazole pharmacokinetics in patients with hepatic encephalopathy." Scand J Gastroenterol 22 (1987):  117-23|"Product Information. MetroGel-Vaginal (metroNIDAZOLE topical)." Curatek Pharmaceuticals Ltd  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7855, 4906, 'Metronidazole (topical)', 'Liver Diseases', 'Metronidazole may be systemically absorbed when applied to the skin or mucosal membranes.  Once absorbed, metronidazole is extensively metabolized by the liver to both pharmacologically active and inactive compounds.  The plasma clearance of metronidazole may be decreased and the half-life prolonged in patients with impaired hepatic function.  Therapy with topical metronidazole should be administered cautiously in patients with liver disease.', '2', 'Lau AH, Evans R, Chang CW, Seligsohn R "Pharmacokinetics of metronidazole in patients with alcoholic liver disease." Antimicrob Agents Chemother 31 (1987):  1662-4|Jensen JC, Gugler R "Single- and multiple-dose metronidazole kinetics." Clin Pharmacol Ther 34 (1983):  481-7|Farrell G, Baird-Lambert J, Cvejic M, Buchanan N "Disposition and metabolism of metronidazole in patients with liver failure." Hepatology 4 (1984):  772-6|Loft S, Dossing M, Poulsen HE, et al. "Influence of dose and route of administration on disposition of metronidazole and its major metabolites." Eur J Clin Pharmacol 30 (1986):  467-73|Loft S, Sonne J, Dossing M, Andreasen PB "Metronidazole pharmacokinetics in patients with hepatic encephalopathy." Scand J Gastroenterol 22 (1987):  117-23|"Product Information. MetroGel-Vaginal (metroNIDAZOLE topical)." Curatek Pharmaceuticals Ltd  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7856, 4930, 'Metronidazole (topical)', 'Liver Diseases', 'Metronidazole may be systemically absorbed when applied to the skin or mucosal membranes.  Once absorbed, metronidazole is extensively metabolized by the liver to both pharmacologically active and inactive compounds.  The plasma clearance of metronidazole may be decreased and the half-life prolonged in patients with impaired hepatic function.  Therapy with topical metronidazole should be administered cautiously in patients with liver disease.', '2', 'Lau AH, Evans R, Chang CW, Seligsohn R "Pharmacokinetics of metronidazole in patients with alcoholic liver disease." Antimicrob Agents Chemother 31 (1987):  1662-4|Jensen JC, Gugler R "Single- and multiple-dose metronidazole kinetics." Clin Pharmacol Ther 34 (1983):  481-7|Farrell G, Baird-Lambert J, Cvejic M, Buchanan N "Disposition and metabolism of metronidazole in patients with liver failure." Hepatology 4 (1984):  772-6|Loft S, Dossing M, Poulsen HE, et al. "Influence of dose and route of administration on disposition of metronidazole and its major metabolites." Eur J Clin Pharmacol 30 (1986):  467-73|Loft S, Sonne J, Dossing M, Andreasen PB "Metronidazole pharmacokinetics in patients with hepatic encephalopathy." Scand J Gastroenterol 22 (1987):  117-23|"Product Information. MetroGel-Vaginal (metroNIDAZOLE topical)." Curatek Pharmaceuticals Ltd  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7857, 6077, 'Metronidazole (topical)', 'Liver Diseases', 'Metronidazole may be systemically absorbed when applied to the skin or mucosal membranes.  Once absorbed, metronidazole is extensively metabolized by the liver to both pharmacologically active and inactive compounds.  The plasma clearance of metronidazole may be decreased and the half-life prolonged in patients with impaired hepatic function.  Therapy with topical metronidazole should be administered cautiously in patients with liver disease.', '2', 'Lau AH, Evans R, Chang CW, Seligsohn R "Pharmacokinetics of metronidazole in patients with alcoholic liver disease." Antimicrob Agents Chemother 31 (1987):  1662-4|Jensen JC, Gugler R "Single- and multiple-dose metronidazole kinetics." Clin Pharmacol Ther 34 (1983):  481-7|Farrell G, Baird-Lambert J, Cvejic M, Buchanan N "Disposition and metabolism of metronidazole in patients with liver failure." Hepatology 4 (1984):  772-6|Loft S, Dossing M, Poulsen HE, et al. "Influence of dose and route of administration on disposition of metronidazole and its major metabolites." Eur J Clin Pharmacol 30 (1986):  467-73|Loft S, Sonne J, Dossing M, Andreasen PB "Metronidazole pharmacokinetics in patients with hepatic encephalopathy." Scand J Gastroenterol 22 (1987):  117-23|"Product Information. MetroGel-Vaginal (metroNIDAZOLE topical)." Curatek Pharmaceuticals Ltd  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7858, 8101, 'Metronidazole (topical)', 'Liver Diseases', 'Metronidazole may be systemically absorbed when applied to the skin or mucosal membranes.  Once absorbed, metronidazole is extensively metabolized by the liver to both pharmacologically active and inactive compounds.  The plasma clearance of metronidazole may be decreased and the half-life prolonged in patients with impaired hepatic function.  Therapy with topical metronidazole should be administered cautiously in patients with liver disease.', '2', 'Lau AH, Evans R, Chang CW, Seligsohn R "Pharmacokinetics of metronidazole in patients with alcoholic liver disease." Antimicrob Agents Chemother 31 (1987):  1662-4|Jensen JC, Gugler R "Single- and multiple-dose metronidazole kinetics." Clin Pharmacol Ther 34 (1983):  481-7|Farrell G, Baird-Lambert J, Cvejic M, Buchanan N "Disposition and metabolism of metronidazole in patients with liver failure." Hepatology 4 (1984):  772-6|Loft S, Dossing M, Poulsen HE, et al. "Influence of dose and route of administration on disposition of metronidazole and its major metabolites." Eur J Clin Pharmacol 30 (1986):  467-73|Loft S, Sonne J, Dossing M, Andreasen PB "Metronidazole pharmacokinetics in patients with hepatic encephalopathy." Scand J Gastroenterol 22 (1987):  117-23|"Product Information. MetroGel-Vaginal (metroNIDAZOLE topical)." Curatek Pharmaceuticals Ltd  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7859, 8102, 'Metronidazole (topical)', 'Liver Diseases', 'Metronidazole may be systemically absorbed when applied to the skin or mucosal membranes.  Once absorbed, metronidazole is extensively metabolized by the liver to both pharmacologically active and inactive compounds.  The plasma clearance of metronidazole may be decreased and the half-life prolonged in patients with impaired hepatic function.  Therapy with topical metronidazole should be administered cautiously in patients with liver disease.', '2', 'Lau AH, Evans R, Chang CW, Seligsohn R "Pharmacokinetics of metronidazole in patients with alcoholic liver disease." Antimicrob Agents Chemother 31 (1987):  1662-4|Jensen JC, Gugler R "Single- and multiple-dose metronidazole kinetics." Clin Pharmacol Ther 34 (1983):  481-7|Farrell G, Baird-Lambert J, Cvejic M, Buchanan N "Disposition and metabolism of metronidazole in patients with liver failure." Hepatology 4 (1984):  772-6|Loft S, Dossing M, Poulsen HE, et al. "Influence of dose and route of administration on disposition of metronidazole and its major metabolites." Eur J Clin Pharmacol 30 (1986):  467-73|Loft S, Sonne J, Dossing M, Andreasen PB "Metronidazole pharmacokinetics in patients with hepatic encephalopathy." Scand J Gastroenterol 22 (1987):  117-23|"Product Information. MetroGel-Vaginal (metroNIDAZOLE topical)." Curatek Pharmaceuticals Ltd  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7860, 14075, 'Metronidazole (topical)', 'Liver Diseases', 'Metronidazole may be systemically absorbed when applied to the skin or mucosal membranes.  Once absorbed, metronidazole is extensively metabolized by the liver to both pharmacologically active and inactive compounds.  The plasma clearance of metronidazole may be decreased and the half-life prolonged in patients with impaired hepatic function.  Therapy with topical metronidazole should be administered cautiously in patients with liver disease.', '2', 'Lau AH, Evans R, Chang CW, Seligsohn R "Pharmacokinetics of metronidazole in patients with alcoholic liver disease." Antimicrob Agents Chemother 31 (1987):  1662-4|Jensen JC, Gugler R "Single- and multiple-dose metronidazole kinetics." Clin Pharmacol Ther 34 (1983):  481-7|Farrell G, Baird-Lambert J, Cvejic M, Buchanan N "Disposition and metabolism of metronidazole in patients with liver failure." Hepatology 4 (1984):  772-6|Loft S, Dossing M, Poulsen HE, et al. "Influence of dose and route of administration on disposition of metronidazole and its major metabolites." Eur J Clin Pharmacol 30 (1986):  467-73|Loft S, Sonne J, Dossing M, Andreasen PB "Metronidazole pharmacokinetics in patients with hepatic encephalopathy." Scand J Gastroenterol 22 (1987):  117-23|"Product Information. MetroGel-Vaginal (metroNIDAZOLE topical)." Curatek Pharmaceuticals Ltd  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7861, 14076, 'Metronidazole (topical)', 'Liver Diseases', 'Metronidazole may be systemically absorbed when applied to the skin or mucosal membranes.  Once absorbed, metronidazole is extensively metabolized by the liver to both pharmacologically active and inactive compounds.  The plasma clearance of metronidazole may be decreased and the half-life prolonged in patients with impaired hepatic function.  Therapy with topical metronidazole should be administered cautiously in patients with liver disease.', '2', 'Lau AH, Evans R, Chang CW, Seligsohn R "Pharmacokinetics of metronidazole in patients with alcoholic liver disease." Antimicrob Agents Chemother 31 (1987):  1662-4|Jensen JC, Gugler R "Single- and multiple-dose metronidazole kinetics." Clin Pharmacol Ther 34 (1983):  481-7|Farrell G, Baird-Lambert J, Cvejic M, Buchanan N "Disposition and metabolism of metronidazole in patients with liver failure." Hepatology 4 (1984):  772-6|Loft S, Dossing M, Poulsen HE, et al. "Influence of dose and route of administration on disposition of metronidazole and its major metabolites." Eur J Clin Pharmacol 30 (1986):  467-73|Loft S, Sonne J, Dossing M, Andreasen PB "Metronidazole pharmacokinetics in patients with hepatic encephalopathy." Scand J Gastroenterol 22 (1987):  117-23|"Product Information. MetroGel-Vaginal (metroNIDAZOLE topical)." Curatek Pharmaceuticals Ltd  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7862, 14080, 'Metronidazole (topical)', 'Liver Diseases', 'Metronidazole may be systemically absorbed when applied to the skin or mucosal membranes.  Once absorbed, metronidazole is extensively metabolized by the liver to both pharmacologically active and inactive compounds.  The plasma clearance of metronidazole may be decreased and the half-life prolonged in patients with impaired hepatic function.  Therapy with topical metronidazole should be administered cautiously in patients with liver disease.', '2', 'Lau AH, Evans R, Chang CW, Seligsohn R "Pharmacokinetics of metronidazole in patients with alcoholic liver disease." Antimicrob Agents Chemother 31 (1987):  1662-4|Jensen JC, Gugler R "Single- and multiple-dose metronidazole kinetics." Clin Pharmacol Ther 34 (1983):  481-7|Farrell G, Baird-Lambert J, Cvejic M, Buchanan N "Disposition and metabolism of metronidazole in patients with liver failure." Hepatology 4 (1984):  772-6|Loft S, Dossing M, Poulsen HE, et al. "Influence of dose and route of administration on disposition of metronidazole and its major metabolites." Eur J Clin Pharmacol 30 (1986):  467-73|Loft S, Sonne J, Dossing M, Andreasen PB "Metronidazole pharmacokinetics in patients with hepatic encephalopathy." Scand J Gastroenterol 22 (1987):  117-23|"Product Information. MetroGel-Vaginal (metroNIDAZOLE topical)." Curatek Pharmaceuticals Ltd  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7863, 15559, 'Metronidazole (topical)', 'Liver Diseases', 'Metronidazole may be systemically absorbed when applied to the skin or mucosal membranes.  Once absorbed, metronidazole is extensively metabolized by the liver to both pharmacologically active and inactive compounds.  The plasma clearance of metronidazole may be decreased and the half-life prolonged in patients with impaired hepatic function.  Therapy with topical metronidazole should be administered cautiously in patients with liver disease.', '2', 'Lau AH, Evans R, Chang CW, Seligsohn R "Pharmacokinetics of metronidazole in patients with alcoholic liver disease." Antimicrob Agents Chemother 31 (1987):  1662-4|Jensen JC, Gugler R "Single- and multiple-dose metronidazole kinetics." Clin Pharmacol Ther 34 (1983):  481-7|Farrell G, Baird-Lambert J, Cvejic M, Buchanan N "Disposition and metabolism of metronidazole in patients with liver failure." Hepatology 4 (1984):  772-6|Loft S, Dossing M, Poulsen HE, et al. "Influence of dose and route of administration on disposition of metronidazole and its major metabolites." Eur J Clin Pharmacol 30 (1986):  467-73|Loft S, Sonne J, Dossing M, Andreasen PB "Metronidazole pharmacokinetics in patients with hepatic encephalopathy." Scand J Gastroenterol 22 (1987):  117-23|"Product Information. MetroGel-Vaginal (metroNIDAZOLE topical)." Curatek Pharmaceuticals Ltd  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7864, 16787, 'Metronidazole (topical)', 'Liver Diseases', 'Metronidazole may be systemically absorbed when applied to the skin or mucosal membranes.  Once absorbed, metronidazole is extensively metabolized by the liver to both pharmacologically active and inactive compounds.  The plasma clearance of metronidazole may be decreased and the half-life prolonged in patients with impaired hepatic function.  Therapy with topical metronidazole should be administered cautiously in patients with liver disease.', '2', 'Lau AH, Evans R, Chang CW, Seligsohn R "Pharmacokinetics of metronidazole in patients with alcoholic liver disease." Antimicrob Agents Chemother 31 (1987):  1662-4|Jensen JC, Gugler R "Single- and multiple-dose metronidazole kinetics." Clin Pharmacol Ther 34 (1983):  481-7|Farrell G, Baird-Lambert J, Cvejic M, Buchanan N "Disposition and metabolism of metronidazole in patients with liver failure." Hepatology 4 (1984):  772-6|Loft S, Dossing M, Poulsen HE, et al. "Influence of dose and route of administration on disposition of metronidazole and its major metabolites." Eur J Clin Pharmacol 30 (1986):  467-73|Loft S, Sonne J, Dossing M, Andreasen PB "Metronidazole pharmacokinetics in patients with hepatic encephalopathy." Scand J Gastroenterol 22 (1987):  117-23|"Product Information. MetroGel-Vaginal (metroNIDAZOLE topical)." Curatek Pharmaceuticals Ltd  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7865, 17956, 'Metronidazole (topical)', 'Liver Diseases', 'Metronidazole may be systemically absorbed when applied to the skin or mucosal membranes.  Once absorbed, metronidazole is extensively metabolized by the liver to both pharmacologically active and inactive compounds.  The plasma clearance of metronidazole may be decreased and the half-life prolonged in patients with impaired hepatic function.  Therapy with topical metronidazole should be administered cautiously in patients with liver disease.', '2', 'Lau AH, Evans R, Chang CW, Seligsohn R "Pharmacokinetics of metronidazole in patients with alcoholic liver disease." Antimicrob Agents Chemother 31 (1987):  1662-4|Jensen JC, Gugler R "Single- and multiple-dose metronidazole kinetics." Clin Pharmacol Ther 34 (1983):  481-7|Farrell G, Baird-Lambert J, Cvejic M, Buchanan N "Disposition and metabolism of metronidazole in patients with liver failure." Hepatology 4 (1984):  772-6|Loft S, Dossing M, Poulsen HE, et al. "Influence of dose and route of administration on disposition of metronidazole and its major metabolites." Eur J Clin Pharmacol 30 (1986):  467-73|Loft S, Sonne J, Dossing M, Andreasen PB "Metronidazole pharmacokinetics in patients with hepatic encephalopathy." Scand J Gastroenterol 22 (1987):  117-23|"Product Information. MetroGel-Vaginal (metroNIDAZOLE topical)." Curatek Pharmaceuticals Ltd  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7866, 17957, 'Metronidazole (topical)', 'Liver Diseases', 'Metronidazole may be systemically absorbed when applied to the skin or mucosal membranes.  Once absorbed, metronidazole is extensively metabolized by the liver to both pharmacologically active and inactive compounds.  The plasma clearance of metronidazole may be decreased and the half-life prolonged in patients with impaired hepatic function.  Therapy with topical metronidazole should be administered cautiously in patients with liver disease.', '2', 'Lau AH, Evans R, Chang CW, Seligsohn R "Pharmacokinetics of metronidazole in patients with alcoholic liver disease." Antimicrob Agents Chemother 31 (1987):  1662-4|Jensen JC, Gugler R "Single- and multiple-dose metronidazole kinetics." Clin Pharmacol Ther 34 (1983):  481-7|Farrell G, Baird-Lambert J, Cvejic M, Buchanan N "Disposition and metabolism of metronidazole in patients with liver failure." Hepatology 4 (1984):  772-6|Loft S, Dossing M, Poulsen HE, et al. "Influence of dose and route of administration on disposition of metronidazole and its major metabolites." Eur J Clin Pharmacol 30 (1986):  467-73|Loft S, Sonne J, Dossing M, Andreasen PB "Metronidazole pharmacokinetics in patients with hepatic encephalopathy." Scand J Gastroenterol 22 (1987):  117-23|"Product Information. MetroGel-Vaginal (metroNIDAZOLE topical)." Curatek Pharmaceuticals Ltd  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7867, 18347, 'Metronidazole (topical)', 'Liver Diseases', 'Metronidazole may be systemically absorbed when applied to the skin or mucosal membranes.  Once absorbed, metronidazole is extensively metabolized by the liver to both pharmacologically active and inactive compounds.  The plasma clearance of metronidazole may be decreased and the half-life prolonged in patients with impaired hepatic function.  Therapy with topical metronidazole should be administered cautiously in patients with liver disease.', '2', 'Lau AH, Evans R, Chang CW, Seligsohn R "Pharmacokinetics of metronidazole in patients with alcoholic liver disease." Antimicrob Agents Chemother 31 (1987):  1662-4|Jensen JC, Gugler R "Single- and multiple-dose metronidazole kinetics." Clin Pharmacol Ther 34 (1983):  481-7|Farrell G, Baird-Lambert J, Cvejic M, Buchanan N "Disposition and metabolism of metronidazole in patients with liver failure." Hepatology 4 (1984):  772-6|Loft S, Dossing M, Poulsen HE, et al. "Influence of dose and route of administration on disposition of metronidazole and its major metabolites." Eur J Clin Pharmacol 30 (1986):  467-73|Loft S, Sonne J, Dossing M, Andreasen PB "Metronidazole pharmacokinetics in patients with hepatic encephalopathy." Scand J Gastroenterol 22 (1987):  117-23|"Product Information. MetroGel-Vaginal (metroNIDAZOLE topical)." Curatek Pharmaceuticals Ltd  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7868, 19075, 'Metronidazole (topical)', 'Liver Diseases', 'Metronidazole may be systemically absorbed when applied to the skin or mucosal membranes.  Once absorbed, metronidazole is extensively metabolized by the liver to both pharmacologically active and inactive compounds.  The plasma clearance of metronidazole may be decreased and the half-life prolonged in patients with impaired hepatic function.  Therapy with topical metronidazole should be administered cautiously in patients with liver disease.', '2', 'Lau AH, Evans R, Chang CW, Seligsohn R "Pharmacokinetics of metronidazole in patients with alcoholic liver disease." Antimicrob Agents Chemother 31 (1987):  1662-4|Jensen JC, Gugler R "Single- and multiple-dose metronidazole kinetics." Clin Pharmacol Ther 34 (1983):  481-7|Farrell G, Baird-Lambert J, Cvejic M, Buchanan N "Disposition and metabolism of metronidazole in patients with liver failure." Hepatology 4 (1984):  772-6|Loft S, Dossing M, Poulsen HE, et al. "Influence of dose and route of administration on disposition of metronidazole and its major metabolites." Eur J Clin Pharmacol 30 (1986):  467-73|Loft S, Sonne J, Dossing M, Andreasen PB "Metronidazole pharmacokinetics in patients with hepatic encephalopathy." Scand J Gastroenterol 22 (1987):  117-23|"Product Information. MetroGel-Vaginal (metroNIDAZOLE topical)." Curatek Pharmaceuticals Ltd  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7869, 19077, 'Metronidazole (topical)', 'Liver Diseases', 'Metronidazole may be systemically absorbed when applied to the skin or mucosal membranes.  Once absorbed, metronidazole is extensively metabolized by the liver to both pharmacologically active and inactive compounds.  The plasma clearance of metronidazole may be decreased and the half-life prolonged in patients with impaired hepatic function.  Therapy with topical metronidazole should be administered cautiously in patients with liver disease.', '2', 'Lau AH, Evans R, Chang CW, Seligsohn R "Pharmacokinetics of metronidazole in patients with alcoholic liver disease." Antimicrob Agents Chemother 31 (1987):  1662-4|Jensen JC, Gugler R "Single- and multiple-dose metronidazole kinetics." Clin Pharmacol Ther 34 (1983):  481-7|Farrell G, Baird-Lambert J, Cvejic M, Buchanan N "Disposition and metabolism of metronidazole in patients with liver failure." Hepatology 4 (1984):  772-6|Loft S, Dossing M, Poulsen HE, et al. "Influence of dose and route of administration on disposition of metronidazole and its major metabolites." Eur J Clin Pharmacol 30 (1986):  467-73|Loft S, Sonne J, Dossing M, Andreasen PB "Metronidazole pharmacokinetics in patients with hepatic encephalopathy." Scand J Gastroenterol 22 (1987):  117-23|"Product Information. MetroGel-Vaginal (metroNIDAZOLE topical)." Curatek Pharmaceuticals Ltd  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7870, 19078, 'Metronidazole (topical)', 'Liver Diseases', 'Metronidazole may be systemically absorbed when applied to the skin or mucosal membranes.  Once absorbed, metronidazole is extensively metabolized by the liver to both pharmacologically active and inactive compounds.  The plasma clearance of metronidazole may be decreased and the half-life prolonged in patients with impaired hepatic function.  Therapy with topical metronidazole should be administered cautiously in patients with liver disease.', '2', 'Lau AH, Evans R, Chang CW, Seligsohn R "Pharmacokinetics of metronidazole in patients with alcoholic liver disease." Antimicrob Agents Chemother 31 (1987):  1662-4|Jensen JC, Gugler R "Single- and multiple-dose metronidazole kinetics." Clin Pharmacol Ther 34 (1983):  481-7|Farrell G, Baird-Lambert J, Cvejic M, Buchanan N "Disposition and metabolism of metronidazole in patients with liver failure." Hepatology 4 (1984):  772-6|Loft S, Dossing M, Poulsen HE, et al. "Influence of dose and route of administration on disposition of metronidazole and its major metabolites." Eur J Clin Pharmacol 30 (1986):  467-73|Loft S, Sonne J, Dossing M, Andreasen PB "Metronidazole pharmacokinetics in patients with hepatic encephalopathy." Scand J Gastroenterol 22 (1987):  117-23|"Product Information. MetroGel-Vaginal (metroNIDAZOLE topical)." Curatek Pharmaceuticals Ltd  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7871, 19079, 'Metronidazole (topical)', 'Liver Diseases', 'Metronidazole may be systemically absorbed when applied to the skin or mucosal membranes.  Once absorbed, metronidazole is extensively metabolized by the liver to both pharmacologically active and inactive compounds.  The plasma clearance of metronidazole may be decreased and the half-life prolonged in patients with impaired hepatic function.  Therapy with topical metronidazole should be administered cautiously in patients with liver disease.', '2', 'Lau AH, Evans R, Chang CW, Seligsohn R "Pharmacokinetics of metronidazole in patients with alcoholic liver disease." Antimicrob Agents Chemother 31 (1987):  1662-4|Jensen JC, Gugler R "Single- and multiple-dose metronidazole kinetics." Clin Pharmacol Ther 34 (1983):  481-7|Farrell G, Baird-Lambert J, Cvejic M, Buchanan N "Disposition and metabolism of metronidazole in patients with liver failure." Hepatology 4 (1984):  772-6|Loft S, Dossing M, Poulsen HE, et al. "Influence of dose and route of administration on disposition of metronidazole and its major metabolites." Eur J Clin Pharmacol 30 (1986):  467-73|Loft S, Sonne J, Dossing M, Andreasen PB "Metronidazole pharmacokinetics in patients with hepatic encephalopathy." Scand J Gastroenterol 22 (1987):  117-23|"Product Information. MetroGel-Vaginal (metroNIDAZOLE topical)." Curatek Pharmaceuticals Ltd  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7872, 19085, 'Metronidazole (topical)', 'Liver Diseases', 'Metronidazole may be systemically absorbed when applied to the skin or mucosal membranes.  Once absorbed, metronidazole is extensively metabolized by the liver to both pharmacologically active and inactive compounds.  The plasma clearance of metronidazole may be decreased and the half-life prolonged in patients with impaired hepatic function.  Therapy with topical metronidazole should be administered cautiously in patients with liver disease.', '2', 'Lau AH, Evans R, Chang CW, Seligsohn R "Pharmacokinetics of metronidazole in patients with alcoholic liver disease." Antimicrob Agents Chemother 31 (1987):  1662-4|Jensen JC, Gugler R "Single- and multiple-dose metronidazole kinetics." Clin Pharmacol Ther 34 (1983):  481-7|Farrell G, Baird-Lambert J, Cvejic M, Buchanan N "Disposition and metabolism of metronidazole in patients with liver failure." Hepatology 4 (1984):  772-6|Loft S, Dossing M, Poulsen HE, et al. "Influence of dose and route of administration on disposition of metronidazole and its major metabolites." Eur J Clin Pharmacol 30 (1986):  467-73|Loft S, Sonne J, Dossing M, Andreasen PB "Metronidazole pharmacokinetics in patients with hepatic encephalopathy." Scand J Gastroenterol 22 (1987):  117-23|"Product Information. MetroGel-Vaginal (metroNIDAZOLE topical)." Curatek Pharmaceuticals Ltd  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7873, 19630, 'Metronidazole (topical)', 'Liver Diseases', 'Metronidazole may be systemically absorbed when applied to the skin or mucosal membranes.  Once absorbed, metronidazole is extensively metabolized by the liver to both pharmacologically active and inactive compounds.  The plasma clearance of metronidazole may be decreased and the half-life prolonged in patients with impaired hepatic function.  Therapy with topical metronidazole should be administered cautiously in patients with liver disease.', '2', 'Lau AH, Evans R, Chang CW, Seligsohn R "Pharmacokinetics of metronidazole in patients with alcoholic liver disease." Antimicrob Agents Chemother 31 (1987):  1662-4|Jensen JC, Gugler R "Single- and multiple-dose metronidazole kinetics." Clin Pharmacol Ther 34 (1983):  481-7|Farrell G, Baird-Lambert J, Cvejic M, Buchanan N "Disposition and metabolism of metronidazole in patients with liver failure." Hepatology 4 (1984):  772-6|Loft S, Dossing M, Poulsen HE, et al. "Influence of dose and route of administration on disposition of metronidazole and its major metabolites." Eur J Clin Pharmacol 30 (1986):  467-73|Loft S, Sonne J, Dossing M, Andreasen PB "Metronidazole pharmacokinetics in patients with hepatic encephalopathy." Scand J Gastroenterol 22 (1987):  117-23|"Product Information. MetroGel-Vaginal (metroNIDAZOLE topical)." Curatek Pharmaceuticals Ltd  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7874, 22672, 'Metronidazole (topical)', 'Liver Diseases', 'Metronidazole may be systemically absorbed when applied to the skin or mucosal membranes.  Once absorbed, metronidazole is extensively metabolized by the liver to both pharmacologically active and inactive compounds.  The plasma clearance of metronidazole may be decreased and the half-life prolonged in patients with impaired hepatic function.  Therapy with topical metronidazole should be administered cautiously in patients with liver disease.', '2', 'Lau AH, Evans R, Chang CW, Seligsohn R "Pharmacokinetics of metronidazole in patients with alcoholic liver disease." Antimicrob Agents Chemother 31 (1987):  1662-4|Jensen JC, Gugler R "Single- and multiple-dose metronidazole kinetics." Clin Pharmacol Ther 34 (1983):  481-7|Farrell G, Baird-Lambert J, Cvejic M, Buchanan N "Disposition and metabolism of metronidazole in patients with liver failure." Hepatology 4 (1984):  772-6|Loft S, Dossing M, Poulsen HE, et al. "Influence of dose and route of administration on disposition of metronidazole and its major metabolites." Eur J Clin Pharmacol 30 (1986):  467-73|Loft S, Sonne J, Dossing M, Andreasen PB "Metronidazole pharmacokinetics in patients with hepatic encephalopathy." Scand J Gastroenterol 22 (1987):  117-23|"Product Information. MetroGel-Vaginal (metroNIDAZOLE topical)." Curatek Pharmaceuticals Ltd  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7875, 22676, 'Metronidazole (topical)', 'Liver Diseases', 'Metronidazole may be systemically absorbed when applied to the skin or mucosal membranes.  Once absorbed, metronidazole is extensively metabolized by the liver to both pharmacologically active and inactive compounds.  The plasma clearance of metronidazole may be decreased and the half-life prolonged in patients with impaired hepatic function.  Therapy with topical metronidazole should be administered cautiously in patients with liver disease.', '2', 'Lau AH, Evans R, Chang CW, Seligsohn R "Pharmacokinetics of metronidazole in patients with alcoholic liver disease." Antimicrob Agents Chemother 31 (1987):  1662-4|Jensen JC, Gugler R "Single- and multiple-dose metronidazole kinetics." Clin Pharmacol Ther 34 (1983):  481-7|Farrell G, Baird-Lambert J, Cvejic M, Buchanan N "Disposition and metabolism of metronidazole in patients with liver failure." Hepatology 4 (1984):  772-6|Loft S, Dossing M, Poulsen HE, et al. "Influence of dose and route of administration on disposition of metronidazole and its major metabolites." Eur J Clin Pharmacol 30 (1986):  467-73|Loft S, Sonne J, Dossing M, Andreasen PB "Metronidazole pharmacokinetics in patients with hepatic encephalopathy." Scand J Gastroenterol 22 (1987):  117-23|"Product Information. MetroGel-Vaginal (metroNIDAZOLE topical)." Curatek Pharmaceuticals Ltd  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7876, 22677, 'Metronidazole (topical)', 'Liver Diseases', 'Metronidazole may be systemically absorbed when applied to the skin or mucosal membranes.  Once absorbed, metronidazole is extensively metabolized by the liver to both pharmacologically active and inactive compounds.  The plasma clearance of metronidazole may be decreased and the half-life prolonged in patients with impaired hepatic function.  Therapy with topical metronidazole should be administered cautiously in patients with liver disease.', '2', 'Lau AH, Evans R, Chang CW, Seligsohn R "Pharmacokinetics of metronidazole in patients with alcoholic liver disease." Antimicrob Agents Chemother 31 (1987):  1662-4|Jensen JC, Gugler R "Single- and multiple-dose metronidazole kinetics." Clin Pharmacol Ther 34 (1983):  481-7|Farrell G, Baird-Lambert J, Cvejic M, Buchanan N "Disposition and metabolism of metronidazole in patients with liver failure." Hepatology 4 (1984):  772-6|Loft S, Dossing M, Poulsen HE, et al. "Influence of dose and route of administration on disposition of metronidazole and its major metabolites." Eur J Clin Pharmacol 30 (1986):  467-73|Loft S, Sonne J, Dossing M, Andreasen PB "Metronidazole pharmacokinetics in patients with hepatic encephalopathy." Scand J Gastroenterol 22 (1987):  117-23|"Product Information. MetroGel-Vaginal (metroNIDAZOLE topical)." Curatek Pharmaceuticals Ltd  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7877, 22679, 'Metronidazole (topical)', 'Liver Diseases', 'Metronidazole may be systemically absorbed when applied to the skin or mucosal membranes.  Once absorbed, metronidazole is extensively metabolized by the liver to both pharmacologically active and inactive compounds.  The plasma clearance of metronidazole may be decreased and the half-life prolonged in patients with impaired hepatic function.  Therapy with topical metronidazole should be administered cautiously in patients with liver disease.', '2', 'Lau AH, Evans R, Chang CW, Seligsohn R "Pharmacokinetics of metronidazole in patients with alcoholic liver disease." Antimicrob Agents Chemother 31 (1987):  1662-4|Jensen JC, Gugler R "Single- and multiple-dose metronidazole kinetics." Clin Pharmacol Ther 34 (1983):  481-7|Farrell G, Baird-Lambert J, Cvejic M, Buchanan N "Disposition and metabolism of metronidazole in patients with liver failure." Hepatology 4 (1984):  772-6|Loft S, Dossing M, Poulsen HE, et al. "Influence of dose and route of administration on disposition of metronidazole and its major metabolites." Eur J Clin Pharmacol 30 (1986):  467-73|Loft S, Sonne J, Dossing M, Andreasen PB "Metronidazole pharmacokinetics in patients with hepatic encephalopathy." Scand J Gastroenterol 22 (1987):  117-23|"Product Information. MetroGel-Vaginal (metroNIDAZOLE topical)." Curatek Pharmaceuticals Ltd  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7878, 22680, 'Metronidazole (topical)', 'Liver Diseases', 'Metronidazole may be systemically absorbed when applied to the skin or mucosal membranes.  Once absorbed, metronidazole is extensively metabolized by the liver to both pharmacologically active and inactive compounds.  The plasma clearance of metronidazole may be decreased and the half-life prolonged in patients with impaired hepatic function.  Therapy with topical metronidazole should be administered cautiously in patients with liver disease.', '2', 'Lau AH, Evans R, Chang CW, Seligsohn R "Pharmacokinetics of metronidazole in patients with alcoholic liver disease." Antimicrob Agents Chemother 31 (1987):  1662-4|Jensen JC, Gugler R "Single- and multiple-dose metronidazole kinetics." Clin Pharmacol Ther 34 (1983):  481-7|Farrell G, Baird-Lambert J, Cvejic M, Buchanan N "Disposition and metabolism of metronidazole in patients with liver failure." Hepatology 4 (1984):  772-6|Loft S, Dossing M, Poulsen HE, et al. "Influence of dose and route of administration on disposition of metronidazole and its major metabolites." Eur J Clin Pharmacol 30 (1986):  467-73|Loft S, Sonne J, Dossing M, Andreasen PB "Metronidazole pharmacokinetics in patients with hepatic encephalopathy." Scand J Gastroenterol 22 (1987):  117-23|"Product Information. MetroGel-Vaginal (metroNIDAZOLE topical)." Curatek Pharmaceuticals Ltd  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7879, 26297, 'Metronidazole (topical)', 'Liver Diseases', 'Metronidazole may be systemically absorbed when applied to the skin or mucosal membranes.  Once absorbed, metronidazole is extensively metabolized by the liver to both pharmacologically active and inactive compounds.  The plasma clearance of metronidazole may be decreased and the half-life prolonged in patients with impaired hepatic function.  Therapy with topical metronidazole should be administered cautiously in patients with liver disease.', '2', 'Lau AH, Evans R, Chang CW, Seligsohn R "Pharmacokinetics of metronidazole in patients with alcoholic liver disease." Antimicrob Agents Chemother 31 (1987):  1662-4|Jensen JC, Gugler R "Single- and multiple-dose metronidazole kinetics." Clin Pharmacol Ther 34 (1983):  481-7|Farrell G, Baird-Lambert J, Cvejic M, Buchanan N "Disposition and metabolism of metronidazole in patients with liver failure." Hepatology 4 (1984):  772-6|Loft S, Dossing M, Poulsen HE, et al. "Influence of dose and route of administration on disposition of metronidazole and its major metabolites." Eur J Clin Pharmacol 30 (1986):  467-73|Loft S, Sonne J, Dossing M, Andreasen PB "Metronidazole pharmacokinetics in patients with hepatic encephalopathy." Scand J Gastroenterol 22 (1987):  117-23|"Product Information. MetroGel-Vaginal (metroNIDAZOLE topical)." Curatek Pharmaceuticals Ltd  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7880, 28488, 'Metronidazole (topical)', 'Liver Diseases', 'Metronidazole may be systemically absorbed when applied to the skin or mucosal membranes.  Once absorbed, metronidazole is extensively metabolized by the liver to both pharmacologically active and inactive compounds.  The plasma clearance of metronidazole may be decreased and the half-life prolonged in patients with impaired hepatic function.  Therapy with topical metronidazole should be administered cautiously in patients with liver disease.', '2', 'Lau AH, Evans R, Chang CW, Seligsohn R "Pharmacokinetics of metronidazole in patients with alcoholic liver disease." Antimicrob Agents Chemother 31 (1987):  1662-4|Jensen JC, Gugler R "Single- and multiple-dose metronidazole kinetics." Clin Pharmacol Ther 34 (1983):  481-7|Farrell G, Baird-Lambert J, Cvejic M, Buchanan N "Disposition and metabolism of metronidazole in patients with liver failure." Hepatology 4 (1984):  772-6|Loft S, Dossing M, Poulsen HE, et al. "Influence of dose and route of administration on disposition of metronidazole and its major metabolites." Eur J Clin Pharmacol 30 (1986):  467-73|Loft S, Sonne J, Dossing M, Andreasen PB "Metronidazole pharmacokinetics in patients with hepatic encephalopathy." Scand J Gastroenterol 22 (1987):  117-23|"Product Information. MetroGel-Vaginal (metroNIDAZOLE topical)." Curatek Pharmaceuticals Ltd  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7881, 28489, 'Metronidazole (topical)', 'Liver Diseases', 'Metronidazole may be systemically absorbed when applied to the skin or mucosal membranes.  Once absorbed, metronidazole is extensively metabolized by the liver to both pharmacologically active and inactive compounds.  The plasma clearance of metronidazole may be decreased and the half-life prolonged in patients with impaired hepatic function.  Therapy with topical metronidazole should be administered cautiously in patients with liver disease.', '2', 'Lau AH, Evans R, Chang CW, Seligsohn R "Pharmacokinetics of metronidazole in patients with alcoholic liver disease." Antimicrob Agents Chemother 31 (1987):  1662-4|Jensen JC, Gugler R "Single- and multiple-dose metronidazole kinetics." Clin Pharmacol Ther 34 (1983):  481-7|Farrell G, Baird-Lambert J, Cvejic M, Buchanan N "Disposition and metabolism of metronidazole in patients with liver failure." Hepatology 4 (1984):  772-6|Loft S, Dossing M, Poulsen HE, et al. "Influence of dose and route of administration on disposition of metronidazole and its major metabolites." Eur J Clin Pharmacol 30 (1986):  467-73|Loft S, Sonne J, Dossing M, Andreasen PB "Metronidazole pharmacokinetics in patients with hepatic encephalopathy." Scand J Gastroenterol 22 (1987):  117-23|"Product Information. MetroGel-Vaginal (metroNIDAZOLE topical)." Curatek Pharmaceuticals Ltd  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7882, 28490, 'Metronidazole (topical)', 'Liver Diseases', 'Metronidazole may be systemically absorbed when applied to the skin or mucosal membranes.  Once absorbed, metronidazole is extensively metabolized by the liver to both pharmacologically active and inactive compounds.  The plasma clearance of metronidazole may be decreased and the half-life prolonged in patients with impaired hepatic function.  Therapy with topical metronidazole should be administered cautiously in patients with liver disease.', '2', 'Lau AH, Evans R, Chang CW, Seligsohn R "Pharmacokinetics of metronidazole in patients with alcoholic liver disease." Antimicrob Agents Chemother 31 (1987):  1662-4|Jensen JC, Gugler R "Single- and multiple-dose metronidazole kinetics." Clin Pharmacol Ther 34 (1983):  481-7|Farrell G, Baird-Lambert J, Cvejic M, Buchanan N "Disposition and metabolism of metronidazole in patients with liver failure." Hepatology 4 (1984):  772-6|Loft S, Dossing M, Poulsen HE, et al. "Influence of dose and route of administration on disposition of metronidazole and its major metabolites." Eur J Clin Pharmacol 30 (1986):  467-73|Loft S, Sonne J, Dossing M, Andreasen PB "Metronidazole pharmacokinetics in patients with hepatic encephalopathy." Scand J Gastroenterol 22 (1987):  117-23|"Product Information. MetroGel-Vaginal (metroNIDAZOLE topical)." Curatek Pharmaceuticals Ltd  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7883, 28491, 'Metronidazole (topical)', 'Liver Diseases', 'Metronidazole may be systemically absorbed when applied to the skin or mucosal membranes.  Once absorbed, metronidazole is extensively metabolized by the liver to both pharmacologically active and inactive compounds.  The plasma clearance of metronidazole may be decreased and the half-life prolonged in patients with impaired hepatic function.  Therapy with topical metronidazole should be administered cautiously in patients with liver disease.', '2', 'Lau AH, Evans R, Chang CW, Seligsohn R "Pharmacokinetics of metronidazole in patients with alcoholic liver disease." Antimicrob Agents Chemother 31 (1987):  1662-4|Jensen JC, Gugler R "Single- and multiple-dose metronidazole kinetics." Clin Pharmacol Ther 34 (1983):  481-7|Farrell G, Baird-Lambert J, Cvejic M, Buchanan N "Disposition and metabolism of metronidazole in patients with liver failure." Hepatology 4 (1984):  772-6|Loft S, Dossing M, Poulsen HE, et al. "Influence of dose and route of administration on disposition of metronidazole and its major metabolites." Eur J Clin Pharmacol 30 (1986):  467-73|Loft S, Sonne J, Dossing M, Andreasen PB "Metronidazole pharmacokinetics in patients with hepatic encephalopathy." Scand J Gastroenterol 22 (1987):  117-23|"Product Information. MetroGel-Vaginal (metroNIDAZOLE topical)." Curatek Pharmaceuticals Ltd  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7884, 28492, 'Metronidazole (topical)', 'Liver Diseases', 'Metronidazole may be systemically absorbed when applied to the skin or mucosal membranes.  Once absorbed, metronidazole is extensively metabolized by the liver to both pharmacologically active and inactive compounds.  The plasma clearance of metronidazole may be decreased and the half-life prolonged in patients with impaired hepatic function.  Therapy with topical metronidazole should be administered cautiously in patients with liver disease.', '2', 'Lau AH, Evans R, Chang CW, Seligsohn R "Pharmacokinetics of metronidazole in patients with alcoholic liver disease." Antimicrob Agents Chemother 31 (1987):  1662-4|Jensen JC, Gugler R "Single- and multiple-dose metronidazole kinetics." Clin Pharmacol Ther 34 (1983):  481-7|Farrell G, Baird-Lambert J, Cvejic M, Buchanan N "Disposition and metabolism of metronidazole in patients with liver failure." Hepatology 4 (1984):  772-6|Loft S, Dossing M, Poulsen HE, et al. "Influence of dose and route of administration on disposition of metronidazole and its major metabolites." Eur J Clin Pharmacol 30 (1986):  467-73|Loft S, Sonne J, Dossing M, Andreasen PB "Metronidazole pharmacokinetics in patients with hepatic encephalopathy." Scand J Gastroenterol 22 (1987):  117-23|"Product Information. MetroGel-Vaginal (metroNIDAZOLE topical)." Curatek Pharmaceuticals Ltd  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7885, 30008, 'Metronidazole (topical)', 'Liver Diseases', 'Metronidazole may be systemically absorbed when applied to the skin or mucosal membranes.  Once absorbed, metronidazole is extensively metabolized by the liver to both pharmacologically active and inactive compounds.  The plasma clearance of metronidazole may be decreased and the half-life prolonged in patients with impaired hepatic function.  Therapy with topical metronidazole should be administered cautiously in patients with liver disease.', '2', 'Lau AH, Evans R, Chang CW, Seligsohn R "Pharmacokinetics of metronidazole in patients with alcoholic liver disease." Antimicrob Agents Chemother 31 (1987):  1662-4|Jensen JC, Gugler R "Single- and multiple-dose metronidazole kinetics." Clin Pharmacol Ther 34 (1983):  481-7|Farrell G, Baird-Lambert J, Cvejic M, Buchanan N "Disposition and metabolism of metronidazole in patients with liver failure." Hepatology 4 (1984):  772-6|Loft S, Dossing M, Poulsen HE, et al. "Influence of dose and route of administration on disposition of metronidazole and its major metabolites." Eur J Clin Pharmacol 30 (1986):  467-73|Loft S, Sonne J, Dossing M, Andreasen PB "Metronidazole pharmacokinetics in patients with hepatic encephalopathy." Scand J Gastroenterol 22 (1987):  117-23|"Product Information. MetroGel-Vaginal (metroNIDAZOLE topical)." Curatek Pharmaceuticals Ltd  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7886, 30543, 'Metronidazole (topical)', 'Liver Diseases', 'Metronidazole may be systemically absorbed when applied to the skin or mucosal membranes.  Once absorbed, metronidazole is extensively metabolized by the liver to both pharmacologically active and inactive compounds.  The plasma clearance of metronidazole may be decreased and the half-life prolonged in patients with impaired hepatic function.  Therapy with topical metronidazole should be administered cautiously in patients with liver disease.', '2', 'Lau AH, Evans R, Chang CW, Seligsohn R "Pharmacokinetics of metronidazole in patients with alcoholic liver disease." Antimicrob Agents Chemother 31 (1987):  1662-4|Jensen JC, Gugler R "Single- and multiple-dose metronidazole kinetics." Clin Pharmacol Ther 34 (1983):  481-7|Farrell G, Baird-Lambert J, Cvejic M, Buchanan N "Disposition and metabolism of metronidazole in patients with liver failure." Hepatology 4 (1984):  772-6|Loft S, Dossing M, Poulsen HE, et al. "Influence of dose and route of administration on disposition of metronidazole and its major metabolites." Eur J Clin Pharmacol 30 (1986):  467-73|Loft S, Sonne J, Dossing M, Andreasen PB "Metronidazole pharmacokinetics in patients with hepatic encephalopathy." Scand J Gastroenterol 22 (1987):  117-23|"Product Information. MetroGel-Vaginal (metroNIDAZOLE topical)." Curatek Pharmaceuticals Ltd  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7887, 33203, 'Metronidazole (topical)', 'Liver Diseases', 'Metronidazole may be systemically absorbed when applied to the skin or mucosal membranes.  Once absorbed, metronidazole is extensively metabolized by the liver to both pharmacologically active and inactive compounds.  The plasma clearance of metronidazole may be decreased and the half-life prolonged in patients with impaired hepatic function.  Therapy with topical metronidazole should be administered cautiously in patients with liver disease.', '2', 'Lau AH, Evans R, Chang CW, Seligsohn R "Pharmacokinetics of metronidazole in patients with alcoholic liver disease." Antimicrob Agents Chemother 31 (1987):  1662-4|Jensen JC, Gugler R "Single- and multiple-dose metronidazole kinetics." Clin Pharmacol Ther 34 (1983):  481-7|Farrell G, Baird-Lambert J, Cvejic M, Buchanan N "Disposition and metabolism of metronidazole in patients with liver failure." Hepatology 4 (1984):  772-6|Loft S, Dossing M, Poulsen HE, et al. "Influence of dose and route of administration on disposition of metronidazole and its major metabolites." Eur J Clin Pharmacol 30 (1986):  467-73|Loft S, Sonne J, Dossing M, Andreasen PB "Metronidazole pharmacokinetics in patients with hepatic encephalopathy." Scand J Gastroenterol 22 (1987):  117-23|"Product Information. MetroGel-Vaginal (metroNIDAZOLE topical)." Curatek Pharmaceuticals Ltd  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7888, 690, 'Metronidazole (topical)', 'Neurotoxicity Syndromes', 'Metronidazole may be systemically absorbed when applied to the skin or mucosal membranes.  The use of oral and intravenous metronidazole has been associated with the development of nervous system toxicity including convulsive seizures and dose-related peripheral neuropathy, the latter characterized primarily by numbness or paresthesia of an extremity.  Persistent peripheral neuropathy has been reported in some patients treated for prolonged periods.  Other neurologic adverse effects include vertigo, incoordination, ataxia, confusion, agitation, hallucinations, and depression.  Therapy with topical metronidazole should be administered cautiously in patients with or predisposed to seizures or other nervous system abnormalities.  Metronidazole therapy should be discontinued promptly if neurologic disturbances occur.', '2', 'Kusumi RK, Plouffe JF, Wyatt RH, Fass RJ "Central nervous sytem toxicity associated with metronidazole therapy." Ann Intern Med 93 (1980):  59-60|Schentag JJ, Ziemniak JA, Greco JM, Rainstein M, Buckley RJ "Mental confusion in a patient treated with metronidazole: a concentration-related effect." Pharmacotherapy 2 (1982):  384-7|Alvarez RS, Richardson DA, Bent AE, Ostergard DR "Central nervous system toxicity related to prolonged metronidazole therapy." Am J Obstet Gynecol 145 (1983):  640-1|Wienbren M, Perinpanayagam RM, Camba L, Lee CA "Convulsions and encephalopathy in a patient with leukaemia after treatment with metronidazole." J Clin Pathol 38 (1985):  1076|Duffy LF, Daum F, Fisher SE, et al. "Peripheral neuropathy in Crohn''s disease patients treated with metronidazole." Gastroenterology 88 (1985):  681-4|Boyce EG, Cookson ET, Bond WS "Persistent metronidazole-induced peripheral neuropathy." DICP 24 (1990):  19-21|Stahlberg D, Barany F, Einarsson K, Ursing B, Elmquist D, Persson A "Neurophysiologic studies of patients with Crohn''s disease on long-term treatment with metronidazole." Scand J Gastroenterol 26 (1991):  219-24|Learned-Coughlin S "Peripheral neuropathy induced by metronidazole." Ann Pharmacother 28 (1994):  536|Ahmed A, Laes DJ, Bressler EL "Reversible magnetic resonance imaging findings in metronidazole-induced encephalopathy." Neurology 45 (1995):  588-9|"Product Information. MetroGel-Vaginal (metroNIDAZOLE topical)." Curatek Pharmaceuticals Ltd  (2022):|Schreiber W, Spernal J "Metronidazole-induced psychotic disorder." Am J Psychiatry 154 (1997):  1170-1', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7889, 691, 'Metronidazole (topical)', 'Neurotoxicity Syndromes', 'Metronidazole may be systemically absorbed when applied to the skin or mucosal membranes.  The use of oral and intravenous metronidazole has been associated with the development of nervous system toxicity including convulsive seizures and dose-related peripheral neuropathy, the latter characterized primarily by numbness or paresthesia of an extremity.  Persistent peripheral neuropathy has been reported in some patients treated for prolonged periods.  Other neurologic adverse effects include vertigo, incoordination, ataxia, confusion, agitation, hallucinations, and depression.  Therapy with topical metronidazole should be administered cautiously in patients with or predisposed to seizures or other nervous system abnormalities.  Metronidazole therapy should be discontinued promptly if neurologic disturbances occur.', '2', 'Kusumi RK, Plouffe JF, Wyatt RH, Fass RJ "Central nervous sytem toxicity associated with metronidazole therapy." Ann Intern Med 93 (1980):  59-60|Schentag JJ, Ziemniak JA, Greco JM, Rainstein M, Buckley RJ "Mental confusion in a patient treated with metronidazole: a concentration-related effect." Pharmacotherapy 2 (1982):  384-7|Alvarez RS, Richardson DA, Bent AE, Ostergard DR "Central nervous system toxicity related to prolonged metronidazole therapy." Am J Obstet Gynecol 145 (1983):  640-1|Wienbren M, Perinpanayagam RM, Camba L, Lee CA "Convulsions and encephalopathy in a patient with leukaemia after treatment with metronidazole." J Clin Pathol 38 (1985):  1076|Duffy LF, Daum F, Fisher SE, et al. "Peripheral neuropathy in Crohn''s disease patients treated with metronidazole." Gastroenterology 88 (1985):  681-4|Boyce EG, Cookson ET, Bond WS "Persistent metronidazole-induced peripheral neuropathy." DICP 24 (1990):  19-21|Stahlberg D, Barany F, Einarsson K, Ursing B, Elmquist D, Persson A "Neurophysiologic studies of patients with Crohn''s disease on long-term treatment with metronidazole." Scand J Gastroenterol 26 (1991):  219-24|Learned-Coughlin S "Peripheral neuropathy induced by metronidazole." Ann Pharmacother 28 (1994):  536|Ahmed A, Laes DJ, Bressler EL "Reversible magnetic resonance imaging findings in metronidazole-induced encephalopathy." Neurology 45 (1995):  588-9|"Product Information. MetroGel-Vaginal (metroNIDAZOLE topical)." Curatek Pharmaceuticals Ltd  (2022):|Schreiber W, Spernal J "Metronidazole-induced psychotic disorder." Am J Psychiatry 154 (1997):  1170-1', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7890, 692, 'Metronidazole (topical)', 'Neurotoxicity Syndromes', 'Metronidazole may be systemically absorbed when applied to the skin or mucosal membranes.  The use of oral and intravenous metronidazole has been associated with the development of nervous system toxicity including convulsive seizures and dose-related peripheral neuropathy, the latter characterized primarily by numbness or paresthesia of an extremity.  Persistent peripheral neuropathy has been reported in some patients treated for prolonged periods.  Other neurologic adverse effects include vertigo, incoordination, ataxia, confusion, agitation, hallucinations, and depression.  Therapy with topical metronidazole should be administered cautiously in patients with or predisposed to seizures or other nervous system abnormalities.  Metronidazole therapy should be discontinued promptly if neurologic disturbances occur.', '2', 'Kusumi RK, Plouffe JF, Wyatt RH, Fass RJ "Central nervous sytem toxicity associated with metronidazole therapy." Ann Intern Med 93 (1980):  59-60|Schentag JJ, Ziemniak JA, Greco JM, Rainstein M, Buckley RJ "Mental confusion in a patient treated with metronidazole: a concentration-related effect." Pharmacotherapy 2 (1982):  384-7|Alvarez RS, Richardson DA, Bent AE, Ostergard DR "Central nervous system toxicity related to prolonged metronidazole therapy." Am J Obstet Gynecol 145 (1983):  640-1|Wienbren M, Perinpanayagam RM, Camba L, Lee CA "Convulsions and encephalopathy in a patient with leukaemia after treatment with metronidazole." J Clin Pathol 38 (1985):  1076|Duffy LF, Daum F, Fisher SE, et al. "Peripheral neuropathy in Crohn''s disease patients treated with metronidazole." Gastroenterology 88 (1985):  681-4|Boyce EG, Cookson ET, Bond WS "Persistent metronidazole-induced peripheral neuropathy." DICP 24 (1990):  19-21|Stahlberg D, Barany F, Einarsson K, Ursing B, Elmquist D, Persson A "Neurophysiologic studies of patients with Crohn''s disease on long-term treatment with metronidazole." Scand J Gastroenterol 26 (1991):  219-24|Learned-Coughlin S "Peripheral neuropathy induced by metronidazole." Ann Pharmacother 28 (1994):  536|Ahmed A, Laes DJ, Bressler EL "Reversible magnetic resonance imaging findings in metronidazole-induced encephalopathy." Neurology 45 (1995):  588-9|"Product Information. MetroGel-Vaginal (metroNIDAZOLE topical)." Curatek Pharmaceuticals Ltd  (2022):|Schreiber W, Spernal J "Metronidazole-induced psychotic disorder." Am J Psychiatry 154 (1997):  1170-1', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7891, 4210, 'Metronidazole (topical)', 'Neurotoxicity Syndromes', 'Metronidazole may be systemically absorbed when applied to the skin or mucosal membranes.  The use of oral and intravenous metronidazole has been associated with the development of nervous system toxicity including convulsive seizures and dose-related peripheral neuropathy, the latter characterized primarily by numbness or paresthesia of an extremity.  Persistent peripheral neuropathy has been reported in some patients treated for prolonged periods.  Other neurologic adverse effects include vertigo, incoordination, ataxia, confusion, agitation, hallucinations, and depression.  Therapy with topical metronidazole should be administered cautiously in patients with or predisposed to seizures or other nervous system abnormalities.  Metronidazole therapy should be discontinued promptly if neurologic disturbances occur.', '2', 'Kusumi RK, Plouffe JF, Wyatt RH, Fass RJ "Central nervous sytem toxicity associated with metronidazole therapy." Ann Intern Med 93 (1980):  59-60|Schentag JJ, Ziemniak JA, Greco JM, Rainstein M, Buckley RJ "Mental confusion in a patient treated with metronidazole: a concentration-related effect." Pharmacotherapy 2 (1982):  384-7|Alvarez RS, Richardson DA, Bent AE, Ostergard DR "Central nervous system toxicity related to prolonged metronidazole therapy." Am J Obstet Gynecol 145 (1983):  640-1|Wienbren M, Perinpanayagam RM, Camba L, Lee CA "Convulsions and encephalopathy in a patient with leukaemia after treatment with metronidazole." J Clin Pathol 38 (1985):  1076|Duffy LF, Daum F, Fisher SE, et al. "Peripheral neuropathy in Crohn''s disease patients treated with metronidazole." Gastroenterology 88 (1985):  681-4|Boyce EG, Cookson ET, Bond WS "Persistent metronidazole-induced peripheral neuropathy." DICP 24 (1990):  19-21|Stahlberg D, Barany F, Einarsson K, Ursing B, Elmquist D, Persson A "Neurophysiologic studies of patients with Crohn''s disease on long-term treatment with metronidazole." Scand J Gastroenterol 26 (1991):  219-24|Learned-Coughlin S "Peripheral neuropathy induced by metronidazole." Ann Pharmacother 28 (1994):  536|Ahmed A, Laes DJ, Bressler EL "Reversible magnetic resonance imaging findings in metronidazole-induced encephalopathy." Neurology 45 (1995):  588-9|"Product Information. MetroGel-Vaginal (metroNIDAZOLE topical)." Curatek Pharmaceuticals Ltd  (2022):|Schreiber W, Spernal J "Metronidazole-induced psychotic disorder." Am J Psychiatry 154 (1997):  1170-1', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7892, 4325, 'Metronidazole (topical)', 'Neurotoxicity Syndromes', 'Metronidazole may be systemically absorbed when applied to the skin or mucosal membranes.  The use of oral and intravenous metronidazole has been associated with the development of nervous system toxicity including convulsive seizures and dose-related peripheral neuropathy, the latter characterized primarily by numbness or paresthesia of an extremity.  Persistent peripheral neuropathy has been reported in some patients treated for prolonged periods.  Other neurologic adverse effects include vertigo, incoordination, ataxia, confusion, agitation, hallucinations, and depression.  Therapy with topical metronidazole should be administered cautiously in patients with or predisposed to seizures or other nervous system abnormalities.  Metronidazole therapy should be discontinued promptly if neurologic disturbances occur.', '2', 'Kusumi RK, Plouffe JF, Wyatt RH, Fass RJ "Central nervous sytem toxicity associated with metronidazole therapy." Ann Intern Med 93 (1980):  59-60|Schentag JJ, Ziemniak JA, Greco JM, Rainstein M, Buckley RJ "Mental confusion in a patient treated with metronidazole: a concentration-related effect." Pharmacotherapy 2 (1982):  384-7|Alvarez RS, Richardson DA, Bent AE, Ostergard DR "Central nervous system toxicity related to prolonged metronidazole therapy." Am J Obstet Gynecol 145 (1983):  640-1|Wienbren M, Perinpanayagam RM, Camba L, Lee CA "Convulsions and encephalopathy in a patient with leukaemia after treatment with metronidazole." J Clin Pathol 38 (1985):  1076|Duffy LF, Daum F, Fisher SE, et al. "Peripheral neuropathy in Crohn''s disease patients treated with metronidazole." Gastroenterology 88 (1985):  681-4|Boyce EG, Cookson ET, Bond WS "Persistent metronidazole-induced peripheral neuropathy." DICP 24 (1990):  19-21|Stahlberg D, Barany F, Einarsson K, Ursing B, Elmquist D, Persson A "Neurophysiologic studies of patients with Crohn''s disease on long-term treatment with metronidazole." Scand J Gastroenterol 26 (1991):  219-24|Learned-Coughlin S "Peripheral neuropathy induced by metronidazole." Ann Pharmacother 28 (1994):  536|Ahmed A, Laes DJ, Bressler EL "Reversible magnetic resonance imaging findings in metronidazole-induced encephalopathy." Neurology 45 (1995):  588-9|"Product Information. MetroGel-Vaginal (metroNIDAZOLE topical)." Curatek Pharmaceuticals Ltd  (2022):|Schreiber W, Spernal J "Metronidazole-induced psychotic disorder." Am J Psychiatry 154 (1997):  1170-1', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7893, 4894, 'Metronidazole (topical)', 'Neurotoxicity Syndromes', 'Metronidazole may be systemically absorbed when applied to the skin or mucosal membranes.  The use of oral and intravenous metronidazole has been associated with the development of nervous system toxicity including convulsive seizures and dose-related peripheral neuropathy, the latter characterized primarily by numbness or paresthesia of an extremity.  Persistent peripheral neuropathy has been reported in some patients treated for prolonged periods.  Other neurologic adverse effects include vertigo, incoordination, ataxia, confusion, agitation, hallucinations, and depression.  Therapy with topical metronidazole should be administered cautiously in patients with or predisposed to seizures or other nervous system abnormalities.  Metronidazole therapy should be discontinued promptly if neurologic disturbances occur.', '2', 'Kusumi RK, Plouffe JF, Wyatt RH, Fass RJ "Central nervous sytem toxicity associated with metronidazole therapy." Ann Intern Med 93 (1980):  59-60|Schentag JJ, Ziemniak JA, Greco JM, Rainstein M, Buckley RJ "Mental confusion in a patient treated with metronidazole: a concentration-related effect." Pharmacotherapy 2 (1982):  384-7|Alvarez RS, Richardson DA, Bent AE, Ostergard DR "Central nervous system toxicity related to prolonged metronidazole therapy." Am J Obstet Gynecol 145 (1983):  640-1|Wienbren M, Perinpanayagam RM, Camba L, Lee CA "Convulsions and encephalopathy in a patient with leukaemia after treatment with metronidazole." J Clin Pathol 38 (1985):  1076|Duffy LF, Daum F, Fisher SE, et al. "Peripheral neuropathy in Crohn''s disease patients treated with metronidazole." Gastroenterology 88 (1985):  681-4|Boyce EG, Cookson ET, Bond WS "Persistent metronidazole-induced peripheral neuropathy." DICP 24 (1990):  19-21|Stahlberg D, Barany F, Einarsson K, Ursing B, Elmquist D, Persson A "Neurophysiologic studies of patients with Crohn''s disease on long-term treatment with metronidazole." Scand J Gastroenterol 26 (1991):  219-24|Learned-Coughlin S "Peripheral neuropathy induced by metronidazole." Ann Pharmacother 28 (1994):  536|Ahmed A, Laes DJ, Bressler EL "Reversible magnetic resonance imaging findings in metronidazole-induced encephalopathy." Neurology 45 (1995):  588-9|"Product Information. MetroGel-Vaginal (metroNIDAZOLE topical)." Curatek Pharmaceuticals Ltd  (2022):|Schreiber W, Spernal J "Metronidazole-induced psychotic disorder." Am J Psychiatry 154 (1997):  1170-1', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7894, 4903, 'Metronidazole (topical)', 'Neurotoxicity Syndromes', 'Metronidazole may be systemically absorbed when applied to the skin or mucosal membranes.  The use of oral and intravenous metronidazole has been associated with the development of nervous system toxicity including convulsive seizures and dose-related peripheral neuropathy, the latter characterized primarily by numbness or paresthesia of an extremity.  Persistent peripheral neuropathy has been reported in some patients treated for prolonged periods.  Other neurologic adverse effects include vertigo, incoordination, ataxia, confusion, agitation, hallucinations, and depression.  Therapy with topical metronidazole should be administered cautiously in patients with or predisposed to seizures or other nervous system abnormalities.  Metronidazole therapy should be discontinued promptly if neurologic disturbances occur.', '2', 'Kusumi RK, Plouffe JF, Wyatt RH, Fass RJ "Central nervous sytem toxicity associated with metronidazole therapy." Ann Intern Med 93 (1980):  59-60|Schentag JJ, Ziemniak JA, Greco JM, Rainstein M, Buckley RJ "Mental confusion in a patient treated with metronidazole: a concentration-related effect." Pharmacotherapy 2 (1982):  384-7|Alvarez RS, Richardson DA, Bent AE, Ostergard DR "Central nervous system toxicity related to prolonged metronidazole therapy." Am J Obstet Gynecol 145 (1983):  640-1|Wienbren M, Perinpanayagam RM, Camba L, Lee CA "Convulsions and encephalopathy in a patient with leukaemia after treatment with metronidazole." J Clin Pathol 38 (1985):  1076|Duffy LF, Daum F, Fisher SE, et al. "Peripheral neuropathy in Crohn''s disease patients treated with metronidazole." Gastroenterology 88 (1985):  681-4|Boyce EG, Cookson ET, Bond WS "Persistent metronidazole-induced peripheral neuropathy." DICP 24 (1990):  19-21|Stahlberg D, Barany F, Einarsson K, Ursing B, Elmquist D, Persson A "Neurophysiologic studies of patients with Crohn''s disease on long-term treatment with metronidazole." Scand J Gastroenterol 26 (1991):  219-24|Learned-Coughlin S "Peripheral neuropathy induced by metronidazole." Ann Pharmacother 28 (1994):  536|Ahmed A, Laes DJ, Bressler EL "Reversible magnetic resonance imaging findings in metronidazole-induced encephalopathy." Neurology 45 (1995):  588-9|"Product Information. MetroGel-Vaginal (metroNIDAZOLE topical)." Curatek Pharmaceuticals Ltd  (2022):|Schreiber W, Spernal J "Metronidazole-induced psychotic disorder." Am J Psychiatry 154 (1997):  1170-1', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7895, 4904, 'Metronidazole (topical)', 'Neurotoxicity Syndromes', 'Metronidazole may be systemically absorbed when applied to the skin or mucosal membranes.  The use of oral and intravenous metronidazole has been associated with the development of nervous system toxicity including convulsive seizures and dose-related peripheral neuropathy, the latter characterized primarily by numbness or paresthesia of an extremity.  Persistent peripheral neuropathy has been reported in some patients treated for prolonged periods.  Other neurologic adverse effects include vertigo, incoordination, ataxia, confusion, agitation, hallucinations, and depression.  Therapy with topical metronidazole should be administered cautiously in patients with or predisposed to seizures or other nervous system abnormalities.  Metronidazole therapy should be discontinued promptly if neurologic disturbances occur.', '2', 'Kusumi RK, Plouffe JF, Wyatt RH, Fass RJ "Central nervous sytem toxicity associated with metronidazole therapy." Ann Intern Med 93 (1980):  59-60|Schentag JJ, Ziemniak JA, Greco JM, Rainstein M, Buckley RJ "Mental confusion in a patient treated with metronidazole: a concentration-related effect." Pharmacotherapy 2 (1982):  384-7|Alvarez RS, Richardson DA, Bent AE, Ostergard DR "Central nervous system toxicity related to prolonged metronidazole therapy." Am J Obstet Gynecol 145 (1983):  640-1|Wienbren M, Perinpanayagam RM, Camba L, Lee CA "Convulsions and encephalopathy in a patient with leukaemia after treatment with metronidazole." J Clin Pathol 38 (1985):  1076|Duffy LF, Daum F, Fisher SE, et al. "Peripheral neuropathy in Crohn''s disease patients treated with metronidazole." Gastroenterology 88 (1985):  681-4|Boyce EG, Cookson ET, Bond WS "Persistent metronidazole-induced peripheral neuropathy." DICP 24 (1990):  19-21|Stahlberg D, Barany F, Einarsson K, Ursing B, Elmquist D, Persson A "Neurophysiologic studies of patients with Crohn''s disease on long-term treatment with metronidazole." Scand J Gastroenterol 26 (1991):  219-24|Learned-Coughlin S "Peripheral neuropathy induced by metronidazole." Ann Pharmacother 28 (1994):  536|Ahmed A, Laes DJ, Bressler EL "Reversible magnetic resonance imaging findings in metronidazole-induced encephalopathy." Neurology 45 (1995):  588-9|"Product Information. MetroGel-Vaginal (metroNIDAZOLE topical)." Curatek Pharmaceuticals Ltd  (2022):|Schreiber W, Spernal J "Metronidazole-induced psychotic disorder." Am J Psychiatry 154 (1997):  1170-1', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7896, 4905, 'Metronidazole (topical)', 'Neurotoxicity Syndromes', 'Metronidazole may be systemically absorbed when applied to the skin or mucosal membranes.  The use of oral and intravenous metronidazole has been associated with the development of nervous system toxicity including convulsive seizures and dose-related peripheral neuropathy, the latter characterized primarily by numbness or paresthesia of an extremity.  Persistent peripheral neuropathy has been reported in some patients treated for prolonged periods.  Other neurologic adverse effects include vertigo, incoordination, ataxia, confusion, agitation, hallucinations, and depression.  Therapy with topical metronidazole should be administered cautiously in patients with or predisposed to seizures or other nervous system abnormalities.  Metronidazole therapy should be discontinued promptly if neurologic disturbances occur.', '2', 'Kusumi RK, Plouffe JF, Wyatt RH, Fass RJ "Central nervous sytem toxicity associated with metronidazole therapy." Ann Intern Med 93 (1980):  59-60|Schentag JJ, Ziemniak JA, Greco JM, Rainstein M, Buckley RJ "Mental confusion in a patient treated with metronidazole: a concentration-related effect." Pharmacotherapy 2 (1982):  384-7|Alvarez RS, Richardson DA, Bent AE, Ostergard DR "Central nervous system toxicity related to prolonged metronidazole therapy." Am J Obstet Gynecol 145 (1983):  640-1|Wienbren M, Perinpanayagam RM, Camba L, Lee CA "Convulsions and encephalopathy in a patient with leukaemia after treatment with metronidazole." J Clin Pathol 38 (1985):  1076|Duffy LF, Daum F, Fisher SE, et al. "Peripheral neuropathy in Crohn''s disease patients treated with metronidazole." Gastroenterology 88 (1985):  681-4|Boyce EG, Cookson ET, Bond WS "Persistent metronidazole-induced peripheral neuropathy." DICP 24 (1990):  19-21|Stahlberg D, Barany F, Einarsson K, Ursing B, Elmquist D, Persson A "Neurophysiologic studies of patients with Crohn''s disease on long-term treatment with metronidazole." Scand J Gastroenterol 26 (1991):  219-24|Learned-Coughlin S "Peripheral neuropathy induced by metronidazole." Ann Pharmacother 28 (1994):  536|Ahmed A, Laes DJ, Bressler EL "Reversible magnetic resonance imaging findings in metronidazole-induced encephalopathy." Neurology 45 (1995):  588-9|"Product Information. MetroGel-Vaginal (metroNIDAZOLE topical)." Curatek Pharmaceuticals Ltd  (2022):|Schreiber W, Spernal J "Metronidazole-induced psychotic disorder." Am J Psychiatry 154 (1997):  1170-1', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7897, 4906, 'Metronidazole (topical)', 'Neurotoxicity Syndromes', 'Metronidazole may be systemically absorbed when applied to the skin or mucosal membranes.  The use of oral and intravenous metronidazole has been associated with the development of nervous system toxicity including convulsive seizures and dose-related peripheral neuropathy, the latter characterized primarily by numbness or paresthesia of an extremity.  Persistent peripheral neuropathy has been reported in some patients treated for prolonged periods.  Other neurologic adverse effects include vertigo, incoordination, ataxia, confusion, agitation, hallucinations, and depression.  Therapy with topical metronidazole should be administered cautiously in patients with or predisposed to seizures or other nervous system abnormalities.  Metronidazole therapy should be discontinued promptly if neurologic disturbances occur.', '2', 'Kusumi RK, Plouffe JF, Wyatt RH, Fass RJ "Central nervous sytem toxicity associated with metronidazole therapy." Ann Intern Med 93 (1980):  59-60|Schentag JJ, Ziemniak JA, Greco JM, Rainstein M, Buckley RJ "Mental confusion in a patient treated with metronidazole: a concentration-related effect." Pharmacotherapy 2 (1982):  384-7|Alvarez RS, Richardson DA, Bent AE, Ostergard DR "Central nervous system toxicity related to prolonged metronidazole therapy." Am J Obstet Gynecol 145 (1983):  640-1|Wienbren M, Perinpanayagam RM, Camba L, Lee CA "Convulsions and encephalopathy in a patient with leukaemia after treatment with metronidazole." J Clin Pathol 38 (1985):  1076|Duffy LF, Daum F, Fisher SE, et al. "Peripheral neuropathy in Crohn''s disease patients treated with metronidazole." Gastroenterology 88 (1985):  681-4|Boyce EG, Cookson ET, Bond WS "Persistent metronidazole-induced peripheral neuropathy." DICP 24 (1990):  19-21|Stahlberg D, Barany F, Einarsson K, Ursing B, Elmquist D, Persson A "Neurophysiologic studies of patients with Crohn''s disease on long-term treatment with metronidazole." Scand J Gastroenterol 26 (1991):  219-24|Learned-Coughlin S "Peripheral neuropathy induced by metronidazole." Ann Pharmacother 28 (1994):  536|Ahmed A, Laes DJ, Bressler EL "Reversible magnetic resonance imaging findings in metronidazole-induced encephalopathy." Neurology 45 (1995):  588-9|"Product Information. MetroGel-Vaginal (metroNIDAZOLE topical)." Curatek Pharmaceuticals Ltd  (2022):|Schreiber W, Spernal J "Metronidazole-induced psychotic disorder." Am J Psychiatry 154 (1997):  1170-1', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7898, 4930, 'Metronidazole (topical)', 'Neurotoxicity Syndromes', 'Metronidazole may be systemically absorbed when applied to the skin or mucosal membranes.  The use of oral and intravenous metronidazole has been associated with the development of nervous system toxicity including convulsive seizures and dose-related peripheral neuropathy, the latter characterized primarily by numbness or paresthesia of an extremity.  Persistent peripheral neuropathy has been reported in some patients treated for prolonged periods.  Other neurologic adverse effects include vertigo, incoordination, ataxia, confusion, agitation, hallucinations, and depression.  Therapy with topical metronidazole should be administered cautiously in patients with or predisposed to seizures or other nervous system abnormalities.  Metronidazole therapy should be discontinued promptly if neurologic disturbances occur.', '2', 'Kusumi RK, Plouffe JF, Wyatt RH, Fass RJ "Central nervous sytem toxicity associated with metronidazole therapy." Ann Intern Med 93 (1980):  59-60|Schentag JJ, Ziemniak JA, Greco JM, Rainstein M, Buckley RJ "Mental confusion in a patient treated with metronidazole: a concentration-related effect." Pharmacotherapy 2 (1982):  384-7|Alvarez RS, Richardson DA, Bent AE, Ostergard DR "Central nervous system toxicity related to prolonged metronidazole therapy." Am J Obstet Gynecol 145 (1983):  640-1|Wienbren M, Perinpanayagam RM, Camba L, Lee CA "Convulsions and encephalopathy in a patient with leukaemia after treatment with metronidazole." J Clin Pathol 38 (1985):  1076|Duffy LF, Daum F, Fisher SE, et al. "Peripheral neuropathy in Crohn''s disease patients treated with metronidazole." Gastroenterology 88 (1985):  681-4|Boyce EG, Cookson ET, Bond WS "Persistent metronidazole-induced peripheral neuropathy." DICP 24 (1990):  19-21|Stahlberg D, Barany F, Einarsson K, Ursing B, Elmquist D, Persson A "Neurophysiologic studies of patients with Crohn''s disease on long-term treatment with metronidazole." Scand J Gastroenterol 26 (1991):  219-24|Learned-Coughlin S "Peripheral neuropathy induced by metronidazole." Ann Pharmacother 28 (1994):  536|Ahmed A, Laes DJ, Bressler EL "Reversible magnetic resonance imaging findings in metronidazole-induced encephalopathy." Neurology 45 (1995):  588-9|"Product Information. MetroGel-Vaginal (metroNIDAZOLE topical)." Curatek Pharmaceuticals Ltd  (2022):|Schreiber W, Spernal J "Metronidazole-induced psychotic disorder." Am J Psychiatry 154 (1997):  1170-1', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7899, 6077, 'Metronidazole (topical)', 'Neurotoxicity Syndromes', 'Metronidazole may be systemically absorbed when applied to the skin or mucosal membranes.  The use of oral and intravenous metronidazole has been associated with the development of nervous system toxicity including convulsive seizures and dose-related peripheral neuropathy, the latter characterized primarily by numbness or paresthesia of an extremity.  Persistent peripheral neuropathy has been reported in some patients treated for prolonged periods.  Other neurologic adverse effects include vertigo, incoordination, ataxia, confusion, agitation, hallucinations, and depression.  Therapy with topical metronidazole should be administered cautiously in patients with or predisposed to seizures or other nervous system abnormalities.  Metronidazole therapy should be discontinued promptly if neurologic disturbances occur.', '2', 'Kusumi RK, Plouffe JF, Wyatt RH, Fass RJ "Central nervous sytem toxicity associated with metronidazole therapy." Ann Intern Med 93 (1980):  59-60|Schentag JJ, Ziemniak JA, Greco JM, Rainstein M, Buckley RJ "Mental confusion in a patient treated with metronidazole: a concentration-related effect." Pharmacotherapy 2 (1982):  384-7|Alvarez RS, Richardson DA, Bent AE, Ostergard DR "Central nervous system toxicity related to prolonged metronidazole therapy." Am J Obstet Gynecol 145 (1983):  640-1|Wienbren M, Perinpanayagam RM, Camba L, Lee CA "Convulsions and encephalopathy in a patient with leukaemia after treatment with metronidazole." J Clin Pathol 38 (1985):  1076|Duffy LF, Daum F, Fisher SE, et al. "Peripheral neuropathy in Crohn''s disease patients treated with metronidazole." Gastroenterology 88 (1985):  681-4|Boyce EG, Cookson ET, Bond WS "Persistent metronidazole-induced peripheral neuropathy." DICP 24 (1990):  19-21|Stahlberg D, Barany F, Einarsson K, Ursing B, Elmquist D, Persson A "Neurophysiologic studies of patients with Crohn''s disease on long-term treatment with metronidazole." Scand J Gastroenterol 26 (1991):  219-24|Learned-Coughlin S "Peripheral neuropathy induced by metronidazole." Ann Pharmacother 28 (1994):  536|Ahmed A, Laes DJ, Bressler EL "Reversible magnetic resonance imaging findings in metronidazole-induced encephalopathy." Neurology 45 (1995):  588-9|"Product Information. MetroGel-Vaginal (metroNIDAZOLE topical)." Curatek Pharmaceuticals Ltd  (2022):|Schreiber W, Spernal J "Metronidazole-induced psychotic disorder." Am J Psychiatry 154 (1997):  1170-1', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7900, 8101, 'Metronidazole (topical)', 'Neurotoxicity Syndromes', 'Metronidazole may be systemically absorbed when applied to the skin or mucosal membranes.  The use of oral and intravenous metronidazole has been associated with the development of nervous system toxicity including convulsive seizures and dose-related peripheral neuropathy, the latter characterized primarily by numbness or paresthesia of an extremity.  Persistent peripheral neuropathy has been reported in some patients treated for prolonged periods.  Other neurologic adverse effects include vertigo, incoordination, ataxia, confusion, agitation, hallucinations, and depression.  Therapy with topical metronidazole should be administered cautiously in patients with or predisposed to seizures or other nervous system abnormalities.  Metronidazole therapy should be discontinued promptly if neurologic disturbances occur.', '2', 'Kusumi RK, Plouffe JF, Wyatt RH, Fass RJ "Central nervous sytem toxicity associated with metronidazole therapy." Ann Intern Med 93 (1980):  59-60|Schentag JJ, Ziemniak JA, Greco JM, Rainstein M, Buckley RJ "Mental confusion in a patient treated with metronidazole: a concentration-related effect." Pharmacotherapy 2 (1982):  384-7|Alvarez RS, Richardson DA, Bent AE, Ostergard DR "Central nervous system toxicity related to prolonged metronidazole therapy." Am J Obstet Gynecol 145 (1983):  640-1|Wienbren M, Perinpanayagam RM, Camba L, Lee CA "Convulsions and encephalopathy in a patient with leukaemia after treatment with metronidazole." J Clin Pathol 38 (1985):  1076|Duffy LF, Daum F, Fisher SE, et al. "Peripheral neuropathy in Crohn''s disease patients treated with metronidazole." Gastroenterology 88 (1985):  681-4|Boyce EG, Cookson ET, Bond WS "Persistent metronidazole-induced peripheral neuropathy." DICP 24 (1990):  19-21|Stahlberg D, Barany F, Einarsson K, Ursing B, Elmquist D, Persson A "Neurophysiologic studies of patients with Crohn''s disease on long-term treatment with metronidazole." Scand J Gastroenterol 26 (1991):  219-24|Learned-Coughlin S "Peripheral neuropathy induced by metronidazole." Ann Pharmacother 28 (1994):  536|Ahmed A, Laes DJ, Bressler EL "Reversible magnetic resonance imaging findings in metronidazole-induced encephalopathy." Neurology 45 (1995):  588-9|"Product Information. MetroGel-Vaginal (metroNIDAZOLE topical)." Curatek Pharmaceuticals Ltd  (2022):|Schreiber W, Spernal J "Metronidazole-induced psychotic disorder." Am J Psychiatry 154 (1997):  1170-1', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7901, 8102, 'Metronidazole (topical)', 'Neurotoxicity Syndromes', 'Metronidazole may be systemically absorbed when applied to the skin or mucosal membranes.  The use of oral and intravenous metronidazole has been associated with the development of nervous system toxicity including convulsive seizures and dose-related peripheral neuropathy, the latter characterized primarily by numbness or paresthesia of an extremity.  Persistent peripheral neuropathy has been reported in some patients treated for prolonged periods.  Other neurologic adverse effects include vertigo, incoordination, ataxia, confusion, agitation, hallucinations, and depression.  Therapy with topical metronidazole should be administered cautiously in patients with or predisposed to seizures or other nervous system abnormalities.  Metronidazole therapy should be discontinued promptly if neurologic disturbances occur.', '2', 'Kusumi RK, Plouffe JF, Wyatt RH, Fass RJ "Central nervous sytem toxicity associated with metronidazole therapy." Ann Intern Med 93 (1980):  59-60|Schentag JJ, Ziemniak JA, Greco JM, Rainstein M, Buckley RJ "Mental confusion in a patient treated with metronidazole: a concentration-related effect." Pharmacotherapy 2 (1982):  384-7|Alvarez RS, Richardson DA, Bent AE, Ostergard DR "Central nervous system toxicity related to prolonged metronidazole therapy." Am J Obstet Gynecol 145 (1983):  640-1|Wienbren M, Perinpanayagam RM, Camba L, Lee CA "Convulsions and encephalopathy in a patient with leukaemia after treatment with metronidazole." J Clin Pathol 38 (1985):  1076|Duffy LF, Daum F, Fisher SE, et al. "Peripheral neuropathy in Crohn''s disease patients treated with metronidazole." Gastroenterology 88 (1985):  681-4|Boyce EG, Cookson ET, Bond WS "Persistent metronidazole-induced peripheral neuropathy." DICP 24 (1990):  19-21|Stahlberg D, Barany F, Einarsson K, Ursing B, Elmquist D, Persson A "Neurophysiologic studies of patients with Crohn''s disease on long-term treatment with metronidazole." Scand J Gastroenterol 26 (1991):  219-24|Learned-Coughlin S "Peripheral neuropathy induced by metronidazole." Ann Pharmacother 28 (1994):  536|Ahmed A, Laes DJ, Bressler EL "Reversible magnetic resonance imaging findings in metronidazole-induced encephalopathy." Neurology 45 (1995):  588-9|"Product Information. MetroGel-Vaginal (metroNIDAZOLE topical)." Curatek Pharmaceuticals Ltd  (2022):|Schreiber W, Spernal J "Metronidazole-induced psychotic disorder." Am J Psychiatry 154 (1997):  1170-1', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7902, 14075, 'Metronidazole (topical)', 'Neurotoxicity Syndromes', 'Metronidazole may be systemically absorbed when applied to the skin or mucosal membranes.  The use of oral and intravenous metronidazole has been associated with the development of nervous system toxicity including convulsive seizures and dose-related peripheral neuropathy, the latter characterized primarily by numbness or paresthesia of an extremity.  Persistent peripheral neuropathy has been reported in some patients treated for prolonged periods.  Other neurologic adverse effects include vertigo, incoordination, ataxia, confusion, agitation, hallucinations, and depression.  Therapy with topical metronidazole should be administered cautiously in patients with or predisposed to seizures or other nervous system abnormalities.  Metronidazole therapy should be discontinued promptly if neurologic disturbances occur.', '2', 'Kusumi RK, Plouffe JF, Wyatt RH, Fass RJ "Central nervous sytem toxicity associated with metronidazole therapy." Ann Intern Med 93 (1980):  59-60|Schentag JJ, Ziemniak JA, Greco JM, Rainstein M, Buckley RJ "Mental confusion in a patient treated with metronidazole: a concentration-related effect." Pharmacotherapy 2 (1982):  384-7|Alvarez RS, Richardson DA, Bent AE, Ostergard DR "Central nervous system toxicity related to prolonged metronidazole therapy." Am J Obstet Gynecol 145 (1983):  640-1|Wienbren M, Perinpanayagam RM, Camba L, Lee CA "Convulsions and encephalopathy in a patient with leukaemia after treatment with metronidazole." J Clin Pathol 38 (1985):  1076|Duffy LF, Daum F, Fisher SE, et al. "Peripheral neuropathy in Crohn''s disease patients treated with metronidazole." Gastroenterology 88 (1985):  681-4|Boyce EG, Cookson ET, Bond WS "Persistent metronidazole-induced peripheral neuropathy." DICP 24 (1990):  19-21|Stahlberg D, Barany F, Einarsson K, Ursing B, Elmquist D, Persson A "Neurophysiologic studies of patients with Crohn''s disease on long-term treatment with metronidazole." Scand J Gastroenterol 26 (1991):  219-24|Learned-Coughlin S "Peripheral neuropathy induced by metronidazole." Ann Pharmacother 28 (1994):  536|Ahmed A, Laes DJ, Bressler EL "Reversible magnetic resonance imaging findings in metronidazole-induced encephalopathy." Neurology 45 (1995):  588-9|"Product Information. MetroGel-Vaginal (metroNIDAZOLE topical)." Curatek Pharmaceuticals Ltd  (2022):|Schreiber W, Spernal J "Metronidazole-induced psychotic disorder." Am J Psychiatry 154 (1997):  1170-1', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7903, 14076, 'Metronidazole (topical)', 'Neurotoxicity Syndromes', 'Metronidazole may be systemically absorbed when applied to the skin or mucosal membranes.  The use of oral and intravenous metronidazole has been associated with the development of nervous system toxicity including convulsive seizures and dose-related peripheral neuropathy, the latter characterized primarily by numbness or paresthesia of an extremity.  Persistent peripheral neuropathy has been reported in some patients treated for prolonged periods.  Other neurologic adverse effects include vertigo, incoordination, ataxia, confusion, agitation, hallucinations, and depression.  Therapy with topical metronidazole should be administered cautiously in patients with or predisposed to seizures or other nervous system abnormalities.  Metronidazole therapy should be discontinued promptly if neurologic disturbances occur.', '2', 'Kusumi RK, Plouffe JF, Wyatt RH, Fass RJ "Central nervous sytem toxicity associated with metronidazole therapy." Ann Intern Med 93 (1980):  59-60|Schentag JJ, Ziemniak JA, Greco JM, Rainstein M, Buckley RJ "Mental confusion in a patient treated with metronidazole: a concentration-related effect." Pharmacotherapy 2 (1982):  384-7|Alvarez RS, Richardson DA, Bent AE, Ostergard DR "Central nervous system toxicity related to prolonged metronidazole therapy." Am J Obstet Gynecol 145 (1983):  640-1|Wienbren M, Perinpanayagam RM, Camba L, Lee CA "Convulsions and encephalopathy in a patient with leukaemia after treatment with metronidazole." J Clin Pathol 38 (1985):  1076|Duffy LF, Daum F, Fisher SE, et al. "Peripheral neuropathy in Crohn''s disease patients treated with metronidazole." Gastroenterology 88 (1985):  681-4|Boyce EG, Cookson ET, Bond WS "Persistent metronidazole-induced peripheral neuropathy." DICP 24 (1990):  19-21|Stahlberg D, Barany F, Einarsson K, Ursing B, Elmquist D, Persson A "Neurophysiologic studies of patients with Crohn''s disease on long-term treatment with metronidazole." Scand J Gastroenterol 26 (1991):  219-24|Learned-Coughlin S "Peripheral neuropathy induced by metronidazole." Ann Pharmacother 28 (1994):  536|Ahmed A, Laes DJ, Bressler EL "Reversible magnetic resonance imaging findings in metronidazole-induced encephalopathy." Neurology 45 (1995):  588-9|"Product Information. MetroGel-Vaginal (metroNIDAZOLE topical)." Curatek Pharmaceuticals Ltd  (2022):|Schreiber W, Spernal J "Metronidazole-induced psychotic disorder." Am J Psychiatry 154 (1997):  1170-1', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7904, 14080, 'Metronidazole (topical)', 'Neurotoxicity Syndromes', 'Metronidazole may be systemically absorbed when applied to the skin or mucosal membranes.  The use of oral and intravenous metronidazole has been associated with the development of nervous system toxicity including convulsive seizures and dose-related peripheral neuropathy, the latter characterized primarily by numbness or paresthesia of an extremity.  Persistent peripheral neuropathy has been reported in some patients treated for prolonged periods.  Other neurologic adverse effects include vertigo, incoordination, ataxia, confusion, agitation, hallucinations, and depression.  Therapy with topical metronidazole should be administered cautiously in patients with or predisposed to seizures or other nervous system abnormalities.  Metronidazole therapy should be discontinued promptly if neurologic disturbances occur.', '2', 'Kusumi RK, Plouffe JF, Wyatt RH, Fass RJ "Central nervous sytem toxicity associated with metronidazole therapy." Ann Intern Med 93 (1980):  59-60|Schentag JJ, Ziemniak JA, Greco JM, Rainstein M, Buckley RJ "Mental confusion in a patient treated with metronidazole: a concentration-related effect." Pharmacotherapy 2 (1982):  384-7|Alvarez RS, Richardson DA, Bent AE, Ostergard DR "Central nervous system toxicity related to prolonged metronidazole therapy." Am J Obstet Gynecol 145 (1983):  640-1|Wienbren M, Perinpanayagam RM, Camba L, Lee CA "Convulsions and encephalopathy in a patient with leukaemia after treatment with metronidazole." J Clin Pathol 38 (1985):  1076|Duffy LF, Daum F, Fisher SE, et al. "Peripheral neuropathy in Crohn''s disease patients treated with metronidazole." Gastroenterology 88 (1985):  681-4|Boyce EG, Cookson ET, Bond WS "Persistent metronidazole-induced peripheral neuropathy." DICP 24 (1990):  19-21|Stahlberg D, Barany F, Einarsson K, Ursing B, Elmquist D, Persson A "Neurophysiologic studies of patients with Crohn''s disease on long-term treatment with metronidazole." Scand J Gastroenterol 26 (1991):  219-24|Learned-Coughlin S "Peripheral neuropathy induced by metronidazole." Ann Pharmacother 28 (1994):  536|Ahmed A, Laes DJ, Bressler EL "Reversible magnetic resonance imaging findings in metronidazole-induced encephalopathy." Neurology 45 (1995):  588-9|"Product Information. MetroGel-Vaginal (metroNIDAZOLE topical)." Curatek Pharmaceuticals Ltd  (2022):|Schreiber W, Spernal J "Metronidazole-induced psychotic disorder." Am J Psychiatry 154 (1997):  1170-1', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7905, 15559, 'Metronidazole (topical)', 'Neurotoxicity Syndromes', 'Metronidazole may be systemically absorbed when applied to the skin or mucosal membranes.  The use of oral and intravenous metronidazole has been associated with the development of nervous system toxicity including convulsive seizures and dose-related peripheral neuropathy, the latter characterized primarily by numbness or paresthesia of an extremity.  Persistent peripheral neuropathy has been reported in some patients treated for prolonged periods.  Other neurologic adverse effects include vertigo, incoordination, ataxia, confusion, agitation, hallucinations, and depression.  Therapy with topical metronidazole should be administered cautiously in patients with or predisposed to seizures or other nervous system abnormalities.  Metronidazole therapy should be discontinued promptly if neurologic disturbances occur.', '2', 'Kusumi RK, Plouffe JF, Wyatt RH, Fass RJ "Central nervous sytem toxicity associated with metronidazole therapy." Ann Intern Med 93 (1980):  59-60|Schentag JJ, Ziemniak JA, Greco JM, Rainstein M, Buckley RJ "Mental confusion in a patient treated with metronidazole: a concentration-related effect." Pharmacotherapy 2 (1982):  384-7|Alvarez RS, Richardson DA, Bent AE, Ostergard DR "Central nervous system toxicity related to prolonged metronidazole therapy." Am J Obstet Gynecol 145 (1983):  640-1|Wienbren M, Perinpanayagam RM, Camba L, Lee CA "Convulsions and encephalopathy in a patient with leukaemia after treatment with metronidazole." J Clin Pathol 38 (1985):  1076|Duffy LF, Daum F, Fisher SE, et al. "Peripheral neuropathy in Crohn''s disease patients treated with metronidazole." Gastroenterology 88 (1985):  681-4|Boyce EG, Cookson ET, Bond WS "Persistent metronidazole-induced peripheral neuropathy." DICP 24 (1990):  19-21|Stahlberg D, Barany F, Einarsson K, Ursing B, Elmquist D, Persson A "Neurophysiologic studies of patients with Crohn''s disease on long-term treatment with metronidazole." Scand J Gastroenterol 26 (1991):  219-24|Learned-Coughlin S "Peripheral neuropathy induced by metronidazole." Ann Pharmacother 28 (1994):  536|Ahmed A, Laes DJ, Bressler EL "Reversible magnetic resonance imaging findings in metronidazole-induced encephalopathy." Neurology 45 (1995):  588-9|"Product Information. MetroGel-Vaginal (metroNIDAZOLE topical)." Curatek Pharmaceuticals Ltd  (2022):|Schreiber W, Spernal J "Metronidazole-induced psychotic disorder." Am J Psychiatry 154 (1997):  1170-1', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7906, 16787, 'Metronidazole (topical)', 'Neurotoxicity Syndromes', 'Metronidazole may be systemically absorbed when applied to the skin or mucosal membranes.  The use of oral and intravenous metronidazole has been associated with the development of nervous system toxicity including convulsive seizures and dose-related peripheral neuropathy, the latter characterized primarily by numbness or paresthesia of an extremity.  Persistent peripheral neuropathy has been reported in some patients treated for prolonged periods.  Other neurologic adverse effects include vertigo, incoordination, ataxia, confusion, agitation, hallucinations, and depression.  Therapy with topical metronidazole should be administered cautiously in patients with or predisposed to seizures or other nervous system abnormalities.  Metronidazole therapy should be discontinued promptly if neurologic disturbances occur.', '2', 'Kusumi RK, Plouffe JF, Wyatt RH, Fass RJ "Central nervous sytem toxicity associated with metronidazole therapy." Ann Intern Med 93 (1980):  59-60|Schentag JJ, Ziemniak JA, Greco JM, Rainstein M, Buckley RJ "Mental confusion in a patient treated with metronidazole: a concentration-related effect." Pharmacotherapy 2 (1982):  384-7|Alvarez RS, Richardson DA, Bent AE, Ostergard DR "Central nervous system toxicity related to prolonged metronidazole therapy." Am J Obstet Gynecol 145 (1983):  640-1|Wienbren M, Perinpanayagam RM, Camba L, Lee CA "Convulsions and encephalopathy in a patient with leukaemia after treatment with metronidazole." J Clin Pathol 38 (1985):  1076|Duffy LF, Daum F, Fisher SE, et al. "Peripheral neuropathy in Crohn''s disease patients treated with metronidazole." Gastroenterology 88 (1985):  681-4|Boyce EG, Cookson ET, Bond WS "Persistent metronidazole-induced peripheral neuropathy." DICP 24 (1990):  19-21|Stahlberg D, Barany F, Einarsson K, Ursing B, Elmquist D, Persson A "Neurophysiologic studies of patients with Crohn''s disease on long-term treatment with metronidazole." Scand J Gastroenterol 26 (1991):  219-24|Learned-Coughlin S "Peripheral neuropathy induced by metronidazole." Ann Pharmacother 28 (1994):  536|Ahmed A, Laes DJ, Bressler EL "Reversible magnetic resonance imaging findings in metronidazole-induced encephalopathy." Neurology 45 (1995):  588-9|"Product Information. MetroGel-Vaginal (metroNIDAZOLE topical)." Curatek Pharmaceuticals Ltd  (2022):|Schreiber W, Spernal J "Metronidazole-induced psychotic disorder." Am J Psychiatry 154 (1997):  1170-1', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7907, 17956, 'Metronidazole (topical)', 'Neurotoxicity Syndromes', 'Metronidazole may be systemically absorbed when applied to the skin or mucosal membranes.  The use of oral and intravenous metronidazole has been associated with the development of nervous system toxicity including convulsive seizures and dose-related peripheral neuropathy, the latter characterized primarily by numbness or paresthesia of an extremity.  Persistent peripheral neuropathy has been reported in some patients treated for prolonged periods.  Other neurologic adverse effects include vertigo, incoordination, ataxia, confusion, agitation, hallucinations, and depression.  Therapy with topical metronidazole should be administered cautiously in patients with or predisposed to seizures or other nervous system abnormalities.  Metronidazole therapy should be discontinued promptly if neurologic disturbances occur.', '2', 'Kusumi RK, Plouffe JF, Wyatt RH, Fass RJ "Central nervous sytem toxicity associated with metronidazole therapy." Ann Intern Med 93 (1980):  59-60|Schentag JJ, Ziemniak JA, Greco JM, Rainstein M, Buckley RJ "Mental confusion in a patient treated with metronidazole: a concentration-related effect." Pharmacotherapy 2 (1982):  384-7|Alvarez RS, Richardson DA, Bent AE, Ostergard DR "Central nervous system toxicity related to prolonged metronidazole therapy." Am J Obstet Gynecol 145 (1983):  640-1|Wienbren M, Perinpanayagam RM, Camba L, Lee CA "Convulsions and encephalopathy in a patient with leukaemia after treatment with metronidazole." J Clin Pathol 38 (1985):  1076|Duffy LF, Daum F, Fisher SE, et al. "Peripheral neuropathy in Crohn''s disease patients treated with metronidazole." Gastroenterology 88 (1985):  681-4|Boyce EG, Cookson ET, Bond WS "Persistent metronidazole-induced peripheral neuropathy." DICP 24 (1990):  19-21|Stahlberg D, Barany F, Einarsson K, Ursing B, Elmquist D, Persson A "Neurophysiologic studies of patients with Crohn''s disease on long-term treatment with metronidazole." Scand J Gastroenterol 26 (1991):  219-24|Learned-Coughlin S "Peripheral neuropathy induced by metronidazole." Ann Pharmacother 28 (1994):  536|Ahmed A, Laes DJ, Bressler EL "Reversible magnetic resonance imaging findings in metronidazole-induced encephalopathy." Neurology 45 (1995):  588-9|"Product Information. MetroGel-Vaginal (metroNIDAZOLE topical)." Curatek Pharmaceuticals Ltd  (2022):|Schreiber W, Spernal J "Metronidazole-induced psychotic disorder." Am J Psychiatry 154 (1997):  1170-1', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7908, 17957, 'Metronidazole (topical)', 'Neurotoxicity Syndromes', 'Metronidazole may be systemically absorbed when applied to the skin or mucosal membranes.  The use of oral and intravenous metronidazole has been associated with the development of nervous system toxicity including convulsive seizures and dose-related peripheral neuropathy, the latter characterized primarily by numbness or paresthesia of an extremity.  Persistent peripheral neuropathy has been reported in some patients treated for prolonged periods.  Other neurologic adverse effects include vertigo, incoordination, ataxia, confusion, agitation, hallucinations, and depression.  Therapy with topical metronidazole should be administered cautiously in patients with or predisposed to seizures or other nervous system abnormalities.  Metronidazole therapy should be discontinued promptly if neurologic disturbances occur.', '2', 'Kusumi RK, Plouffe JF, Wyatt RH, Fass RJ "Central nervous sytem toxicity associated with metronidazole therapy." Ann Intern Med 93 (1980):  59-60|Schentag JJ, Ziemniak JA, Greco JM, Rainstein M, Buckley RJ "Mental confusion in a patient treated with metronidazole: a concentration-related effect." Pharmacotherapy 2 (1982):  384-7|Alvarez RS, Richardson DA, Bent AE, Ostergard DR "Central nervous system toxicity related to prolonged metronidazole therapy." Am J Obstet Gynecol 145 (1983):  640-1|Wienbren M, Perinpanayagam RM, Camba L, Lee CA "Convulsions and encephalopathy in a patient with leukaemia after treatment with metronidazole." J Clin Pathol 38 (1985):  1076|Duffy LF, Daum F, Fisher SE, et al. "Peripheral neuropathy in Crohn''s disease patients treated with metronidazole." Gastroenterology 88 (1985):  681-4|Boyce EG, Cookson ET, Bond WS "Persistent metronidazole-induced peripheral neuropathy." DICP 24 (1990):  19-21|Stahlberg D, Barany F, Einarsson K, Ursing B, Elmquist D, Persson A "Neurophysiologic studies of patients with Crohn''s disease on long-term treatment with metronidazole." Scand J Gastroenterol 26 (1991):  219-24|Learned-Coughlin S "Peripheral neuropathy induced by metronidazole." Ann Pharmacother 28 (1994):  536|Ahmed A, Laes DJ, Bressler EL "Reversible magnetic resonance imaging findings in metronidazole-induced encephalopathy." Neurology 45 (1995):  588-9|"Product Information. MetroGel-Vaginal (metroNIDAZOLE topical)." Curatek Pharmaceuticals Ltd  (2022):|Schreiber W, Spernal J "Metronidazole-induced psychotic disorder." Am J Psychiatry 154 (1997):  1170-1', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7909, 18347, 'Metronidazole (topical)', 'Neurotoxicity Syndromes', 'Metronidazole may be systemically absorbed when applied to the skin or mucosal membranes.  The use of oral and intravenous metronidazole has been associated with the development of nervous system toxicity including convulsive seizures and dose-related peripheral neuropathy, the latter characterized primarily by numbness or paresthesia of an extremity.  Persistent peripheral neuropathy has been reported in some patients treated for prolonged periods.  Other neurologic adverse effects include vertigo, incoordination, ataxia, confusion, agitation, hallucinations, and depression.  Therapy with topical metronidazole should be administered cautiously in patients with or predisposed to seizures or other nervous system abnormalities.  Metronidazole therapy should be discontinued promptly if neurologic disturbances occur.', '2', 'Kusumi RK, Plouffe JF, Wyatt RH, Fass RJ "Central nervous sytem toxicity associated with metronidazole therapy." Ann Intern Med 93 (1980):  59-60|Schentag JJ, Ziemniak JA, Greco JM, Rainstein M, Buckley RJ "Mental confusion in a patient treated with metronidazole: a concentration-related effect." Pharmacotherapy 2 (1982):  384-7|Alvarez RS, Richardson DA, Bent AE, Ostergard DR "Central nervous system toxicity related to prolonged metronidazole therapy." Am J Obstet Gynecol 145 (1983):  640-1|Wienbren M, Perinpanayagam RM, Camba L, Lee CA "Convulsions and encephalopathy in a patient with leukaemia after treatment with metronidazole." J Clin Pathol 38 (1985):  1076|Duffy LF, Daum F, Fisher SE, et al. "Peripheral neuropathy in Crohn''s disease patients treated with metronidazole." Gastroenterology 88 (1985):  681-4|Boyce EG, Cookson ET, Bond WS "Persistent metronidazole-induced peripheral neuropathy." DICP 24 (1990):  19-21|Stahlberg D, Barany F, Einarsson K, Ursing B, Elmquist D, Persson A "Neurophysiologic studies of patients with Crohn''s disease on long-term treatment with metronidazole." Scand J Gastroenterol 26 (1991):  219-24|Learned-Coughlin S "Peripheral neuropathy induced by metronidazole." Ann Pharmacother 28 (1994):  536|Ahmed A, Laes DJ, Bressler EL "Reversible magnetic resonance imaging findings in metronidazole-induced encephalopathy." Neurology 45 (1995):  588-9|"Product Information. MetroGel-Vaginal (metroNIDAZOLE topical)." Curatek Pharmaceuticals Ltd  (2022):|Schreiber W, Spernal J "Metronidazole-induced psychotic disorder." Am J Psychiatry 154 (1997):  1170-1', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7910, 19075, 'Metronidazole (topical)', 'Neurotoxicity Syndromes', 'Metronidazole may be systemically absorbed when applied to the skin or mucosal membranes.  The use of oral and intravenous metronidazole has been associated with the development of nervous system toxicity including convulsive seizures and dose-related peripheral neuropathy, the latter characterized primarily by numbness or paresthesia of an extremity.  Persistent peripheral neuropathy has been reported in some patients treated for prolonged periods.  Other neurologic adverse effects include vertigo, incoordination, ataxia, confusion, agitation, hallucinations, and depression.  Therapy with topical metronidazole should be administered cautiously in patients with or predisposed to seizures or other nervous system abnormalities.  Metronidazole therapy should be discontinued promptly if neurologic disturbances occur.', '2', 'Kusumi RK, Plouffe JF, Wyatt RH, Fass RJ "Central nervous sytem toxicity associated with metronidazole therapy." Ann Intern Med 93 (1980):  59-60|Schentag JJ, Ziemniak JA, Greco JM, Rainstein M, Buckley RJ "Mental confusion in a patient treated with metronidazole: a concentration-related effect." Pharmacotherapy 2 (1982):  384-7|Alvarez RS, Richardson DA, Bent AE, Ostergard DR "Central nervous system toxicity related to prolonged metronidazole therapy." Am J Obstet Gynecol 145 (1983):  640-1|Wienbren M, Perinpanayagam RM, Camba L, Lee CA "Convulsions and encephalopathy in a patient with leukaemia after treatment with metronidazole." J Clin Pathol 38 (1985):  1076|Duffy LF, Daum F, Fisher SE, et al. "Peripheral neuropathy in Crohn''s disease patients treated with metronidazole." Gastroenterology 88 (1985):  681-4|Boyce EG, Cookson ET, Bond WS "Persistent metronidazole-induced peripheral neuropathy." DICP 24 (1990):  19-21|Stahlberg D, Barany F, Einarsson K, Ursing B, Elmquist D, Persson A "Neurophysiologic studies of patients with Crohn''s disease on long-term treatment with metronidazole." Scand J Gastroenterol 26 (1991):  219-24|Learned-Coughlin S "Peripheral neuropathy induced by metronidazole." Ann Pharmacother 28 (1994):  536|Ahmed A, Laes DJ, Bressler EL "Reversible magnetic resonance imaging findings in metronidazole-induced encephalopathy." Neurology 45 (1995):  588-9|"Product Information. MetroGel-Vaginal (metroNIDAZOLE topical)." Curatek Pharmaceuticals Ltd  (2022):|Schreiber W, Spernal J "Metronidazole-induced psychotic disorder." Am J Psychiatry 154 (1997):  1170-1', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7911, 19077, 'Metronidazole (topical)', 'Neurotoxicity Syndromes', 'Metronidazole may be systemically absorbed when applied to the skin or mucosal membranes.  The use of oral and intravenous metronidazole has been associated with the development of nervous system toxicity including convulsive seizures and dose-related peripheral neuropathy, the latter characterized primarily by numbness or paresthesia of an extremity.  Persistent peripheral neuropathy has been reported in some patients treated for prolonged periods.  Other neurologic adverse effects include vertigo, incoordination, ataxia, confusion, agitation, hallucinations, and depression.  Therapy with topical metronidazole should be administered cautiously in patients with or predisposed to seizures or other nervous system abnormalities.  Metronidazole therapy should be discontinued promptly if neurologic disturbances occur.', '2', 'Kusumi RK, Plouffe JF, Wyatt RH, Fass RJ "Central nervous sytem toxicity associated with metronidazole therapy." Ann Intern Med 93 (1980):  59-60|Schentag JJ, Ziemniak JA, Greco JM, Rainstein M, Buckley RJ "Mental confusion in a patient treated with metronidazole: a concentration-related effect." Pharmacotherapy 2 (1982):  384-7|Alvarez RS, Richardson DA, Bent AE, Ostergard DR "Central nervous system toxicity related to prolonged metronidazole therapy." Am J Obstet Gynecol 145 (1983):  640-1|Wienbren M, Perinpanayagam RM, Camba L, Lee CA "Convulsions and encephalopathy in a patient with leukaemia after treatment with metronidazole." J Clin Pathol 38 (1985):  1076|Duffy LF, Daum F, Fisher SE, et al. "Peripheral neuropathy in Crohn''s disease patients treated with metronidazole." Gastroenterology 88 (1985):  681-4|Boyce EG, Cookson ET, Bond WS "Persistent metronidazole-induced peripheral neuropathy." DICP 24 (1990):  19-21|Stahlberg D, Barany F, Einarsson K, Ursing B, Elmquist D, Persson A "Neurophysiologic studies of patients with Crohn''s disease on long-term treatment with metronidazole." Scand J Gastroenterol 26 (1991):  219-24|Learned-Coughlin S "Peripheral neuropathy induced by metronidazole." Ann Pharmacother 28 (1994):  536|Ahmed A, Laes DJ, Bressler EL "Reversible magnetic resonance imaging findings in metronidazole-induced encephalopathy." Neurology 45 (1995):  588-9|"Product Information. MetroGel-Vaginal (metroNIDAZOLE topical)." Curatek Pharmaceuticals Ltd  (2022):|Schreiber W, Spernal J "Metronidazole-induced psychotic disorder." Am J Psychiatry 154 (1997):  1170-1', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7912, 19078, 'Metronidazole (topical)', 'Neurotoxicity Syndromes', 'Metronidazole may be systemically absorbed when applied to the skin or mucosal membranes.  The use of oral and intravenous metronidazole has been associated with the development of nervous system toxicity including convulsive seizures and dose-related peripheral neuropathy, the latter characterized primarily by numbness or paresthesia of an extremity.  Persistent peripheral neuropathy has been reported in some patients treated for prolonged periods.  Other neurologic adverse effects include vertigo, incoordination, ataxia, confusion, agitation, hallucinations, and depression.  Therapy with topical metronidazole should be administered cautiously in patients with or predisposed to seizures or other nervous system abnormalities.  Metronidazole therapy should be discontinued promptly if neurologic disturbances occur.', '2', 'Kusumi RK, Plouffe JF, Wyatt RH, Fass RJ "Central nervous sytem toxicity associated with metronidazole therapy." Ann Intern Med 93 (1980):  59-60|Schentag JJ, Ziemniak JA, Greco JM, Rainstein M, Buckley RJ "Mental confusion in a patient treated with metronidazole: a concentration-related effect." Pharmacotherapy 2 (1982):  384-7|Alvarez RS, Richardson DA, Bent AE, Ostergard DR "Central nervous system toxicity related to prolonged metronidazole therapy." Am J Obstet Gynecol 145 (1983):  640-1|Wienbren M, Perinpanayagam RM, Camba L, Lee CA "Convulsions and encephalopathy in a patient with leukaemia after treatment with metronidazole." J Clin Pathol 38 (1985):  1076|Duffy LF, Daum F, Fisher SE, et al. "Peripheral neuropathy in Crohn''s disease patients treated with metronidazole." Gastroenterology 88 (1985):  681-4|Boyce EG, Cookson ET, Bond WS "Persistent metronidazole-induced peripheral neuropathy." DICP 24 (1990):  19-21|Stahlberg D, Barany F, Einarsson K, Ursing B, Elmquist D, Persson A "Neurophysiologic studies of patients with Crohn''s disease on long-term treatment with metronidazole." Scand J Gastroenterol 26 (1991):  219-24|Learned-Coughlin S "Peripheral neuropathy induced by metronidazole." Ann Pharmacother 28 (1994):  536|Ahmed A, Laes DJ, Bressler EL "Reversible magnetic resonance imaging findings in metronidazole-induced encephalopathy." Neurology 45 (1995):  588-9|"Product Information. MetroGel-Vaginal (metroNIDAZOLE topical)." Curatek Pharmaceuticals Ltd  (2022):|Schreiber W, Spernal J "Metronidazole-induced psychotic disorder." Am J Psychiatry 154 (1997):  1170-1', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7913, 19079, 'Metronidazole (topical)', 'Neurotoxicity Syndromes', 'Metronidazole may be systemically absorbed when applied to the skin or mucosal membranes.  The use of oral and intravenous metronidazole has been associated with the development of nervous system toxicity including convulsive seizures and dose-related peripheral neuropathy, the latter characterized primarily by numbness or paresthesia of an extremity.  Persistent peripheral neuropathy has been reported in some patients treated for prolonged periods.  Other neurologic adverse effects include vertigo, incoordination, ataxia, confusion, agitation, hallucinations, and depression.  Therapy with topical metronidazole should be administered cautiously in patients with or predisposed to seizures or other nervous system abnormalities.  Metronidazole therapy should be discontinued promptly if neurologic disturbances occur.', '2', 'Kusumi RK, Plouffe JF, Wyatt RH, Fass RJ "Central nervous sytem toxicity associated with metronidazole therapy." Ann Intern Med 93 (1980):  59-60|Schentag JJ, Ziemniak JA, Greco JM, Rainstein M, Buckley RJ "Mental confusion in a patient treated with metronidazole: a concentration-related effect." Pharmacotherapy 2 (1982):  384-7|Alvarez RS, Richardson DA, Bent AE, Ostergard DR "Central nervous system toxicity related to prolonged metronidazole therapy." Am J Obstet Gynecol 145 (1983):  640-1|Wienbren M, Perinpanayagam RM, Camba L, Lee CA "Convulsions and encephalopathy in a patient with leukaemia after treatment with metronidazole." J Clin Pathol 38 (1985):  1076|Duffy LF, Daum F, Fisher SE, et al. "Peripheral neuropathy in Crohn''s disease patients treated with metronidazole." Gastroenterology 88 (1985):  681-4|Boyce EG, Cookson ET, Bond WS "Persistent metronidazole-induced peripheral neuropathy." DICP 24 (1990):  19-21|Stahlberg D, Barany F, Einarsson K, Ursing B, Elmquist D, Persson A "Neurophysiologic studies of patients with Crohn''s disease on long-term treatment with metronidazole." Scand J Gastroenterol 26 (1991):  219-24|Learned-Coughlin S "Peripheral neuropathy induced by metronidazole." Ann Pharmacother 28 (1994):  536|Ahmed A, Laes DJ, Bressler EL "Reversible magnetic resonance imaging findings in metronidazole-induced encephalopathy." Neurology 45 (1995):  588-9|"Product Information. MetroGel-Vaginal (metroNIDAZOLE topical)." Curatek Pharmaceuticals Ltd  (2022):|Schreiber W, Spernal J "Metronidazole-induced psychotic disorder." Am J Psychiatry 154 (1997):  1170-1', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7914, 19085, 'Metronidazole (topical)', 'Neurotoxicity Syndromes', 'Metronidazole may be systemically absorbed when applied to the skin or mucosal membranes.  The use of oral and intravenous metronidazole has been associated with the development of nervous system toxicity including convulsive seizures and dose-related peripheral neuropathy, the latter characterized primarily by numbness or paresthesia of an extremity.  Persistent peripheral neuropathy has been reported in some patients treated for prolonged periods.  Other neurologic adverse effects include vertigo, incoordination, ataxia, confusion, agitation, hallucinations, and depression.  Therapy with topical metronidazole should be administered cautiously in patients with or predisposed to seizures or other nervous system abnormalities.  Metronidazole therapy should be discontinued promptly if neurologic disturbances occur.', '2', 'Kusumi RK, Plouffe JF, Wyatt RH, Fass RJ "Central nervous sytem toxicity associated with metronidazole therapy." Ann Intern Med 93 (1980):  59-60|Schentag JJ, Ziemniak JA, Greco JM, Rainstein M, Buckley RJ "Mental confusion in a patient treated with metronidazole: a concentration-related effect." Pharmacotherapy 2 (1982):  384-7|Alvarez RS, Richardson DA, Bent AE, Ostergard DR "Central nervous system toxicity related to prolonged metronidazole therapy." Am J Obstet Gynecol 145 (1983):  640-1|Wienbren M, Perinpanayagam RM, Camba L, Lee CA "Convulsions and encephalopathy in a patient with leukaemia after treatment with metronidazole." J Clin Pathol 38 (1985):  1076|Duffy LF, Daum F, Fisher SE, et al. "Peripheral neuropathy in Crohn''s disease patients treated with metronidazole." Gastroenterology 88 (1985):  681-4|Boyce EG, Cookson ET, Bond WS "Persistent metronidazole-induced peripheral neuropathy." DICP 24 (1990):  19-21|Stahlberg D, Barany F, Einarsson K, Ursing B, Elmquist D, Persson A "Neurophysiologic studies of patients with Crohn''s disease on long-term treatment with metronidazole." Scand J Gastroenterol 26 (1991):  219-24|Learned-Coughlin S "Peripheral neuropathy induced by metronidazole." Ann Pharmacother 28 (1994):  536|Ahmed A, Laes DJ, Bressler EL "Reversible magnetic resonance imaging findings in metronidazole-induced encephalopathy." Neurology 45 (1995):  588-9|"Product Information. MetroGel-Vaginal (metroNIDAZOLE topical)." Curatek Pharmaceuticals Ltd  (2022):|Schreiber W, Spernal J "Metronidazole-induced psychotic disorder." Am J Psychiatry 154 (1997):  1170-1', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7915, 19630, 'Metronidazole (topical)', 'Neurotoxicity Syndromes', 'Metronidazole may be systemically absorbed when applied to the skin or mucosal membranes.  The use of oral and intravenous metronidazole has been associated with the development of nervous system toxicity including convulsive seizures and dose-related peripheral neuropathy, the latter characterized primarily by numbness or paresthesia of an extremity.  Persistent peripheral neuropathy has been reported in some patients treated for prolonged periods.  Other neurologic adverse effects include vertigo, incoordination, ataxia, confusion, agitation, hallucinations, and depression.  Therapy with topical metronidazole should be administered cautiously in patients with or predisposed to seizures or other nervous system abnormalities.  Metronidazole therapy should be discontinued promptly if neurologic disturbances occur.', '2', 'Kusumi RK, Plouffe JF, Wyatt RH, Fass RJ "Central nervous sytem toxicity associated with metronidazole therapy." Ann Intern Med 93 (1980):  59-60|Schentag JJ, Ziemniak JA, Greco JM, Rainstein M, Buckley RJ "Mental confusion in a patient treated with metronidazole: a concentration-related effect." Pharmacotherapy 2 (1982):  384-7|Alvarez RS, Richardson DA, Bent AE, Ostergard DR "Central nervous system toxicity related to prolonged metronidazole therapy." Am J Obstet Gynecol 145 (1983):  640-1|Wienbren M, Perinpanayagam RM, Camba L, Lee CA "Convulsions and encephalopathy in a patient with leukaemia after treatment with metronidazole." J Clin Pathol 38 (1985):  1076|Duffy LF, Daum F, Fisher SE, et al. "Peripheral neuropathy in Crohn''s disease patients treated with metronidazole." Gastroenterology 88 (1985):  681-4|Boyce EG, Cookson ET, Bond WS "Persistent metronidazole-induced peripheral neuropathy." DICP 24 (1990):  19-21|Stahlberg D, Barany F, Einarsson K, Ursing B, Elmquist D, Persson A "Neurophysiologic studies of patients with Crohn''s disease on long-term treatment with metronidazole." Scand J Gastroenterol 26 (1991):  219-24|Learned-Coughlin S "Peripheral neuropathy induced by metronidazole." Ann Pharmacother 28 (1994):  536|Ahmed A, Laes DJ, Bressler EL "Reversible magnetic resonance imaging findings in metronidazole-induced encephalopathy." Neurology 45 (1995):  588-9|"Product Information. MetroGel-Vaginal (metroNIDAZOLE topical)." Curatek Pharmaceuticals Ltd  (2022):|Schreiber W, Spernal J "Metronidazole-induced psychotic disorder." Am J Psychiatry 154 (1997):  1170-1', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7916, 22672, 'Metronidazole (topical)', 'Neurotoxicity Syndromes', 'Metronidazole may be systemically absorbed when applied to the skin or mucosal membranes.  The use of oral and intravenous metronidazole has been associated with the development of nervous system toxicity including convulsive seizures and dose-related peripheral neuropathy, the latter characterized primarily by numbness or paresthesia of an extremity.  Persistent peripheral neuropathy has been reported in some patients treated for prolonged periods.  Other neurologic adverse effects include vertigo, incoordination, ataxia, confusion, agitation, hallucinations, and depression.  Therapy with topical metronidazole should be administered cautiously in patients with or predisposed to seizures or other nervous system abnormalities.  Metronidazole therapy should be discontinued promptly if neurologic disturbances occur.', '2', 'Kusumi RK, Plouffe JF, Wyatt RH, Fass RJ "Central nervous sytem toxicity associated with metronidazole therapy." Ann Intern Med 93 (1980):  59-60|Schentag JJ, Ziemniak JA, Greco JM, Rainstein M, Buckley RJ "Mental confusion in a patient treated with metronidazole: a concentration-related effect." Pharmacotherapy 2 (1982):  384-7|Alvarez RS, Richardson DA, Bent AE, Ostergard DR "Central nervous system toxicity related to prolonged metronidazole therapy." Am J Obstet Gynecol 145 (1983):  640-1|Wienbren M, Perinpanayagam RM, Camba L, Lee CA "Convulsions and encephalopathy in a patient with leukaemia after treatment with metronidazole." J Clin Pathol 38 (1985):  1076|Duffy LF, Daum F, Fisher SE, et al. "Peripheral neuropathy in Crohn''s disease patients treated with metronidazole." Gastroenterology 88 (1985):  681-4|Boyce EG, Cookson ET, Bond WS "Persistent metronidazole-induced peripheral neuropathy." DICP 24 (1990):  19-21|Stahlberg D, Barany F, Einarsson K, Ursing B, Elmquist D, Persson A "Neurophysiologic studies of patients with Crohn''s disease on long-term treatment with metronidazole." Scand J Gastroenterol 26 (1991):  219-24|Learned-Coughlin S "Peripheral neuropathy induced by metronidazole." Ann Pharmacother 28 (1994):  536|Ahmed A, Laes DJ, Bressler EL "Reversible magnetic resonance imaging findings in metronidazole-induced encephalopathy." Neurology 45 (1995):  588-9|"Product Information. MetroGel-Vaginal (metroNIDAZOLE topical)." Curatek Pharmaceuticals Ltd  (2022):|Schreiber W, Spernal J "Metronidazole-induced psychotic disorder." Am J Psychiatry 154 (1997):  1170-1', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7917, 22676, 'Metronidazole (topical)', 'Neurotoxicity Syndromes', 'Metronidazole may be systemically absorbed when applied to the skin or mucosal membranes.  The use of oral and intravenous metronidazole has been associated with the development of nervous system toxicity including convulsive seizures and dose-related peripheral neuropathy, the latter characterized primarily by numbness or paresthesia of an extremity.  Persistent peripheral neuropathy has been reported in some patients treated for prolonged periods.  Other neurologic adverse effects include vertigo, incoordination, ataxia, confusion, agitation, hallucinations, and depression.  Therapy with topical metronidazole should be administered cautiously in patients with or predisposed to seizures or other nervous system abnormalities.  Metronidazole therapy should be discontinued promptly if neurologic disturbances occur.', '2', 'Kusumi RK, Plouffe JF, Wyatt RH, Fass RJ "Central nervous sytem toxicity associated with metronidazole therapy." Ann Intern Med 93 (1980):  59-60|Schentag JJ, Ziemniak JA, Greco JM, Rainstein M, Buckley RJ "Mental confusion in a patient treated with metronidazole: a concentration-related effect." Pharmacotherapy 2 (1982):  384-7|Alvarez RS, Richardson DA, Bent AE, Ostergard DR "Central nervous system toxicity related to prolonged metronidazole therapy." Am J Obstet Gynecol 145 (1983):  640-1|Wienbren M, Perinpanayagam RM, Camba L, Lee CA "Convulsions and encephalopathy in a patient with leukaemia after treatment with metronidazole." J Clin Pathol 38 (1985):  1076|Duffy LF, Daum F, Fisher SE, et al. "Peripheral neuropathy in Crohn''s disease patients treated with metronidazole." Gastroenterology 88 (1985):  681-4|Boyce EG, Cookson ET, Bond WS "Persistent metronidazole-induced peripheral neuropathy." DICP 24 (1990):  19-21|Stahlberg D, Barany F, Einarsson K, Ursing B, Elmquist D, Persson A "Neurophysiologic studies of patients with Crohn''s disease on long-term treatment with metronidazole." Scand J Gastroenterol 26 (1991):  219-24|Learned-Coughlin S "Peripheral neuropathy induced by metronidazole." Ann Pharmacother 28 (1994):  536|Ahmed A, Laes DJ, Bressler EL "Reversible magnetic resonance imaging findings in metronidazole-induced encephalopathy." Neurology 45 (1995):  588-9|"Product Information. MetroGel-Vaginal (metroNIDAZOLE topical)." Curatek Pharmaceuticals Ltd  (2022):|Schreiber W, Spernal J "Metronidazole-induced psychotic disorder." Am J Psychiatry 154 (1997):  1170-1', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7918, 22677, 'Metronidazole (topical)', 'Neurotoxicity Syndromes', 'Metronidazole may be systemically absorbed when applied to the skin or mucosal membranes.  The use of oral and intravenous metronidazole has been associated with the development of nervous system toxicity including convulsive seizures and dose-related peripheral neuropathy, the latter characterized primarily by numbness or paresthesia of an extremity.  Persistent peripheral neuropathy has been reported in some patients treated for prolonged periods.  Other neurologic adverse effects include vertigo, incoordination, ataxia, confusion, agitation, hallucinations, and depression.  Therapy with topical metronidazole should be administered cautiously in patients with or predisposed to seizures or other nervous system abnormalities.  Metronidazole therapy should be discontinued promptly if neurologic disturbances occur.', '2', 'Kusumi RK, Plouffe JF, Wyatt RH, Fass RJ "Central nervous sytem toxicity associated with metronidazole therapy." Ann Intern Med 93 (1980):  59-60|Schentag JJ, Ziemniak JA, Greco JM, Rainstein M, Buckley RJ "Mental confusion in a patient treated with metronidazole: a concentration-related effect." Pharmacotherapy 2 (1982):  384-7|Alvarez RS, Richardson DA, Bent AE, Ostergard DR "Central nervous system toxicity related to prolonged metronidazole therapy." Am J Obstet Gynecol 145 (1983):  640-1|Wienbren M, Perinpanayagam RM, Camba L, Lee CA "Convulsions and encephalopathy in a patient with leukaemia after treatment with metronidazole." J Clin Pathol 38 (1985):  1076|Duffy LF, Daum F, Fisher SE, et al. "Peripheral neuropathy in Crohn''s disease patients treated with metronidazole." Gastroenterology 88 (1985):  681-4|Boyce EG, Cookson ET, Bond WS "Persistent metronidazole-induced peripheral neuropathy." DICP 24 (1990):  19-21|Stahlberg D, Barany F, Einarsson K, Ursing B, Elmquist D, Persson A "Neurophysiologic studies of patients with Crohn''s disease on long-term treatment with metronidazole." Scand J Gastroenterol 26 (1991):  219-24|Learned-Coughlin S "Peripheral neuropathy induced by metronidazole." Ann Pharmacother 28 (1994):  536|Ahmed A, Laes DJ, Bressler EL "Reversible magnetic resonance imaging findings in metronidazole-induced encephalopathy." Neurology 45 (1995):  588-9|"Product Information. MetroGel-Vaginal (metroNIDAZOLE topical)." Curatek Pharmaceuticals Ltd  (2022):|Schreiber W, Spernal J "Metronidazole-induced psychotic disorder." Am J Psychiatry 154 (1997):  1170-1', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7919, 22679, 'Metronidazole (topical)', 'Neurotoxicity Syndromes', 'Metronidazole may be systemically absorbed when applied to the skin or mucosal membranes.  The use of oral and intravenous metronidazole has been associated with the development of nervous system toxicity including convulsive seizures and dose-related peripheral neuropathy, the latter characterized primarily by numbness or paresthesia of an extremity.  Persistent peripheral neuropathy has been reported in some patients treated for prolonged periods.  Other neurologic adverse effects include vertigo, incoordination, ataxia, confusion, agitation, hallucinations, and depression.  Therapy with topical metronidazole should be administered cautiously in patients with or predisposed to seizures or other nervous system abnormalities.  Metronidazole therapy should be discontinued promptly if neurologic disturbances occur.', '2', 'Kusumi RK, Plouffe JF, Wyatt RH, Fass RJ "Central nervous sytem toxicity associated with metronidazole therapy." Ann Intern Med 93 (1980):  59-60|Schentag JJ, Ziemniak JA, Greco JM, Rainstein M, Buckley RJ "Mental confusion in a patient treated with metronidazole: a concentration-related effect." Pharmacotherapy 2 (1982):  384-7|Alvarez RS, Richardson DA, Bent AE, Ostergard DR "Central nervous system toxicity related to prolonged metronidazole therapy." Am J Obstet Gynecol 145 (1983):  640-1|Wienbren M, Perinpanayagam RM, Camba L, Lee CA "Convulsions and encephalopathy in a patient with leukaemia after treatment with metronidazole." J Clin Pathol 38 (1985):  1076|Duffy LF, Daum F, Fisher SE, et al. "Peripheral neuropathy in Crohn''s disease patients treated with metronidazole." Gastroenterology 88 (1985):  681-4|Boyce EG, Cookson ET, Bond WS "Persistent metronidazole-induced peripheral neuropathy." DICP 24 (1990):  19-21|Stahlberg D, Barany F, Einarsson K, Ursing B, Elmquist D, Persson A "Neurophysiologic studies of patients with Crohn''s disease on long-term treatment with metronidazole." Scand J Gastroenterol 26 (1991):  219-24|Learned-Coughlin S "Peripheral neuropathy induced by metronidazole." Ann Pharmacother 28 (1994):  536|Ahmed A, Laes DJ, Bressler EL "Reversible magnetic resonance imaging findings in metronidazole-induced encephalopathy." Neurology 45 (1995):  588-9|"Product Information. MetroGel-Vaginal (metroNIDAZOLE topical)." Curatek Pharmaceuticals Ltd  (2022):|Schreiber W, Spernal J "Metronidazole-induced psychotic disorder." Am J Psychiatry 154 (1997):  1170-1', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7920, 22680, 'Metronidazole (topical)', 'Neurotoxicity Syndromes', 'Metronidazole may be systemically absorbed when applied to the skin or mucosal membranes.  The use of oral and intravenous metronidazole has been associated with the development of nervous system toxicity including convulsive seizures and dose-related peripheral neuropathy, the latter characterized primarily by numbness or paresthesia of an extremity.  Persistent peripheral neuropathy has been reported in some patients treated for prolonged periods.  Other neurologic adverse effects include vertigo, incoordination, ataxia, confusion, agitation, hallucinations, and depression.  Therapy with topical metronidazole should be administered cautiously in patients with or predisposed to seizures or other nervous system abnormalities.  Metronidazole therapy should be discontinued promptly if neurologic disturbances occur.', '2', 'Kusumi RK, Plouffe JF, Wyatt RH, Fass RJ "Central nervous sytem toxicity associated with metronidazole therapy." Ann Intern Med 93 (1980):  59-60|Schentag JJ, Ziemniak JA, Greco JM, Rainstein M, Buckley RJ "Mental confusion in a patient treated with metronidazole: a concentration-related effect." Pharmacotherapy 2 (1982):  384-7|Alvarez RS, Richardson DA, Bent AE, Ostergard DR "Central nervous system toxicity related to prolonged metronidazole therapy." Am J Obstet Gynecol 145 (1983):  640-1|Wienbren M, Perinpanayagam RM, Camba L, Lee CA "Convulsions and encephalopathy in a patient with leukaemia after treatment with metronidazole." J Clin Pathol 38 (1985):  1076|Duffy LF, Daum F, Fisher SE, et al. "Peripheral neuropathy in Crohn''s disease patients treated with metronidazole." Gastroenterology 88 (1985):  681-4|Boyce EG, Cookson ET, Bond WS "Persistent metronidazole-induced peripheral neuropathy." DICP 24 (1990):  19-21|Stahlberg D, Barany F, Einarsson K, Ursing B, Elmquist D, Persson A "Neurophysiologic studies of patients with Crohn''s disease on long-term treatment with metronidazole." Scand J Gastroenterol 26 (1991):  219-24|Learned-Coughlin S "Peripheral neuropathy induced by metronidazole." Ann Pharmacother 28 (1994):  536|Ahmed A, Laes DJ, Bressler EL "Reversible magnetic resonance imaging findings in metronidazole-induced encephalopathy." Neurology 45 (1995):  588-9|"Product Information. MetroGel-Vaginal (metroNIDAZOLE topical)." Curatek Pharmaceuticals Ltd  (2022):|Schreiber W, Spernal J "Metronidazole-induced psychotic disorder." Am J Psychiatry 154 (1997):  1170-1', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7921, 26297, 'Metronidazole (topical)', 'Neurotoxicity Syndromes', 'Metronidazole may be systemically absorbed when applied to the skin or mucosal membranes.  The use of oral and intravenous metronidazole has been associated with the development of nervous system toxicity including convulsive seizures and dose-related peripheral neuropathy, the latter characterized primarily by numbness or paresthesia of an extremity.  Persistent peripheral neuropathy has been reported in some patients treated for prolonged periods.  Other neurologic adverse effects include vertigo, incoordination, ataxia, confusion, agitation, hallucinations, and depression.  Therapy with topical metronidazole should be administered cautiously in patients with or predisposed to seizures or other nervous system abnormalities.  Metronidazole therapy should be discontinued promptly if neurologic disturbances occur.', '2', 'Kusumi RK, Plouffe JF, Wyatt RH, Fass RJ "Central nervous sytem toxicity associated with metronidazole therapy." Ann Intern Med 93 (1980):  59-60|Schentag JJ, Ziemniak JA, Greco JM, Rainstein M, Buckley RJ "Mental confusion in a patient treated with metronidazole: a concentration-related effect." Pharmacotherapy 2 (1982):  384-7|Alvarez RS, Richardson DA, Bent AE, Ostergard DR "Central nervous system toxicity related to prolonged metronidazole therapy." Am J Obstet Gynecol 145 (1983):  640-1|Wienbren M, Perinpanayagam RM, Camba L, Lee CA "Convulsions and encephalopathy in a patient with leukaemia after treatment with metronidazole." J Clin Pathol 38 (1985):  1076|Duffy LF, Daum F, Fisher SE, et al. "Peripheral neuropathy in Crohn''s disease patients treated with metronidazole." Gastroenterology 88 (1985):  681-4|Boyce EG, Cookson ET, Bond WS "Persistent metronidazole-induced peripheral neuropathy." DICP 24 (1990):  19-21|Stahlberg D, Barany F, Einarsson K, Ursing B, Elmquist D, Persson A "Neurophysiologic studies of patients with Crohn''s disease on long-term treatment with metronidazole." Scand J Gastroenterol 26 (1991):  219-24|Learned-Coughlin S "Peripheral neuropathy induced by metronidazole." Ann Pharmacother 28 (1994):  536|Ahmed A, Laes DJ, Bressler EL "Reversible magnetic resonance imaging findings in metronidazole-induced encephalopathy." Neurology 45 (1995):  588-9|"Product Information. MetroGel-Vaginal (metroNIDAZOLE topical)." Curatek Pharmaceuticals Ltd  (2022):|Schreiber W, Spernal J "Metronidazole-induced psychotic disorder." Am J Psychiatry 154 (1997):  1170-1', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7922, 28488, 'Metronidazole (topical)', 'Neurotoxicity Syndromes', 'Metronidazole may be systemically absorbed when applied to the skin or mucosal membranes.  The use of oral and intravenous metronidazole has been associated with the development of nervous system toxicity including convulsive seizures and dose-related peripheral neuropathy, the latter characterized primarily by numbness or paresthesia of an extremity.  Persistent peripheral neuropathy has been reported in some patients treated for prolonged periods.  Other neurologic adverse effects include vertigo, incoordination, ataxia, confusion, agitation, hallucinations, and depression.  Therapy with topical metronidazole should be administered cautiously in patients with or predisposed to seizures or other nervous system abnormalities.  Metronidazole therapy should be discontinued promptly if neurologic disturbances occur.', '2', 'Kusumi RK, Plouffe JF, Wyatt RH, Fass RJ "Central nervous sytem toxicity associated with metronidazole therapy." Ann Intern Med 93 (1980):  59-60|Schentag JJ, Ziemniak JA, Greco JM, Rainstein M, Buckley RJ "Mental confusion in a patient treated with metronidazole: a concentration-related effect." Pharmacotherapy 2 (1982):  384-7|Alvarez RS, Richardson DA, Bent AE, Ostergard DR "Central nervous system toxicity related to prolonged metronidazole therapy." Am J Obstet Gynecol 145 (1983):  640-1|Wienbren M, Perinpanayagam RM, Camba L, Lee CA "Convulsions and encephalopathy in a patient with leukaemia after treatment with metronidazole." J Clin Pathol 38 (1985):  1076|Duffy LF, Daum F, Fisher SE, et al. "Peripheral neuropathy in Crohn''s disease patients treated with metronidazole." Gastroenterology 88 (1985):  681-4|Boyce EG, Cookson ET, Bond WS "Persistent metronidazole-induced peripheral neuropathy." DICP 24 (1990):  19-21|Stahlberg D, Barany F, Einarsson K, Ursing B, Elmquist D, Persson A "Neurophysiologic studies of patients with Crohn''s disease on long-term treatment with metronidazole." Scand J Gastroenterol 26 (1991):  219-24|Learned-Coughlin S "Peripheral neuropathy induced by metronidazole." Ann Pharmacother 28 (1994):  536|Ahmed A, Laes DJ, Bressler EL "Reversible magnetic resonance imaging findings in metronidazole-induced encephalopathy." Neurology 45 (1995):  588-9|"Product Information. MetroGel-Vaginal (metroNIDAZOLE topical)." Curatek Pharmaceuticals Ltd  (2022):|Schreiber W, Spernal J "Metronidazole-induced psychotic disorder." Am J Psychiatry 154 (1997):  1170-1', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7923, 28489, 'Metronidazole (topical)', 'Neurotoxicity Syndromes', 'Metronidazole may be systemically absorbed when applied to the skin or mucosal membranes.  The use of oral and intravenous metronidazole has been associated with the development of nervous system toxicity including convulsive seizures and dose-related peripheral neuropathy, the latter characterized primarily by numbness or paresthesia of an extremity.  Persistent peripheral neuropathy has been reported in some patients treated for prolonged periods.  Other neurologic adverse effects include vertigo, incoordination, ataxia, confusion, agitation, hallucinations, and depression.  Therapy with topical metronidazole should be administered cautiously in patients with or predisposed to seizures or other nervous system abnormalities.  Metronidazole therapy should be discontinued promptly if neurologic disturbances occur.', '2', 'Kusumi RK, Plouffe JF, Wyatt RH, Fass RJ "Central nervous sytem toxicity associated with metronidazole therapy." Ann Intern Med 93 (1980):  59-60|Schentag JJ, Ziemniak JA, Greco JM, Rainstein M, Buckley RJ "Mental confusion in a patient treated with metronidazole: a concentration-related effect." Pharmacotherapy 2 (1982):  384-7|Alvarez RS, Richardson DA, Bent AE, Ostergard DR "Central nervous system toxicity related to prolonged metronidazole therapy." Am J Obstet Gynecol 145 (1983):  640-1|Wienbren M, Perinpanayagam RM, Camba L, Lee CA "Convulsions and encephalopathy in a patient with leukaemia after treatment with metronidazole." J Clin Pathol 38 (1985):  1076|Duffy LF, Daum F, Fisher SE, et al. "Peripheral neuropathy in Crohn''s disease patients treated with metronidazole." Gastroenterology 88 (1985):  681-4|Boyce EG, Cookson ET, Bond WS "Persistent metronidazole-induced peripheral neuropathy." DICP 24 (1990):  19-21|Stahlberg D, Barany F, Einarsson K, Ursing B, Elmquist D, Persson A "Neurophysiologic studies of patients with Crohn''s disease on long-term treatment with metronidazole." Scand J Gastroenterol 26 (1991):  219-24|Learned-Coughlin S "Peripheral neuropathy induced by metronidazole." Ann Pharmacother 28 (1994):  536|Ahmed A, Laes DJ, Bressler EL "Reversible magnetic resonance imaging findings in metronidazole-induced encephalopathy." Neurology 45 (1995):  588-9|"Product Information. MetroGel-Vaginal (metroNIDAZOLE topical)." Curatek Pharmaceuticals Ltd  (2022):|Schreiber W, Spernal J "Metronidazole-induced psychotic disorder." Am J Psychiatry 154 (1997):  1170-1', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7924, 28490, 'Metronidazole (topical)', 'Neurotoxicity Syndromes', 'Metronidazole may be systemically absorbed when applied to the skin or mucosal membranes.  The use of oral and intravenous metronidazole has been associated with the development of nervous system toxicity including convulsive seizures and dose-related peripheral neuropathy, the latter characterized primarily by numbness or paresthesia of an extremity.  Persistent peripheral neuropathy has been reported in some patients treated for prolonged periods.  Other neurologic adverse effects include vertigo, incoordination, ataxia, confusion, agitation, hallucinations, and depression.  Therapy with topical metronidazole should be administered cautiously in patients with or predisposed to seizures or other nervous system abnormalities.  Metronidazole therapy should be discontinued promptly if neurologic disturbances occur.', '2', 'Kusumi RK, Plouffe JF, Wyatt RH, Fass RJ "Central nervous sytem toxicity associated with metronidazole therapy." Ann Intern Med 93 (1980):  59-60|Schentag JJ, Ziemniak JA, Greco JM, Rainstein M, Buckley RJ "Mental confusion in a patient treated with metronidazole: a concentration-related effect." Pharmacotherapy 2 (1982):  384-7|Alvarez RS, Richardson DA, Bent AE, Ostergard DR "Central nervous system toxicity related to prolonged metronidazole therapy." Am J Obstet Gynecol 145 (1983):  640-1|Wienbren M, Perinpanayagam RM, Camba L, Lee CA "Convulsions and encephalopathy in a patient with leukaemia after treatment with metronidazole." J Clin Pathol 38 (1985):  1076|Duffy LF, Daum F, Fisher SE, et al. "Peripheral neuropathy in Crohn''s disease patients treated with metronidazole." Gastroenterology 88 (1985):  681-4|Boyce EG, Cookson ET, Bond WS "Persistent metronidazole-induced peripheral neuropathy." DICP 24 (1990):  19-21|Stahlberg D, Barany F, Einarsson K, Ursing B, Elmquist D, Persson A "Neurophysiologic studies of patients with Crohn''s disease on long-term treatment with metronidazole." Scand J Gastroenterol 26 (1991):  219-24|Learned-Coughlin S "Peripheral neuropathy induced by metronidazole." Ann Pharmacother 28 (1994):  536|Ahmed A, Laes DJ, Bressler EL "Reversible magnetic resonance imaging findings in metronidazole-induced encephalopathy." Neurology 45 (1995):  588-9|"Product Information. MetroGel-Vaginal (metroNIDAZOLE topical)." Curatek Pharmaceuticals Ltd  (2022):|Schreiber W, Spernal J "Metronidazole-induced psychotic disorder." Am J Psychiatry 154 (1997):  1170-1', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7925, 28491, 'Metronidazole (topical)', 'Neurotoxicity Syndromes', 'Metronidazole may be systemically absorbed when applied to the skin or mucosal membranes.  The use of oral and intravenous metronidazole has been associated with the development of nervous system toxicity including convulsive seizures and dose-related peripheral neuropathy, the latter characterized primarily by numbness or paresthesia of an extremity.  Persistent peripheral neuropathy has been reported in some patients treated for prolonged periods.  Other neurologic adverse effects include vertigo, incoordination, ataxia, confusion, agitation, hallucinations, and depression.  Therapy with topical metronidazole should be administered cautiously in patients with or predisposed to seizures or other nervous system abnormalities.  Metronidazole therapy should be discontinued promptly if neurologic disturbances occur.', '2', 'Kusumi RK, Plouffe JF, Wyatt RH, Fass RJ "Central nervous sytem toxicity associated with metronidazole therapy." Ann Intern Med 93 (1980):  59-60|Schentag JJ, Ziemniak JA, Greco JM, Rainstein M, Buckley RJ "Mental confusion in a patient treated with metronidazole: a concentration-related effect." Pharmacotherapy 2 (1982):  384-7|Alvarez RS, Richardson DA, Bent AE, Ostergard DR "Central nervous system toxicity related to prolonged metronidazole therapy." Am J Obstet Gynecol 145 (1983):  640-1|Wienbren M, Perinpanayagam RM, Camba L, Lee CA "Convulsions and encephalopathy in a patient with leukaemia after treatment with metronidazole." J Clin Pathol 38 (1985):  1076|Duffy LF, Daum F, Fisher SE, et al. "Peripheral neuropathy in Crohn''s disease patients treated with metronidazole." Gastroenterology 88 (1985):  681-4|Boyce EG, Cookson ET, Bond WS "Persistent metronidazole-induced peripheral neuropathy." DICP 24 (1990):  19-21|Stahlberg D, Barany F, Einarsson K, Ursing B, Elmquist D, Persson A "Neurophysiologic studies of patients with Crohn''s disease on long-term treatment with metronidazole." Scand J Gastroenterol 26 (1991):  219-24|Learned-Coughlin S "Peripheral neuropathy induced by metronidazole." Ann Pharmacother 28 (1994):  536|Ahmed A, Laes DJ, Bressler EL "Reversible magnetic resonance imaging findings in metronidazole-induced encephalopathy." Neurology 45 (1995):  588-9|"Product Information. MetroGel-Vaginal (metroNIDAZOLE topical)." Curatek Pharmaceuticals Ltd  (2022):|Schreiber W, Spernal J "Metronidazole-induced psychotic disorder." Am J Psychiatry 154 (1997):  1170-1', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7926, 28492, 'Metronidazole (topical)', 'Neurotoxicity Syndromes', 'Metronidazole may be systemically absorbed when applied to the skin or mucosal membranes.  The use of oral and intravenous metronidazole has been associated with the development of nervous system toxicity including convulsive seizures and dose-related peripheral neuropathy, the latter characterized primarily by numbness or paresthesia of an extremity.  Persistent peripheral neuropathy has been reported in some patients treated for prolonged periods.  Other neurologic adverse effects include vertigo, incoordination, ataxia, confusion, agitation, hallucinations, and depression.  Therapy with topical metronidazole should be administered cautiously in patients with or predisposed to seizures or other nervous system abnormalities.  Metronidazole therapy should be discontinued promptly if neurologic disturbances occur.', '2', 'Kusumi RK, Plouffe JF, Wyatt RH, Fass RJ "Central nervous sytem toxicity associated with metronidazole therapy." Ann Intern Med 93 (1980):  59-60|Schentag JJ, Ziemniak JA, Greco JM, Rainstein M, Buckley RJ "Mental confusion in a patient treated with metronidazole: a concentration-related effect." Pharmacotherapy 2 (1982):  384-7|Alvarez RS, Richardson DA, Bent AE, Ostergard DR "Central nervous system toxicity related to prolonged metronidazole therapy." Am J Obstet Gynecol 145 (1983):  640-1|Wienbren M, Perinpanayagam RM, Camba L, Lee CA "Convulsions and encephalopathy in a patient with leukaemia after treatment with metronidazole." J Clin Pathol 38 (1985):  1076|Duffy LF, Daum F, Fisher SE, et al. "Peripheral neuropathy in Crohn''s disease patients treated with metronidazole." Gastroenterology 88 (1985):  681-4|Boyce EG, Cookson ET, Bond WS "Persistent metronidazole-induced peripheral neuropathy." DICP 24 (1990):  19-21|Stahlberg D, Barany F, Einarsson K, Ursing B, Elmquist D, Persson A "Neurophysiologic studies of patients with Crohn''s disease on long-term treatment with metronidazole." Scand J Gastroenterol 26 (1991):  219-24|Learned-Coughlin S "Peripheral neuropathy induced by metronidazole." Ann Pharmacother 28 (1994):  536|Ahmed A, Laes DJ, Bressler EL "Reversible magnetic resonance imaging findings in metronidazole-induced encephalopathy." Neurology 45 (1995):  588-9|"Product Information. MetroGel-Vaginal (metroNIDAZOLE topical)." Curatek Pharmaceuticals Ltd  (2022):|Schreiber W, Spernal J "Metronidazole-induced psychotic disorder." Am J Psychiatry 154 (1997):  1170-1', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7927, 30008, 'Metronidazole (topical)', 'Neurotoxicity Syndromes', 'Metronidazole may be systemically absorbed when applied to the skin or mucosal membranes.  The use of oral and intravenous metronidazole has been associated with the development of nervous system toxicity including convulsive seizures and dose-related peripheral neuropathy, the latter characterized primarily by numbness or paresthesia of an extremity.  Persistent peripheral neuropathy has been reported in some patients treated for prolonged periods.  Other neurologic adverse effects include vertigo, incoordination, ataxia, confusion, agitation, hallucinations, and depression.  Therapy with topical metronidazole should be administered cautiously in patients with or predisposed to seizures or other nervous system abnormalities.  Metronidazole therapy should be discontinued promptly if neurologic disturbances occur.', '2', 'Kusumi RK, Plouffe JF, Wyatt RH, Fass RJ "Central nervous sytem toxicity associated with metronidazole therapy." Ann Intern Med 93 (1980):  59-60|Schentag JJ, Ziemniak JA, Greco JM, Rainstein M, Buckley RJ "Mental confusion in a patient treated with metronidazole: a concentration-related effect." Pharmacotherapy 2 (1982):  384-7|Alvarez RS, Richardson DA, Bent AE, Ostergard DR "Central nervous system toxicity related to prolonged metronidazole therapy." Am J Obstet Gynecol 145 (1983):  640-1|Wienbren M, Perinpanayagam RM, Camba L, Lee CA "Convulsions and encephalopathy in a patient with leukaemia after treatment with metronidazole." J Clin Pathol 38 (1985):  1076|Duffy LF, Daum F, Fisher SE, et al. "Peripheral neuropathy in Crohn''s disease patients treated with metronidazole." Gastroenterology 88 (1985):  681-4|Boyce EG, Cookson ET, Bond WS "Persistent metronidazole-induced peripheral neuropathy." DICP 24 (1990):  19-21|Stahlberg D, Barany F, Einarsson K, Ursing B, Elmquist D, Persson A "Neurophysiologic studies of patients with Crohn''s disease on long-term treatment with metronidazole." Scand J Gastroenterol 26 (1991):  219-24|Learned-Coughlin S "Peripheral neuropathy induced by metronidazole." Ann Pharmacother 28 (1994):  536|Ahmed A, Laes DJ, Bressler EL "Reversible magnetic resonance imaging findings in metronidazole-induced encephalopathy." Neurology 45 (1995):  588-9|"Product Information. MetroGel-Vaginal (metroNIDAZOLE topical)." Curatek Pharmaceuticals Ltd  (2022):|Schreiber W, Spernal J "Metronidazole-induced psychotic disorder." Am J Psychiatry 154 (1997):  1170-1', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7928, 30543, 'Metronidazole (topical)', 'Neurotoxicity Syndromes', 'Metronidazole may be systemically absorbed when applied to the skin or mucosal membranes.  The use of oral and intravenous metronidazole has been associated with the development of nervous system toxicity including convulsive seizures and dose-related peripheral neuropathy, the latter characterized primarily by numbness or paresthesia of an extremity.  Persistent peripheral neuropathy has been reported in some patients treated for prolonged periods.  Other neurologic adverse effects include vertigo, incoordination, ataxia, confusion, agitation, hallucinations, and depression.  Therapy with topical metronidazole should be administered cautiously in patients with or predisposed to seizures or other nervous system abnormalities.  Metronidazole therapy should be discontinued promptly if neurologic disturbances occur.', '2', 'Kusumi RK, Plouffe JF, Wyatt RH, Fass RJ "Central nervous sytem toxicity associated with metronidazole therapy." Ann Intern Med 93 (1980):  59-60|Schentag JJ, Ziemniak JA, Greco JM, Rainstein M, Buckley RJ "Mental confusion in a patient treated with metronidazole: a concentration-related effect." Pharmacotherapy 2 (1982):  384-7|Alvarez RS, Richardson DA, Bent AE, Ostergard DR "Central nervous system toxicity related to prolonged metronidazole therapy." Am J Obstet Gynecol 145 (1983):  640-1|Wienbren M, Perinpanayagam RM, Camba L, Lee CA "Convulsions and encephalopathy in a patient with leukaemia after treatment with metronidazole." J Clin Pathol 38 (1985):  1076|Duffy LF, Daum F, Fisher SE, et al. "Peripheral neuropathy in Crohn''s disease patients treated with metronidazole." Gastroenterology 88 (1985):  681-4|Boyce EG, Cookson ET, Bond WS "Persistent metronidazole-induced peripheral neuropathy." DICP 24 (1990):  19-21|Stahlberg D, Barany F, Einarsson K, Ursing B, Elmquist D, Persson A "Neurophysiologic studies of patients with Crohn''s disease on long-term treatment with metronidazole." Scand J Gastroenterol 26 (1991):  219-24|Learned-Coughlin S "Peripheral neuropathy induced by metronidazole." Ann Pharmacother 28 (1994):  536|Ahmed A, Laes DJ, Bressler EL "Reversible magnetic resonance imaging findings in metronidazole-induced encephalopathy." Neurology 45 (1995):  588-9|"Product Information. MetroGel-Vaginal (metroNIDAZOLE topical)." Curatek Pharmaceuticals Ltd  (2022):|Schreiber W, Spernal J "Metronidazole-induced psychotic disorder." Am J Psychiatry 154 (1997):  1170-1', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7929, 33203, 'Metronidazole (topical)', 'Neurotoxicity Syndromes', 'Metronidazole may be systemically absorbed when applied to the skin or mucosal membranes.  The use of oral and intravenous metronidazole has been associated with the development of nervous system toxicity including convulsive seizures and dose-related peripheral neuropathy, the latter characterized primarily by numbness or paresthesia of an extremity.  Persistent peripheral neuropathy has been reported in some patients treated for prolonged periods.  Other neurologic adverse effects include vertigo, incoordination, ataxia, confusion, agitation, hallucinations, and depression.  Therapy with topical metronidazole should be administered cautiously in patients with or predisposed to seizures or other nervous system abnormalities.  Metronidazole therapy should be discontinued promptly if neurologic disturbances occur.', '2', 'Kusumi RK, Plouffe JF, Wyatt RH, Fass RJ "Central nervous sytem toxicity associated with metronidazole therapy." Ann Intern Med 93 (1980):  59-60|Schentag JJ, Ziemniak JA, Greco JM, Rainstein M, Buckley RJ "Mental confusion in a patient treated with metronidazole: a concentration-related effect." Pharmacotherapy 2 (1982):  384-7|Alvarez RS, Richardson DA, Bent AE, Ostergard DR "Central nervous system toxicity related to prolonged metronidazole therapy." Am J Obstet Gynecol 145 (1983):  640-1|Wienbren M, Perinpanayagam RM, Camba L, Lee CA "Convulsions and encephalopathy in a patient with leukaemia after treatment with metronidazole." J Clin Pathol 38 (1985):  1076|Duffy LF, Daum F, Fisher SE, et al. "Peripheral neuropathy in Crohn''s disease patients treated with metronidazole." Gastroenterology 88 (1985):  681-4|Boyce EG, Cookson ET, Bond WS "Persistent metronidazole-induced peripheral neuropathy." DICP 24 (1990):  19-21|Stahlberg D, Barany F, Einarsson K, Ursing B, Elmquist D, Persson A "Neurophysiologic studies of patients with Crohn''s disease on long-term treatment with metronidazole." Scand J Gastroenterol 26 (1991):  219-24|Learned-Coughlin S "Peripheral neuropathy induced by metronidazole." Ann Pharmacother 28 (1994):  536|Ahmed A, Laes DJ, Bressler EL "Reversible magnetic resonance imaging findings in metronidazole-induced encephalopathy." Neurology 45 (1995):  588-9|"Product Information. MetroGel-Vaginal (metroNIDAZOLE topical)." Curatek Pharmaceuticals Ltd  (2022):|Schreiber W, Spernal J "Metronidazole-induced psychotic disorder." Am J Psychiatry 154 (1997):  1170-1', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7930, 7520, 'Metoprolol', 'Atrioventricular Block', 'The use of beta-adrenergic receptor blocking agents (aka beta-blockers) is contraindicated in patients with sinus bradyarrhythmia or heart block greater than the first degree (unless a functioning pacemaker is present).  Due to their negative inotropic and chronotropic effects on the heart, the use of beta-blockers is likely to exacerbate these conditions.', '3', 'Crean PA, Williams DO "Effect of intravenous and oral acebutolol in patients with bundle branch block." Int J Cardiol 10 (1986):  119-26|Mashford ML, Coventry D, Hecker R, et al. "Adverse Drug Reactions Advisory Committee: ADRAC report for 1980." Med J Aust 1 (1982):  416-9|Treseder AS, Thomas TP "Sinus arrest due to timolol eye drops." Br J Clin Pract 40 (1986):  256-8|"Product Information. Sectral (acebutolol)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Tenormin (atenolol)." ICN Pharmaceuticals Inc  (2002):|"Product Information. Normodyne (labetalol)." Schering Corporation  (2002):|"Product Information. Trandate (labetalol)." Glaxo Wellcome  (2002):|"Product Information. Corgard (nadolol)." Bristol-Myers Squibb  (2002):|"Product Information. Inderal (propranolol)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|"Product Information. Brevibloc (esmolol)." DuPont Pharmaceuticals  (2001):|"Product Information. Cartrol (carteolol)." Abbott Pharmaceutical  (2001):|"Product Information. Kerlone (betaxolol)." Searle  (2001):|"Product Information. Lopressor (metoprolol)." Novartis Pharmaceuticals  (2001):|"Product Information. Betapace (sotalol)." Berlex Laboratories  (2001):|"Product Information. Zebeta (bisoprolol)." Lederle Laboratories  (2001):|"Product Information. Visken (pindolol)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Levatol (penbutolol)." Reed and Carnrick  (2001):|"Product Information. Coreg (carvedilol)." SmithKline Beecham  (2001):|Frishman WH "Carvedilol." N Engl J Med 339 (1998):  1759-65|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):|"Product Information. Bystolic (nebivolol)." Forest Pharmaceuticals  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7931, 7520, 'Metoprolol', 'Shock, Cardiogenic', 'The use of beta-adrenergic receptor blocking agents (aka beta-blockers) is contraindicated in patients with hypotension or cardiogenic shock.  Due to their negative inotropic and chronotropic effects on the heart, the use of beta-blockers is likely to further depress cardiac output and blood pressure, which can be detrimental in these patients.', '3', 'Kholeif M, Isles C "Profound hypotension after atenolol in severe hypertension." Br Med J 298 (1989):  161-2|Tirlapur VG, Evans PJ, Jones MK "Shock syndrome after acebutolol." Br J Clin Pract 40 (1986):  33-4|"Product Information. Sectral (acebutolol)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Tenormin (atenolol)." ICN Pharmaceuticals Inc  (2002):|"Product Information. Normodyne (labetalol)." Schering Corporation  (2002):|"Product Information. Trandate (labetalol)." Glaxo Wellcome  (2002):|"Product Information. Corgard (nadolol)." Bristol-Myers Squibb  (2002):|"Product Information. Inderal (propranolol)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|"Product Information. Brevibloc (esmolol)." DuPont Pharmaceuticals  (2001):|"Product Information. Cartrol (carteolol)." Abbott Pharmaceutical  (2001):|"Product Information. Kerlone (betaxolol)." Searle  (2001):|"Product Information. Lopressor (metoprolol)." Novartis Pharmaceuticals  (2001):|"Product Information. Betapace (sotalol)." Berlex Laboratories  (2001):|"Product Information. Zebeta (bisoprolol)." Lederle Laboratories  (2001):|"Product Information. Visken (pindolol)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. OptiPranolol (metipranolol ophthalmic)." Bausch and Lomb Americas, Inc.  (2022):|"Product Information. Levatol (penbutolol)." Reed and Carnrick  (2001):|"Product Information. Betagan (levobunolol ophthalmic)." Allergan Inc  (2022):|"Product Information. Coreg (carvedilol)." SmithKline Beecham  (2001):|"Product Information. Acupress (carteolol ophthalmic)." Otsuka American Pharmaceuticals Inc, Rockville, MD.|"Product Information. Betoptic (betaxolol ophthalmic)." Alcon Laboratories Inc  (2001):|Frishman WH "Carvedilol." N Engl J Med 339 (1998):  1759-65|"Product Information. Bystolic (nebivolol)." Forest Pharmaceuticals  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7932, 7520, 'Metoprolol', 'Heart Failure', 'Beta-adrenergic receptor blocking agents (aka beta-blockers) in general should not be used in patients with overt congestive heart failure (CHF).  Sympathetic stimulation may be important in maintaining the hemodynamic function in these patients, thus beta-blockade can worsen the heart failure.  However, therapy with beta-blockers may be beneficial and can be administered cautiously in some CHF patients provided they are well compensated and receiving digitalis, diuretics, an ACE inhibitor, and/or nitrates.  Carvedilol, specifically, is indicated for use with these agents in the treatment of mild to severe heart failure of ischemic or cardiomyopathic origin.  There is also increasing evidence that the addition of a beta-blocker to standard therapy can improve morbidity and mortality in patients with advanced heart failure, although it is uncertain whether effectiveness varies significantly with the different agents.  Data from one meta-analysis study suggest a greater reduction of mortality risk for nonselective beta-blockers than for beta-1 selective agents.', '3', 'Michelson EL, Frishman WH, Lewis JE, et al. "Multicenter clinical evaluation of long-term efficacy and safety of labetalol in treatment of hypertension." Am J Med Oct 17 (1983):  68-80|Myers J, Morgan T, Waga S, et al. "Long-term experiences with labetalol." Med J Aust 1 (1980):  665-6|Tcherdakoff P "Side-effects with long-term labetalol: an open study of 251 patients in a single centre." Pharmatherapeutica 3 (1983):  342-8|Altus P "Timolol-induced congestive heart failure." South Med J 74 (1981):  88|Mashford ML, Coventry D, Hecker R, et al. "Adverse Drug Reactions Advisory Committee: ADRAC report for 1980." Med J Aust 1 (1982):  416-9|"Product Information. Sectral (acebutolol)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Tenormin (atenolol)." ICN Pharmaceuticals Inc  (2002):|"Product Information. Normodyne (labetalol)." Schering Corporation  (2002):|"Product Information. Trandate (labetalol)." Glaxo Wellcome  (2002):|"Product Information. Corgard (nadolol)." Bristol-Myers Squibb  (2002):|"Product Information. Inderal (propranolol)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|"Product Information. Brevibloc (esmolol)." DuPont Pharmaceuticals  (2001):|"Product Information. Cartrol (carteolol)." Abbott Pharmaceutical  (2001):|"Product Information. Kerlone (betaxolol)." Searle  (2001):|"Product Information. Lopressor (metoprolol)." Novartis Pharmaceuticals  (2001):|"Product Information. Betapace (sotalol)." Berlex Laboratories  (2001):|"Product Information. Zebeta (bisoprolol)." Lederle Laboratories  (2001):|"Product Information. Visken (pindolol)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Levatol (penbutolol)." Reed and Carnrick  (2001):|Lechat P, Jaillon P, Fontaine ML, Chanton E, Mesenge C, Gagey S, Guillardeau A, Dussous V "A randomized trial of beta-blockade in heart failure - the cardiac insufficiency bisoprolol study (CIBIS)." Circulation 90 (1994):  1765-73|Maisel AS "Beneficial effects of metoprolol treatment in congestive heart failure - reversal of sympathetic-induced alterations of immunologic function." Circulation 90 (1994):  1774-80|Persson H, Rythenalder E, Melcher A, Erhardt L "Effects of beta receptor antagonists in patients with clinical evidence of heart failure after myocardial infarction: double blind comparison of metoprolol and xamoterol." Br Heart J 74 (1995):  140-8|Kelly DT "Carvedilol in heart failure." Cardiology 82 Suppl 3 (1993):  45-9|Olsen SL, Gilbert EM, Renlund DG, Taylor DO, Yanowitz FD, Bristow MR "Carvedilol improves left ventricular function and symptoms in chronic heart failure: a double-blind randomized study." J Am Coll Cardiol 25 (1995):  1225-31|Krum H, Sackner-Bernstein JD, Goldsmith RL, et al. "Double-blind, placebo-controlled study of the long-term efficacy of carvedilol in patients with severe chronic heart failure." Circulation 92 (1995):  1499-506|Australia-New Zealand Heart Failure Research Collaborative Group. "Effects of carvedilol, a vasodilator-B-blocker, in patients with congestive heart failure due to ischemic heart disease." Circulation 92 (1995):  212-8|Kalman J, Buchholz C, Steinmetz M, Courtney M, Gass A, Lansman S, Kukin ML "Safety and efficacy of beta blockade in patients with chronic congestive heart failure awaiting transplantation." J Heart Lung Transplant 14 (1995):  1212-7|Adams KF Jr "Current perspectives on B-receptor antagonists in the treatment of symptomatic ventricular dysfunction." Pharmacotherapy 16(2 Pt 2) (1996):  69-77|Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM, Shusterman NH "The effect of carvedilol on morbidity and mortality in patients with chronic heart failure." N Engl J Med 334 (1996):  1349-55|Persson SV, Erhardt L "Effects of beta receptor antagonists on left ventricular function in patients with clinical evidence of heart failure after myocardial infarction. A double-blind comparison of metoprolol and xamoterol: echocardiographic results from the Metoprolol and..." Eur Heart J 17 (1996):  741-9|Cleland JGF, Swedberg K "Carvedilol for heart failure, with care." Lancet 347 (1996):  1199-201|Moye LA, Abernethy D "Carvedilol in patients with chronic heart failure." N Engl J Med 335 (1996):  1318|Von Olshausen K, Pop T, Berger J "Carvedilol in patients with chronic heart failure." N Engl J Med 335 (1996):  1318-20|Packer M, Cohn JN, Colucci WS "Carvedilol in patients with chronic heart failure." N Engl J Med 335 (1996):  1310-20|Colucci WS, Packer M, Bristow MR, Gilbert EM, Cohn JN, Fowler MB, Krueger SK, Hershberger R, Uretsky BF, Bowers JA, Sackne "Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure." Circulation 94 (1996):  2800-6|Macmahon S, Sharpe N, Doughty R, Krum H, Tonkin A, Trotter A, Burton R, Garrett J, Lane G, Owensby D, Ryan J, Shepherd J, Sing "Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease." Lancet 349 (1997):  375-80|Bristow MR, Gilbert EM, Abraham WT, et al. "Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. MOCHA Investigators." Circulation 94 (1996):  2807-16|Packer M, Colucci WS, Sackner-Bernstein JD, Liang CS, Goldscher DA, Freeman I, Kukin ML, Kinhal V, Udelson JE, Klapholz M, Gottlieb SS, Pearle D "Double-blind, placebo-controlled study of the effects of carvedilol in patients with moderate to severe heart failure. The PRECISE Trial Prospective Randomized Evaluation of Carvedilol on Symptoms an Exercise." Circulation 94 (1996):  2793-9|Doughty RN, Whalley GA, Gamble G, MacMahon S, Sharpe N "Left ventricular remodeling with carvedilol in patients with congestive heart failure due to ischemic heart disease. Australia-Ne Zealand Heart Failure Research Collaborative Group." J Am Coll Cardiol 29 (1997):  1060-6|Lechat P, Packer M, Chalon S, Cucherat M, Arab T, Boissel JP "Clinical effects of beta-adrenergic blockade in chronic heart failure: A meta-analysis of double-blind, placebo-controlled, randomized trials." Circulation 98 (1998):  1184-91|Frishman WH "Carvedilol." N Engl J Med 339 (1998):  1759-65|CIBIS-II Investigators and Committees. "The cardiac insufficiency bisoprolol study II (CIBIS-II): a randomised trial." Lancet 353 (1999):  9-13|Macdonald PS, Keogh AM, Aboyoun CL, Lund M, Amor R, McCaffrey DJ "Tolerability and efficacy of carvedilol in patients with New York Heart Association class IV heart failure." J Am Coll Cardiol 33 (1999):  924-31|Hjalmarson A, Goldstein S, Fagerberg B, et al. "Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF)." JAMA 283 (2000):  1295-302|Phillips KA, Shlipak MG, Coxson P, et al. "Health and economic benefits of increased B-blocker use following myocardial infarction." JAMA 284 (2000):  2748-54|Hart SM "Influence of B-blockers on mortality in chronic heart failure." Ann Pharmacother 34 (2000):  1440-51|"Product Information. Bystolic (nebivolol)." Forest Pharmaceuticals  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7933, 7520, 'Metoprolol', 'Diabetes Mellitus', 'Beta-adrenergic receptor blocking agents (aka beta-blockers) may mask symptoms of hypoglycemia such as tremors, tachycardia and blood pressure changes.  In addition, the nonselective beta-blockers (e.g., propranolol, pindolol, timolol) may inhibit catecholamine-mediated glycogenolysis, thereby potentiating insulin-induced hypoglycemia and delaying the recovery of normal blood glucose levels.  Since cardioselectivity is not absolute, larger doses of beta-1 selective agents may demonstrate these effects as well.  Therapy with beta-blockers should be administered cautiously in patients with diabetes or predisposed to spontaneous hypoglycemia.', '3', 'Darga LL, Hakim MJ, Lucas CP, Franklin BA "Comparison of the effects of guanadrel sulfate and propranolol on blood pressure, functional capacity, serum lipoproteins and glucose in systemic hypertension." Am J Cardiol 67 (1991):  590-6|Uusitupa M, Aro A, Pietikainen M "Severe hypoglycaemia caused by physical strain and pindolol therapy." Ann Clin Res 12 (1980):  25-7|Velde TM, Kaiser FE "Ophthalmic timolol treatment causing altered hypoglycemic response in a diabetic patient." Arch Intern Med 143 (1983):  1627|Grimaldi A, Bennett P, Delas B, et al. "Beta-blockers and hypoglycaemia: assessment of cardioselective and intrinsic sympathomimetic properties in relation to severity of hypoglycaemia." Curr Ther Res Clin Exp 36 (1984):  361-73|"Product Information. Sectral (acebutolol)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Tenormin (atenolol)." ICN Pharmaceuticals Inc  (2002):|"Product Information. Normodyne (labetalol)." Schering Corporation  (2002):|"Product Information. Trandate (labetalol)." Glaxo Wellcome  (2002):|"Product Information. Corgard (nadolol)." Bristol-Myers Squibb  (2002):|"Product Information. Inderal (propranolol)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|"Product Information. Brevibloc (esmolol)." DuPont Pharmaceuticals  (2001):|"Product Information. Cartrol (carteolol)." Abbott Pharmaceutical  (2001):|"Product Information. Kerlone (betaxolol)." Searle  (2001):|"Product Information. Lopressor (metoprolol)." Novartis Pharmaceuticals  (2001):|"Product Information. Betapace (sotalol)." Berlex Laboratories  (2001):|"Product Information. Zebeta (bisoprolol)." Lederle Laboratories  (2001):|"Product Information. Visken (pindolol)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Levatol (penbutolol)." Reed and Carnrick  (2001):|Giugliano D, Acampora R, Marfella R, DeRosa N, Ziccardi P, Ragone R, DeAngelis L, DOnofrio F "Metabolic and cardiovascular effects of carvedilol and atenolol in non-insulin-dependent diabetes mellitus and hypertension - A randomized, controlled trial." Ann Intern Med 126 (1997):  955-9|"Product Information. Bystolic (nebivolol)." Forest Pharmaceuticals  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7934, 7520, 'Metoprolol', 'Diseases requiring hemodialysis', 'Therapy with beta-adrenergic receptor blocking agents (aka beta-blockers) should be administered cautiously in patients requiring hemodialysis.  When given after dialysis, hemodynamic stability should be established prior to drug administration to avoid marked falls in blood pressure.  The hemodynamic status should be closely monitored before and after the dose.', '3', '"Product Information. Normodyne (labetalol)." Schering Corporation  (2002):|"Product Information. Trandate (labetalol)." Glaxo Wellcome  (2002):|"Product Information. Corgard (nadolol)." Bristol-Myers Squibb  (2002):|"Product Information. Inderal (propranolol)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|"Product Information. Cartrol (carteolol)." Abbott Pharmaceutical  (2001):|"Product Information. Kerlone (betaxolol)." Searle  (2001):|"Product Information. Lopressor (metoprolol)." Novartis Pharmaceuticals  (2001):|"Product Information. Zebeta (bisoprolol)." Lederle Laboratories  (2001):|"Product Information. Visken (pindolol)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Levatol (penbutolol)." Reed and Carnrick  (2001):|Deetjen A, Heidland A, Pangerl A, Meyer-Sabellek W, Schaefer RM "Antihypertensive treatment with a vasodilating beta-blocker, carvedilol, in chronic hemodialysis patients." Clin Nephrol 43 (1995):  47-52|Miki S, Masumura H, Kaifu Y, Yuasa S "Pharmacokinetics and efficacy of carvedilol in chronic hemodialysis patients with hypertension." J Cardiovasc Pharmacol 18 Suppl 4 (1991):  s62-8|"Product Information. Coreg (carvedilol)." SmithKline Beecham  (2001):|"Product Information. Bystolic (nebivolol)." Forest Pharmaceuticals  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7935, 7520, 'Metoprolol', 'Hypersensitivity', 'The use of beta-adrenergic receptor blocking agents (aka beta-blockers) in patients with a history of allergic reactions or anaphylaxis may be associated with heightened reactivity to culprit allergens.  The frequency and/or severity of attacks may be increased during beta-blocker therapy.  In addition, these patients may be refractory to the usual doses of epinephrine used to treat acute hypersensitivity reactions and may require a beta-agonist such as isoproterenol.', '3', '"Product Information. Sectral (acebutolol)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Tenormin (atenolol)." ICN Pharmaceuticals Inc  (2002):|"Product Information. Normodyne (labetalol)." Schering Corporation  (2002):|"Product Information. Trandate (labetalol)." Glaxo Wellcome  (2002):|"Product Information. Corgard (nadolol)." Bristol-Myers Squibb  (2002):|"Product Information. Inderal (propranolol)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|"Product Information. Brevibloc (esmolol)." DuPont Pharmaceuticals  (2001):|"Product Information. Cartrol (carteolol)." Abbott Pharmaceutical  (2001):|"Product Information. Kerlone (betaxolol)." Searle  (2001):|"Product Information. Lopressor (metoprolol)." Novartis Pharmaceuticals  (2001):|"Product Information. Betapace (sotalol)." Berlex Laboratories  (2001):|"Product Information. Zebeta (bisoprolol)." Lederle Laboratories  (2001):|"Product Information. Visken (pindolol)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Levatol (penbutolol)." Reed and Carnrick  (2001):|"Product Information. Coreg (carvedilol)." SmithKline Beecham  (2001):|"Product Information. Bystolic (nebivolol)." Forest Pharmaceuticals  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7936, 7520, 'Metoprolol', 'Myocardial Ischemia', 'Heightened sensitivity to catecholamines may occur after prolonged use of beta-adrenergic receptor blocking agents (aka beta-blockers).  Exacerbation of angina, myocardial infarction and ventricular arrhythmias have been reported in patients with coronary artery disease following abrupt withdrawal of therapy.  Cessation of beta-blocker therapy, whenever necessary, should occur gradually with incrementally reduced dosages over a period of 1 to 2 weeks in patients with coronary insufficiency.  Patients should be advised not to discontinue treatment without first consulting with the physician.  In patients who experience an exacerbation of angina following discontinuation of beta-blocker therapy, the medication should generally be reinstituted, at least temporarily, along with other clinically appropriate measures.', '3', 'Miller RR, Olson HG, Amsterdam EA, Mason DT "Propranolol-withdrawal rebound phenomenon: exacerbation of coronary events after abrupt cessation of antianginal therapy." N Engl J Med 293 (1975):  416-8|Rangno RE, Langlois S "Comparison of withdrawal phenomena after propranolol, metoprolol, and pindolol." Am Heart J 104 (1982):  473-8|Szecsi E, Kohlschutter S, Schiess W, Lang E "Abrupt withdrawal of pindolol or metoprolol after chronic therapy." Br J Clin Pharmacol 13 (1982):  s353-7|Walden RJ, Hernandez J, Yu Y, et al. "Withdrawal of beta-blocking drugs." Am Heart J 104 (1982):  515-20|"Product Information. Sectral (acebutolol)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Tenormin (atenolol)." ICN Pharmaceuticals Inc  (2002):|"Product Information. Normodyne (labetalol)." Schering Corporation  (2002):|"Product Information. Trandate (labetalol)." Glaxo Wellcome  (2002):|"Product Information. Corgard (nadolol)." Bristol-Myers Squibb  (2002):|"Product Information. Inderal (propranolol)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|"Product Information. Cartrol (carteolol)." Abbott Pharmaceutical  (2001):|"Product Information. Kerlone (betaxolol)." Searle  (2001):|"Product Information. Lopressor (metoprolol)." Novartis Pharmaceuticals  (2001):|"Product Information. Betapace (sotalol)." Berlex Laboratories  (2001):|"Product Information. Zebeta (bisoprolol)." Lederle Laboratories  (2001):|"Product Information. Visken (pindolol)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Levatol (penbutolol)." Reed and Carnrick  (2001):|"Product Information. Coreg (carvedilol)." SmithKline Beecham  (2001):|"Product Information. Bystolic (nebivolol)." Forest Pharmaceuticals  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7937, 7520, 'Metoprolol', 'Peripheral Vascular Diseases', 'Due to their negative inotropic and chronotropic effects on the heart, beta-adrenergic receptor blocking agents (aka beta-blockers) reduce cardiac output and may precipitate or aggravate symptoms of arterial insufficiency in patients with peripheral vascular disease.  In addition, the nonselective beta-blockers (e.g., propranolol, pindolol, timolol) may attenuate catecholamine-mediated vasodilation during exercise by blocking beta-2 receptors in peripheral vessels.  Therapy with beta-blockers should be administered cautiously in patients with peripheral vascular disease.  Close monitoring for progression of arterial obstruction is advised.', '3', 'Michelson EL, Frishman WH, Lewis JE, et al. "Multicenter clinical evaluation of long-term efficacy and safety of labetalol in treatment of hypertension." Am J Med Oct 17 (1983):  68-80|Eliasson K, Danielson M, Hylander B, Lindblad LE "Raynaud''s phenomenon caused by beta-receptor blocking drugs." Acta Med Scand 215 (1984):  333-9|Myers J, Morgan T, Waga S, et al. "Long-term experiences with labetalol." Med J Aust 1 (1980):  665-6|Tcherdakoff P "Side-effects with long-term labetalol: an open study of 251 patients in a single centre." Pharmatherapeutica 3 (1983):  342-8|Eliasson K, Lins L-E, Sundqvist K "Peripheral vasospasm during beta-receptor blockade: a comparison between metoprolol and pindolol." Acta Med Scand 665 (1982):  109-12|Lepantalo M "Beta blockade and intermittent claudication." Acta Med Scand 700 (1985):  1-48|Mashford ML, Coventry D, Hecker R, et al. "Adverse Drug Reactions Advisory Committee: ADRAC report for 1980." Med J Aust 1 (1982):  416-9|Coppeto JR "Transient ischemic attacks and amaurosis fugax from timolol." Ann Ophthalmol 17 (1985):  64-5|"Product Information. Sectral (acebutolol)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Tenormin (atenolol)." ICN Pharmaceuticals Inc  (2002):|"Product Information. Normodyne (labetalol)." Schering Corporation  (2002):|"Product Information. Trandate (labetalol)." Glaxo Wellcome  (2002):|"Product Information. Corgard (nadolol)." Bristol-Myers Squibb  (2002):|"Product Information. Inderal (propranolol)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|"Product Information. Brevibloc (esmolol)." DuPont Pharmaceuticals  (2001):|"Product Information. Cartrol (carteolol)." Abbott Pharmaceutical  (2001):|"Product Information. Kerlone (betaxolol)." Searle  (2001):|"Product Information. Lopressor (metoprolol)." Novartis Pharmaceuticals  (2001):|"Product Information. Betapace (sotalol)." Berlex Laboratories  (2001):|Broeder CE, Thomas EL, Martin NB, Hofman Z, Jesek JK, Scruggs KD, Wambsgans KC, Wilmore JH "Effects of propranolol and pindolol on cardiac output during extended periods of low-intensity physical activity." Am J Cardiol 72 (1993):  1188-95|"Product Information. Zebeta (bisoprolol)." Lederle Laboratories  (2001):|Holti G "A double-blind study of the peripheral vasoconstrictor effects of the beta-blocking drug penbutolol in patients with Raynaud''s phenomenon." Curr Med Res Opin 6 (1979):  267-70|"Product Information. Visken (pindolol)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Levatol (penbutolol)." Reed and Carnrick  (2001):|Breckenridge A, Roberts DH "Antihypertensive treatment in concomitant peripheral vascular disease: current experience and the potential of carvedilol." J Cardiovasc Pharmacol 18 Suppl 4 (1991):  s78-81|"Product Information. Bystolic (nebivolol)." Forest Pharmaceuticals  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7938, 7520, 'Metoprolol', 'Liver Diseases', 'Metoprolol is primarily metabolized by the liver.  Patients with liver disease may be at greater risk for adverse effects from metoprolol due to decreased drug clearance.  Therapy with metoprolol should be administered cautiously in patients with liver disease.  Dosage adjustments may be necessary.', '3', 'Regardh CG, Borg KO, Johansson R, et al. "Pharmacokinetic studies on the selective beta1-receptor antagonist metoprolol in man." J Pharmacokinet Biopharm 2 (1974):  347-64|Regardh C-G, Jordo L, Ervik M, et al. "Pharmacokinetics of metoprolol in patients with hepatic cirrhosis." Clin Pharmacokinet 6 (1981):  375-88|Silas JH, McGourty JC, Lennard MS, Tucker GT, Woods HF "Polymorphic metabolism of metoprolol: clinical studies." Eur J Clin Pharmacol 28 (1985):  85-8|Johnson JA, Burlew BS "Metoprolol metabolism via cytochrome p4502d6 in ethnic populations." Drug Metab Dispos 24 (1996):  350-5', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7939, 7520, 'Metoprolol', 'Cerebrovascular Disorders', 'Beta-adrenergic blocking agents (beta-blockers), should be used with caution in patients with cerebrovascular insufficiency because of their potential effects relative to blood pressure and pulse.  If signs or symptoms suggesting reduced cerebral blood flow are observed, consideration should be given to discontinuing these agents.', '2', '"Product Information. Sectral (acebutolol)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Tenormin (atenolol)." ICN Pharmaceuticals Inc  (2002):|"Product Information. Trandate (labetalol)." Glaxo Wellcome  (2002):|"Product Information. Corgard (nadolol)." Bristol-Myers Squibb  (2002):|"Product Information. Inderal (propranolol)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|"Product Information. Brevibloc (esmolol)." DuPont Pharmaceuticals  (2001):|"Product Information. Cartrol (carteolol)." Abbott Pharmaceutical  (2001):|"Product Information. Kerlone (betaxolol)." Searle  (2001):|"Product Information. Lopressor (metoprolol)." Novartis Pharmaceuticals  (2001):|"Product Information. Betapace (sotalol)." Berlex Laboratories  (2001):|"Product Information. Zebeta (bisoprolol)." Lederle Laboratories  (2001):|"Product Information. Visken (pindolol)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Levatol (penbutolol)." Reed and Carnrick  (2001):|"Product Information. Coreg (carvedilol)." SmithKline Beecham  (2001):|"Product Information. Bystolic (nebivolol)." Forest Pharmaceuticals  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7940, 7520, 'Metoprolol', 'Glaucoma', 'Systemic beta-adrenergic receptor blocking agents (aka beta-blockers) may lower intraocular pressure.  Therefore, patients with glaucoma or intraocular hypertension may require adjustments in their ophthalmic regimen following a dosing change or discontinuation of beta-blocker therapy.', '2', '"Product Information. Sectral (acebutolol)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Tenormin (atenolol)." ICN Pharmaceuticals Inc  (2002):|"Product Information. Normodyne (labetalol)." Schering Corporation  (2002):|"Product Information. Trandate (labetalol)." Glaxo Wellcome  (2002):|"Product Information. Corgard (nadolol)." Bristol-Myers Squibb  (2002):|"Product Information. Inderal (propranolol)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|"Product Information. Cartrol (carteolol)." Abbott Pharmaceutical  (2001):|"Product Information. Kerlone (betaxolol)." Searle  (2001):|"Product Information. Lopressor (metoprolol)." Novartis Pharmaceuticals  (2001):|"Product Information. Betapace (sotalol)." Berlex Laboratories  (2001):|"Product Information. Zebeta (bisoprolol)." Lederle Laboratories  (2001):|"Product Information. Visken (pindolol)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Levatol (penbutolol)." Reed and Carnrick  (2001):|"Product Information. Coreg (carvedilol)." SmithKline Beecham  (2001):|"Product Information. Bystolic (nebivolol)." Forest Pharmaceuticals  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7941, 7520, 'Metoprolol', 'Hyperlipidemias', 'Beta-adrenergic receptor blocking agents (aka beta-blockers) may alter serum lipid profiles.  Increases in serum VLDL and LDL cholesterol and triglycerides, as well as decreases in HDL cholesterol, have been reported with some beta-blockers.  Patients with preexisting hyperlipidemia may require closer monitoring during beta-blocker therapy, and adjustments made accordingly in their lipid-lowering regimen.', '2', 'Rossner S, Weiner L "Atenolol and metoprolol: comparison of effects on blood pressure and serum lipoproteins, and side effects." Eur J Clin Pharmacol 24 (1983):  573-7|Valimaki M, Maass L, Harno K, Nikkila EA "Lipoprotein lipids and apoproteins during beta-blocker administration: comparison of penbutolol and atenolol." Eur J Clin Pharmacol 30 (1986):  17-20|Disler LJ, Joffe BI, Seftel HC "Massive hypertriglyceridemia associated with atenolol." Am J Med 85 (1988):  586-7|Harvengt C, Heller FR, Martiat P, Nieuwenhuyze YV "Short-term effects of beta blockers atenolol, nadolol, pindolol, and propranolol on lipoprotein metabolism in normolipemic subjects." J Clin Pharmacol 27 (1987):  475-80|Darga LL, Hakim MJ, Lucas CP, Franklin BA "Comparison of the effects of guanadrel sulfate and propranolol on blood pressure, functional capacity, serum lipoproteins and glucose in systemic hypertension." Am J Cardiol 67 (1991):  590-6|Rossner S, Weiner L "Atenolol and metoprolol: comparison of effects on blood pressure and serum lipoproteins, and side effects." Eur J Clin Pharmacol 24 (1983):  573-7|Weiner L, Rossner S "Atenolol 50 mg or metoprolol 200 mg: a comparison of antihypertensive efficacy, side effects and lipoprotein changes." Acta Med Scand 677 (1983):  153-7|Ferrara LA, Marotta T, Scilla A, et al. "Effect of oxprenolol and metoprolol on serum lipid concentration." Eur J Clin Pharmacol 26 (1984):  331-4|Pasotti C, Capra A, Fiorella G, et al. "Effects of pindolol and metoprolol on plasma lipids and lipoproteins." Br J Clin Pharmacol 13 (1982):  s435-9|Carlson LA, Ribacke M, Terent A "A long-term study on the effect of pindolol on serum lipoproteins: a preliminary report." Br J Clin Pharmacol 24 (1987):  s61-2|Samuel P, Chin B, Schoenfeld BH, et al. "Comparison of the effect of pindolol versus propranolol on the lipid profile in patients treated for hypertension." Br J Clin Pharmacol 24 (1987):  s63-4|Terent A, Ribacke M, Carlson LA "Long-term effect of pindolol on lipids and lipoproteins in men with newly diagnosed hypertension." Eur J Clin Pharmacol 36 (1989):  347-50|Sasaki J, Saku K, Ideishi M, et al. "Effects of pindolol on serum lipids, apolipoproteins, and lipoproteins in patients with mild to moderate essential hypertension." Clin Ther 11 (1989):  219-24|Szollar LG, Meszaros I, Tornoci L, et al. "Effect of metoprolol and pindolol monotherapy on plasma lipid- and lipoprotein-cholesterol levels (including the HDL subclasses) in mild hypertensive males and females." J Cardiovasc Pharmacol 15 (1990):  911-7|Leren P, Foss PO, Nordvik B, Fossbakk B "The effect of enalapril and timolol on blood lipids." Acta Med Scand 223 (1988):  321-6|"Product Information. Sectral (acebutolol)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Tenormin (atenolol)." ICN Pharmaceuticals Inc  (2002):|"Product Information. Normodyne (labetalol)." Schering Corporation  (2002):|"Product Information. Trandate (labetalol)." Glaxo Wellcome  (2002):|"Product Information. Corgard (nadolol)." Bristol-Myers Squibb  (2002):|"Product Information. Inderal (propranolol)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|Northcote RJ, Packard CJ, Ballantyne D "The effect of sotalol on plasma lipoproteins and apolipoproteins." Clin Chim Acta 158 (1986):  187-91|Lehtonen A, Hietanen E, Marniemi J, Peltonen P, Nikkila EA "Effect of sotalol withdrawal on serum lipids and lipoprotein lipase activity." Int J Clin Pharmacol Ther Toxicol 21 (1983):  73-6|"Product Information. Cartrol (carteolol)." Abbott Pharmaceutical  (2001):|"Product Information. Kerlone (betaxolol)." Searle  (2001):|"Product Information. Lopressor (metoprolol)." Novartis Pharmaceuticals  (2001):|"Product Information. Betapace (sotalol)." Berlex Laboratories  (2001):|"Product Information. Zebeta (bisoprolol)." Lederle Laboratories  (2001):|Safran AB, Simona F, Sansonetti A, Pometta D, James R "Effects of ocular carteolol and timolol on plasma high-density lipoprotein cholesterol level." Am J Ophthalmol 117 (1994):  683|"Product Information. Visken (pindolol)." Sandoz Pharmaceuticals Corporation  (2001):|Clucas A, Miller N "Effects of acebutolol on the serum lipid profile." Drugs 36 Suppl 2 (1988):  41-50|"Product Information. Levatol (penbutolol)." Reed and Carnrick  (2001):|Kasiske BL, Ma JZ, Kalil RS, Louis TA "Effects of antihypertensive therapy on serum lipids." Ann Intern Med 122 (1995):  133-41|Lind L, Pollare T, Berne C, Lithell H "Long-term metabolic effects of antihypertensive drugs." Am Heart J 128 (1994):  1177-83|Sasaki J, Kajiyama G, Kusukawa R, Mori H, Koga S, Takagi R, Tanaka N, Ogawa N, Arakawa K "Effect of bevantolol and propranolol on serum lipids in patients with essential hypertension." Int J Clin Pharmacol Ther 32 (1994):  660-4|"Product Information. Coreg (carvedilol)." SmithKline Beecham  (2001):|Lithell H, Andersson PE "Metabolic effects of carvedilol in hypertensive patients." Eur J Clin Pharmacol 52 (1997):  13-7|Gordon NF, Scott CB, Duncan JJ "Effects of atenolol versus enalapril on cardiovascular fitness and serum lipids in physically active hypertensive men." Am J Cardiol 79 (1997):  1065-9|"Product Information. Bystolic (nebivolol)." Forest Pharmaceuticals  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7942, 7520, 'Metoprolol', 'Hyperthyroidism', 'When beta-adrenergic receptor blocking agents (aka beta-blockers) are used to alleviate symptoms of hyperthyroidism such as tachycardia, anxiety, tremor and heat intolerance, abrupt withdrawal can exacerbate thyrotoxicosis or precipitate a thyroid storm.  To minimize this risk, cessation of beta-blocker therapy, when necessary, should occur gradually with incrementally reduced dosages over a period of 1 to 2 weeks.  Patients should be advised not to discontinue treatment without first consulting with the physician.  Close monitoring is recommended during and after therapy withdrawal.', '2', '"Product Information. Sectral (acebutolol)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Tenormin (atenolol)." ICN Pharmaceuticals Inc  (2002):|"Product Information. Normodyne (labetalol)." Schering Corporation  (2002):|"Product Information. Trandate (labetalol)." Glaxo Wellcome  (2002):|"Product Information. Corgard (nadolol)." Bristol-Myers Squibb  (2002):|"Product Information. Inderal (propranolol)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|"Product Information. Cartrol (carteolol)." Abbott Pharmaceutical  (2001):|"Product Information. Kerlone (betaxolol)." Searle  (2001):|"Product Information. Lopressor (metoprolol)." Novartis Pharmaceuticals  (2001):|"Product Information. Betapace (sotalol)." Berlex Laboratories  (2001):|"Product Information. Zebeta (bisoprolol)." Lederle Laboratories  (2001):|"Product Information. Visken (pindolol)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Levatol (penbutolol)." Reed and Carnrick  (2001):|"Product Information. Coreg (carvedilol)." SmithKline Beecham  (2001):|"Product Information. Bystolic (nebivolol)." Forest Pharmaceuticals  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7943, 7520, 'Metoprolol', 'Myasthenia Gravis', 'Beta-adrenergic receptor blocking agents (aka beta-blockers) may potentiate muscle weakness consistent with certain myasthenic symptoms such as diplopia, ptosis, and generalized weakness.  Several beta-blockers have been associated rarely with aggravation of muscle weakness in patients with preexisting myasthenia gravis or myasthenic symptoms.  Use cautiously in patients with myasthenia gravis.', '2', 'Confavreux C, Charles N, Aimard G "Fulminant myasthenia gravis soon after initiation of acebutolol therapy." Eur Neurol 30 (1990):  279-81|Berstein LP, Henkind P "Additional information on adverse reactions to timolol." Am J Ophthalmol 92 (1981):  295-6|Coppeto JR "Timolol-associated myasthenia gravis." Am J Ophthalmol 98 (1984):  244-5|Verkijk A "Worsening of myasthenia gravis with timolol maleate eyedrops." Ann Neurol 17 (1985):  211-2|Herishanu Y, Rosenberg P "Beta-blockers and myasthenia gravis." Ann Intern Med 83 (1975):  834-5|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|Choi KL, Wat MS, Ip TP, Kung AWC, Lam KSL "Phaeochromocytoma associated with myasthenia gravis precipitated by propranolol treatment." Aust N Z J Med 25 (1995):  257', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7944, 7520, 'Metoprolol', 'Pheochromocytoma', 'Administration of beta-blockers alone in the setting of pheochromocytoma has been associated with a paradoxical increase in blood pressure due to the attenuation of beta-mediated vasodilatation in skeletal muscle.  In patients with pheochromocytoma, an alpha-blocking agent should be initiated prior to the use of any beta-blocking agent.  Caution should be taken in the administration of these agents to patients suspected of having pheochromocytoma.', '2', '"Product Information. Sectral (acebutolol)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Tenormin (atenolol)." ICN Pharmaceuticals Inc  (2002):|"Product Information. Trandate (labetalol)." Glaxo Wellcome  (2002):|"Product Information. Corgard (nadolol)." Bristol-Myers Squibb  (2002):|"Product Information. Inderal (propranolol)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|"Product Information. Brevibloc (esmolol)." DuPont Pharmaceuticals  (2001):|"Product Information. Cartrol (carteolol)." Abbott Pharmaceutical  (2001):|"Product Information. Kerlone (betaxolol)." Searle  (2001):|"Product Information. Lopressor (metoprolol)." Novartis Pharmaceuticals  (2001):|"Product Information. Betapace (sotalol)." Berlex Laboratories  (2001):|"Product Information. Zebeta (bisoprolol)." Lederle Laboratories  (2001):|"Product Information. Visken (pindolol)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Levatol (penbutolol)." Reed and Carnrick  (2001):|"Product Information. Coreg (carvedilol)." SmithKline Beecham  (2001):|"Product Information. Bystolic (nebivolol)." Forest Pharmaceuticals  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7945, 7520, 'Metoprolol', 'Psoriasis', 'The use of beta-blockers in psoriatic patients should be carefully weighed since the use of these agents may cause an aggravation in psoriasis.', '2', '"Product Information. Sectral (acebutolol)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Tenormin (atenolol)." ICN Pharmaceuticals Inc  (2002):|"Product Information. Normodyne (labetalol)." Schering Corporation  (2002):|"Product Information. Trandate (labetalol)." Glaxo Wellcome  (2002):|"Product Information. Corgard (nadolol)." Bristol-Myers Squibb  (2002):|"Product Information. Inderal (propranolol)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|"Product Information. Brevibloc (esmolol)." DuPont Pharmaceuticals  (2001):|"Product Information. Cartrol (carteolol)." Abbott Pharmaceutical  (2001):|"Product Information. Kerlone (betaxolol)." Searle  (2001):|"Product Information. Lopressor (metoprolol)." Novartis Pharmaceuticals  (2001):|"Product Information. Betapace (sotalol)." Berlex Laboratories  (2001):|"Product Information. Zebeta (bisoprolol)." Lederle Laboratories  (2001):|"Product Information. Visken (pindolol)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Levatol (penbutolol)." Reed and Carnrick  (2001):|"Product Information. Bystolic (nebivolol)." Forest Pharmaceuticals  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7946, 7520, 'Metoprolol', 'Tachycardia', 'Beta-adrenergic blockade in patients with Wolff-Parkinson-White syndrome and tachycardia has been associated with severe bradycardia requiring treatment with a pacemaker.  In one case, this result was reported after an initial dose of 5 mg propranolol.  The use of beta-adrenergic receptor blocking agents (aka beta-blockers) should be administered cautiously in these patients.', '2', '"Product Information. Sectral (acebutolol)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Tenormin (atenolol)." ICN Pharmaceuticals Inc  (2002):|"Product Information. Normodyne (labetalol)." Schering Corporation  (2002):|"Product Information. Trandate (labetalol)." Glaxo Wellcome  (2002):|"Product Information. Corgard (nadolol)." Bristol-Myers Squibb  (2002):|"Product Information. Inderal (propranolol)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|"Product Information. Brevibloc (esmolol)." DuPont Pharmaceuticals  (2001):|"Product Information. Cartrol (carteolol)." Abbott Pharmaceutical  (2001):|"Product Information. Kerlone (betaxolol)." Searle  (2001):|"Product Information. Lopressor (metoprolol)." Novartis Pharmaceuticals  (2001):|"Product Information. Betapace (sotalol)." Berlex Laboratories  (2001):|"Product Information. Zebeta (bisoprolol)." Lederle Laboratories  (2001):|"Product Information. Visken (pindolol)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Levatol (penbutolol)." Reed and Carnrick  (2001):|"Product Information. Bystolic (nebivolol)." Forest Pharmaceuticals  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7947, 7520, 'Metoprolol', 'Asthma', 'Patients with bronchospastic disease, should, in general, not receive beta blockers, including cardioselective beta-blockers.  Because of the relative beta-1 selectivity, cardioselective beta-blockers may be used in patients with bronchospastic disease who do not respond to, or cannot tolerate, other antihypertensive treatment.  Because beta-1 selectivity is not absolute, the lowest possible dose of these agents should be used.  Consider administering in smaller doses to avoid the higher plasma levels associated with the longer dosing intervals.  If dosage must be increased, dividing the dose should be considered to achieve lower peak blood levels.  It is recommended to have bronchodilators, including beta-2 agonists, readily available or administered concomitantly if necessary.', '2', '"Product Information. Sectral (acebutolol)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Tenormin (atenolol)." ICN Pharmaceuticals Inc  (2002):|"Product Information. Brevibloc (esmolol)." DuPont Pharmaceuticals  (2001):|"Product Information. Kerlone (betaxolol)." Searle  (2001):|"Product Information. Lopressor (metoprolol)." Novartis Pharmaceuticals  (2001):|"Product Information. Zebeta (bisoprolol)." Lederle Laboratories  (2001):|"Product Information. Bystolic (nebivolol)." Forest Pharmaceuticals  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7948, 690, 'Metronidazole', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7949, 691, 'Metronidazole', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7950, 692, 'Metronidazole', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7951, 4210, 'Metronidazole', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7952, 4325, 'Metronidazole', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7953, 4894, 'Metronidazole', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7954, 4903, 'Metronidazole', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7955, 4904, 'Metronidazole', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7956, 4905, 'Metronidazole', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7957, 4906, 'Metronidazole', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7958, 4930, 'Metronidazole', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7959, 6077, 'Metronidazole', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7960, 8101, 'Metronidazole', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7961, 8102, 'Metronidazole', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7962, 14075, 'Metronidazole', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7963, 14076, 'Metronidazole', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7964, 14080, 'Metronidazole', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7965, 15559, 'Metronidazole', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7966, 16787, 'Metronidazole', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7967, 17956, 'Metronidazole', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7968, 17957, 'Metronidazole', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7969, 18347, 'Metronidazole', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7970, 19075, 'Metronidazole', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7971, 19077, 'Metronidazole', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7972, 19078, 'Metronidazole', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7973, 19079, 'Metronidazole', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7974, 19085, 'Metronidazole', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7975, 19630, 'Metronidazole', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7976, 22672, 'Metronidazole', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7977, 22676, 'Metronidazole', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7978, 22677, 'Metronidazole', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7979, 22679, 'Metronidazole', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7980, 22680, 'Metronidazole', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7981, 26297, 'Metronidazole', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7982, 28488, 'Metronidazole', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7983, 28489, 'Metronidazole', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7984, 28490, 'Metronidazole', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7985, 28491, 'Metronidazole', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7986, 28492, 'Metronidazole', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7987, 30008, 'Metronidazole', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7988, 30543, 'Metronidazole', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7989, 33203, 'Metronidazole', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7990, 690, 'Metronidazole', 'Hematologic Diseases', 'The use of nitroimidazoles (e.g., metronidazole, tinidazole) has rarely been associated with hematologic adverse effects such as mild, transient leukopenia, thrombocytopenia, and bone marrow aplasia.  The manufacturers recommend that therapy with nitroimidazoles be administered cautiously in patients with evidence of or a history of blood dyscrasias, and that total and differential leukocyte counts be performed before and after treatment with these drugs, particularly in patients receiving repeated courses of therapy.', '3', 'Smith JA "Neutropenia associated with metronidazole therapy." Can Med Assoc J 123 (1980):  202|White CM, Price JJ, Hunt KM "Bone marrow aplasia associated with metronidazole." Br Med J 280 (1980):  647|"Product Information. Flagyl (metronidazole)." Searle  (2002):|"Product Information. Tindamax (tinidazole)." Presutti Laboratories Inc  (2004):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7991, 691, 'Metronidazole', 'Hematologic Diseases', 'The use of nitroimidazoles (e.g., metronidazole, tinidazole) has rarely been associated with hematologic adverse effects such as mild, transient leukopenia, thrombocytopenia, and bone marrow aplasia.  The manufacturers recommend that therapy with nitroimidazoles be administered cautiously in patients with evidence of or a history of blood dyscrasias, and that total and differential leukocyte counts be performed before and after treatment with these drugs, particularly in patients receiving repeated courses of therapy.', '3', 'Smith JA "Neutropenia associated with metronidazole therapy." Can Med Assoc J 123 (1980):  202|White CM, Price JJ, Hunt KM "Bone marrow aplasia associated with metronidazole." Br Med J 280 (1980):  647|"Product Information. Flagyl (metronidazole)." Searle  (2002):|"Product Information. Tindamax (tinidazole)." Presutti Laboratories Inc  (2004):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7992, 692, 'Metronidazole', 'Hematologic Diseases', 'The use of nitroimidazoles (e.g., metronidazole, tinidazole) has rarely been associated with hematologic adverse effects such as mild, transient leukopenia, thrombocytopenia, and bone marrow aplasia.  The manufacturers recommend that therapy with nitroimidazoles be administered cautiously in patients with evidence of or a history of blood dyscrasias, and that total and differential leukocyte counts be performed before and after treatment with these drugs, particularly in patients receiving repeated courses of therapy.', '3', 'Smith JA "Neutropenia associated with metronidazole therapy." Can Med Assoc J 123 (1980):  202|White CM, Price JJ, Hunt KM "Bone marrow aplasia associated with metronidazole." Br Med J 280 (1980):  647|"Product Information. Flagyl (metronidazole)." Searle  (2002):|"Product Information. Tindamax (tinidazole)." Presutti Laboratories Inc  (2004):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7993, 4210, 'Metronidazole', 'Hematologic Diseases', 'The use of nitroimidazoles (e.g., metronidazole, tinidazole) has rarely been associated with hematologic adverse effects such as mild, transient leukopenia, thrombocytopenia, and bone marrow aplasia.  The manufacturers recommend that therapy with nitroimidazoles be administered cautiously in patients with evidence of or a history of blood dyscrasias, and that total and differential leukocyte counts be performed before and after treatment with these drugs, particularly in patients receiving repeated courses of therapy.', '3', 'Smith JA "Neutropenia associated with metronidazole therapy." Can Med Assoc J 123 (1980):  202|White CM, Price JJ, Hunt KM "Bone marrow aplasia associated with metronidazole." Br Med J 280 (1980):  647|"Product Information. Flagyl (metronidazole)." Searle  (2002):|"Product Information. Tindamax (tinidazole)." Presutti Laboratories Inc  (2004):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7994, 4325, 'Metronidazole', 'Hematologic Diseases', 'The use of nitroimidazoles (e.g., metronidazole, tinidazole) has rarely been associated with hematologic adverse effects such as mild, transient leukopenia, thrombocytopenia, and bone marrow aplasia.  The manufacturers recommend that therapy with nitroimidazoles be administered cautiously in patients with evidence of or a history of blood dyscrasias, and that total and differential leukocyte counts be performed before and after treatment with these drugs, particularly in patients receiving repeated courses of therapy.', '3', 'Smith JA "Neutropenia associated with metronidazole therapy." Can Med Assoc J 123 (1980):  202|White CM, Price JJ, Hunt KM "Bone marrow aplasia associated with metronidazole." Br Med J 280 (1980):  647|"Product Information. Flagyl (metronidazole)." Searle  (2002):|"Product Information. Tindamax (tinidazole)." Presutti Laboratories Inc  (2004):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7995, 4894, 'Metronidazole', 'Hematologic Diseases', 'The use of nitroimidazoles (e.g., metronidazole, tinidazole) has rarely been associated with hematologic adverse effects such as mild, transient leukopenia, thrombocytopenia, and bone marrow aplasia.  The manufacturers recommend that therapy with nitroimidazoles be administered cautiously in patients with evidence of or a history of blood dyscrasias, and that total and differential leukocyte counts be performed before and after treatment with these drugs, particularly in patients receiving repeated courses of therapy.', '3', 'Smith JA "Neutropenia associated with metronidazole therapy." Can Med Assoc J 123 (1980):  202|White CM, Price JJ, Hunt KM "Bone marrow aplasia associated with metronidazole." Br Med J 280 (1980):  647|"Product Information. Flagyl (metronidazole)." Searle  (2002):|"Product Information. Tindamax (tinidazole)." Presutti Laboratories Inc  (2004):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7996, 4903, 'Metronidazole', 'Hematologic Diseases', 'The use of nitroimidazoles (e.g., metronidazole, tinidazole) has rarely been associated with hematologic adverse effects such as mild, transient leukopenia, thrombocytopenia, and bone marrow aplasia.  The manufacturers recommend that therapy with nitroimidazoles be administered cautiously in patients with evidence of or a history of blood dyscrasias, and that total and differential leukocyte counts be performed before and after treatment with these drugs, particularly in patients receiving repeated courses of therapy.', '3', 'Smith JA "Neutropenia associated with metronidazole therapy." Can Med Assoc J 123 (1980):  202|White CM, Price JJ, Hunt KM "Bone marrow aplasia associated with metronidazole." Br Med J 280 (1980):  647|"Product Information. Flagyl (metronidazole)." Searle  (2002):|"Product Information. Tindamax (tinidazole)." Presutti Laboratories Inc  (2004):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7997, 4904, 'Metronidazole', 'Hematologic Diseases', 'The use of nitroimidazoles (e.g., metronidazole, tinidazole) has rarely been associated with hematologic adverse effects such as mild, transient leukopenia, thrombocytopenia, and bone marrow aplasia.  The manufacturers recommend that therapy with nitroimidazoles be administered cautiously in patients with evidence of or a history of blood dyscrasias, and that total and differential leukocyte counts be performed before and after treatment with these drugs, particularly in patients receiving repeated courses of therapy.', '3', 'Smith JA "Neutropenia associated with metronidazole therapy." Can Med Assoc J 123 (1980):  202|White CM, Price JJ, Hunt KM "Bone marrow aplasia associated with metronidazole." Br Med J 280 (1980):  647|"Product Information. Flagyl (metronidazole)." Searle  (2002):|"Product Information. Tindamax (tinidazole)." Presutti Laboratories Inc  (2004):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7998, 4905, 'Metronidazole', 'Hematologic Diseases', 'The use of nitroimidazoles (e.g., metronidazole, tinidazole) has rarely been associated with hematologic adverse effects such as mild, transient leukopenia, thrombocytopenia, and bone marrow aplasia.  The manufacturers recommend that therapy with nitroimidazoles be administered cautiously in patients with evidence of or a history of blood dyscrasias, and that total and differential leukocyte counts be performed before and after treatment with these drugs, particularly in patients receiving repeated courses of therapy.', '3', 'Smith JA "Neutropenia associated with metronidazole therapy." Can Med Assoc J 123 (1980):  202|White CM, Price JJ, Hunt KM "Bone marrow aplasia associated with metronidazole." Br Med J 280 (1980):  647|"Product Information. Flagyl (metronidazole)." Searle  (2002):|"Product Information. Tindamax (tinidazole)." Presutti Laboratories Inc  (2004):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7999, 4906, 'Metronidazole', 'Hematologic Diseases', 'The use of nitroimidazoles (e.g., metronidazole, tinidazole) has rarely been associated with hematologic adverse effects such as mild, transient leukopenia, thrombocytopenia, and bone marrow aplasia.  The manufacturers recommend that therapy with nitroimidazoles be administered cautiously in patients with evidence of or a history of blood dyscrasias, and that total and differential leukocyte counts be performed before and after treatment with these drugs, particularly in patients receiving repeated courses of therapy.', '3', 'Smith JA "Neutropenia associated with metronidazole therapy." Can Med Assoc J 123 (1980):  202|White CM, Price JJ, Hunt KM "Bone marrow aplasia associated with metronidazole." Br Med J 280 (1980):  647|"Product Information. Flagyl (metronidazole)." Searle  (2002):|"Product Information. Tindamax (tinidazole)." Presutti Laboratories Inc  (2004):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8000, 4930, 'Metronidazole', 'Hematologic Diseases', 'The use of nitroimidazoles (e.g., metronidazole, tinidazole) has rarely been associated with hematologic adverse effects such as mild, transient leukopenia, thrombocytopenia, and bone marrow aplasia.  The manufacturers recommend that therapy with nitroimidazoles be administered cautiously in patients with evidence of or a history of blood dyscrasias, and that total and differential leukocyte counts be performed before and after treatment with these drugs, particularly in patients receiving repeated courses of therapy.', '3', 'Smith JA "Neutropenia associated with metronidazole therapy." Can Med Assoc J 123 (1980):  202|White CM, Price JJ, Hunt KM "Bone marrow aplasia associated with metronidazole." Br Med J 280 (1980):  647|"Product Information. Flagyl (metronidazole)." Searle  (2002):|"Product Information. Tindamax (tinidazole)." Presutti Laboratories Inc  (2004):', 'DDInter', 0);
